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1. ABSTRACT 
	Chemotherapy	still	represents	the	most	common	and	sometimes	the	only	possible	therapeutic	option	 for	 advanced	 breast	 cancer.	 Its	 efficacy	 is	 profoundly	 threatened	 by	 intrinsic	 or	acquired	 chemoresistance,	 which,	 in	 some	 cases,	 can	 be	 unexpectedly	 promoted	 by	 the	chemotherapeutic	 drugs	 used.	 ETV7,	 a	 poorly	 characterized	 ETS	 factor	with	 no	 established	roles	 in	breast	 cancer	so	 far,	 is	 reported	here	 to	be	activated	at	 the	 transcriptional	 level	by	chemotherapy	 and	 be	 able	 to	 promote	 breast	 cancer	 cells	 chemoresistance.	 This	 project	proposes	a	novel	drug	resistance	circuitry	 in	breast	cancer	cells,	specifically	to	Doxorubicin,	governed	 by	 the	 ETV7	 repressive	 action	 on	 DNAJC15,	 a	 gene	 whose	 low	 expression	 was	previously	associated	with	drug	resistance	in	breast	and	ovarian	cancer.	Moreover,	the	impact	of	ETV7	in	causing	drug	resistance	is	proved	here	to	extend	also	to	another	type	of	drug,	5-Fluorouracil	 (5-FU),	 a	 chemotherapeutic	 agent	 commonly	 used	 in	 combination	 with	Doxorubicin	 for	 breast	 cancer	 treatment.	 In	 this	 case,	 additional	 novel	ETV7	 targets	 (DPYD	and	 DPEP1)	 were	 established	 and	 can	 represent	 important	 mediators	 for	 ETV7-mediated	resistance	 to	 5-FU.	 Additional	 relevant	 data,	 relative	 to	 biological	 implications	 for	 ETV7	 in	breast	cancer	progression,	is	provided	here	by	the	ETV7	ChIP-seq	analysis,	which	reveals	the	first	 reported	 in	 vivo	mapping	 of	 ETV7	 occupancy.	 Through	 ChIP-seq	 novel	 ETV7	 direct	targets	 have	 been	 identified,	 some	 of	 them	 yet	 unexplored	 in	 breast	 cancer;	 notably,	 their	expression	revealed	to	be	capable	of	predicting	breast	cancer	patients	outcome.	Furthermore,	a	possible	control	exerted	by	ETV7	on	the	TGF-β	pathway,	discovered	by	enrichment	analysis	on	ChIP-seq	ETV7	targets,	suggests	a	different	and	opposing	role	for	ETV7	activation	in	either	advanced	stage	cancers	or	normal	and	early	stage	breast	cancers.	Taken	 collectively,	 the	 results	 from	 this	 project	 propose	 an	 important	 key	 role	 for	ETV7	 in	triggering	 breast	 cancer	multi-drug	 resistance	 phenotype	 in	 response	 to	 chemotherapy,	 by	controlling	the	expression	of	specific	targets.			 	
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2. INTRODUCTION 
	
2.1	BREAST	CANCER		
	
2.1.1	Subtypes		
	Breast	 cancer	 still	 represents	 the	most	 frequently	diagnosed	 type	of	 cancer	worldwide	 and	the	 second	 leading	 cause	 of	 cancer	 death	 among	 women	 (Jemal,	 Bray	 and	 Ferlay,	 2011;	American	Cancer	 Society,	 2016).	 It	 is	 a	 very	heterogenous	disease	 in	 terms	of	 genetics	 and	phenotype	 features,	 relative	 to	 different	 subtypes	 (inter-tumor	 heterogeneity)	 or	 different	cancer	 cells	 present	 inside	 cancer	 (intra-tumor	heterogeneity)	 (Skibinski	 and	Kuperwasser,	2015).	 Subtype	 classification	 is	 meant	 to	 simplify	 heterogenity	 and	 direct	 therapeutic	decision.	 In	 the	 clinics,	 the	most	 common	 type	 of	 classification	 relies	 on	 histo-pathological	features:	 expression	 of	 estrogen	 and	 progesterone	 receptors	 (since	 mammary	 epithelium	where	breast	cancer	usually	originates	depends	on	estrogens),	HER2	(also	known	as	EGFR2)	amplification	 or	 the	 absence	 of	 the	 three	 receptors	 (generally	 known	 as	 triple	 negative	group).	 Another	 type	 of	 classification,	 called	 the	 molecular	 classification,	 is	 based	 on	microarray-based	technology	and	next	generation	sequencing	gene	expression,	mutation	and	chromosomal	 aberration	 data	 and	 allows	 a	 better	 stratification	 of	 patients	 in	 terms	 of	prognosis	 and	 a	 deeper	 understanding	 of	 molecular	 mechanisms	 and	 mutations	characterizing	each	subtype.	For	example,	molecular	characterization	of	the	pathologic	group	triple	 negative,	 showed	 that	 some	 subtypes	 of	 triple	 negative	 breast	 cancer	 could	 be	successfully	 treated	 with	 immunotherapy	 (Anders	 et	 al.,	 2016).	 According	 to	 molecular	classification,	 there	 are	 at	 least	 six	 different	 breast	 cancer	 subtypes:	 Luminal	A,	 Luminal	B,	HER2-enriched,	 Claudin-low,	Basal-like	 and	 a	Normal	Breast-like	 group	 (Perou	 et	al.,	 2000;	Prat	 and	 Perou,	 2011).	 Each	 subtype	 is	 characterized	 by	 different	 mutational	 spectra,	 and	specifically	Basal-like	subtype	displays	a	high	number	of	somatic	mutation,	with	p53	being	the	most	frequent	mutated	gene	(Skibinski	and	Kuperwasser,	2015).	In	2009	Parker	and	co-workers	proposed	a	50-gene	panel	called	PAM50	(Predictive	Analysis	of	Microarrays	(Nanostring	Technologies	 Inc.,	Seattle,	Washington)	based	on	 the	expression	analysis	 of	 50	 classifier	 genes	 and	 5	 controls,	 for	 standardizing	 the	 classification	 of	 the	aforementioned	breast	 cancer	 subtypes,	 that	was	 validated	 also	 for	 formalin-fixed-paraffin-embedded	 (FFPE)	samples	 (Parker	et	al.,	2009).	More	recently,	different	groups,	using	RNA	
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extracted	 from	 patient-derived	 biopsies,	 have	 tried	 to	 identify	 gene	 signatures,	 whose	expression	 levels	 could	 generate	 more	 precise	 prognosis	 for	 breast	 cancer	 patients;	 for	instance,	Mammaprint	 (a	70-gene	microarray	 test,	Agendia,	 Irvine,	CA	and	Amsterdam,	The	Netherlands)	 (Veer	 et	 al.,	 2002),	 Oncotype	 DX	 (a	 21-gene	 RT-qPCR	 based	 assay,	 Genomic	Health,	 Inc.,	 San	 Francisco,	 CA)	 (Paik	 et	 al.,	 2004)	 and	 76-gene	 Rotterdam	 set	 (a	 76-gene	microarray	 test,	 Veridex,	 LLC,	 Johnson	 &	 Johnson,	Warren,	 NJ)	 (Foekens	 et	 al.,	 2006).	 The	presence	 of	 such	 high	 number	 of	 classification	 systems	 underlines	 the	 extremely	heterogenous	 nature	 of	 breast	 cancer	 and	 its	 complex	 biology	 and	 the	 importance	 of	identifying	novel	markers	to	improve	patients’	prognosis	and	treatment.				
2.1.2	p53’s	role	in	breast	cancer		p53,	 known	 as	 the	 “guardian	 of	 the	 genome”,	 is	 a	 key	 factor	 for	 normal	 breast	 cancer	development	and	for	the	control	of	breast	cancer	progression	(Walerych	et	al.,	2012).	Being	activated	 by	 various	 stressor	 stimuli,	 such	 as	 DNA	 damage,	 oncogenes	 activation,	 hypoxia,	oxidative	 stress,	 and	 telomeres	 erosion,	 p53	 can	 control	 the	 DNA	 repair,	 growth	 arrest,	apoptosis,	 senescence	 and	 metabolic	 homeostasis	 (Levine	 and	 Oren,	 2009).	 p53	 protein	stability	 is	 tightly	regulated	by	MDM2,	which	ubiquitinates	p53	 targeting	 it	 for	proteasomal	degradation.	 Upon	 p53	 activating	 stimuli	 MDM2-p53	 interaction	 is	 prevented	 by	 serine	phosphorylations	 in	 the	p53	N-terminal	domain.	 Inhibition	of	MDM2	binding	 to	p53	can	be	also	directly	achieved	by	the	pharmacological	treatment	with	the	MDM2	antagonists,	such	as	Nutlin-3a,	resulting	 in	 inhibition	of	proliferation	of	cancer	cells	bearing	wild	type	p53.	Once	activated	p53	protein	can	rapidly	accumulate	into	the	nucleus	where	it	can	carry	out	most	of	its	properties	that	rely	on	its	 funtions	as	transcription	factor.	The	DNA	binding	of	p53	to	its	target	 sequences	 is	 an	 accurately	 regulated	 process,	 influenced	 by	 p53	 post	 translational	modifications	 and	 by	 the	 conformation	 of	 p53	 response	 elements	 (RE),	 which	 are	 usually	composed	 of	 two	 decamers,	 called	 half	 sites,	 divided	 by	 a	 spacer	 typically	 with	 a	 length	ranging	from	0	to	13	bases.	The	canonical	consensus	sequence		recognized	by	the	p53	is	5’	-	RRRCWWGYYY	n	RRRCWWGYYY	–	3’	(R:purine,	Y:pyrimidine;	W:A/T,	n:spacer)	(Menendez,	Inga	and	Resnick,	2009).		The	 importance	of	p53	relatively	 for	breast	cancer	 is	strongly	supported	by	the	high	risk	of		developing	breast	cancer	in	patients	affected	by	the	Li-Fraumeni	syndrome,	a	genetic	disorder	characterized	 by	 a	 germline	 p53	 mutation	 at	 heterozygous	 level	 (Walerych	 et	 al.,	 2012).	Another	 important	 relevance	 is	 given	 by	 the	 high	 rate	 of	 p53	 mutations	 in	 breast	 cancer,	
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which	can	be	responsible	for	transforming	p53	into	a	“rebel	angel”,	a	driving	factor	in	breast	carcinogenesis	(Walerych	et	al.,	2012).			
2.1.3	Chemotherapy	and	Chemoresistance		Chemotherapy	 is	 still	 representing	 the	 basic	 standard	 treatment	 for	 breast	 cancer,	particularly	 if	 locally	 advanced,	 non-responding	 to	 endocrine	 therapy	 and	 in	 the	 case	 of	metastatic	dissemination.	Chemotherapy	 serves	 as	 the	only	 treatment	option	when	 surgery	cannot	 be	 done,	 or,	 alternatively,	 is	 used	 to	 reduce	 tumor	 burden	 before	 surgery	(neoadjuvant)	 or	 after	 surgery	 (adjuvant),	 and	 it	 also	 proved	 very	 efficacious	 in	 boosting	immunotherapy.		Chemotherapy	 relies	 on	 different	 groups	 of	 cytotoxic	 drugs:	 anthracyclines	 (Doxorubicin,	Epirubicin,	 Mitoxantrone),	 taxanes	 (Paclitaxel,	 Docetaxel)	 alkylating	 agents	(Cyclophosphamide),	 fluoropyrimidines	 (Capecitabine,	 5-Fluorouracil),	 antimetabolites	(Methotrexate),	 vinca	 alkaloids	 (Vinolerbine,	 Vinblastine,	 Vincristine),	 and	 platinum	compounds	 (Carboplatin,	Cisplatin).	Anthracyclines	are	mostly	used	 in	adjuvant	 setting	and	among	 them,	 Doxorubicin,	 which	 acts	 by	 inhibiting	 topoisomerase	 2,	 causing	 DNA	 damage	and	 subsequently	 cancer	 cell	 death,	 by	 potently	 inducing	 p53	 (Yardley,	 2013).	 Similarly	 to	Doxorubicin,	also	 the	 fluoroquinolone	Etoposide	acts	by	 inhibiting	 topoisomerase	2,	 leading	to	DNA	damage	(Heisig,	2009).	Topoisomerase	1	is	inhibited	by	Camptothecin,	which	blocks	the	 Topoisomerase	 1-DNA	 cleavage	 complex	 and	 leads	 again	 to	 DNA	 damage	 (Sakasai	 and	Iwabuchi,	 2015).	 5-Fluorouracil	 (5-FU),	 another	 commonly	 used	 antineoplastic	 drug,	 is	responsible	 for	 the	 misincorporation	 of	 fluoronucleotides	 into	 RNA	 and	 DNA,	 and	 to	 the	inhibition	 of	 the	 nucleotide	 synthetic	 enzyme	 thymidylate	 synthase,	 causing	 DNA	 damage	(Curtin,	Harris	and	Aherne,	1991;	Peters	et	al.,	2000).			Chemotherapy	is	still	one	of	the	most	effective	treatments	for	breast	cancer	but	in	general	50	to	 70%	 of	 breast	 cancer	 patients	 experience	 a	 relapse	within	 a	 year,	 usually	 associated	 to	chemoresistance	(Fernández-Cabezudo	et	al.,	2016;	Majidinia	and	Yousefi,	2017).	Thus	there	is	an	urgent	need	to	better	understand	the	mechanisms	underlying	drug	resistance,	in	order	to	improve	the	effectiveness	of	breast	cancer	treatments.			Drug	resistance,	either	intrinsic	or	acquired,	is	a	complex	and	dynamic	process	and	involves	various	 mechanisms:	 increased	 drug	 efflux	 or	 decreased	 drug	 influx,	 lack	 of	 response	 to	cytotoxicity,	topoisomerase	poison,	spiked	expression	of	detoxyfying	proteins,	suppression	of	
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apoptosis,	deregulated	autophagy,	alterations	in	DNA	repair,	in	drug	targets	and	in	signaling	pathways	(Huang,	Li	and	Ren,	2015;	Pan	et	al.,	2016;	Q.	Chen	et	al.,	2016).			Increased	drug	efflux	is	frequently	associated	to	the	up-regulated	expression	of	ATP-binding	cassette	(ABC)	transporters;	among	them,	P-glycoprotein/MDR1/ABCB1	is	the	most	studied,	and	 it	 is	 involved	 in	 the	 efflux	 of	 various	 types	 of	 drug	 (antracyclines,	 antimetabolites,	taxanes,	and	vinca-alkaloids).	ABC	transporters	are	often	responsible	for	causing	resistance	to	totally	unrelated	drugs,	the	so	called	multi-drug	resistance	phenotype	(Yardley,	2013).		Alterations	 in	drug-metabolizing	 enzymes	 can	 affect	 both	 the	 response	 to	 the	drug	 and	 the	drug-related	 toxicity.	 For	 example,	 polymorphisms	 in	 the	 DPYD	 gene,	 encoding	 the	dihydropyrimidine	dehydrogenase	 (controlling	 the	catabolism	of	pyrimidines),	 can	cause	5-Fluorouracil	 severe	 toxicity	 in	various	 types	of	 cancer,	 including	breast	 cancer	 (Gross	et	al.,	2008).	At	the	same	time,	DPYD	repression	by	EZH2	can	increase	drug	sensitivity	to	5-FU,	and	it	 is	associated	with	better	survival	 in	colorectal	as	well	as	gastric	 cancer	 (Wu	et	al.,	2016).	Conflicting	evidence	regarding	the	role	of	DPYD	in	chemoresistance	is	reported	by	Deng	and	colleagues,	 which	 observed	 an	 increased	 resistance	 to	 5-FU	 upon	 increased	 expression	 of	miR-21	and	consequent	downregulation	of	DPYD	expression	(Deng	et	al.,	2014).	Conversely,	cytochrome	 P450	 monooxygenases,	 involved	 in	 the	 catabolism	 of	 most	 drugs,	 like	 several	detoxifying	 enzymes,	 are	 often	 found	 over-expressed	 in	 resistant	 cancer	 cells	 and	 also	 in	breast	 cancer	 stem	 cells	 (Yao	 et	al.,	 2000;	McFadyen,	Melvin	 and	Murray,	 2004;	 Al-Dhfyan,	Alhoshani	and	Korashy,	2017).					Crosstalk	with	the	microenviroment	plays	an	important	role	in	shaping	drug	resistance	and	in	promoting	epithelial	 to	mesenchymal	 transition	 (EMT),	a	phenotype	which	confers	 invasive	properties,	de-differentiation,	reduction	in	adhesion,	increased	proliferation	and	cancer	stem	cells	 features	 (Huang,	 Li	 and	 Ren,	 2015).	 	 The	 presence	 of	 cancer	 stem	 cells	 is	 another	important	 hurdle	 to	 overcome	 drug	 resistance:	 these	 cells	 usually	 display	 high	 expression	levels	 of	ABC	 transporters,	 anti-apoptotic	 proteins,	 are	 largly	 quiescent,	 slowly	 cycling,	 and	rich	of	adehyde	dehydrogenase,	an	enzyme	that	contributes	to	metabolizing	cytotoxic	drugs.		Drug	 resistance	 can	 be	mediated	 by	 different	 pathways:	 increased	 secretion	 of	 insulin-like	growth	 factor,	 p27	 dysregulation,	 EGFR	 up-regulation,	 activation	 of	 Akt,	 decreased	 PTEN	(Huang,	 Li	 and	 Ren,	 2015).	 The	 extreme	 complexity	 of	 known	mechanisms	 responsible	 for	drug	 resistance	 renders	 the	 treatment	 of	 drug	 resistant	 breast	 cancers	 particularly	challenging,	and	underlines	the	importance	of	discovering	and	targeting	novel	key	regulators	of	 drug	 resistance,	 possibly	 able	 to	 control	 simoultaneously	 multiple	 drug	 resistance	pathways.			
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2.1.4	The	role	of	chemotherapy	in	triggering	breast	cancer	resistance		Drug	 resistance	 is	 governed	 by	 a	 complex	 and	 dynamic	 network	 of	 factors,	 therefore	 it	 is	difficult	 to	 target.	 In	 order	 to	 prevent	 chemoresistance	 outbreak,	 acting	 upstream	 could	represent	a	possible	 strategy.	To	 reach	 this	aim,	 it	 is	 essential	 to	understand	which	are	 the	mechanisms	responsible	for	triggering	chemoresistance.		These	 mechanisms	 sometimes	 can	 also	 be	 directly	 activated	 by	 chemotherapy.	 Generally,	chemotherapeutic	 drugs	 generate	 chronic	 inflammation,	 which	 consequently	 promotes	survival,	cancer	proliferation,	angiogenesis,	metastasis	and	chemoresistance	(Vyas,	Laput	and	Vyas,	 2014).	 Inflammation	 can	 also	 play	 tumor	 suppressive	 roles,	 by	 promoting	 the	recognition	 of	 early	 cancer	 progression;	 therefore,	 inflammation	 is	 generally	 considered	 a	double-edged	 sword	 in	 oncology	 (Hagemann,	 Balkwill	 and	 Lawrence,	 2008).	 Typically,	 if	inflammation	becomes	chronic,	it	can	promote	cancer	by	modulating	NFκB	functions.		For	 example,	 Cisplatin,	 Paclitaxel,	 5-Fluorouracil	 and	 Doxorubicin	 can	 activate	 the	 NFκB	pathway,	leading	to	the	activation	of	pro-survival,	inflammatory	genes	and	the	production	of	various	 cytokines	 (Vyas,	 Laput	 and	 Vyas,	 2014).	 The	 NFκB	 pathway	 relies	 on	 a	 family	 of	transcription	 factors,	 able	 to	 bind	 as	 dimers	 to	 small	 response	 element	 (κB	 sites),	characterized	by	the	consensus	sequence	5′	-	GGGRNWYYCC	-	3′	(R:	purine,	Y:	pyrimidine,	W:	A/T,	N:all)	(Hoffmann,	Natoli	and	Ghosh,	2006).	There	are	five	transcription	factors	belonging	to	 the	NFκB	 family:	p50,	p52,	p65	(RelA),	 c-Rel,	and	RelB.	They	are	negatively	regulated	by	IκB	 (Inhibitor	 of	 κB),	 which	 is	 responsible	 for	 their	 sequestration	 into	 the	 cytoplasm	 in	absence	 of	 NFκB-stimulating	 signals.	 Among	 the	 secreted	 cytokines	 activated	 by	 the	 NFκB	transcriptional	 activity,	 IL-6	 plays	 an	 important	 role	 because	 it	 activates	 STAT3	 (Signal	Transducer	 and	Activator	of	Transcription	3),	 a	 transcription	 factor	 itself,	 considered	as	 an	oncogene	 and	 able	 to	 promote	 multi-drug	 resistance	 and	 the	 acquisition	 of	 stem	 cell	properties	(Conze	et	al.,	2001;	Vyas,	Laput	and	Vyas,	2014;	Saha	et	al.,	2016).	NFκB	and	other	pathways	 activated	 by	 chemotherapy	 (such	 as	 PARP,	 Poly	 ADP-Ribose	 polymerase,	 and	MAPK,	Mitogen-Activated	Protein	Kinase,	 pathways)	 can	 also	 induce	TNF-α,	which	 in	 turns	keeps	 inflammation	 continuously	active	 (Vyas,	 Laput	 and	Vyas,	2014).	 Inflammation	 can	be	further	increased	in	presence	of	mutant	p53,	through	its	control	on	DAB2IP,	promoting	NFκB	activation	(Minin	et	al.,	2014).	DAB2IP	is	often	hypermethylated	in	breast	cancer,	where	it	is	responsible	for	the	inhibition	of	EMT	(Dote	et	al.,	2004;	Xie	et	al.,	2010).	
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All	 DNA	 damaging	 drugs	 cause	 genotoxic	 stress,	 which	 activates	 MAPK	 (JNK	 in	 case	 of	cisplatin	 and	 p38	 upon	 5-Fluorouracil),	 which	 ultimately	 promotes	 EMT.	 Doxorubicin	 also	induces	the	production	of	TGF-β,	which	activates	its	related	signaling,	characterized	by	a	bi-phasic	role	in	cancer:	being	an	oncosuppressor	in	normal	tissue	and	in	early	stage	of	cancer	and	an	oncogene	in	advanced	stage	cancer,	where	it	can	promote	EMT,	invasion	and	survival	and	acts	on	the	tumor	stroma	promoting	immunosuppression	and	angiogenesis	(Roberts	and	Wakefield,	2003).	TGF-β	pathway	effects	are	also	largely	affected	by	the	presence	of	mutant	p53	 and	oncogenic	Ras,	which	 together	with	TGF-β	 activated	 Smads	 (Small	Mother	Against	Decapentaplegic,	 the	 effectors	 of	 TGF-β	 signal)	 are	 inhibiting	 TAp63	 tumor	 suppressive	functions	leading	to	migration	and	metastasis	(Adorno	et	al.,	2009).	Doxorubicin	can	further	promote	drug	resistance	by	increasing	the	expression	of	some	drug	efflux	pumps	like	MRP1	in	breast	cancer	(B.	Kim	et	al.,	2015).		Chemotherapy	also	alters	tumor	stroma,	favouring	the	development	of	drug	resistance,	which	can	 be	 also	 mediated	 through	 exosomes	 signalling	 (Deng	 et	 al.,	 2016;	 Wang	 et	 al.,	 2016).	Moreover,	chemotherapy	has	been	demonstrated	to	cause	a	stromal	reaction	that	resulted	in	the	production	of	TNF-α	by	endothelial	 and	other	 stromal	 cells	 and	 therefore	 it	 can	 trigger	survival,	chemoresistance	and	metastatic	spread	of	breast	cancer	cells	through	a	CXCL1/2	and	S100A8/9	axis	(Acharyya	et	al.,	2012).	Furthermore,	chemotherapy	can	provoke	damages	in	mitochondrial	DNA,	 that	 in	 addition	 to	 altered	mitochondrial	 respiration	 can	promote	drug	resistance	 and	metastasis	 (Roesch	 et	al.,	 2013;	 Porporato	 et	al.,	 2014;	 van	Gisbergen	 et	al.,	2015).	 In	 fact,	 genes	 controlling	mitochondrial	 respiration,	 such	 as	 DNAJC15,	 have	 already	reported	roles	in	drug	resistance	(Shridhar	et	al.,	2001;	Fernández-Cabezudo	et	al.,	2016).			
2.1.5	Transcription	factors	can	be	crucial	players	in	triggering	breast	cancer	chemoresistance		To	 simplify	 the	 complexity	 of	 drug	 resistance	 mechanisms	 originated	 by	 chemotherapy	treatment,	 it	 is	 important	 to	 discover	 primary	 triggers,	 linking	 chemotherapy	 to	 drug	resistance.	Transcription	factors,	 thanks	to	their	 large	spectra	of	regulation,	could	represent	critical	 triggers	 activating	 this	 deleterious	 process.	 Furthermore,	 changes	 in	 DNA	 are	observed	very	soon	after	drug	exposure,	and	epigenetic	factors	are	acquiring	more	and	more	importance	in	the	drug	resistance	therapy;	meaning	that	discovering	key	transcription	factors	involved	in	the	epigenetic	control	upon	chemotherapy	could	be	a	promising	strategy	(Yardley,	2013).	 Inflammation	 and	 its	 related	 pathways	 are	 important	modulators	 of	 chemotherapy-
	 8	
derived	chemoresistance;	 thus	 it	could	be	relevant	to	uncover	transcription	 factors	strongly	activated	by	chemotherapy	combined	with	inflammation.			
2.1.6	Thesis’	experimental	background		This	PhD	project	arises	from	a	study	aiming	at	the	analysis	of	genes	synergistically	activated	by	the	combined	treatment	with	Doxorubicin	and	TNF-α,	mimicking	a	condition	often	found	in	 breast	 cancer	 patients	 treated	 with	 chemotherapy	 (as	 explained	 above),	 resulting	 in	 a	signature	 of	 genes	 (Figure	 1A),	 responsible	 for	 increased	migratory	 potential	 of	 the	 breast	cancer-derived	MCF7	cells	(Figure	1B)	(Bisio	et	al.,	2014).	Among	the	highly	synergistically	activated	genes,	a	transcription	factor	member	of	ETS	family	(ETV7)	 came	 to	 my	 attention	 given	 its	 conserved	 induction	 upon	 Doxorubicin	 and	 TNF-α	treatment	observed,	not	only	in	breast	cancer	MCF7	cells,	but	also	in	lung	cancer	cells	(A549)	and	 normal	 endothelial	 cells	 (HUVEC).	 Furthermore,	 this	 gene	 could	 represent	 a	 very	promising	 player	 as	 a	 promoter	 for	 cancer	 cells	 chemoresistance,	 given	 its	 conserved	mechanism	of	activation	upon	a	wide	spectra	of	chemotherapeutic	drugs	and	in	different	cell	types	 (see	 Results	 section,	 Figure1).	 Another	 supporting	 evidence	 for	 the	 choice	 of	 ETV7	could	 by	 simply	 represented	 by	 the	 relevant	 functions	 and	 implications	 of	 the	 other	 ETS	family	 members	 in	 cancer,	 including	 breast	 cancer	 (see	 section	 below),	 and	 the	 still	unexplored	features	of	ETV7	itself.		
	
INTRODUCTION-Figure	 1:	 A)	 Microarray	 data	 heatmap	 of	 top	 29	 synergistically	 up-regulated	 genes	 by	Doxorubicin	 and	 TNF-α	 combined	 treatment	 in	MCF7	 cells.	 B)	 Migration	 analysis	 of	 MCF7	 cells	 treated	with	Doxorubicin,	TNF-α	 and	 combined	 treatment,	 analyzed	by	 real-time	 cell	migration	 xCELLIGENCE.	 (Bisio	et	al.,	2014).	
A B
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2.2	ETS	FAMILY	(“E26-Transformation-Specific”)	
	
2.2.1	ETS	complexity	and	common	features		ETS	is	a	large	family	of	transcription	factors	(27	members)	bearing	important	roles	in	various	physiological	 biological	 processes,	 such	 as	 differentiation,	 development,	 hematopoiesis,	proliferation,	 some	more	 directly	 relevant	 	 to	 cancer,	 such	 as	 apoptosis,	 metastasis,	 tissue	remodelling,	and	angiogenesis.		The	main	 characteristic	 of	 ETS	 family	 proteins	 is	 represented	 by	 the	DNA	binding	 domain,	called	ETS	domain,	composed	of	a	winged	helix-turn-helix	motif,	binding	to	a	purine-rich	core	sequence	 GGAA/T.	 Multiple	 ETS	 factors	 can	 bind	 the	 same	 target	 region,	 resulting	 in	redundancy	and	competition	in	binding.	Flanking	 nucleotides	 and	 interaction	 with	 cofactors	 are	 key	 determinants	 for	 the	 binding	specificity	 of	 each	 ETS	 member.	 Normally,	 there	 is	 less	 redundancy	 among	 ETS	 family	proteins	 in	 genes	 containing	 a	 low	 affinity	 ETS	 binding	 site,	 especially	 in	 enhancer	 region,	where	adjacent	or	nearby	binding	sites	for	other	transcription	factors	contribute	to	specificity	(Hollenhorst,	 McIntosh	 and	 Graves,	 2011).	 Some	 ETS	 can	 act	 as	 transcription	 activators,	others	as	repressor	and	others	can	do	both.	Transcriptional	activity	is	also	controlled	by	the	typical	 autoinhibition	 ability,	 obtained	 by	 regions	 flanking	 the	 ETS	 domain,	 and	 by	 post	translational	 modifications,	 mainly	 phosphorylation	 by	 MAP	 kinases	 (Hagman	 and	Grosschedl,	1992;	Wasylyk,	Kerckaert	and	Wasylyk,	1992;	Wasylyk,	Hagman	and	Gutierrez-hartmann,	 1998).	 	 Another	 common	 domain	 in	 ETS	 family	 proteins	 is	 the	 Pointed	 domain	(PNT)	responsible	for	protein-protein	interaction	and	oligomerization.	ETS	 family	 can	 be	 divided	 in	 4	 subgroups	 according	 to	 binding	 sequence	 specificity,	 and	 a	schematic	view	of	this	subgroups	is	represented	in	Figure	2	(Wei	et	al.,	2010).		
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INTRODUCTION-Figure	2:	Adapted	from	the	work	of	Wei	and	colleagues	(Wei	et	al.,	2010).	ETS	family		is	divided	into	4	groups	according	to	sequence	binding	specificity.	In	blue	is	depicted	the	ETS	domain,	in	green	the	PNT	domain,	in	grey	the	Proline-Rich	domain			
2.2.2	ETS	role	in	breast	cancer		The	 involvement	of	ETS	 in	breast	cancer	can	be	seen	as	a	complex	and	dynamic	network	of	transcriptional	 regulation;	which	 can	 be	 subtype-specific,	 time	 and	 cancer	 stage-dependent	and	sometimes	even	contradictory	(Turner,	Findlay,	et	al.,	2007).		SPDEF,	a	prostate-derived	ETS	factor	with	known	roles	in	breast	cancer	biology,	represents	a	great	 example	 both	 for	 the	 ETS	 family	 complexity	 and	 its	 contradictory	 network	 in	 breast	cancer.	 SPDEF	 was	 found	 over-expressed	 in	 breast	 cancer	 tissues,	 where	 it	 promotes	migration	and	invasion	(Ghadersohi	and	Sood,	2001;	Gunawardane	et	al.,	2005).		Conversely,	SPDEF	loss	was	observed	in	invasive	breast	cancer,	where	it	negatively	controls	breast	cancer	invasion	by	both	 increasing	p21	expression	 (one	of	 the	most	 important	protein	 involved	 in	cell	 cycle	 arrest)	 	 and	 repressing	 urokinase	 plasminogen	 activator	 (uPA)	 (Feldman	 et	 al.,	2003;	 Turner,	Moussa,	 et	al.,	 2007).	 Urokinase	 plasminogen	 activator	 is	 directly	 associated	with	 increased	 invasion	and	poor	survival,	and	 the	same	ETS	binding	site,	 can	be	bound	by	another	ETS	factor,	ETS-1,	 	but	resulting	in	transcriptional	activation	(Turner,	Findlay,	et	al.,	2007).	ETS-1	itself	is	not	devoid	of	contradictory	actions,	as	it	is	found	upregulated	in	breast	
ETS domain
PNT domain
Proline-Rich domain
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cancer	tissues	and	associated	to	metastasis	by	some	groups	(Buggy	et	al.	2004),	but	it	is	also	reported	 to	 be	 downregulated	with	 respect	 to	 normal	mammary	 epithelia	 by	 other	 groups	(He	et	al.,	2007).		Similarly,	ELF5	roles	in	breast	cancer	are	conflicting	and	strictly	dependent	on	the	specific	subtype.	In	ER	negative	breast	cancers,	ELF5	has	a	tumor	suppressor	role,	by	directly	 repressing	 SNAI2	 and	 the	 EMT	 process	 (Chakrabarti	 et	 al.,	 2012).	 Conversely,	 	 in	luminal	 A	 breast	 cancers,	 tumor	 ELF5	 is	 implicated	 in	 endocrine	 therapy	 resistance	 and	promotes	 metastasis	 to	 the	 lung	 by	 directly	 cooperating	 with	 the	 innate	 immune	 system	(Kalyuga	et	al.,	2012;	Gallego-Ortega	et	al.,	2015).		Similarly	to	SPDEF,	other	ETS	are	important	players	in	both	prostate	and	breast	cancer,	two	hormone-driven	 type	 of	 cancers	 that	 can	 be	 considered	 ”more	 similar	 than	 different”	(Risbridger	et	al.,	2010).	ESE3/EHF	negatively	controls	EMT	and	stemness	acquisition	in	prostate	cancer	(Cangemi	et	
al.,	2008;	Albino	et	al.,	2012).	The	stemness	control	exerted	by	ESE3/EHF	was	first	found	to	involve	the	Lin28/let7	axis	(Albino,	Civenni,	Dallavalle,	et	al.,	2016).	Later	ESE3/EHF	was	also	decribed	as	regulator	of	STAT3	pathway	either	by	direct	repression	of	IL-6	promoter	(Albino,	Civenni,	 Rossi,	 et	 al.,	 2016)	 or	 by	 controling	 the	 miR-424/E3	 ubiquitin	 ligase	 COP1	 axis	responsible	 for	STAT3	degradation	 (Dallavalle	et	al.,	 2016).	 	These	 studies	 suggested	 that	a	similar	 mechanism	 could	 possibily	 be	 present	 in	 breast	 cancer:	 IL-6	 is	 often	 found	 up-regulated	in	breast	cancer	and	directly	linked	to	the	acquisition	of	stemness;	miR-424	is	up-regulated	 in	 cancer;	 ubiquitin	 ligase	 COP1	positively	 correlates	with	ESE3/EHF	 expression;	and	Lin28/let7	axis	is	a	known	stemness	controller	in	breast	cancer	(Albino,	Civenni,	Rossi,	et	
al.,	 2016;	 Dallavalle	 et	 al.,	 2016).	 Another	 evidence,	 yet	 unpublished	 in	 scientific	 journal,	comes	from	a	dissertation	thesis	data	reporting	a	down-regulation	of	EHF/ESE3	in	aggressive	breast	cancer	cells,	which	correlates	with	poor	prognosis	(Pferdehirt,	2015)	.		Another	very	good	example	of	common	ETS	in	breast	and	prostate	cancer,	is	ESE1/ELF3,	the	first	ETS	found	to	be	 linked	to	breast	cancer	(Chang	et	al.,	1997).	ESE1/ELF3	can	transform	mammary	 epithelial	 cells	 and	 controls	 ERα	 transcriptional	 activity	 (Prescott	 et	 al.,	 2004;	Gajulapalli	et	al.,	2016).	Similarly,	in	prostate	cancer,	ESE1/ELF3	regulates	NFκB	and	EZH2,	it	controls	tumor	growth	and	metastasis	and	correlates	with	adverse	prognosis	(Kunderfranco	
et	al.,	2010;	Longoni	et	al.,	2013;	Semenchenko	et	al.,	2016).			A	comprehensive	analysis	of	all	ETS	factors	expression	in	breast	cancer	conducted	by	He	and	co-workers,	 confirmed	up-regulation	of	 some	already	known	ETS	 factors	 involved	 in	breast	cancer	biology,	such	as	SPDEF,	ELF3	and	showed	increased	expression	for	a	relatively	novel	
	 12	
one,	 Tel2/ETV7(He	 et	 al.,	 2007).	 ETV7	 showed	 a	 peculiar	 expression	 in	 breast	 cancer	 cell	lines:	it	was	expressed	at	high	level	in	3	breast	cancer	cell	lines	(MDA-MB-468,	T47D,	BT474)	compared	 to	 the	 non-transformed	 MCF10a	 taken	 as	 normal	 counterpart,	 it	 was	 slightly	expressed	 in	 MDA-MB-231,	 and	 down-regulated	 in	 SkBr3,	 ZR75.1,	 and	 MB453	 (He	 et	 al.,	2007).	 No	 clear-cut	 connection	 between	 ETV7	 expression	 and	 subtypes	 was	 observable	 in	cancer	 cell	 lines	 studies,	 but	 when	 comparing	 breast	 cancer	 tissue	with	 normal	mammary	tissue,	 the	 increase	 in	 the	 former	was	 consistently	 observed	 (He	 et	 al.,	 2007)	 (Figure	 3A).		Later,	RNA-seq	experiments	confirmed	the	upregulation	of	ETV7	in	breast	cancer,	especially	in	the	basal	subtype	(Piggin	et	al.,	2016)	(Figure	3B).	Publicly	available	data	from	the	Metabric	study	 confirmed	 the	 up-regulation	 of	 this	 factor	 in	 breast	 cancer	 tissues,	 which	 positively	correlated	with	increasing	with	histopathological	grade	(Figure	3C-D).		Taking	advantage	from	these	observations	and	given	the	poorly	characterized	nature	of	this	ETS	factor,	this	project	aims	at	better	understanding	the	role	of	ETV7	in	breast	cancer.		
	
INTRODUCTION-Figure	3:	A)	ETV7	expression	in	breast	cancer	(depicted	as	circles)	compared	with	normal	mammary	tissue	(triangles),	taken	from	He	and	collegues	(He	et	al.,	2007).	B)	ETV7	expression	in	different	
A B
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cancer	subtypes,	adapted	from	Piggin	and	co-workers	(Piggin	et	al.,	2016).	C-D)	ETV7	expression	in	Metabric	dataset	relative	to	breast	cancer	histological	grade	(1	to	3,	with	a	numeric	increasing	severity)	(C)	and	breast	cancer	subtypes	(according	to	molecular	classification)	(D).			
2.3	ETV7/TEL2		
	
2.3.1	ETV7	domain	organization		ETV7	 discovery	 was	 reported	 simultaneously	 by	 three	 different	 groups	 as	 a	 novel	 ETS	member	closely	related	to	ETV6/TEL	(Poirel	et	al.,	2000;	Potter	et	al.,	2000;	Gu	et	al.,	2001).	ETV7	 is	 a	 transcriptional	 repressor	 composed	 of	 a	 Pointed	 domain	 (PNT)	 at	 the	 amino-terminal,	and	an	ETS	domain	at	the	carboxy-terminal:	these	are	the	regions	where	ETV7	and	ETV6	share	the	highest	aminoacid	homology	(Poirel	et	al.,	2000;	Potter	et	al.,	2000;	Gu	et	al.,	2001).	 PNT	 domain	 is	 required	 for	 protein-protein	 interaction	 and	mediates	 both	 the	 self-association	of	ETV7	with	itself	and	with	ETV6.	ETS	domain	and	PNT	domain	are	necessary	for	an	efficient	 transcriptional	 repression,	 thus	suggesting	 that	ETV7-mediated	repression	 is	an	active	 process	 and	 requires	 co-repressors	 (Poirel	 et	al.,	 2000;	 Potter	 et	al.,	 2000;	 Gu	 et	al.,	2001).	ETV6	 and	 ETV7	 are	 very	 different	 in	 their	 central	 region,	 ETV7	 has	 a	 PEST	 sequence	responsible	for	its	rapid	intracellular	proteolysis	(Gu	et	al.,	2001),	whereas	ETV6	contains	the	interaction	domain	with	epigenetic	 factors	such	as	HDAC3	(Chakrabarti	and	Nucifora,	1999;	Lopez	 et	 al.,	 1999).	 They	 also	 show	 different	 expression	 patterns	 (ETV6	 is	 abundant	 and	ubiquitous,	ETV7	is	expressed	at	low	level	and	in	specific	tissues)	(Potter	et	al.,	2000;	Gu	et	al.,	2001)	and	display	opposing	biological	roles:	ETV7	exerts	a	pro-tumorigenic	role	and	ETV6	a	tumor	 suppressive	 one	 (Van	Rompaey	 et	al.,	 1999;	 Irvin	 et	al.,	 2003;	 Kawagoe	 et	al.,	 2004;	Cardone	et	al.,	2005).			
2.3.2	ETV7	isoforms		ETV7	is	present	in	6	different	splice	isoforms	(ETV7-a,	b,	c,	d,	e,	 f)	with	different	expression	patterns	 (Figure	 4).	 All	 variants	 comprise	 the	 first	 exon	 containing	 the	 5’UTR;	 ETV7-a	 and	ETV7-b	are	composed	of	8	exons,	ETV7-a	has	an	alternative	splice	variant	of	exon	3	(exon3a)	which	interrupts	the	open	reading	frame;	ETV7-c	doesn’t	have	exon	2,	ETV7-d	is	missing	exon	3,	ETV7-e	and	–f	lack	exon	8	but	have	exon	9	and	ETV7-f	also	lacks	exon	3	(Gu	et	al.,	2001).	
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The	exon	9	present	 in	–e	and	–f	can	gives	additional	unknown	biological	 roles	 to	 these	 two	isoforms,	encoding	a	leucine/isoleucine-rich	region.	Exons	2,3,4	are	encoding	the	PNT	domain,	whereas	exons	6,7,8	are	required	for	ETS	domain.		ETV7-b	is	the	principal	isoform,	the	most	closely	related	to	ETV6,	and	encodes	the	full-length	protein	of	341	aa	 corresponding	 to	39	KDa	 (Gu	et	al.,	 2001).	All	biological	data	 reported	 in	next	sections	and	this	thesis	project	are	referring	to	this	isoform.			ETV7-d	 is	 the	most	 abundant	 isoform	 in	 human	 tissues,	 whereas	 ETV7-a	 and	 -c	 show	 the	lowest	expression	and	only	in	specific	tissues.	Variants	with	exon	8	are	mostly	expressed	in	placenta,	lung,	liver,	pancreas,	peripheral	blood	leukocytes,	and	fetal	lung,	whereas	isoforms	–e	and	–f	are	mostly	expressed	in	placenta,	spleen,	prostate,	thymus,	and	ovary.	ETV7-b	acts	as	a	 transcriptional	repressor,	ETV7-a	slightly	enhanced	transcription	probably	by	binding	to	a	co-repressor	and	preventing	its	binding	to	other	transcription	factors	and	has	low	 level	associated	to	DNA.	ETV7-c	 isoform	is	very	stable,	can	bind	to	DNA	but	 it	does	not	affect	 transcription.	When	analyzed	 in	western	blot,	 all	 isoforms	show	an	additional	22KDa	protein,	probably	due	to	the	presence	of	an	additional	ETV7	protein	isoform	translated	from	a	internal	translation	start	site	located	upstream	of	the	ETS	domain	(Gu	et	al.,	2001).	ETV7	mutants	 studied	 in	vitro	 lacking	 either	 the	 PNT	 or	 the	 ETS	 domain	were	 reported	 to	exert	 an	 inhibitory	 role	 on	 the	 ETV7	 transcriptional	 repression	 and	 are	 responsible	 for	increasing	 the	 differentiation	 and	 the	 growth	 of	 U937	 human	 myeloid	 leukemia	 cells;	however,	 in	 vivo	 ETV7-c	 isoform	 (missing	 part	 of	 PNT	 domain)	 is	 down-regulated	 during	differentiation	 similar	 to	 ETV7-b	 (with	 an	 intact	 PNT),	 therefore	 probably	 the	 dominant	negative	effects	of	the	ETV7-c	seen	in	vitro	is	not	relevant	in	vivo	(Kawagoe	et	al.,	2004).		
	
INTRODUCTION-Figure	4:	Genomic	organization	of	the	ETV7	gene	and	exon	configuration	of	the	six	ETV7	splice	isoforms.	Exons	are	represented	by	boxes	and	introns	by	connecting	lines;	their	length	is	reported	above	the	introns	(in	kb)	and	below	exons	(in	bp).	Adapted	from	the	work	of	Gu	and	colleagues	(Gu	et	al.,	2001).	
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2.3.3	ETV7	expression	regulation		ETV7	is	deleted	in	most	rodents,	but	found	in	all	other	vertebrates;	it	localizes	to	the	nucleus	and	 it	 is	 generally	 expressed	 at	 low	 level	 in	 tissues	 and	 cells	 (Potter	 et	al.,	 2000;	 Gu	 et	al.,	2001;	Quintana	 et	al.,	 2014).	 ETV7	mRNA	 is	mostly	 found	 in	 placenta,	 liver,	 prostate,	 lung,	ovary,	 spleen,	 thymus,	 hematopoietic	 system	 and	 in	 fetal	 lung	 and	 kidney;	 in	 cell	 lines	 in	culture	 it	 is	 highly	 expressed	 in	 epithelial	 A431	 squamous	 carcinoma	 cells	 and	 in	 non-epithelial	 U937	 monocytic	 cells,	 synovial	 fibroblasts,	 and	 primary	 human	 chondrocytes	(Potter	 et	 al.,	 2000;	 Gu	 et	 al.,	 2001).	 In	 vitro	 translation	 showed	 two	 in	 frame	 alternative	translation	 start	 sites	 (at	 position	 1	 and	 17)	 which	 results	 in	 two	 proteins	 with	 similar	molecular	weight	(Poirel	et	al.,	2000;	Gu	et	al.,	2001).	Upstream	 the	 transcriptional	 start	 site,	 an	 initiatior	 Inr	 element	 is	 found	with	 overlapping	binding	sites	for	ETS	and	E2F	factors	and	further	upstream	there	are	also	other	additional	ETS	binding	sites	and	binding	regions	for	NFκB,	AP1,	Ikaros,	and	transcription	factors	having	the	HLH	DNA	binding	domain	(Gu	et	al.,	2001).		A	strong	 induction	of	ETV7	 transcription	upon	Doxorubicin	and	TNFα	 combined	 treatment,	and	 the	 associated	 p53	 and	 p65	 transcriptional	 control	 are	 reported	 in	 this	 thesis	 and	 the	relative	publication	(Bisio	et	al.,	2014).		Interferon	alfa	is	another	known	inducer	of	ETV7	expression	through	the	JAK-STAT	pathway	(Park	et	al.,	2013;	Rempel	et	al.,	2013;	Contreras	et	al.,	2015;	Ignatius	Irudayam	et	al.,	2015).	Relatively	recently,	interferon	stimulated	genes	have	gained	interest	in	breast	cancer	research	thanks	 to	 their	 predictive	 role	 in	 drug	 resistance,	 experimentally	 demonstrated	 for	 STAT1,	ISG15,	 and	 IFIT1	 (Weichselbaum	 et	 al.,	 2008).	 This	 thesis	 project,	 extended	 those	observations	to	ETV7.	Not	surprisingly,	being	an	interferon	stimulated	gene,	ETV7	is	activated	by	 	 infection,	observed	for	Hepatitis	C	(Ignatius	Irudayam	et	al.,	2015),	HIV-1	(Rempel	et	al.,	2013);	 in	 fact	 ETV7	 induction	has	been	proposed	 in	 a	 patented	 assay	 for	 detecting	 specific	RSV	infection	(Ginsburg	et	al.,	2014),	but	its	role	in	viral	infection	is	still	unknown.		ETV7	is	probably	regulated	by	phosphorylation	like	most	ETS	factors,	and	contains	putative	phosphorylation	 sites	 for	 AKT,	 p90rsk,	 Protein	 Kinase	 C,	 Casein	 Kinase	 2,	 CDC2	 Kinase,	Tyrosine	Kinase,	and	for	some	MAP	kinases	suc	as	ERK,	JNK,	and	p38	(Gu	et	al.,	2001)	.	One	MAPK	site	localizes	in	a	small	region	upstream	the	PNT	domain	(37	aa	upstream),	which	is	 highly	 conserved	 between	 ETV6	 and	 ETV7	 (Potter	 et	 al.,	 2000;	 Gu	 et	 al.,	 2001).	
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Phosphorylation	by	MAPK	is	generally	very	important	for	ETS	factors	transcriptional	activity	(Wasylyk,	 Hagman	 and	 Gutierrez-hartmann,	 1998).	 ERK-mediated	 phosphorylation	 can	positively	regulate	trascription	(as	for	ETS1	ans	ETS2)	or	negatively	(as	for	ETV6)	and	it	can	also	 convert	 a	 repressor	 into	 an	activator	of	 transcription	 (Gu	et	al.,	 2001;	Vivekanand	and	Rebay,	 2012).	 Phosphorylation	 could	 possibly	 represent	 a	 relevant	 mechanism	 for	 ETV7	regulation,	given	that	among	all	the	ETS	factors	ETV7	ranked	sixth	for	the	presence	of	MAPK	interaction	 motifs	 and	 displayed	 the	 highest	 affinity	 for	 p38α	 followed	 by	 JNK1	 (Selvaraj,	Kedage	and	Hollenhorst,	2015).		
	
	
	
2.3.4	ETV7	consensus,	targets	and	mechanism	of	repression	
	
2.3.4A	ETV7	consensus	DNA	binding	site		ETV7	consensus	sequence	in	vitro	was	first	reported	as	identical	to	the	ETV6	one	(Potter	et	al.,	2000);	 later	 on	 more	 specificity	 was	 added	 (Gu	 et	 al.,	 2001),	 and	 the	 latest	 one	 was	determined	 by	microwell-based	 transcription	 factor-DNA-binding	 assays	 (Wei	 et	 al.,	 2010)	(Figure	5).	This	project	reports	the	first	in	vivo	consensus	sequence	for	ETV7.			
	
INTRODUCTION-Figure	5:	ETV7	in	vitro	consensus	sequences,	reported	in	chronological	order	respect	to	their	literature	evidence;	consensus	sequences	refer	to	the	studies	of	Potter	and	co-workers	(Potter	et	al.	2000,	sequence	1),	to	the	work	of	Gu	and	colleagues	(Gu	et	al.	2001,	sequence	2),	and	to	the	analysis	of	Wei	and	colleagues(Wei	et	al.	2010,	sequence	3).			
2.3.4B	ETV7	targets		Low-throughput	 microarray	 analysis	 on	 MG-63	 osteosarcoma	 cells	 ectopically	 transfected	with	 an	 ETV7	 expression	 vector	 showed	 only	 a	 few	 genes	 changing	 in	 a	 significant	 way,	among	 them	 Thymosin	 β-10	 was	 up-regulated	 around	 3	 fold,	 BMP-6	 was	 down-regulated	5/10	fold,	RARα	was	repressed	5	fold	and	interleukin-6	was	repressed	2	fold;	but	no	binding	
1.
2.
3.
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analysis	was	performed,	thus	some	of	them	the	could	represent	also	indirect	targets	(Gu	et	al.,	2001).	Therefore,	investigation	and	validation	of	ETV7	targets	represents	a	totally	unexplored	research	 area,	 which	 can	 provide	 promising	 information	 also	 regarding	 the	 few	 ETV7	biological	roles	reported	so	far.				
2.3.4C	ETV7-mediated	repression	mechanism			ETV7	acts	as	a	transcriptional	repressor	 in	vitro	and	the	level	of	ETV7	expression	correlates	with	 the	 degree	 of	 down-regulation	 (Gu	 et	 al.,	 2001).	 ETV7	 can	 bind	 to	 DNA	 as	 homo-oligomers,	forming	cooperative	and	insoluble	polymers		(Kar	and	Gutierrez-Hartmann,	2013;	Selvaraj,	Kedage	and	Hollenhorst,	2015).	Similarly	 to	ETV6,	both	PNT	and	ETS	domains	are	required	for	an	efficacious	transcriptional	repression	(Gu	et	al.,	2001)	.		ETV7	 central	 domain	 	 (aa	 113-210)	 was	 proved	 to	 have	 important	 roles	 for	 the	 active	repression	of	transcription,	therefore	suggesting	that	probably	some	corepressors	could	bind	to	 this	 region	 (Poirel	et	al.,	 2000).	Also	 the	ETV6	central	 region	provides	 for	 the	binding	 to	many	co-repressors;	however,	ETV7	and	ETV6	are	very	different	in	their	central	region	,	thus	probably	they	are	not	sharing	the	same	interactors	within	this	region	(Cardone	et	al.,	2005).	Nevertheless,	 some	corepressors	 like	Sin3a	bind	ETV6	 in	 the	Pointed	domain,	which	 is	also	highly	conserved	in	ETV7	(Lopez	et	al.,	1999),	therefore	they	could	be	account	also	as	ETV7	cofactors.	 It	 could	 also	 be	 that	 ETV7	 through	 its	 PNT	 could	 interact	 with	 other	 proteins	containing	SAM	domain	 like	 the	Polycomb	group	of	proteins	 (Gu	et	al.,	 2001),	 that	 are	 also	involved	 in	 transcriptional	 repression.	 ETV7	 can	 also	 block	 the	 transcriptional	 activity	 of	ETS1,	ETS2	and	ETV6,	by	direct	binding	via	its	PNT	domain;	specifically,	the	isoform	ETV7-a	(made	of	only	the	PNT	domain)	was	the	most	effective	in	antagonizing	the	repressive	activity	of	ETS1,	ETS2	and	ETV6	(Vivekanand	and	Rebay,	2012).				
2.3.5	ETV7	oncogenic	role	in	cancer		Insights	of	ETV7’s	role	as	an	oncogene	were	present	already	from	its	discovery:	 its	genomic	location	at	6q21.3	was	frequently	rearranged	in	different	types	of	cancer	(Poirel	et	al.,	2000;	Gu	et	al.,	2001;	La	Starza	et	al.,	2006)	and	its	sequence	was	found	within	the	cDNA	library	of	various	cancer	tissues,	such	as	colon	cancer,	adenocarcinoma,	lung	carcinoma,	B-cell	chronic	
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lymphocytic	 leukemia,	 adrenal	 adenoma,	 germ	 cell	 tumor,	 ovarian	 and	 endometrial	cancer(Potter	et	al.,	2000;	Gu	et	al.,	2001).	More	recently	an	increased	expression	of	ETV7	was	reported	also	in	primary	human	leukemia	samples,	pediatric	B-ALL,	lung	cancer,	rectal	cancer	and	 in	 hepatocellular	 carcinoma	 (Kawagoe	 et	 al.,	 2004;	 Cardone	 et	 al.,	 2005;	 Matos	 et	 al.,	2009).	ETV7	definition	 as	 an	oncogene	was	based	on	 correlative	data	until	 the	 report	 of	 its	 direct		involvement	 in	 cellular	 transformation	 (Kawagoe	 et	 al.,	 2004).	 In	 particular	 it	 was	demonstrated	 that	 over-expression	 of	 ETV7	 can	 promote	 the	 Ras-driven	 cellular	transformation	 by	 blocking	 the	 tumor	 suppressing	 action	 of	 ETV6	 in	 NIH3T3-UCLA;	 for	exerting	this	action	both	PNT	and	DNA	binding	domain	are	required	(Kawagoe	et	al.,	2004).	The	ability	of	ETV7	to	bind	to	ETV6	was	already	known	from	its	discovery	(Poirel	et	al.,	2000;	Potter	et	al.,	2000)	but	the	functional	relevance	of	this	binding	was	not	known.	Another	effect	of	 ETV7	 binding	 to	 ETV6	 is	 the	 inhibition	 of	 ETV6-mediated	 transcription,	 which	 was	specifically	 reported	 for	 the	 ETV7/Tel2a	 isoform,	 also	 able	 to	 block	 ETS1	 and	 ETS2	transcriptional	output	(Vivekanand	and	Rebay,	2012).		Another	direct	involvement	of	ETV7	in	tumorigenesis	refers	to	the	ability	of	ETV7	to	interact	with	 Myc	 and	 promote	 lymphomagenesis	 (Cardone	 et	 al.,	 2005).	 Bone	 marrow	 cells	 over-expressing	 ETV7	 or	 an	 empty	 control	 were	 transplanted	 in	 a	 transgenic	 mouse	 model	 of	Burkitt	 lymphoma	 (Eµ-Myc)	 and	 it	 was	 observed	 that	 ETV7	 over-expressing	 cells	 were	growing	 quicker	 and	 were	 developing	 B-cell	 lymphoma	 faster	 than	 the	 empty	 control	(Cardone	et	al.,	2005).	Specifically,	ETV7	accelerated	the	lymphomagenesis	by	decreasing	the	apoptosis	 driven	 by	 Myc	 over-expression	 and	 by	 increasing	 the	 cell	 growth;	 both	 the	 ETS	domain	and	the	PNT	domain	were	essential	for	mediating	these	roles	(Cardone	et	al.,	2005).	A	common	 characteristic	 of	 ETV7-	 Eµ-Myc-derived	 lymphomas	 was	 the	 inactivation	 of	 p53	pathway	by	mutations	or	by	Mdm2	over-expression	and	the	consequent	Arf	protein	increase,	which	suggests	a	possible	negative	interaction	between	p53	and	ETV7	(Cardone	et	al.,	2005).	ETV7	expression	is	often	found	up-regulated	in	pediatric	B-ALL	with	increased	MYC	or	MYCN	expression,	 indicating	 that	 the	 cooperation	between	ETV7	 and	MYC	 is	 recapitulated	 also	 in	clinical	 data	 (Cardone	 et	al.,	 2005).	 In	vitro	 it	was	 seen	 that	 ETV7	 over-expression	 in	 bone	marrow	cells	 from	Eµ-Myc	 transgenic	mice	 led	 to	 increased	proliferation	 (corresponding	 to	increased	 expression	 of	 c-Myc	 and	 E2f1),	 decreasead	 apoptosis	 (corresponding	 to	 Bcl-2	upregulation)	 and	 immortalization	 (corresponding	 to	 Arf	 loss)	 (Cardone	 et	 al.,	 2005).	Decreased	apoptotic	levels	and	associated	Bcl2	protein	up-regulation	was	observed	also	after	
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ETV7	over-expression	 in	bone	marrow	derived	Lin-	hematopoietic	 stem	cells	 (Carella	et	al.,	2006).	A	microarray	analysis	in	these	cells	showed	an	increased	expression	for	pro-apoptotic	genes	 (Trp53inp1,	 Stk17b,	 Dapk2,	 Bmf)	 and	 c-Kit,	 and	 down-regulation	 of	 antiproliferative	genes	(Btg1,	Btg2,	Cdkn1B,	Rb1cc1)	and	gene	associated	with	differentiation	(cFes,	Btg1,	Btg2,	Tgfbr2)	 (Carella	 et	 al.,	 2006).	 ETV7	 over-expression	 in	 bone	 marrow	 derived	 Lin-	hematopoietic	 stem	 cells	 provided	 a	 growth	 advantage	 especially	 when	 interacting	 with	stromal	 cells	 and	 it	 caused	a	myeloproliferative	disease	 characterized	by	an	 increase	 in	 the	population	of	early	myeloid	progenitor	cells	and	a	long-latency	period,	suggesting	that	ETV7	overexpression	 requires	 additional	 mutations	 for	 causing	 leukemia	 (Carella	 et	 al.,	 2006).		Furthermore,	over-expression	of	ETV7	in	hematopoietic	cell	was	also	indirectly	stimulating	T-cell	lymphomagenesis	(Carella	et	al.,	2006).			According	 to	 TCGA	 and	 METABRIC	 databases,	 only	 1%	 of	 breast	 cancers	 present	 an	amplification	of	the	ETV7	region	and	according	to	TCGA	only	a	0.3%	frequency	of	mutation.	The	 low	mutation	 frequency	does	not	exclude	ETV7’s	oncogenic	potential,	 and	 in	 fact	ETV7	was	 listed	 among	 	 genes	 that	 are	 associated	with	 low	mutation	 frequency	 but	 have	 a	 high	normalized	 mutation	 burden	 in	 their	 protein	 interaction	 network,	 and	 could	 therefore	represents	 important	 cancer	 driver	 genes	 (Horn	 et	 al.,	 2015).	 	 Taken	 collectively,	 a	 better	understanding	 of	 ETV7	 role	 in	 cancer	 and	 ETV7	 targets	 identification	 and	 validation,	 can	represent	a	novel	and	promising	research	aim.			
	
	
2.3.6	ETV7	role	in	differentiation		Other	 indirect	 data	 supporting	 the	 oncogenic	 function	 of	 ETV7	 refers	 to	 its	 ability	 to	 block	differentiation,	 specifically	 observed	 in	monocytic	 differentiation	 driven	 by	 vitamin	D3	 and	12-O-tetradecanoylphorbol	 13-acetate	 (TPA)	 in	 U937	 and	 HL60	 human	 myeloid	 leukemia	cells	 (Kawagoe	 et	 al.,	 2004).	 The	 ETV7	 negative	 role	 on	monocytic	 differentiation	was	 not	driven	by	an	 inhibitory	binding	to	ETV6,	and	both	PNT	and	ETS	domains	were	essential	 for	this	function	(Kawagoe	et	al.,	2004).		The	 role	 in	 differentiation	 can	 also	 be	 indirectly	 inferred	 from	 the	 effects	 of	 ETV7	 over-expression	 causing	 the	 repression	 of	 the	 differentiation	 inducers	 retinoic	 acid	 receptor	 α	(RARα)	 and	 Bone	 Morphogenetic	 Protein-6	 (BMP-6)	 (Gu	 et	 al.,	 2001).	 Furthermore,	 ETV7	
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expression	 increases	 during	 differentiation	 of	 K562	 human	 chronic	myeloid	 leukemia	 cells	into	megakaryocyte	by	TPA	(Sakurai	et	al.,	2003).			By	studying	ETV7	physiological	role	 in	zebrafish	 it	was	discovered	an	 important	role	 in	red	blood	 cell	 differentiation:	 ETV7	 positively	 regulates	 the	 Lanosterol	 Synthase	 (LSS)	 gene,	responsible	 for	 the	 cholesterol	 synthesis,	 essential	 for	 normal	 red	 blood	 cell	 development	(Quintana	et	al.,	 2014).	Given	 that	 the	positive	 regulation	on	 the	LSS	gene	comes	only	 from	over-expression	and	silencing	studies,	it	is	still	not	known	if	ETV7	contrarily	from	its	reported	repressive	 role,	 can,	 in	 this	 case,	 activate	 the	 transcription	 of	 this	 gene,	 or	 by	 repressing	negative	 regulators	 of	 LSS,	 promotes	 its	 activation	 indirectly.	 	 It	 has	 been	 postulated	 that	ETV7	can	have	a	differentiation	role	also	in	platelets	(Schick	et	al.,	2016).				
2.3.7	ETV7	tumor	suppressor	roles		Many	 data	 are	 supporting	 the	 oncogenic	 role	 of	 ETV7,	 nevertheless,	 in	 nasopharyngeal	carcinoma	 ETV7	 can	 directly	 inhibit	 migration	 and	 invasion	 of	 cancer	 cells	 by	 repressing	SERPINE1	gene	expression	(Sang	et	al.,	2015).		Similarly,	a	decreased	expression	of	ETV7	was	observed	 in	5-Fluoruracil-	and	cisplatin-resistant	cancers	(Maeda	et	al.,	2014).	 Indirect	data	on	a	possible	tumor	suppressor	role	of	ETV7	in	prostate	cancer	comes	from	the	evidence	of	its	down-regulation	 in	 the	 stroma	 of	 peripheral	 zone	 (more	 prone	 to	 develop	 cancer)	 with	respect	to	the	transitional	zone	(Shaikhibrahim	et	al.,	2012).	This	contradictory	evidences	suggest	a	cell	type-	and	time-dependent	effect	of	ETV7	in	cancer	cells	 and	 in	 cancer	progression,	probably	 influenced	by	different	ETV7	 interaction	partners	present	in	different	cells	and	at	a	different	time,	an	observation	that	is	in	line	with	the	role	of	other	ETS	factors	in	breast	cancer.			This	 project	 reports	 for	 the	 first	 time	 a	 role	 for	 ETV7	 in	 breast	 cancer,	 in	 particular	 in	promoting	drug	 resistance	 to	Doxorubicin	 and	5-Fluorouracil.	 In	particular,	ETV7-mediated	repression	 of	 the	 co-chaperone	 DNAJC15	 is	 reported	 as	 a	mechanism	 responsible	 for	 drug	resistance.							
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2.4	DNAJ	FAMILY	
	HSP40/DNAJ	 is	a	very	 large	(49	members)	and	heterogenous	 family	of	Heat	Shock	Proteins	(HSP).	Its	main	function	is	co-chaperoning	HSP70,	but	recent	evidence	also	supports	a	role	for	DNAJ	 independent	 from	HSP70,	 possibly	 acting	with	 other	 chaperones	 (Sterrenberg,	Blatch	and	 Edkins,	 2011).	 Chaperones	 are	 key	 regulators	 of	 protein	 homeostasis.	 Both	 in	physiological	 and	 stressful	 conditions;	 they	 assist	 protein	 folding,	 stability,	 transport,	 and	interactions.	Co-chaperones	stimulate	the	chaperones,	regulate	the	client	specificity	and	assist	in	the	formation	of	multi-chaperone	complexes.	DNAJ	 family	can	be	divided	 into	3	subgroups	according	 to	 the	domain	organization:	DNAJA,	DNAJB,	and	DNAJC.	The	typical	feature	of	DNAJ	family	is	the	J-domain	of	70	aa	(containing	a	characteristic	 tripeptide),	 which	 is	 required	 for	 the	 stimulation	 of	 the	 ATPase	 activity	 of	HSP70.	 Some	 DNAJ,	 especially	 members	 of	 the	 DNAJC	 subgroup,	 can	 also	 have	 functions	independently	from	the	J-domain	(Sterrenberg,	Blatch	and	Edkins,	2011).		
2.4.1	DNAJ	role	in	breast	cancer		A	 role	 in	breast	 cancer	has	been	 recognized	only	 relatively	 recently	 for	DNAJ	 co-chaperone	protein	family.		The	 large	 isoform	 of	 DNAJB6/MRJ	 blocks	 breast	 cancer	 migration,	 growth,	 metastasis	 and	triggers	 a	 partial	 Mesenchimal	 to	 Epithelial	 transition	 (MET)	 (Mitra	 et	 al.,	 2008,	 2010;	 De	Bock	et	al.,	2010;	Menezes	et	al.,	2012)	and	it	can	be	regulated	by	miR-632	(Mitra	et	al.,	2012).	Similarly,	 also	 DNAJA3/TID	 can	 block	 breast	 cancer	 cells	 migration	 (Kim	 et	 al.,	 2005).	DNAJC12/JDP1	 shows	 higher	 expression	 in	 ER+	 breast	 cancer	 and	 may	 be	 involved	 in	controlling	ER	signaling	(De	Bessa	et	al.,	2006).	DNAJC12	together	with	DNAJC10	was	found	up-regulated	 in	mammospheres	 derived	 from	 ER+	 tumors	 (Kok	 et	al.,	 2009)	 DNAJC13	 and	DNAJB1	are	listed	in	the	breast	cancer	invasiveness	signature,	being	found	highly	expressed	in	breast	cancer	stem	cells	(Liu	et	al.,	2007).		Some	DNAJ	proteins	 are	 important	 also	 for	 the	 tumorigenesis	driven	by	viral	 infection.	 For	example,	 DNAJC14/HSJ3	 is	 required	 by	 Flaviviridae	 to	 replicate	 and	 cause	 hepatocellular	carcinoma	 (Yi	 et	 al.,	 2011).	 Other	 DNAJ,	 plays	 important	 role	 in	 cancer	 chemoresistance.	DNAJB11/ERDJ3	is	involved	in	paclitaxel	resistance	(Di	Michele	et	al.,	2010);	DNAJA1/HDJ2	in	glioblastoma	radiotherapy	resistance	(Wang	et	al.,	2006).	Certainly,	the	DNAJ	member	which	has	the	most	consistent	role	in	breast	cancer	chemoresistance	is	DNAJC15.		
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2.5	DNAJC15			DNAJC15	is	a	small	protein	of	147aa	(around	17	KDa)	belonging	to	the	type	II	transmembrane	co-chaperone.	 It	 has	 a	 J	 domain	 at	 the	 C-terminus	 (essential	 for	 chemoresistance),	 a	 non-conserved	N-terminal	region	and	a	 transmembrane	domain,	which	 is	not	a	common	feature	for	DNAJ	proteins	that	are	mostly	soluble	(Hatle	et	al.,	2007;	Sinha	and	D’Silva,	2014).	Its	 direct	 evolutionary	 ancestor	 is	 yeast	 TIM14,	 an	 inner	mitochondrial	membrane	 protein,	and	it	probably	originated	from	gene	duplication	of	DNAJC19,	a	mitochondrial	co-chaperone,	with	whom	it	shares	a	similar	C-terminal	domain	(Hatle	et	al.,	2007).			
	
2.5.1	Regulation	of	DNAJC15	gene	expression		DNAJC15	was	named	MCJ	(Methylation	Controlled	J	protein),	because	it	was	discovered	as	a	highly	methylated	and	thus	repressed	gene	in	ovarian	cancer	and	it	was	induced	upon	5-Aza-2-deoxycytidine	 treatment	 in	 those	 cells	 (Shridhar	 et	al.,	 2001).	 Frequently,	methylation	 at	one	allele	is	combined	with	the	deletion	of	the	other	allele,	resulting	in	DNAJC15	loss	in	many	ovarian	cancers	(Shridhar	et	al.,	2001).	Increased	methylation	of	DNAJC15	in	CpG	islands,	localized	within	the	first	exon	and	the	first	intron,	was	observed	 in	epithelial	 cells	 compared	 to	non-epithelial	 cells	and	was	associated	with	 reduced	histone	acetylation,	 also	 in	 the	promoter	 region	 (Strathdee	et	al.,	 2004).	Very	high	 level	of	CpG	 islands	methylation	was	observed	 in	some	ovarian	 tumors	and	associated	with	 poor	 prognosis	 (Strathdee	 et	 al.,	 2005).	 Also	 in	 malignant	 pediatric	 brain	 tumor	 an	extensive	 pattern	 of	 methylation	 in	 most	 of	 the	 CpG	 sites	 of	 the	 intronic	 CpG	 island	 was	observed	 (Lindsey	 et	 al.,	 2006).	 Conversely,	 in	 neuroblastoma	 DNAJC15	 gene	 methylation	localizes	in	the	promoter	region	(-179	to	the	Transcription	Start	Site	–TSS-)	and	is	often	found	in	neuroblastoma	samples	bearing	MYCN	amplification	(Lau	et	al.,	2012).	Similarly,	in	breast	cancer,	methylation	was	also	reported	in	the	proximal	promoter	region	(Fernández-Cabezudo	
et	al.,	2016).		In	murine	macrophages,	DNAJC15	was	reported	to	be	regulated	by	another	type	of	repression	independent	from	methylation,	but	relying	on	the	Ikaros	transcription	factor.	Ikaros	binds	at	the	 position	 of	 -350,	 -361	 from	 TSS	 of	 DNAJC15	 and	 it	 is	 activated	 by	 IFNγ	 through	 post-translational	modifications	by	Casein	Kinase	2	(Navasa	et	al.,	2015).		This	project	reports	a	new	type	of	DNAJC15	repression,	mediated	by	the	ETS	factor	ETV7.	
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2.5.2	DNAJC15	biological	functions	and	its	role	in	drug	resistance		The	impact	of	DNAJC15	on	drug	resistance	was	very	clear	from	its	discovery:	it	was	seen	that	DNAJC15	 repression	 in	 ovarian	 cancer	 cells	 was	 able	 to	 induce	 resistance	 to	 topotecan,	cisplatin	 and	 paclitaxel	 (Shridhar	 et	 al.,	 2001;	Witham	 et	 al.,	 2008).	 Same	 observation	was	made	also	in	breast	cancer	cells	in	response	to	doxorubicin	(Boettcher,	Kischkel	and	Hoheise,	2010;	Sinha	and	D’Silva,	2014).	Later	on,	an	 increased	DNAJC15	promoter	methylation	was	also	 found	very	often	 in	Wilm’s	tumor	 (90%	 cases),	 neuroblastoma	 (50%	 primary	 neuroblastoma),	 malignant	 pediatric	tumors,	melanoma	(50%cases)	and	resistant	breast	cancer	(Ehrlich	et	al.,	2002;	Lindsey	et	al.,	2006;	Muthusamy	et	al.,	2006;	Boettcher,	Kischkel	and	Hoheise,	2010;	Lau	et	al.,	2012;	Hatle	
et	al.,	2013;	Fernández-Cabezudo	et	al.,	2016).	It	was	first	shown	in	vitro	that	DNAJC15	expression	was	lower	in	drug	resistant	breast	cancer	cell	lines	(MCF7/ADR,	MD22)	when	compared	with	drug-sensitive	cell	lines	(MCF7	and	MDA-MB-231),	 and,	 similarly,	 in	 uterine	 multi	 drug	 resistant	 cells	 (MES-SA/Dx5	 cell	 line)	 with	respect	to	the	sensitive	cells	(MES-SA)	(Hatle	et	al.,	2007).		In	MCF7	cells,	DNAJC15	silencing	leads	 to	 doxorubicin	 and	 paclitaxel	 resistance	 by	 increasing	 the	 drug	 efflux	 (Hatle	 et	 al.,	2007).	In	details,	DNAJC15	can	bind	to	c-Jun	and	promotes	its	degradation,	thus	if	lower	level	of	 DNAJC15	 are	 present,	 c-Jun	 escapes	 the	 DNAJC15	 control	 and	 dimerizes	 to	 activate	 the	transcription	of	ABCB1,	which	 increases	 the	drug	efflux,	 thereby	promoting	drug	resistance	(Hatle	 et	 al.,	 2007).	 	 Furthermore,	 the	 autocrine	 IL-6	 production	 observed	 in	 multi-drug	resistant	cells,	was	also	able	to	decrease	the	expression	of	DNAJC15	via	unknown	mechanisms	(Conze	et	al.,	2001;	Hatle	et	al.,	2007).	DNAJC15	was	first	described	as	localized	in	the	Golgi	apparatus,	oriented	with	its	C-terminus	in	the	Golgi	lumen	and	bearing	a	cytoplasmic	N-terminus	(Hatle	et	al.,	2007).		Then,	all	the	following	studies,	starting	from	Schusdziarra	and	collaborators,	report	DNAJC15	localization	 inside	 the	 mitochondrial	 inner	 membrane	 with	 the	 J	 domain	 oriented	 to	 the	matrix	(Schusdziarra	et	al.,	2013).	 	It	can	be	that	DNAJC15	over-expression	led	to	a	partially	artifactual	Golgi	 localization,	neverthess,	 its	negative	action	on	 JNK	pathway	was	confirmed	also	 by	 recent	 studies	 regarding	 mitochondrial	 DNAJC15	 in	 macrophages	 (Navasa	 et	 al.,	2015).		
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Inside	 the	 mitochondrial	 membrane,	 DNAJC15	 can	 carry	 out	 various	 important	 functions:	controlling	 the	 protein	 import	 into	 mitochondria,	 controlling	 in	 a	 negative	 fashion	 the	respiratory	chain	complexes,	and	regulating	 the	 transition	pore	complex	 (Hatle	et	al.,	2013;	Schusdziarra	et	al.,	2013;	Sinha	and	D’Silva,	2014).		DNAJC15	 exerts	 its	 co-chaperone	 role	 by	 promoting	 ATPase	 activity	 of	 mortalin,	 a	 core	component	 of	 the	 TIM23	 translocase	 A	 complex	 (a	 pre-protein	 import	 complex	 mostly	involved	 in	 the	 regulation	 of	 mitochondrial	 DNA	 copy	 number	 and	 Nodal	 signalling	molecules).	 Its	 homolog	 DNAJC19	 is	 essential	 for	 the	 functioning	 of	 TIM23	 translocase	complex	 B1	 and	 B2,	 which	 are	 the	 most	 important	 complexes	 for	 the	 import	 of	 proteins	(Schusdziarra	et	al.,	2013;	Sinha	et	al.,	2014).	Therefore,	DNAJC19	is	essential	for	the	protein	import,	 whereas	 DNAJC15	 is	 dispensable	 (Sinha,	 Srivastava	 and	 D’Silva,	 2016).	 MAGMAS	controls	 the	 binding	 of	DNAJC15	 to	mortalin	 (Schusdziarra	 et	al.,	 2013;	 Sinha	 et	al.,	 2014).	Despite	the	fact	that	there	is	no	direct	link	between	DNAJC15	loss,	its	role	on	protein	import,	and	chemoresistance,	it	could	be	that	its	influence	on	mitochondria	could	affect	the	apoptotic	response.	Other	data	 supporting	 this	hypothesis	 comes	 from	 the	 fact	 that	MAGMAS	 is	often	up-regulated	 in	 many	 prostate	 cancers	 and	 mortalin	 is	 also	 involved	 in	 tumorigenesis	(Jubinsky	et	al.,	2005;	Kaul,	Deocaris	and	Wadhwa,	2007;	Schusdziarra	et	al.,	2013).		The	direct	evidence	connnecting	DNAJC15	and	apoptosis	comes	from	a	study	observing	that	DNAJC15	 over-expression	 can	 lead	 to	 mitochondrial	 permeability	 transition	 pore	 (MPTP)		opening	and	apoptosis	 induction	 (Shridhar	et	al.,	 2001).	Upon	high	 level	of	ROS	or	 calcium,	MPTP	forms	a	non-specific	pore	leading	to	loss	of	potential,	osmotic	gradient	and	organelles	disruption.	Peptidyl-proline	isomerase	cyclophilin	D	(CypD)	is	the	motor	core	of	MPTP	and	is	recruited	to	MPTP	by	DNAJC15,	specifically	by	binding	to	its	J	domain	(Shridhar	et	al.,	2001).		Negative	 regulation	 by	DNAJC15	 on	 the	mitochondrial	 respiration	 is	 exerted	 by	 interacting	and	blocking	 complex	 I,	 therefore	DNAJC15	 loss	 is	 responsible	 for	 an	 increase	 in	 complex	 I	activity,	 membrane	 potential	 and	 ATP	 production,	 which	 is	 critical	 in	 case	 of	 metabolic	alterations	 such	 as	 fasting:	 DNAJC15	 loss	 determines	 a	 rapid	 metabolism	 preventing	 lipid	accumulation	and	liver	steatosis	(Hatle	et	al.,	2013).			Increased	 ROS	 production	 and	 apoptosis	 induction	 provide	 a	 direct	 link	 between	mitochondrial	DNAJC15	and	chemoresistance.	The	negative	role	on	respiratory	complex	could	link	 also	 the	 DNAJC15	 loss	 to	 drug	 resistance,	 given	 that	 most	 metastatic	 cancer	 cells	 are	strongly	dependent	on	mitochondrial	respiration	for	their	metabolism	(Fernández-Cabezudo	
et	al.,	2016).	The	inhibitory	role	on	respiratory	chain	exerted	by	DNAJC15	was	observed	also	in	immune	cells	as	mean	of	metabolic	control,	specifically	in	macrophages	and	in	CD8+	cells,	
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where	 it	 controls	 the	 response	 to	 inflammatory	 stimuli,	 and	 for	 instance	 its	 expression	 in	CD8+	cells	also	controls	the	response	to	influenza	virus	(Navasa	et	al.,	2015;	Champagne	et	al.,	2016).		High	expression	of	DNAJC15	is	associated	to	insulin	resistance,	confiming	a	role	for	DNAJC15	in	the	control	of	metabolism	(Do	et	al.,	2015).	Moreover,	insulin	treatment	can	directly	down-regulate	DNAJC15	expression	(Gupta	and	Tikoo,	2012).		Recently,	 a	 different	 promoter	 methylation	 in	 DNAJC15	 was	 associated	 also	 to	 a	predisposition	 for	more	aggressive	 cancer	 that	has	been	observed	 in	 afro-american	women	(Conway	 et	 al.,	 2015).	 Lack	 of	 DNAJC15	 expression	 was	 observed	 to	 drive	 to	 multi-drug	resistance	also	in	mice	(Fernández-Cabezudo	et	al.,	2016).		In	breast	cancer	patients,	 the	 lowest	expression	of	DNAJC15	 is	observable	 in	 triple	negative	breast	cancer	patients,	and	it	represents	a	good	predictive	marker	for	chemotherapy	response	inside	this	subgroup	(Fernández-Cabezudo	et	al.,	2016).			This	PhD	project	uncovered	a	novel	direct	link	between	DNAJC15	and	ETV7	which	is	critically	important	 for	 breast	 cancer	 chemoresistance	 and	 could	 represent	 a	 promising	 target	 to	improve	therapeutic	efficacy.			 	
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3. AIM OF THE THESIS 
	ETS	 factors	 are	 key	 regulators	 of	 many	 biological	 processes	 both	 in	 physiological	 and	pathological	conditions,	including	cancer	progression.	Among	several	ETS	family	members,	I	decided	 to	 focus	 my	 attention	 on	 ETV7.	 ETV7	 has	 a	 very	 limited	 literature	 with	 some	promising	 data	 on	 proposed	 tumor-promoting	 actions.	 Most	 evidence	 is	 centered	 on	 the	oncogenic	 role	 of	 ETV7	 in	 liquid	 tumors,	 but	 increased	 ETV7	 expression	 is	 also	 found	 in	various	solid	tumors,	where	its	role	is	completely	unknown.	This	project	aims	to	address	the	role	 of	 ETV7	 specifically	 in	 breast	 cancer.	 ETV7	 ranked	 at	 the	 top	 of	 a	 signature	 of	 genes	synergistically	 activated	 by	 Doxorubicin	 and	 TNF-α	 in	 breast	 cancer	 cells,	 a	 condition	associated	 with	 increased	 cancer	 aggressiveness.	 Furthermore,	 the	 observation	 that	 many	chemotherapeutic	drugs	are	able	 to	 consistently	activate	ETV7	expression	 in	different	 solid	cancer-derived	 cell	 lines,	 including	 breast	 cancer,	 suggests	 a	 possible	 role	 for	 ETV7	 in	response	to	drug	treatment.	For	 these	reasons	one	of	 the	main	objectives	 in	 this	 study	 is	 represented	by	 the	analysis	of	ETV7-mediated	drug	resistance	to	Doxorubicin	in	breast	cancer	cells	as	a	first	step;	this	aspect	will	 also	 be	 extended	 the	 resistance	 analysis	 to	 5-FU	 often	 used	 in	 combination	 with	Doxorubicin	in	breast	cancer	chemotherapy.		The	lack	of	evidence	regarding	in	vivo	validated	ETV7	targets	and	consensus	sequences	have	been	 exploited	 in	 this	 study	 in	 order	 to	 provide	 the	 first	 reported	 ChIP-seq	 for	 this	transcription	factor.	The	results	may	lead	to	the	discovery	of	novel	direct	ETV7	targets	with	known	 roles	 in	 drug	 response	 and	 involved	 in	 key	 cancer	 pathways;	 this	 might	 strongly	support	the	oncogenic	role	for	ETV7	in	breast	cancer	proposed	by	this	project,	which	appears	remarkably	 promising.	 Moreover,	 this	 project	 also	 aims	 to	 better	 characterize	 how	chemotherapeutic	drugs	can	promote	ETV7	activation	at	the	transcriptional	level,	to	envision	possible	therapeutic	strategy	minimizing	the	activation	of	the	pathway	ETV7	regulates.		Summarizing	 in	 few	 words,	 this	 thesis	 aims	 at	 the	 characterization	 of	 the	 ETV7	 role	 in	triggering	 breast	 cancer	 chemoresistance,	 focusing	 on	 the	 identification	 of	 novel	 targets	regulated	by	the	ETV7	transcriptional	activity.			 	
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4. MATERIALS AND METHODS 
	
4.1	Cell	lines	and	culture	conditions		MCF7	 and	U2OS	 cells	 (obtained	 from	 Interlab	 Cell	 Line	 Collection	 bank,	 Genoa,	 Italy)	were	cultured	 in	 DMEM	 supplemented	 with	 10%	 FBS,	 2mM	 L-Glutamine	 and	 2mM	 of	Penicillin/Streptomycin.	 MDA-MB-231	 cells	 (gift	 from	 Prof.	 A.	 Provenzani,	 CIBIO,	 Trento,	Italy)	were	cultured	in	DMEM	supplemented	with	1%	Non	Essential	amminoacids,	10%	FBS,	2mM	 L-Glutamine	 and	 2mM	 of	 Penicillin/Streptomycin.	 A549	 (from	 ATCC,	 Manassas,	 VA,	USA)	and	A375M	cells	 (gift	 from	Dr.	D.	Bergamaschi,	Centre	 for	Cell	Biology	and	Cutaneous	Research,	Blizard	Institute,	Barts	and	The	London	School	of	Medicine	&	Dentistry,	UK)	were	grown	in	RPMI	medium	+	10%	FBS,	2mM	L-Glutamine	and	2mM	of	Penicillin/Streptomycin.	HUVEC	cells	(Human	Umbilical	Vein	Endothelial	Cells,	from	Interlab	Cell	Line	Collection	bank,	Genoa,	Italy)	were	cultured	on	0.1%	gelatin	pre-coated	plastics	in	Medium	199	(Lonza	Milan,	Italy)	 supplemented	with	50	units/	ml	Low	Serum	Growth	Supplements	 (Life	Technologies,	Milan,	Italy).	BJ1-hTERT	cells	(obtained	from	Dr.	K	Lobachev,	Georgia	Institute	of	Technology,	GA,	USA)	were	grown	in	MEM	medium	supplemented	with	10%	FBS,	2mM	L-Glutamine,	2mM	of	 Penicillin/Streptomycin	 and	 Puromycin.	 CRL-4050	 (HSAEC1-KT)	were	 cultured	 in	 SABM	Basal	 Medium	 (Lonza	 CC3119)	 supplemented	 with	 SAGM	 BulletKit	 medium	 (CC4124).  Lymphocytes	 were	 obtained	 from	 the	 Clinical	 Research	 Unit	 at	 the	 National	 Institute	 of	Environmental	Health	Sciences	(NIEHS,	NIH,	Research	Triangle	Park,	NC,	USA);	lymphocytes	culture	 and	 treatment	 conditions	 are	 reported	within	Methods	 section	 in	Menenedez	et	al.,	2011	(Menendez	et	al.,	2011).				
4.2	Drug	Treatments		All	drugs	were	obtained	from	Sigma-Aldrich,	with	the	exception	of	Etoposide	purchased	from	Enzo	Life	Science	(Rome,	Italy).	Treatments	were	performed	for	16	hours	with	the	following	concentrations:	1.5µM	for	Doxorubicin	 (0.5µM	only	 for	U2OS	and	BJ1-hTERT	cells),	5ng/ml	for	TNF-α,	10µM	for	Nutlin-3a,	375µM	for	5-Fluorouracil,	0.5µM	for	Camptothecin,	50µM	for	Etoposide.	 Prolonged	 Doxorubicin	 treatment	 was	 achieved	 treating	 cells	 with	 0.5µM	Doxorubicin	(for	MCF7	cells)	and	0.8µM	Doxorubicin	(for	MDA-MB-231)	for	a	total	of	14	days	
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of	 treatment,	 replacing	 exhausted	 medium	 with	 fresh	 one	 containing	 Doxorubicin	 every	 3	days.	 Ionizing	 radiation	dose	was	set	at	4	Gy	using	Shepherd	cesium	 irradiator	 (NIEHS,	NC,	USA)	 at	 room	 temperature,	 and	 cell	were	 kept	 in	 the	 incubator	 for	 6	 hours	 after	 radiation.	Quercetin	 and	 Genistein	 (purchased	 from	 Extrasynthese,	 Genay,	 Lyon,	 France)	 were	 used	respectively	at	the	concentration	of	50µM	and	30µM	for	16	hours	treatment.				
4.3	Plasmids		The	expression	vectors	tagged	with	DDK-Myc	(pCMV6-Entry-Empty,	pCMV6-Entry-ETV7	and	pCMV6-Entry-DNAJC15)	were	bought	from	Origene	(Tema	Ricerca,	Bologna,	Italy).		To	 get	 the	 pCMV6-ETV7-AC-GFP	 expression	 vector	where	 ETV7	 gene	 is	 fused	 to	 AC-Green	Fluorescent	Protein,	ETV7	coding	sequence	was	digested	(overnight	at	37°C	using	Mlu	I	and	Asis	I	enzymes)	from	pCMV6-Entry-ETV7	and	ligated	(overnight	at	16°C)	into	the	pCMV6-AC-GFP	expression	vector	(gift	from	Chromosomal	Stability	group,	NIEHS).		The	pGL4.26-DNAJC15	and	pGL4.26-DNAJC14	reporter	plasmids	were	generated	by	cloning	a	portion	of	the	promoter	region	of	DNAJC15	(-299	to	+512	from	TSS)	or	DNAJC14	(-1335	to	+8	from	TSS)	 into	 the	 pGL4.26	 backbone.	 DNAJC15	 and	DNAJC14	 promoter	 regions	were	 first	amplified	 using	Q5	High	 Fidelity	DNA	Polymerase	 (New	England	Biolabs,	 Euroclone,	Milan,	Italy)	 and	 primers	 containing	 Xho	 I	 and	 Hind	 III	 recognition	 sites	 (Eurofins	 Genomics,	Ebersberg,	 Germany):	 DNAJC15_Fw:	 GCCTCGAGCAGCACAAACTCATTTGAGGG,	 DNAJC15_Rv:	GCAAGCTTAGGCGGCCCGGAGACTCAAG,DNAJC14_Fw:GCCTCGAGAGGGTGGAGAAAGGGGACAG,DNAJC14_Rv:GCAAGCTTCCAGGGTGAGCTACGAGAG.		Purified	PCR	product	and	backbone	were	then	 digested	 overnight	 using	 Xho	 I	 and	 Hind	 III	 restriction	 endonucleases,	 and	 ligated	overnight	 at	 16°C.	 Restriction	 analysis	 and	 direct	 sequencing	 were	 used	 to	 determine	successful	 cloning	 (Eurofins	 Genomics).	 Plasmids	 used	 for	 over-expressing	 mutant	 p53	(R282Q	and	G279E)	and	relative	control	are	pcDNA3.1	based	expression	plasmid	and	were	a	gift	from	Laboratory	of	Transcriptional	Networks	(CIBIO,	University	of	Trento).					
4.4	RNA	isolation	and	RT-qPCR		Total	 RNA	 extraction	 was	 performed	 using	 the	 Illustra	 RNA	 spin	 Mini	 Kit	 (GE	 Healthcare,	Milan,	 Italy),	 and	RNA	was	 reverse-transcribed	 into	 cDNA	using	 the	RevertAid	 First	 Strand	
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cDNA	Synthesis	Kit	 (Thermo	Fisher	Scientific).	 	RT-qPCR	was	performed	 in	384	wells-plate	(BioRad,	Milan,	 Italy)	with	25	ng	of	template	cDNA,	using	the	KAPA	SYBR	Fast	qPCR	Master	Mix	 (Kapa	Biosystems,	Resnova,	Ancona,	 Italy)	 and	 the	CFX384	Detection	System	 (BioRad).	Relative	fold	change	was	calculated	using	the	ΔΔCt	method,	and	YWHAZ	and	B2M	genes	were	used	as	housekeeping	genes	for	all	samples	except	for	lymphocytes-derived	cDNA,	for	which	the	18S	ribosomal	RNA	gene	was	used	as	housekeeping	gene.	Primer	sequences	(reported	in	Table	 1)	 were	 designed	 using	 Primer-BLAST	 designing	 tool	(https://www.ncbi.nlm.nih.gov/tools/primer-blast/),	and	checked	for	specificity	by	standard	PCR	using	the	KAPA2G	Fast	PCR	Kit	(Kapa	Biosystems,	Resnova,	Ancona,	Italy).			
PRIMERS used for RT-qPCR sequence 
ETV7-Fw CAAGATCTTCCGAGTTGTGGA  
ETV7-RV GTTCACCCGGTTCTTGTGAT  
BRCA1_Fw CTCGCTGAGACTTCCTGGAC 
BRCA1_Rv TCAACTCCAGACAGATGGGAC 
ESR1_Fw CCGGCATTCTACAGGCCAAATTCA 
ESR1_Rv AGTCTCCTTGGCAGATTCCATAGC 
SKI_Fw GGGGCTTCGACTCGGCCAAC 
SKI_Rv TCAGAGGAGACCCGGGGCAC 
SMAD6_Fw GCACCCCATCTTCGTCAACT 
SMAD6_Rv CGCTCGAAGTCGAACACCT 
ID1_Fw AATCCGAAGTTGGAACCCCC 
ID1_Rv GATCTGGATCTCACCTCGGC 
FKBP1A_Fw GGGTTGCCCAGATGAGTGT 
FKBP1A_Rv CATCGAAGACGAGAGTGGCAT 
DPEP1_Fw TGACAACCTGCTGAGGGTCTT 
DPEP1_Rv TGAGGTTGCTGGCCTGTTCC 
DPYD_Fw ACTCTGTGTTCCACTTCGGC 
DPYD_Rv TCCAGCTTCTCACAATTAAAGCA 
DNAJC14-Fw GTAGCTAGTGGGCGCTACTG  
DNAJC14-Rv GCTGCTCGCAAAACCTTGAA  
DNAJC15-Fw TGGTGTCATCGCTCCAGTTG  
DNAJC15-Rv  ATGCGTAGCGACCTGCAAAT  
SPDEF_Fw GACTTCACCTGGGGCGATTC 
SPDEF_Rv TGATGAGTCCACCTCGCTGT 
ELF2_Fw TAGTCCAACAACAGCGACCTC 
ELF2_Rv AGCTGGCATCACAGTAGGGA 
ABCB1_FW TGCCTATGGAGACAACAGCC 
ABCB1_RV TGAAGGCATGTATGTTGGCCT 
YWHAZ-Fw ACTTTTGGTACTTTGTGGCTTCAA 
YWHAZ-Rv CCGCCAAGGGACAAACCAGTAT 
B2M-Fw AGGCTATCCAGCGTACTCCA 
B2M-Rv TGGATGAAACCCAGACACA 
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PRIMERS used for ChIP-qPCR sequence 
ETV7REChIP_Fw AGCTCCGTGGCTGGCGTTTC  
ETV7REChIP-Rv AGGGGTTGCCTCCTGGTGGG  
ETV7TATAChIP_Fw GCTGGCCTAGAGCTTGTGAT 
ETV7TATAChIP-Rv ACAAACCAGAAGACACCGAAGA 
DNAJC15ChIP_Fw TGCGAACAGAAGTTGAGAGTGG 
DNAJC15ChIp_Rv AGTAAGCTCGGAGTCTAGCTGT 
GTF2H5ChIP_Fw GAAGCGAAGTAAGAAGTATGGCA 
GTF2H5ChIP_Rv GGCCCTACTAAGAGGCAAAGG 
ACTBChIP_Fw TCTCCCTCCTCCCTTCTTCAAT 
ACTBChIP-Rv TCGCGCCGCTGGGTTTTATA 
p21REChIP_Fw GTGGCTCTGATTGGCTTTCTG  
p21REChIP_Rv CTCCTACCATCCCCTTCCTC  
p21TATAChIP_Fw TATTGTGGGGCTTTTCTG 
p21TATAChIP_Rv CTGTTAGAATGAGCCCCCTTT 
MCP1REChIP_Fw TGTTCCCAGCACAGCCCCTAGT  
MCP1REChIP_Rv TCCCCCGCTGGGAGGTCAGT  
MCP1TATAChIP_Fw ACAGGATGCTGCATTTGCTC 
MCP1TATAChIP_Rv GCCTCTTATTGAAAGCGGGC 
SKIChIP_Fw TGGAGCCAGTGACCTCATTTC 
SKIChIP_Rv GCACAGTGTGTTGCATACAGG 
SMAD6ChIP_Fw AAAAGCAGCAGCAGCAGGAA 
SMAD6ChIP_Rv CTCAGGGCTCACTTAGCAGG 
ID1ChIP_Fw AGGCAGGCGCCACTTTC 
ID1ChIP_Rv GTCCAGGGAGATAAGGGCA 
FKBP1AChIP_Fw TCACGCTTTAAGTCCCTGGT 
FKBP1AChIP_Rv GCCAGTGAGGAGACAACTACC 
DPEP1ChIP_Fw GCCTGTAATCCCAGCACTTT 
DPEP1ChIP_Rv CCTGCCTTAACCTCCCAAGT 
DPYDChIP_Fw ACACGCCTTGTCGCTTATCT 
DPYDChIP_Rv TTTGGTGGTATGGGTGACCT 
Table		1:	Sequence	of	primers	used	for	qPCR	analysis.		
		
4.5	Western	Blot		Proteins	 were	 extracted	 using	 the	 RIPA	 buffer	 supplemented	with	 Protease	 inhibitors	 and	quantified	by	the	BCA	method	(Pierce,	Thermo	Fisher	Scientific).		For	chromatin	and	nuclear	extraction	 Subcellular	 Protein	 Fractionation	 Kit	 (Thermo	 Fisher	 Scientific)	 was	 used.	 For	cytoplasmic	 and	 nuclear	 extraction,	 protein	 fractions	 were	 extracted	 following	 the	instructions	 of	 NE-PER	 kit	 (Thermo	 Fisher	 Scientific),	 and	 to	 increase	 the	 chromatin-associated	 proteins	 present	 in	 the	 nuclear	 fraction,	 pellets	 remaining	 from	 cytoplasmic	extraction	were	 directly	 resuspended	 in	 1x	 Loading	 Buffer	 and	 boiled.	 Antibodies	 used	 for	
	 31	
detection	were:	anti-p53	(DO-1,	Santa	Cruz	Biotechnologies,	Milan,	 Italy),	anti-RelA/p65	(C-20,	 Santa	 Cruz	 Biotechnologies,	Milan,	 Italy),	 anti-GAPDH	 (6C5	 Santa	 Cruz	 Biotechnologies,	Milan,	 Italy),	 anti-ETV7/TEL2(F-8,	 sc-376137X	 Santa	 Cruz	 Biotechnologies),	 Histone	 H3	(ab1791,	 Abcam),	 anti-Alfa-Actinin	 (H-2	 sc-17829,	 Santa	 Cruz	 Biotechnologies),	 anti-pSTAT3(Y705)	(D3A7	XP(R),	PhosphoPlus,	Cell	Signaling),	anti-STAT3	(124H6,	PhosphoPlus,	Cell	 Signaling).	 ECL	 Select	 reagent	 (GE	 Healthcare)	 was	 used	 for	 detection	 at	 the	 UVITec	Alliance	LD2.				
4.6	Gene	Reporter	Assay		Cells	were	seeded	in	24	well-plate	at	a	concentration	of	70,000	and	45,000	for	MCF7	cells	and	MDA-MB-231	 respectively,	 and	 transfected	 with	 250ng	 pGL4.26-DNAJC15	 or	 pGL4.26-DNAJC14,	 along	 with	 250ng	 pCMV6-Entry-Empty	 or	 pCMV6-Entry-ETV7	 vectors,	 and	 50ng	pRL-SV40	for	each	well	using	Fugene	HD	for	MCF7	(Promega,	Milan,	Italy)	and	Lipofectamine	LTX	for	MDA-MB-231	cells	(Life	Technologies,	Thermo	Fisher	Scientific,	Milan,	Italy).	48	hours	after	transfection,	cells	were	lysed	in	1X	PLB	buffer	and	luciferase	activity	was	measured	with	the	Dual-Luciferase	Reporter	Assay	System	 (Promega)	using	 the	 Infinite	M200	plate	 reader	(Tecan,	Milan,	 Italy).	 Relative	 Light	 Unit	 (RLU)	measures	were	 determined	 considering	 the	transfection	 efficiency	 values	 obtained	 by	 transfecting	 the	 pRL-SV40	 (Promega)	 vector,	constitutively	expressing	the	Renilla	reniformis	luciferase	cDNA.				
4.7	Single	cell	cloning	
4.7.1	Generation	of	CRISPR/Cas9	p53	and	CRISPR/Cas9	p65	MCF7	and	MDA-MB-231	cells		MCF7	and	MDA-MB-231	cells	were	seeded	in	a	6-well	plate	respectively	at	a	concentration	of	600,000	 and	 300,000	 respectively	 and	 transfected	with	 1.5	µg	 of	 CRISPR/Cas9	 p53	 or	 p65	vectors	(4	different	vectors	each;	All-in-one	CRISPR/Cas9	vectors;	ATUM/ex	DNA	2.0)	using	Fugene	 HD	 for	 MCF7	 cells	 and	 Lipofectamine	 LTX	 for	 MDA-MB-231	 cells.	 48	 hours	 after	transfection,	 serial	 dilution	 for	 single	 cell	 cloning	was	 performed	 according	 to	 the	 Corning	protocol	 for	 cell	 cloning	 in	 96-well	 plate.	 Single	 cell	 clones	were	 checked	 by	Western	 Blot	analysis.				
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4.7.2	Generation	of	stable	pCVM6-Entry-ETV7	and	-Empty	MDA-MB-231	cells			MDA-MB-231	cells	were	seeded	in	a	p60	dish	at	a	concentration	of	500,000	and	transfected	with	1	µg	of	pCMV6-Entry-Empty	or	pCMV6-Entry-ETV7	(Origene)	using	Lipofectamine	3000	(Life	Technologies,	Thermo	Fisher	Scientific,	Milan,	Italy).	After	48	hours,	cells	were	splitted	and	800mg/ml	of	Geneticin	(Life	Technologies)	was	added.	Medium	was	replaced	with	fresh	and	containing	Geneticin	each	2/3	days,	for	a	total	of	4	cycles	of	selection.	Afterwards,	single	cell	cloning	in	a	96-well	plate	was	performed	(Corning	protocol)	and	Geneticin	concentration	was	gradually	reduced	to	400	µg/ml.			
4.7.3	Generation	of	stable	pCVM6-ETV7-GFP	and	–GFP	U2OS	cells		U2OS	cells	were	seeded	in	a	12-well	plate	(100,000	cells/well)	and	transfected	with	1	µg	of	either	pCMV6-ETV7-AC-GFP	or	pCMV6-AC-GFP	using	FuGene	HD	(Promega).	48	hours	after	transfection	 cells	were	 transferred	 into	 a	 p100	 dish	 and	 selection	 started	 using	 800mg/ml	G418.	 After	 3	 rounds	 of	 G418	 selection,	 AC-GFP	 positive	 cells	 were	 sorted	 using	 FACS	(Fluorescence	 Activated	 Cell	 Sorter),	 and	 seeded	 in	 a	 6-well	 plate.	 Once	 cells	 reached	confluence,	 serial	 dilution	 for	 single	 cell	 cloning	 was	 performed	 in	 a	 96-well	 plate	 and	Geneticin	concentration	was	gradually	reduced	to	400	µg/ml.		
	
	
4.8	Doxorubicin	Efflux	Analysis		MDA-MB-231	cells	were	seeded	in	a	96-well	plate	at	a	concentration	of	1.5	x	104,	and	after	24	hours,	 10	 or	 20	 µM	Doxorubicin	 was	 added	 for	 3	 hours	 and	 Doxorubicin	 localization	 was	measured	 exploiting	 its	 intrinsic	 fluorescence	 using	 the	 520-	 to	 550-nm/560-	 to	 630-nm	DsRed	 excitation/emission	 filters	 of	 the	 Operetta	 High	 Content	 Imaging	 System	 (Perkin	Elmer,	 Milan,	 Italy)	 at	 CIBIO	 High	 Throughput	 Screening	 Facility.	 The	 Harmony	 4.1	PhenoLOGIC	 software	 was	 used	 to	 first	 determine	 nuclear	 and	 cytoplasmic	 regions	 using	segmentation	 by	 digital	 phase	 contrast	 mode	 and	 then	 to	 calculate	 the	 ratio	 of	 nuclear	 to	cyoplasmic	of	Doxorubicin	and	the	total	area	of	the	Doxorubicin	spot	area	into	the	cytoplasm	(METHODS-Figure	1).		
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METHODS-Figure	1:	Detection	and	analysis	by	Operetta	Perkin	Elmer	of	Doxorubicin	intensity	in	nuclei	and	area	of	Doxorubicin	efflux:	first	Doxorucibin	image	was	taken	in	the	DsRed	acquisiton,	nuclear	and	cytoplasmic	regions	were	defined	by	dynamic	light	scattering	acquisition	and	then	cytoplasmic	area	of	Doxorubicin	efflux	was	calculated	as	total	spots	area.			
4.9	Viability	Assay		Cells	were	seeded	in	a	96-well	plate	and	treated	for	72	hours	with	increasing	concentrations	of	Doxorubicin	or	5-Fluorouracil.	To	avoid	possible	reduction	effects	of	the	added	compounds	with	MTT	reagent	(Sigma-Aldrich),	cells	were	washed	with	1X	PBS	and	10	µl	of	MTT	(5	mg/ml	in	PBS	1X)	was	added	to	100	µl	of	fresh	medium,	and	left	3	hours	in	incubation	protected	from	light.	Cells	were	then	lysed	using	100	µl	of	DMSO	(Sigma-Aldrich)	and	reduction	of	MTT	was	measured	 at	 the	 Infinite	M200	plate	 reader	 (Tecan).	 Viability	was	 reported	 as	 a	%	of	MTT	absorbance	at	the	indicated	treatment	concentration	respect	to	the	untreated	control.				
4.10	RSV	infection		Cells	were	seeded	in	p100	dishes;	medium	was	removed	at	the	time	of	the	 infection	and	1X	PBS	containing	the	desired	RSV	dilution	was	added	and	left	in	the	incubator	for	1	hour,	then	additional	6	ml	of	medium	was	added	and	cells	were	kept	for	the	desidered	time	of	infection	inside	the	incubator.						
MDA-MB-231 Empty
MDA-MB-231 ETV7
A B C D
A B C D
A DsRed image
B Find nuclei
C Find cytoplasm
D Find spots in cytoplasm
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4.11	Chromatin	enriched	Co-IP		Cells	were	seeded	in	p150	dishes	and	harvested	using	Farnham	Buffer	(supplemented	with	1X	PI	and	PMSF).	Cells	were	then	spun	down	at	4°C	for	5	minutes	at	2,000	rpm,	then	lysed	using	ChIP	 Lysis	 Buffer	 (supplemented	with	 PI	 and	 PMSF),	 vortexed	 and	 incubated	 on	 ice	 for	 15	minutes;	 the	 extracts	 were	 quickly	 sheared	 with	 the	 Covaris	 sonicator	 (4	 minutes),	 spun	down	 again	 at	 14,000	 rpm	 for	 15	minutes	 at	 4°C.	 Protein	G	Beads	 (50	µl	 for	 each	 sample)	were	coupled	overnight	with	5	µg	of	the	desired	antibody	and	1mg	of	cell	lysate	enriched	in	chromatin	fraction	was	used	for	immunoprecipitation	(performed	overnight	at	4°C),	keeping	1/10	for	input	control.		Washings	were	 performed	 once	 using	 PBS-Tween20	 0,02%	 and	 4	 times	 using	RIPA	 buffer.	Finally,	 beads-antibody-antigen	 complex	 was	 eluted	 in	 40	 µl	 elution	 +	 20	 µl	 NuPAGE	 LDS	sample	buffer,	heated	for	10	minutes	at	70°	C	and	supernatant	was	transferred	to	clean	tubes.	4	 µl	 of	 the	 Input	 and	 25	 µl	 of	 the	 IP	 samples	 were	 loaded	 on	 a	 12%	 polyacrylamide	 gel	following	the	standard	Western	Blotting	procedure.			
	
	
4.12	ChIP-qPCR		Cells	were	seeded	on	five	p150	dishes	for	each	treatment	condition	and	treated	for	16	hours	when	reaching	80%	of	confluence.	Upon	treatment	completion,	cells	were	crosslinked	at	room	temperature	 for	8	minutes	using	1%	Formaldehyde,	and	afterwards	quenched	with	125mM	Glycine	for	5	minutes	at	room	temperature.	After	washing	dishes	twice	with	cold	PBS	1X,	cells	were	 scraped	 in	 1ml	 1X	 PBS	 +	 1X	 protease	 inhibitors	 and	 centrifuged	 at	 2,900	 rpm	 for	 10	minutes	at	4°C.	Lysis	was	performed	in	ice	for	10	minutes	using	1%	SDS	supplemented	with	0.1mg/ml	salmon	sperm	DNA	and	1X	PI,	cells	were	centrifuged	at	2,900	rpm	for	10	minutes	at	4°C	 and	 pellet	 was	 resuspended	 in	 300	 µl	 of	 sonication	 buffer	 (0.25%	 SDS,	 200mM	 NaCl,	0.1mg/ml	 salmon	 sperm	 DNA	 and	 PI	 1X).	 Sonication	 was	 performed	 using	 the	 Bioruptor	(Diagenode,	Seraing	(Ougrée)	-	Belgium	;30sec	ON/OFF	for	25	cycles)	and	checked	by	running	5	µl	 of	 purified	 sample	 on	 a	 2%	 TAE	 1X	 gel	 (after	 Proteinase	 K	 and	 RNAse	 A	 treatment).	Sonicated	samples	were	spun	down	at	13,000	rpm	for	10	minutes	at	4°C	and	supernatant	was	used	for	immunoprecipitation,	performed	at	4°C	overnight.	10%	of	sample	were	kept	as	Input	control,	 40	 µl	 of	 protein	 G	 were	 used	 for	 each	 immunoprecipitation	 using	 1	 µg	 of	 each	antibody.	 The	 following	 antibodies	 were	 used	 for	 IP:	 anti-p53	 (DO-1,	 Santa	 Cruz	Biotechnologies)	anti-p65	(C-20,	Santa	Cruz	Biotechnologies),	anti-acetyl	Histone	H4	(06-866,	
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Millipore),	 anti-Histone	 H3	 (trimethyl	 K4;	 ab8580,	 Abcam),	 anti-Histone	 H4	 (acetyl	 K16;	ab109463;	 Abcam),	 normal	 IgG	 mouse	 (sc-2025,	 Santa	 Cruz	 Biotechnologies),	 normal	 IgG	rabbit	 (sc-2027,	 Santa	 Cruz	 Biotechnologies).	 IP	 samples	 were	 washed	 once	 with	 dilution	buffer,	then	low	salt	washing	buffer,	and	then	twice	with	high	salt	washing	buffer,	followed	by	a	 wash	 with	 Litium	 Cloride,	 and	 1X	 TE	 (pH8).	 De-crosslinking	 was	 performed	 at	 65°C	overnight,	followed	by	a	treatment	with	Proteinase	K	(50	µg)	at	56°C	for	2	hours	to	remove	proteins,	and	 then	 to	remove	RNA,	50	µg	of	RNAse	was	added	and	kept	 for	1	hour	at	37°C.	QIAquick	 PCR	 Purification	 Kit	 (Qiagen)	 and	 provided	 protocol	 was	 used	 to	 purify	 chipped	DNA,	eluting	using	75	μl	of	EB	Buffer	pre-warmed	at	65	°C.	2	µl	of	chipped	DNA	was	used	for	subsequent	qPCR	analysis.	
	
	
4.13	ChIP-seq		Cells	were	seeded	 in	 the	p150	dishes	 (5	dishes	each	condition)	and	 treated	 for	16	hours.	A	revised	version	of	the	Myers	Lab	ChIP-seq	v011014	(Jan	2014)	was	used	as	described.	Fresh	Formaldehyde	 (Pierce™	 16%	 Formaldehyde	 (w/v)	 was	 used	 for	 crosslinking	 8	 minutes	 at	room	temperature.	Crosslinking	was	blocked	by	adding	0.125M	of	2.5M	Glycine	 (20x)	 for	2	minutes;	fixed	cells	were	washed	twice	with	PBS	supplemented	with	1X	PI	and	harvested	by	scraping	in	5	ml	Farnham	Buffer	(+1X	PI	and	1X	PMSF).	Cells	were	centrifuged	at	2,000	rpm	for	5	minutes	at	4°C	and	the	pellet	was	resuspended	in	1	ml	Farnham	buffer	(+1X	PI	and	1X	PMSF),	 passed	 through	 a	 gauge	 needle	 10	 times	 and	 centrifuged	 again.	 Pellet	 was	resuspended	 in	 RIPA	 Lysis	 Buffer	 (+1X	 PI	 and	 1X	 PMSF)	 and	 added	 to	 the	 AFA	 Fiber	milliTUBEs	(Covaris	S-220).	Sonication	was	performed	using	Covaris	S-220	and	the	following	settings:	 5%	 Duty	 Cycle,	 140	 watts	 peak	 incident	 power,	 200	 cycle/burst,	 4°C	 bath	temperature,	 8	 water	 level,	 and	 20	 minutes	 processing	 time.	 Sonicated	 samples	 were	centrifuged	at	14,000	rpm	15	minutes	at	4°C	and	supernatant	was	collected.		A	small	aliquot	(50	µl)	was	 used	 for	 sonication	 control	 by	 electrophoresis	 (after	 protein	 and	RNA	 removal	and	purification).	200	µl	 re-suspended	protein	G	magnetic	bead	slurry	was	washed	3	 times	using	1	ml	of	ice	cold	PBS/BSA	(+1X	PI)	and	finally	resuspended	in	200	µl	of	ice	cold	PBS/BSA	(+1X	PI)	containing	5	µg	of	primary	antibody.	Coupled	beads	were	incubated	overnight	on	a	rotator	at	4°C,	then	washed	3	times	with	1	ml	of	ice	cold	PBS/BSA	(+1X	PI)	and	resuspended	in	100	µl.	Sonicated	samples	were	diluted	in	RIPA	buffer	up	to	a	300	µl	volume	and	coupled	beads	 were	 added;	 1/10	 of	 each	 sonicated	 sample	 was	 kept	 for	 the	 Input.	 Samples	 were	
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incubated	overnight	on	a	rotator	at	4°C	and	then	beads	were	washed	5	times	using	 ice	cold	LiCl	 Buffer	 (+1X	 PI),	 1	 time	 using	 TE	 1X	 Buffer	 and	 finally	 resuspended	 in	 200	 µl	 Elution	Buffer.	 IP	 Samples	 were	 incubated	 for	 1	 hour	 at	 65°C	 at	 300	 rpm	 in	 a	 thermoshaker	 and	finally	 supernatant	was	 collected	 after	 centrifugation	 at	 14,000	 rpm	 for	 3	minutes	 at	 room	temperature	using	the	magnetic	rack.	Elution	Buffer	was	also	added	to	the	Input	samples	to	reach	 a	 final	 volume	of	200	µl	 and	both	 IP	 and	 Input	 samples	were	 incubated	overnight	 at	65°C	at	300	rpm.	To	remove	proteins,	50	µg	of	Proteinase	K	(Qiagen	19131)	was	added		and	incubated	at	56°C	for	2	hours		for	1	hour,	and	then	50	µg		of	RNAse	A	(Quiagen)	was	added	and	incubated	at	37°C	for	30	minutes.	QIAquick	PCR	Purification	Kit	was	used	for	purification,	using	30	µl	of	pre-warmed	DNAse-free	molecular	grade	water	and	repeating	the	elution	twice.	Purified	DNA	was	quantified	using	Qubit	and	the	HS	dsDNA	Buffer.	Libraries	were	prepared	and	run	on	the	MiSeq	by	the	DNA	sequencing	core	at	the	NIEHS	using	10	ng	of	each	sample.	Bioinformatic	analysis	including	quality	control,	mapping	and	peak	detection,	was	performed	by	Sara	Grimm	(Integrative	Bioinformatics	Support	Group,	NIEHS).			
4.14	Wound	healing	Assay		MDA-MB-231	cells	over-expressing	ETV7	and	their	control	were	seeded	in	a	24-well	plate	and	when	 reaching	 confluence	 a	 wound	 was	 created	 using	 a	 p200	 tip.	 Pictures	 were	 taken	immediately	after	the	wound	generation	and	after	16	hours.	Wound	diameter	was	measured	using	 the	 Leica	 LASX	 software	 and	 percentage	 of	 reclosure	 was	 calculated	 as	 %	 (time	 0	diameter-time	16	diameter/time	0	diameter).		
4.15	Soft	Agar	colony	formation	Assay			In	a	24-well	plate,	500	µl	of	pre-heated	base	agar	(0,5%	agarose	in	DMEM1X)	was	distributed	evenly	in	each	well	and	left	10	minutes	under	the	hood	to	solidify,	on	the	top	of	it,	2500	cells	(MDA-MB-231-ETV7	 and	MDA-MB-231-Empty)	were	mixed	 in	 the	 specific	medium	 (DMEM	1X	supplemented	with	1%	Non	Essential	amminoacids,	10%	FBS,	2mM	L-Glutamine	and	2mM	of	 Penicillin/Streptomycin,	 400	 µg/ml	 Geneticin)	 containing	 0,35%	 agarose.	 After	solidification	of	the	top	layer	(15	minutes),	250	µl	of	specific	medium	was	added	on	the	top	and	 replaced	 every	 3	 days.	 After	 20	 days	 colonies	were	 stained	 for	 2	 hours	 using	 0,005%	methylene	 blue	 and	 extensively	 washed	 with	 deionized	 water.	 Pictures	 were	 taken	 at	 the	stereomicroscope	(EVOS	XL	Cell	Imaging	System)	and	manually	counted.	
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4.16	Transient	silencing		150.000	MDA-MB-231	cells	were	seeded	in	each	well	of	a	6-well	plate	and	25	nM	of	siRNA	for	p53	 and	 relative	 control	 siRNA	 were	 transfected	 using	 Interferin	 (Polyplus)	 transfectant	agent.	Cells	were	harvested	72	hours	after	transfection.		
4.17	Statistical	Analysis		Statistical	 analyses	 were	 performed	 by	 first	 applying	 a	 Fisher-test	 for	 comparing	 variance	among	two	different	groups.	Relative	results	were	used	to	set	the	T-test	analysis	as	following:	homoskedastic	 test	 (type	 2)	 if	 p-value	 (Fisher-test)	 was	 higher	 than	 0.05	 and	 an	heteroskedastic	test	(type	3)	if	p-value	(Fisher-test)	was	lower	than	0.05.	T-test	results	were	represented	graphically	using	“*”	for	a	p-value	<	0.05	and	“**”	for	a	p-value	<	0.01.	The	ANOVA	test	for	variance	was	not	chosen,	given	the	interest	in	the	comparison	between	two	different	groups	 (mainly	 treated	 and	 not	 treated)	 rather	 than	 a	 total	 analysis	 of	 the	 variance.	 Prism	GraphPad	software	was	chosen	for	graphical	representation	of	data.	 			 	
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5. RESULTS 		
5.1	 ETV7	 can	 represent	 a	 promising	 transcription	 factor	 in	 chemotherapy-derived	
chemoresistance			Unexpectedly,	 chemotherapy	 itself	 can,	 in	 some	 cases,	 promote	 chemoresistance.	Molecular	mechanisms	mediating	 this	 deleterious	 effect	 can	often	 rely	 on	 the	 activity	 of	 transcription	factors,	 that	 once	 stimulated	 by	 chemotherapy,	 can	 consequently	 control	 the	 expression	 of	key	 target	 genes,	 leading	 eventually	 to	 drug	 resistance.	 My	 PhD	 project	 was	 specifically	focused	 on	 the	 role	 of	 ETV7	 as	 transcription	 factor	 in	 response	 to	 chemotherapy	 and	 its	possible	 implication	 in	 mediating	 chemoresistance	 in	 breast	 cancer	 cells.	 I	 interrogated	microarray	data	from	breast	cancer	cells	MCF7	treated	with	Doxorubicin	already	available	in	the	 lab	 (Gene	 Expression	 Omnibus,	 GEO,	 accession	 number:	 GSE24065).	 In	 particular,	 I	considered	 only	 top	 differentially	 expressed	 genes	 (DEGs)	 showing	 a	 log[fold	change(Doxorubicin	to	Untreated)]	higher	than	1	(considered	as	up-regulated)	or	lower	than	-1(considered	 as	 repressed)	 and	 searched	 for	 over-represented	 clusters	 of	 transcription	factor	binding	sites		using	the	oPOSSUM	tool	(http://opossum.cisreg.ca).	Transcription	factor	binding	 sites	 (TFBS)	 best	 enrichment	 results	 are	 reported	 in	 Figure	 1A	 and	 Figure	 1B,	indicating	 DEGs	 consistently	 up-regulated	 and	 repressed	 by	 Doxorubicin,	 respectively.	According	to	gene	ontologies,	I	then	searched	for	transcription	factor	enrichment	among	the	up-regulated	 DEGs	 by	 using	 the	 Panther	 Protein	 Class	 classification	 system	(http://pantherdb.org)	 and	 the	 top	 up-regulated	 ones	 were	 reported	 in	 Figure	 1C.	Interestingly,	ETV7	ranked	as	the	transcription	factor	with	the	highest	score	among	the	ones	activated	 by	 Doxorubicin	 in	 terms	 of	 gene	 expression	 (Fig.	 1C).	 Moreover,	 a	 remarkably	relevant	 enrichment	 for	 its	 binding	 site	 (ETS)	 was	 observable	 predominantly	 in	 in	downregulated	 DEGs	 group	 (Figure	 1B),	 in	 line	 with	 its	 known	 transcriptional	 repressive	action,	but	it	was	also	visible	among	the	up-regulated	DEGs	(Fig.1A).	Notably,	ETV7	appeared	as	 the	 only	 ETS	 factor	 consistently	 up-regulated	 by	 Doxorubicin	 in	 MCF7	 cells	 from	 the	microarray	 analysis	 data	 (GSE24065)	 (Fig.	 1D).	 Conversely,	 two	 other	 ETS	 factors	 with	reported	tumor	suppressive	roles	in	cancer,	SPDEF	and	ELF2,	showed	decreased	expression	upon	 Doxorubicin	 treatment	 in	 the	 microarray	 data	 from	 MCF7	 cells,	 which	 was	 also	confirmed	by	qPCR	analysis	(Fig.	1E).	Given	the	encouraging	data	 in	support	of	a	promising	role	 for	 ETV7	 as	 a	 transcriptional	 regulator	 in	 response	 to	 chemotherapy,	 I	 decided	 to	
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characterize	 the	 activation	of	ETV7	upon	 treatment	with	different	DNA	damaging	agents	 in	breast	 cancer	 cells.	 Specifically,	 I	 treated	 MCF7	 cells	 with	 various	 drugs	 for	 16	 hours	 and	analyzed	ETV7	 induction	by	qPCR	analysis	 (Fig.	1F).	DNA	damaging	drugs	and,	particularly,	p53-activating	 agents	 proved	 to	 efficiently	 induce	 the	 ETV7	 expression	 in	 MCF7	 cells,	suggesting	 that	p53	 could	positively	 control	 the	 expression	of	 this	 interesting	 transcription	factor	(Fig.	1F).	To	check	whether	ETV7	activation	in	response	to	DNA	damaging	drugs	was	a	common	feature	also	relevant	for	other	breast	cancer	cells,	I	extended	the	analysis	to	a	breast	cancer	cell	 line	of	a	different	histologic	sub-type	and	bearing	the	R280K	mutant	p53	protein	(MDA-MB-231).	Notably,	 in	 these	cells,	ETV7	 transcriptional	activation	was	 still	observable,	even	 if	 at	 a	 lower	 level	 in	 comparison	 to	 MCF7,	 and	 specifically	 only	 in	 response	 to	 the	treatment	with	the	topoisomerase	inhibitors	Doxorubicin,	Etoposide,	and	Camptothecin	(Fig.	1G).	As	expected,	the	MDM2	inhibitor	Nutlin-3a	wasn’t	able	to	affect	ETV7	expression	in	MDA-MB-231.	Also,	5-Fluorouracil,	was	unable	to	activate	the	expression	of	ETV7	in	this	cell	 line,	possibly	due	to	the	fact	that	it	is	relying	on	a	different	DNA	damaging	mechanism	with	respect	to	Doxorubicin,	Etoposide,	and	Camptothecin	(Fig.	1G).	Curiously,	 in	 both	MCF7	 and	MDA-MB-231	 cells,	 Doxorubicin	 was	 the	most	 efficient	 ETV7	inducer	drug;	therefore,	the	ETV7	activation	upon	Doxorubicin	was	also	tested	and	positively	confirmed	in	other	cancer	cell	lines	derived	from	melanoma	(A375M),	lung	cancer	(A549)	and	osteosarcoma	(U2OS)	(Fig.	1I).	To	test	whether	the	same	transcriptional	activation	was	also	shared	by	normal	cells,	I	tested	ETV7	transcriptional	activation	 in	healthy	donor-derived	 lymphocytes	upon	Doxorubicin,	5-Fluorouracil,	Nutlin-3a	and	ionizing	radiation.	Despite	the	expected	variability,	the	majority	of	samples	showed	a	clear	ETV7	induction	upon	all	the	treatment	conditions	(Fig.	1H).	To	better	verify	 the	 conservation	 of	 ETV7	 activation	 in	 normal	 cells,	 immortalized	 normal	mammary	cells	(MCF10a),	immortalized	normal	foreskin	fibroblasts	BJ1	cells	and	Human	Umbilical	Vein	Endothelial	 Cells	 (HUVEC)	 were	 treated	 with	 Doxorubicin,	 and	 ETV7	 was	 observed	 to	 be	strongly	 induced	 also	 in	 these	 non-cancerous	 cell	 lines	 (Fig.	 1I).	 ETV7	 activation	 upon	Doxorubicin	was	also	responsible	 for	an	 increased	protein	expression	 in	nuclear	extracts	of	MCF7	cells	(Fig.	1J).	Endogenous	ETV7	expression	was	observable	only	when	more	than	50	µg	of	 nuclear	 extracts	 were	 loaded,	 given	 that	 ETV7	 protein	 levels	 in	 breast	 cancer	 cells	 are	considerably	 low.	 To	 better	 explore	 if	 Doxorubicin-mediated	 ETV7	 activation	 could	 be	involved	 in	 drug	 resistance,	 I	 first	 checked	 if	 also	 a	 prolonged	 treatment	with	Doxorubicin	could	lead	to	an	increase	in	ETV7	expression	in	breast	cancer	cells.	I	treated	both	MCF7	and	MDA-MB-231	cells	with	Doxorubicin	for	14	days	and	analyzed	the	ETV7	expression	by	qPCR	
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(Fig.1K).	In	MCF7	cells	ETV7	activation	revealed	to	be	modest,	whereas	in	MDA-MB-231	cells	ETV7	activation	was	massive	 (Fig.	1K),	 in	contrast	with	 the	results	obtained	upon	 transient	Doxorubicin	 treatment,	where	a	higher	ETV7	activation	was	 seen	 in	MCF7	cells	 (Fig.	1F-G).	These	results	are	suggesting	that	ETV7	induction	upon	DNA	damaging	drugs,	and	especially	Doxorubicin,	 could	be	a	 relevant	mechanism	 involved	 in	breast	 cancer	drug	 resistance,	 and	particularly	in	MDA-MB-231	cells,	given	the	results	upon	prolonged	Doxorubicin	treatment.			
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RESULTS-Figure	 1:	 A-B)	 Transcription	 factor	 binding	 sites	 (TFBS)	 enrichment	 analysis	 in	 Doxorubicin	 up-regulated	 (A)	 and	 repressed	 (B)	 DEGs	 relative	 to	 microarray	 analysis	 in	 MCF7	 cells.	 C)	 List	 of	 transcription	factors	with	highest	score	among	the	ones	up-regulated	by	Doxorubicin	in	microarray	analysis	from	MCF7	cells.	
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D)	 Expression	 values	 for	 ETS	 genes	 from	 microarray	 data	 of	 MCF7	 cells	 treated	 with	 Doxorubicin.	 E)	 qPCR	validation	of	Doxorubicin-repressed	ETS	 factors	SPDEF	and	ELF2	 in	MCF7	cells	F-G-H)	qPCR	analysis	of	ETV7	transcriptional	 activation	upon	DNA	damaging	 and	p53	activating	drugs	 in	MCF7	 cells	 (F),	MDA-MB-231	 cells	(G),	and	in	healthy	donor-derived	lymphocytes	(H,	each	color	corresponds	to	a	different	donor).	I)	qPCR	analysis	of	ETV7	expression	upon	Doxorubicin	treatment	in	different	cancer	cell	lines	(A375	melanoma,	A549	lung,	U2OS	osteosarcoma)	 and	 non	 cancerous	 cell	 lines	 (MCF10a,	 BJ1	 and	 HUVEC).	 J)	 Western	 Blot	 Analysis	 of	 ETV7	expression	from	nuclear	and	cytoplasmic	extracts	of	MCF7	cells	treated	with	Doxorubicin	(1,5	µM)	for	either	6	or	16	hours.		Histone	3	is	used	as	a	control	for	nuclear	extraction	efficiency.	K)	qPCR	analysis	for	ETV7	expression	upon	prolonged	Doxorubicin	treatment	(14	days)	using	0,5	µM	and	0,8	µM	Doxorubicin	respectively	 for	MCF7	and	MDA-MB-231	cells.	*	indicates	P-value	(T	test-treatment	vs	untreated	control-)	<0.05,	**	if	P-value	<0.01.	
		
5.2	 ETV7	 is	 synergistically	 activated	 by	 p53	 and	 p65	 upon	 combined	 treatment	 with	
Doxorubicin	and	TNF-α 		Microarray	 data	 in	 MCF7	 cells	 (GSE24065)	 showed	 that	 ETV7	 was	 one	 of	 the	 top	synergistically	 activated	 genes	 upon	 Doxorubicin	 and	 TNF-α	 treatment.	 I	 wanted	 to	experimentally	validate	by	qPCR	the	ETV7	activation	upon	Doxorubicin	and	TNF-α	 in	MCF7	cells	and	also	to	check	if	this	synergy	was	conserved	in	another	breast	cancer-derived	cellular	system,	MDA-MB-231.	Synergy	was	confirmed	 in	both	MCF7	and	MDA-MB-231	cells	but	 the	reported	ETV7	activation	and	synergy	levels	were	lower	in	MDA-MB-231	cells	in	comparison	to	MCF7	cells,	probably	due	to	the	fact	that	mutant	p53	is	not	as	effective	as	wild	type	p53	in	recruiting	 transcriptional	 co-activators	 (Fig.	 2A	and	Fig.	 2B,	 parental	 cells).	Given	 that	both	p53	 and	 p65	 transcription	 factors	 are	 strongly	 activated	 respectively	 by	 Doxorubicin	 and	TNF-α	treatment,	I	tested	by	ChIP-qPCR	assays	if	they	are	able	to	bind	the	ETV7	promoter	in	MCF7	 cells	 (Fig.	 2G	 and	 Fig.	 2H).	 MCP-1/CCL2	 and	 p21	 promoter	 regions	 were	 used	 as	positive	 controls	 for	 testing	 the	 activation	 and	 the	 immunoprecipitation	 efficacy	 of	respectively	p53	and	p65	proteins.	Localization	of	p53	and	p65	binding	sites	in	the	ETV7,	p21	and	MCP-1	genes	and	regions	amplified	by	ChIP-qPCR	experiments	are	depicted	in	Figure	2J.		Both	p53	and	p65	showed	occupancy	within	the	ETV7	promoter	and	in	their	positive	controls	p21	and	MCP-1	upon	all	treatments.	Moreover,	to	better	determine	the	involvement	of	these	two	 transcription	 factors	 in	 ETV7	 activation,	 I	 generated	 	MCF7	 and	MDA-MB-231	 cellular	clones	negative	for	the	expression	of	either	p53	and	p65	using	the	CRISPR/Cas9	technology	(Fig.	 2C-D-E-F).	 In	 MCF7	 cells,	 the	 transcriptional	 activation	 of	 ETV7	 was	 decreased	 upon	Doxorubicin	 and	 combined	 treatment	 in	 the	 absence	 of	 either	 p53	 or	 p65	 (Fig.	 2A).	Nevertheless,	 the	 synergistic	 activation	 of	 ETV7	was	 still	 observable,	 suggesting	 that	 these	factors	 alone	 are	 not	 essential	 for	 the	 transcriptional	 activation	 (Fig.	 2A).	 In	MDA-MB-231	cells,	the	impact	of	p53	or	p65	ablation	was	more	substantial	in	comparison	with	MCF7	cells	
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(Fig.	2B).	Synergy	was	lost	upon	deletion	of	either	p53	or	p65,	suggesting	that	possibly	also	mutant	 p53	 retained	 the	 potential	 to	 positively	 regulate	 ETV7	 expression.	 Furthermore,	 to	check	if	mutant	p53	was	able	to	bind	to	the	ETV7	promoter,	I	performed	ChIP-qPCR	assays	in	MDA-MB-231	 cells	 treated	with	Doxorubicin	 and	 I	was	 able	 to	 detect	 occupancy	 of	mutant	p53	already	in	the	mock	condition,	which	was	further	increased	upon	Doxorubicin	treatment	(Fig.	2I).	Mutant	p53	and	p65	cooperation	was	confirmed	as	a	critical	activatory	stimuli	 for	ETV7	expression	in	MDA-MB-231	cells,	where	even	in	basal	conditions	both	are	expressed	at	high	 level,	 thus	 justifying	also	the	reduced	 increased	 in	expression	of	ETV7	upon	single	and	combined	treatment	with	Doxorubicin	and	TNF-α	treatment	in	comparison	to	what	was	seen	with	MCF7	cells.				
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RESULTS-Figure	2:	A-B)	qPCR	analysis	of	ETV7	activation	upon	Doxorubicin,	TNF-α	and	combined	treatment	in	parental	or	p53	knock-out	 (KO)	or	p65	KO	MCF7	(A)	or	MDA-MB-231	cells	 (B).	C-D)	Western	Blot	analysis	of	
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CRISPR/Cas9	for	p53	generated	in	MCF7	cells	(C)	and	in	MDA-MB-231	cells	(D);	respectively,	clone	4a	for	MCF7	cells	 and	 clone	 4b	 for	 MDA-MB-231	 cells	 have	 been	 selected	 for	 following	 experiments.	 E-F)	 Western	 Blot	analysis	of	CRISPR/Cas9	for	p65	generated	in	MCF7	(E)	and	in	MDA-MB-231	cells	(F);	respectively,	clone	5e	for	MCF7	cells	and	clone	4b	for	MDA-MB-231	cells	have	been	selected	for	following	experiments.	G)	ChIP-qPCR	for	p53	 occupancy	 on	 ETV7	 promoter	 in	 MCF7	 cells	 upon	 Doxorubicin,	 TNF-α	 and	 combined	 treatment.	 P21	promoter	region	was	used	as	positive	control	for	p53	immunoprecipitation,	whereas	NSB	represented	the	non	specific	binding	control,	setting	the	threshold	for	specific	antibody	binding.	IgG	was	an	additional	control	for	the	binding	specificity	of	the	p53	antibody.	H)	ChIP-qPCR	for	p65	occupancy	on	ETV7	promoter	in	MCF7	cells	upon	Doxorubicin,	 TNF-α	 and	 combined	 treatment.	 MCP1	 promoter	 region	 was	 used	 as	 positive	 control	 for	 p65	activation	 and	 immunoprecipitation	 efficiency	 I)	 ChIP-qPCR	 analysis	 for	mutant	 p53	 occupancy	 on	 the	 ETV7	promoter	upon	Doxorubicin	 treatment	 in	MDA-MB-231	cells.	 J)	Graphical	 representation	of	 the	 localization	of	predicted	p53	and	p65	Response	Elements	 (RE)	 and	 the	 relative	 to	 the	TSS	 (Transcriptional	 Start	 Site)	 in	 the	ETV7,	p21	and	MCP1	genes.	Arrows	 indicate	 regions	amplified	by	 the	primers	used	 for	 the	ChIP-qPCR	assays.	Localization	 is	 reported	 using	 the	 human	 GRCh38/hg38	 as	 reference	 genome.	 NSB	 was	 the	 control	 for	 non-specific	binding.	*	indicates	a	P-value(T-test)		<	0.05,	**	if	<	0.01.	§	indicates	synergistic	activation	(sum	of	each	treatment	activation	is	statistically	lower	then	the	combined	treatment	activation,	§§	p	value(T-test)		<	0.01;	§	p	value(T-test)		<	0.05).			
5.3	STAT3	is	involved	in	transcriptional	activation	of	ETV7	in	MDA-MB-231	cells		So	 far,	 the	 involvement	 of	 p53	 and	 p65	 in	 the	 induction	 of	 ETV7	 has	 been	 considered,	 but	additional	transcription	factors	can	cooperate	in	the	activation	of	ETV7.	Among	the	possible	transcriptional	controllers,	I	decided	to	focus	on	STAT3,	being	an	important	mediator	linking	inflammation	 and	 cancer.	 I	 decided	 to	 more	 precisely	 analyze	 the	 role	 of	 STAT3	 in	 the	induction	 of	 ETV7	 transcription	 by	 generating	 cells	 negative	 for	 its	 expression	 using	 the	CRISPR/Cas9	technology	(Fig.	3E	and	3F).	In	MCF7	cells,	abrogation	of	STAT3	expression	led	to	 increased	expression	of	ETV7,	meaning	 that	 STAT3	exerts	 a	negative	 regulation	of	ETV7	transcription	(Fig.	3C).	In	fact,	in	MCF7	cells	no	STAT3	activation	was	seen	upon	all	treatment	conditions	(Fig.	3A).	Conversely,	in	MDA-MB-231	cells,	where	an	increase	of	phosphorylated	form	of	STAT3	(pSTAT3,	the	activate	form	of	the	protein)	was	seen	upon	Doxorubicin	and	the	combined	 treatment	 (Fig.	 3B),	 the	 depletion	 of	 STAT3	 diminished	 the	 ETV7	 activation,	although	 it	 is	 still	 synergistically	 induced	 (Fig.	 3D).	 This	 result	 suggests	 that	 STAT3	 has	probably	a	supporting	role	in	ETV7	transcription	in	MDA-MB-231	cells,	but	it	is	not	essential	like	p53	and	p65.				
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RESULTS-Figure	3:	A)	Western	Blot	analysis	of	STAT3	phosphorylation	in	MCF7	(A)	and	MDA-MB-231	cells	(B)	upon	Doxorubicin,	 TNF-α	 and	 combined	 treatment.	 C-D)	 qPCR	 analysis	 of	 ETV7	 activation	 upon	Doxorubicin,	TNF-α	and	combined	treatment	in	parental	or	STAT3	KO	MCF7	(C)	or	MDA-MB-231	cells	(D).	E-F)	Western	Blot	analysis	of	CRISPR/Cas9	for	STAT3	generated	in	MCF7	(E)	and	in	MDA-MB-231	cells	(F);	respectively	clone	3a	for	MCF7	cells	and	clone	5d	for	MDA-MB-231	cells	have	been	selected	for	following	experiments.	**	indicates	P-value	(T-test)		<	0.01;	§	indicates	synergistic	activation	(sum	of	each	treatment	activation	was	statistically	lower	then	the	combined	treatment	activation,	§§	p	value	(T-test)	<	0.01).				
5.4	ETV7	transcriptional	activation	is	determined	by	an	increase	in	H3K4me3		To	investigate	the	epigenetic	regulation	of	ETV7	transcription	upon	Doxorubicin	and	TNF-α,	I	performed	a	ChIP-qPCR	analysis	for	three	different	histone	marks	of	active	transcription,	one	involving	 methylation	 of	 Histone	 3	 and	 the	 other	 the	 acetylation	 of	 Histone	 4	 (H3K4me3,	H4PanAce,	H4K16Ace).	MCP-1	and	p21	served	as	positive	controls	of	activation.	An	increase	in	 H3K4me3	 upon	 Doxorubicin	 and	 TNF-α	 combined	 treatment,	 with	 respect	 to	 Mock	
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condition,	was	observable	both	in	the	region	where	p53	and	p65	are	binding	(RE)	and	also	in	the	region	comprising	the	TATA	box	(TATA).	Upon	single	treatment,	an	increase	in	H3K4me3	was	observed	only	 in	 the	RE	region	 (Fig.	4A).	Acetylation	of	H4K16	didn’t	 change	upon	 the	treatments,	whereas	Doxorubicin	treatment	was	responsible	for	an	enrichment	in	Histone	4	pan-acetylation	at	the	ETV7	promoter	(Fig.	4B).		
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RESULTS-Figure	 4:	ChIP-PCR	analysis	 for	 the	occupancy	of	 the	 transcriptional	 activation	mark	H3K4me3	 (A)	and	 H4	 pan	 acetylation	 and	 H4K16ace	 (B)	 in	 MFC7	 cells	 treated	 with	 Doxorubicin,	 TNF-α	 and	 combined	treatment.	IgG	signal	was	a	control	for	the	specificity	of	the	binding	of	H3K4me3	antibody,	p21	and	MCP1	served	as	a	controls	for	activated	genes	upon	the	tested	treatments.	H3K4me3	is	expressed	as	a	ratio	to	total	H3	signal	and	%	of	Input.	*	P-value(T-test)		<	0.05;	**	P-value(T-test)		<	0.01.	
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5.5	ETV7	triggers	breast	cancer	resistance	to	Doxorubicin			To	test	the	possible	role	for	ETV7	in	improving	cell	survival	upon	Doxorubicin	treatment	and	mediating	 a	 drug	 resistance	 phenotype,	 I	 generated	 a	 MDA-MB-231	 cell	 line	 stably	 over-expressing	ETV7.	MDA-MB-231	cell	line	was	chosen	being	representative	for	a	triple	negative	and	 therefore	more	advanced	breast	 cancer	 compared	 to	MCF7,	 thus	being	a	more	 suitable	model	for	the	clinical	condition	where	chemotherapy	with	cytotoxic	drugs	is	usually	adopted.	Furthermore,	a	higher	ETV7	activation	upon	Doxorubicin	prolonged	treatment	was	observed	in	MDA-MB-231	cells	with	respect	to	MCF7	cells	(Fig.	1K),	thus	suggesting	a	possible	greater	impact	 of	 ETV7	 in	 drug	 resistance	 in	 this	 cell	 line.	 In	 addition,	 both	 p53	 and	 p65	 were	reported	to	be	responsible	for	ETV7	transcriptional	activation	upon	Doxorubicin	and	TNF-α	treatment,	and	in	MDA-MB-231	cells	both	proteins	are	active	even	in	basal	conditions,	being	p53	kept	stable	in	its	mutant	form	and	p65	fired	by	the	presence	of	mutant	p53.	Therefore,	I	reasoned	that	MDA-MB-231	cell	 line	 itself	could	somehow	recapitulate	 the	Doxorubicin	and	TNF-α	condition	without	the	need	of	treatment.	Lastly,	given	the	observed	massive	mortality	of	 cells	 upon	 ETV7	 silencing	 (laboratory	 colleague’s	 project)	 and	 the	 low	 protein	 levels	 of	endogenous	ETV7	 ,	 I	was	 forced	 to	use	 over-expression	 as	 a	 tool	 for	 studying	ETV7-driven	biological	roles	in	breast	cancer.		For	the	aforementioned	reasons,	I	generated	MDA-	MB-231	cells	stably	over-expressing	ETV7	and	 the	 respective	 empty	 control	 cells	 (Fig.	 5B).	 I	 compared	 their	 survival	 upon	 72	 hours	treatment	with	increasing	concentration	of	Doxorubicin	by	MTT	assay.	ETV7	over-expressing	cells	were	characterized	by	an	increased	survival	at	all	tested	doses	(Fig.	5A).	To	determine	if	this	better	survival	in	ETV7	over-expressing	cells	could	be	linked	to	a	different	intra-cellular	accumulation	of	drug,	I	decided	to	quantify	the	levels	of	Doxorubicin	present	inside	the	nuclei	of	 the	 two	 cell	 lines.	 Notably,	 ETV7	 over-expressing	 cells	 showed	 a	 decreased	Doxorubicin	accumulation	 inside	 nuclei	with	 respect	 to	 cytoplasm,	 and	 the	 counted	 perinuclear	 area	 of	Doxorubicin	efflux	was	larger	when	compared	with	the	empty	counterpart	(Fig.	5C	and	5D).	The	observation	of	 higher	 expression	of	 the	ABC	 transporter	ABCB1	 in	MDA-MB-231-ETV7	cells	 may	 support	 the	 increased	 Doxorubicin	 efflux	 (Fig.	 5E).	 To	 check	 whether	 ETV7-mediated	 resistance	 mechanism	 was	 also	 conserved	 in	 other	 types	 of	 cancer,	 I	 generated	osteosarcoma	U2OS	cell	line	over-expressing	ETV7	(Fig.	5G).	One	colleague	demonstrated	that	also	 MCF7	 cells	 over-expressing	 ETV7	 better	 survived	 to	 Doxorubicin	 treatment	 (data	submitted,	 see	 Annex	 2.4).	 Similarly,	 U2OS	 over-expressing	 cells	 were	 more	 resistant	 to	Doxorubicin	 treatment	 in	 comparison	 with	 their	 empty	 control	 (Fig.	 5F),	 despite	 their	
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intrinsic	 higher	 sensitivity	 to	 Doxorubicin,	 thus	 suggesting	 that	 ETV7	 could	 trigger	Doxorubicin	resistance	in	different	types	of	cancer.	Furthermore,	U2OS	cells	over-expressing	ETV7	showed	a	small	increase	in	the	expression	of	ABCB1,	as	seen	in	MDA-MB-231-ETV7	cells	(Fig.	5H).	
	
RESULTS-Figure	5:	A)	MTT	assay	for	MDA-MB-231	cells	over-expressing	ETV7	and	the	empty	control	upon	72	hours	 of	 Doxorubicin	 treatment	 at	 increasing	 concentrations.	 B)	 Western	 Blot	 for	 checking	 the	 stable	 over-expression	 of	 	 ETV7	 protein	 in	 MDA-MB-231	 cells	 (20µg	 of	 total	 protein	 extract).	 C)	 Ratio	 of	 nuclear	 to	cytoplasmic	 intensity	 of	 Doxorubicin	 (10µM,	 3	 hours	 treatment)	 in	MDA-MB-231	 cells	 over-expressing	 ETV7	compared	with	the	empty	control.	D)	Total	cytoplasmic	area	of	Doxorubicin	efflux,	represented	as	Pixel	2	(1	pixel	in	20x	WD	is	0,5	μm).	Pictures	on	the	right	show	an	example	of	Doxorubicin	efflux	observed	at	the	Operetta	Perkin	
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Elmer	as	green	spots	area.	E)	qPCR	analysis	of	ETV7	over-expression	and	increase	of	ABCB1	expression	in	MDA-MB-231	 cells	 over-expressing	 ETV7	 compared	 with	 the	 empty	 control.	 F)	 MTT	 Assay	 for	 survival	 of	 ETV7	 over-expressing	 U2OS	 cells	 upon	 Doxorubicin	 treatment	 (72	 hours,	 increasing	 doses).	 G)	Western	 Blot	 analysis	 of	ETV7	over-expressing	U2OS	cells.	H)	qPCR	analysis	of	ETV7	over-expression	and	increase	of	ABCB1	expression	in	U2OS	cells	over-expressing	ETV7	compared	with	the	empty	control.	*	P-value(T-test)		<	0.05;	**	P-value(T-test)	<	0.01.	
	
5.6	DNAJC15	represents	a	good	candidate	for	mediating	ETV7-driven	drug	resistance		Given	 the	 relevant	 role	 observed	 for	 ETV7	 in	 breast	 cancer	 drug	 resistance,	 I	 wanted	 to	determine	possible	ETV7	targets	playing	key	roles	in	mediating	this	ETV7-driven	phenotype.	ETV7	 is	 a	 transcriptional	 repressor,	 therefore	 when	 searching	 for	 putative	 ETV7	 targets	involved	 in	 the	 drug	 resistance	 phenotype,	 I	 considered	 a	 list	 of	 hypermethylated	 ,thus	repressed	genes,	 directly	 associated	with	drug	 resistance	 (Boettcher,	Kischkel	 and	Hoheise,	2010).	I	restricted	the	analysis	to	DNA	methylation-type	of	regulation	because	it	was	recently	highlighted	as	an	 important	epigenetic	hallmark	for	drug	resistance,	and	found	enriched	for	some	ETS	factors	binding	site	(Hogart,	Lichtenberg	and	Ajay,	2012;	Strauss	and	Figg,	2016).		I	then	apply	a	filter	for	the	search	of	putative	ETV7	targets,	by	considering	the	expression	of	the	 reported	 genes	 in	 the	 microarray	 analysis	 performed	 in	 MCF7	 cells	 upon	 Doxorubicin	treatment	 available	 in	 the	 laboratory	 (Gene	 Expression	 Omnibus,	 GEO,	 accession	 number:	GSE24065).	Out	of	6	genes	,	3	were	remarkably	down-regulated	(Fig.	6A).	To	further	filter	and	confirm	this	data,	I	analyzed	by	qPCR	the	expression	of	these	3	genes	upon	Doxorubicin,	TNF-
α	 and	 the	 combined	 treatment	 (Fig.	 6B).	 The	 only	 gene	 which	 was	 synergistically	 down-regulated	 by	 the	 combined	 treatment	 was	 DNAJC15	 (Fig.	 6B).	 Interestingly,	 DNAJC15	 is	 a	known	negative	modulator	 of	 ABCB1	 expression	 by	 controlling	 c-Jun	 pathway	 (Hatle	 et	al.,	2007),	 and	 thus	 could	 directly	 link	 the	 observed	 ABCB1	 increased	 expression	 upon	 ETV7	over-expression.	To	 further	 investigate	ETV7	and	DNAJC15	 linkage,	 I	 analyzed	by	qPCR	 the	DNAJC15	expression	upon	ETV7	activating	stimuli	 in	breast	cancer	cells	and	in	lymphocytes	(Fig.	6C-D-E).	As	expected,	DNAJC15	repression	was	observed	upon	DNA	damaging	drugs	in	both	MCF7	 and	MDA-MB-231	 cells	 (Fig.	 6C	 and	 6D).	 Notably,	 similarly	 to	 ETV7	 activation,	Doxorubicin	 was	 the	 most	 effective	 drug	 in	 repressing	 DNAJC15	 expression	 and	 this	mechanism	 proved	 to	 be	 conserved	 also	 in	 normal	 cells,	 being	 down-regulated	 by	 DNA	damaging	and	p53	activating	drugs	even	in	healthy	donors-derived	lymphocytes	(Fig.	6E).	By	comparing	 ETV7	 activation	 (Fig.	 1C)	 and	 DNAJC15	 repression	 in	 lymphocytes	 (Fig.	 6E),	 a	relevant	inverse	correlation	was	observable	for	some	donors,	such	as	the	orange-depicted	one	in	the	case	of	Doxorubicin,	5-Fluorouracil	and	Nutlin-3a.	Moreover,	DNAJC15	repression	was	observed	also	upon	prolonged	exposure	to	Doxorubicin	(14	days)	in	MCF7	and	MDA-MB-231	
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cells,	 further	 supporting	 the	promising	 involvement	of	DNAJC15	 in	breast	 cancer	 cells	drug	resistance	(Fig.	6F).				
	
RESULTS-Figure	6	A)	Expression	microarray	data	of	MCF7	cells	treated	with	Doxorubicin	for	genes	commonly	found	 hypermethylated	 and	 repressed	 in	 drug	 resistant	 breast	 cancer.	 B)	 qPCR	 analysis	 for	 comparing	repression	of	BRCA1,	ESR1,	DNAJC15	and	activation	of	ETV7	upon	Doxorubicin,	TNF-α	and	combined	treatment.	§	 indicates	 synergistic	 activation	 (sum	 of	 each	 treatment	 activation	 is	 statistically	 lower	 then	 the	 combined	treatment	activation,	§§	P-value	T-test	<	0.01).	C-E)	DNAJC15	repression	upon	different	DNA	damaging	and	p53	activating	drugs	 in	MCF7	 (C),	 in	MDA-MB-231	 cells(D)	 and	 in	healthy	donor-derived	 lymphocytes	 (each	 color	represents	a	different	donor,	the	same	used	for	ETV7	analysis)	(E).		F)	DNAJC15	expression	levels	measured	by	
BR
CA
1
ES
R1
DN
AJ
C1
5
CD
H1
RA
B6
C
SU
LF
2
-1.5
-1.0
-0.5
0.0
0.5
1.0
Lo
g 
FC
BR
CA
1
ES
R1
DN
AJ
C1
5
ET
V7
 
0.0
0.5
1.0
1.5
5
15
25
35
45
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
Doxorubicin
TNF
Doxorubicin+TNF
§§
§§
A B
C
Do
xo
rub
ici
n
Eto
po
sid
e
5-F
luo
ro
ur
ac
il
Nu
tlin
-3a
Ca
mp
tot
he
cin
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
**
**
**
**
**
Do
xo
rub
ici
n  
 
Eto
po
sid
e
5-F
luo
ro
ur
ac
il
Nu
tlin
-3a
Ca
mp
tot
he
cin
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
**
** **
D E
Doxorubicin treated MCF7 Microarray Synergy Analysis in MCF7
MCF7 MDA-MB-231 Lymphocytes
Do
xo
rub
ici
n 
Ion
izi
ng
 ra
dia
tio
n
5-F
luo
ro
ur
ac
il
Nu
tlin
-3a
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
F DNAJC15 upon Doxorubicin 
prolonged treatment
MC
F7
MD
A-
MB
-23
1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
Untreated
Doxorubicin
14 days
** **
	 53	
qPCR	upon	prolonged	Doxorubicin	treatment	(14	days)	in	MCF7	cells	(0,5µM	Doxorubicin)	and	in	MDA-MB-231	cells	(0,8µM	Doxorubicin).	**	P-value	T-test	(treated	versus	untreated)<	0.01.		
5.7	ETV7	can	regulate	DNAJC15	expression		To	verify	if	DNAJC15	can	be	considered	a	direct	ETV7	target,	I	checked	DNAJC15	expression	upon	ETV7	transient	transfection	in	MCF7	and	in	the	generated	ETV7	over-expressing	MDA-MB-231	 cells.	 DNAJC15	 repression	 was	 observable	 upon	 both	 transient	 and	 stable	overexpression	of	ETV7	(Fig.	7A	and	Fig.	7B).	I	then	cloned	an	800	bp	portion	of	the	DNAJC15	promoter	region	upstream	the	 firefly	 luciferase	reporter	gene	and	monitored	 its	expression	upon	ETV7	transient	transfection.	Using	Gene	Reporter	Assays,	the	repression	was	observable	as	a	decrease	 in	Relative	Light	Units	 (RLU)	 in	both	MCF7	parental	 cells	and	also	 in	 the	p53	deleted	version	(Fig.	7C);	whereas	in	MDA-MB-231	cells	the	repression	was	observable	only	in	the	absence	of	mutant	p53	(Fig.	7D).	To	specifically	demonstrate	the	recruitment	of	ETV7	on	 the	 promoter	 of	 DNAJC15,	 I	 performed	 ChIP-qPCR	 Assays	 in	 MDA-MB-231	 cells	 over-expressing	ETV7.	Experiments	confirmed	ETV7	occupancy	on	the	DNAJC15	promoter,	which	consistently	increased	in	the	presence	of	Doxorubicin	(Fig.	7E),	an	observation	in	line	with	the	strongly	 increased	 amount	 of	 ETV7	 protein	 in	 chromatin	 and	 nuclear	 fraction	 upon	 this	treatment	 (Fig.	 7F).	 Gene	Reporter	 Assays	 also	 showed	 a	 significant	 decrease	 in	 basal	 RLU	relative	to	MCF7	and	MDA-MB-231	cells	without	p53	in	comparison	with	the	parental	ones,	thus	suggesting	that,	probably,	p53	may	control	DNAJC15	expression.	To	check	if	the	decrease	in	DNAJC15	expression	was	not	 just	 linked	 to	 the	procedures	 for	 the	generation	of	 this	 cell	line,	 but	 directly	 dependent	 on	 the	 absence	 of	 p53,	 I	 transiently	 silenced	 p53	 with	oligonucleotides	 and	 checked	DNAJC15	expression	by	qPCR	 in	MDA-MB-231	 cells	 (Fig.	 7G).	While	 effective	 in	 reducing	 the	 endogenous	 levels	 of	 p53,	 no	 statistically	 significant	differences	in	the	expression	of	DNAJC15	upon	p53	silencing	in	the	untreated	condition	were	determined	 (Fig.	 7G).	 Conversely,	 p53	 silencing	 increased	 the	 DNAJC15	 down-regulation	potential	upon	Doxorubicin	treatment.	This	could	suggest	that	mutant	p53-dependent	control	on	 DNAJC15	 expression	 is	more	 relevant	 upon	Doxorubicin	 treatment	 rather	 than	 in	 basal	conditions.	To	better	 investigate	 the	 role	of	p53	on	 the	expression	of	DNAJC15,	 I	 also	over-express	transiently	(48	hours)	either	the	wild	type	p53	or	two	different	type	of	mutant	p53	(respectively,	 R282Q	 and	 G279E)	 in	 MDA-MB-231	 p53	 KO	 cells	 (Fig.	 7H).	 There	 were	 no	statistically	 relevant	 differences	 in	 DNAJC15	 expression	 upon	 any	 type	 of	 the	 p53	 over-expression,	 further	 supporting	 the	 conclusion	 that	 probably	 p53	 alone	without	 stimulation	upon	 Doxorubicin	 is	 not	 able	 to	 influence	 DNAJC15	 expression.	 Nevertheless,	 to	 better	
	 54	
understand	the	reasons	why	in	MDA-MB-231	cells	the	promoter	of	DNAJC15	was	not	affected	by	ETV7	over-expression,	I	checked	if	p53	could	bind	nearby	the	ETV7	binding	site	within	the	DNAJC15	 promoter,	 thus	 probably	masking	 the	 binding	 site	 for	 ETV7	 and	 impacting	 on	 its	capability	to	bind	to	DNA.	In	fact,	a	half	site	consensus	site	for	p53	was	found	nearby	the	ETV7	binding	 region	 (Fig.	 7I).	 To	 verify	 this	 hypothesis,	 I	 performed	 a	 ChIP-qPCR	 by	immunoprecipitating	wild	 type	p53	 in	MCF7	cells	 (Fig.	7J)	and	mutant	p53	 in	MDA-MB-231	cells	(Fig.	7L)	and	checking	p53	occupancy	in	the	same	region	where	ETV7	is	binding	on	the	DNAJC15	 promoter	 (Fig.	 7I).	 In	 MCF7	 cells	 wild	 type	 p53	 was	 retrieved	 on	 the	 DNAJC15	promoter,	which	was	decreased	in	presence	of	Doxorubicin	(Fig.	7J),	whereas	mutant	p53	was	also	able	to	bind	to	DNAJC15	promoter	already	in	the	untreated	condition	(even	if	at	a	lower	extent),	 but	 its	 occupancy	 slightly	 increased	 upon	 Doxorubicin	 treatment	 (Fig.	 7L).	 This	binding	ability	of	p53	suggests	that	probably	in	parental	MDA-MB-231	cells	ETV7	binding	site	within	DNAJC15	promoter	could	be	masked	by	mutant	p53	or,	alternatively,	mutant	p53	could	possibly	 negatively	 interfere	 with	 the	 transcriptional	 function	 of	 ETV7.	 In	 fact,	 given	 the	presence	of	high	concentrations	of	reporter	plasmid	in	the	Gene	Reporter	Assays,	the	mutant	p53-dependent	negative	effect	on	ETV7	repressive	action	can	be	more	evident.	The	fact	that	wild	type	p53	binds,	even	with	higher	stronger	potential	compared	with	mutant	p53,	but	 in	Gene	Reporter	Assays,	doesn’t	 inhibit	ETV7	 repressive	action,	 could	 suggest	 that	 a	possible	direct	 or	 indirect	 link	 between	 ETV7	 and	 p53	 is	more	 relevant	 in	 presence	 of	mutant	 p53	rather	 than	 the	 wild	 type	 form.	 According	 to	 the	 hypothesis	 of	 a	 possible	 masking	 effect	exerted	 by	mutant	 p53,	 it	 can	 be	 that	 probably	 p53	 could	 bind	more	 tightly	 to	 the	 cloned	promoter	 with	 respect	 to	 the	 endogenous	 DNAJC15	 promoter,	 possibly	 due	 to	 different	chromatin	conformation	or	the	presence	of	other	transcription	factors.	Moreover,	the	putative	binding	of	p65	to	DNAJC15	promoter	was	also	checked,	to	determine	if	wild	type	or	mutant	p53	 and	 p65	 eventually	 cooperate	 in	 controlling	 DNAJC15	 expression	 (Fig.7K	 and	 7M	respectively).	ChIP-qPCR	assay	showed	that	p65	can	bind	to	the	DNAJC15	promoter	mainly	in	the	mock	condition	and	it	is	remarkably	reduced	(Fig.	7K,	MCF7	cells)	or	abolished	(Fig.	7M,	MDA-MB-231)	 upon	 Doxorubicin	 treatment.	 This	 result	 can	 suggest	 that	 possibly	 p53	silencing	alone	was	not	sufficient	to	appreciate	effects	on	DNAJC15	expression,	because	bound	p65	could	 compensate	 the	absence	of	p53,	whereas	upon	Doxorubicin	 treatment	being	 just	p53	bound,	p53	silencing	resulted	in	a	consistent	down-regulation	of	DNAJC15	expression.					
	 55	
	
0
20000
40000
60000
80000
100000
R
LU
MCF7 parental + pCMV6 Empty
MCF7 parental + pCMV6 ETV7
MCF7 p53 KO+ pCMV6 Empty
MCF7 p53 KO+ pCMV6 ETV7
**
**
MCF7
 parental
MCF7
 CRISPRp53
**
0
2000
4000
6000
8000
10000
R
LU
MDA-MB-231 parental + pCMV6 Empty
MDA-MB-231 parental + pCMV6 ETV7
MDA-MB-231 p53 KO + pCMV6 Empty
MDA-MB-231 p53 KO + pCMV6 ETV7
MDA-MB-231
 parental
MDA-MB-231
 CRISPRp53
**
**
ET
V7
DN
AJ
C1
5 
0.0
0.2
0.4
0.6
0.8
1.0
100
150
200
250
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
**
**
A B C
ET
V7
DN
AJ
C1
5 
0.0
0.2
0.4
0.6
0.8
1.0
80
100
120
140
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
**
**
DN
AJ
C1
5
NS
B
DN
AJ
C1
5
NS
B
0.0
0.2
0.4
0.6
0.8
1.0
 %
 IN
PU
T
ETV7
IgG
Mock Doxorubicin
**
**
		






	
	

	
	 ! !
D
E F
MCF7 MDA-MB-231 Gene Reporter Assay
 in MCF7
Gene Reporter Assay 
in MDA-MB-231
ChIP-qPCR in 
MDA-MB-231-ETV7
Western Blot Analysis 
MDA-MB-231-ETV7
	 56	
	
RESULTS-Figure	7:	A-B)	DNAJC15	repression	upon	transient	ETV7	expression	in	MCF7	cells	(A)	and	upon	stable	ETV7	expression	in	MDA-MB-231	cells	(B).	C-D)	Gene	Reporter	Assay	for	ETV7	binding	on	DNAJC15	promoter	reporter	 in	 parental	 or	 p53	 KO	 MCF7	 (C)	 or	 MDA-MB-231	 cells	 (D).	 E)	 ChIP-qPCR	 for	 ETV7	 occupancy	 on	DNAJC15	promoter	 in	MDA-MB-231	cells	over-expressing	ETV7	and	 treated	with	Doxorubicin.	NSB	 is	 the	non	specific	binding	control	(GTF2H5	was	used).	F)	Western	Blot	analysis	of	chromatin	and	nuclear	fraction	of	MDA-MB-231	 cells	 over-expressing	 ETV7	 upon	 Doxorubicin	 treatment.	 H3	 was	 used	 as	 control	 for	 chromatin	fractions.	G)	qPCR	analysis	for	the	measurement	of	DNAJC15	and	p53	expression	upon	p53	silencing	(25nM,	72	hours)	 and	 Doxorubicin	 treatment	 (1,5µM,	 16	 hours)	 in	 MDA-MB-231	 cells.	 H)	 qPCR	 analysis	 for	 the	measurement	of	DNAJC15	and	p53	expression	upon	 transient	 (48	hours)	overexpression	of	p53	 (wild	 type	or	mutant	R282Q	and	G279E)	 in	MDA-MB-231	p53	KO	 cells.	 I)	 Graphical	 representation	 of	 of	 the	 localization	 of	predicted	ETV7,	p53	and	p65	Response	Elements	(REs)	and	the	TSS	in	the	DNAJC15	promoter.	Arrows	indicate	regions	amplified	by	the	primers	used	for	the	ChIP-qPCR	assay.	Localization	is	reported	using	the	human	UCSC	GRCh38/hg38	as	reference	genome.	J-M)	ChIP-qPCR	for	mutant	p53	occupancy	(J,L)	and	p65	(K,M)	on	DNAJC15	promoter	in	MCF7	(J,	K)	and	MDA-MB-231	cells(L,M)	treated	with	Doxorubicin	(1,5µM,	16	hours).	NSB	is	the	non	
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specific	binding	control	(ACTB	in	MCF7	cells	and	GTF2H5	in	MDA-MB-231	cells).	 	*	indicates	a	P-value(T-test)	<	0.05	and	**	a	P-value(T-test)	<	0.01.			
5.8	 ETV7	 drug	 resistance	 phenotype	 can	 be	 rescued	 by	 DNAJC15	 over-expression	 or	
flavonoids	administration	
	To	better	check	if	DNAJC15	could	really	represent	a	key	mediator	in	ETV7-driven	resistance	phenotype,	I	 tried	to	rescue	the	resistant	phenotype	by	performing	an	ectopic	expression	of	DNAJC15	 in	 the	ETV7	over-expressing	 cell	 line	 and	monitoring	 cell	 survival	 upon	72	hours	Doxorubicin	 treatment.	DNAJC15	over-expression	 revealed	able	 to	 sensitize	 the	ETV7	over-expressing	 cells	 to	 Doxorubicin	 (studied	 with	 two	 different	 concentrations)	 that	 was	 also	associated	with	a	down-regulation	of	ABCB1	expression	(Fig.	8A	and	Fig.	8B).	Furthermore,	I	wanted	 to	 analyze	 the	 clinical	 relevance	 of	 this	 novel	 ETV7-DNAJC15	 circuitry	 in	 breast	cancer	patients	using	available	expression	data.	In	particular,	the	dataset	GSE43502	gathered	data	 similar	 to	 the	 in	vitro	 condition	 studied,	 since	Yu	 and	 co-workers	 collected	 expression	data	 from	 recurrent	 or	 non-recurrent	 triple	 negative	 breast	 cancer	 patients	 after	 adjuvant	chemotherapy	(Yu	et	al.,	2013).	ETV7	expression	was	increased	in	recurrent	samples	(P-value	was	not	significant	 -0.08-,	but	a	 trend	was	clearly	visible)	while	 the	expression	of	DNAJC15	was	reduced	in	a	statistically	significant	manner	in	the	same	patients	(Fig.	8C).	The	online	tool	Kaplan	Meier-plotter,	allowing	the	analysis	of	the	effects	of	different	genes	on	breast	cancer	prognosis	(Szász	et	al.,	2016),	was	interrogated	for	DNAJC15	expression	in	relation	to	relapse-free	survival	 from	breast	cancer	patients	and	showed	a	quite	relevant	Hazard	Ratio	of	0.73,	supporting	the	association	between	its	 low	expression	and	increased	patients’	susceptibility	to	 cancer	 relapses	 (Fig.	 8D).	 Given	 the	 relevance	 of	 the	 mechanism	 discovered,	 and	 the	technical	problems	in	the	over-expression	of	a	gene	such	as	DNAJC15	for	clinical	applications,	I	decided	to	test	 if	Quercetin	was	able	to	sensitize	ETV7	over-expressing	cells.	The	selection	was	 motivated	 by	 the	 fact	 that	 it	 has	 been	 demonstrated	 that	 this	 flavonoid	 can	 increase	Doxorubicin	 efficacy	 and	 reduce	 related	 cardiotoxicity	 in	 cancer	 patients.	 Interestingly,	Quercetin	 can	 sensitize	 MDA-MB-231	 over-expressing	 ETV7,	 and	 it	 is	 also	 able	 to	 repress	ETV7	expression	 in	MDA-MB-231	 cells	 (Fig.	 8E	 and	Fig.	 8F).	This	 last	 observation	was	 also	evident	 from	 the	 treatment	 of	 MDA-MB-231	 cells	 with	 another	 class	 of	 flavonoid,	 such	 as	Genistein	 (Fig.	 8F).	Therefore,	 a	 combination	of	Doxorubicin	with	 flavonoids	 could	possibly	improve	treatment	efficacy,	by	reducing	associated	ETV7	activation.	
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RESULTS-Figure	8:	A)	MTT	Assay	of	MDA-MB-231	cells	stably	over-expressing	ETV7	and	transiently	transfected	with	either	DNAJC15	or	Empty	control.	B)	qPCR	analysis	for	ABCB1	expression	in	MDA-MB-231	cells	stably	over-expressing	ETV7	 and	 transiently	 transfected	with	DNAJC15.	 C)	 ETV7	 and	DNAJC15	 expression	 analysis	 in	 the	dataset	GSE43502,	 relative	 to	 recurrent	or	non-recurrent	 triple	negative	breast	 cancer	patients	after	adjuvant	chemotherapy	(each	color	represents	a	different	patient).	D)	Kaplan	Meier-plotter	analysis	for	DNAJC15	(probe	227808_at)	expression	 in	breast	 cancer	patients	and	 relapse	 free	 survival	 (RFS).	E)	MTT	Assay	 for	 survival	of	
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MDA-MB-231	cells	stably	over-expressing	ETV7	and	empty	control,	treated	with	Quercetin.	F)	qPCR	analysis	of	ETV7	 repression	upon	Quercetin	and	Genistein	 treatment	 in	MDA-MB-231	cells.	 	*	P-value(T-test)	<	0.05;	 **	P-value(T-test)	<	0.01.		
	
5.9	DNAJC	family	response	to	Doxorubicin	and	possible	involvement	of	DNAJC14	in	drug	
resistance		According	 to	microarray	data	obtained	by	our	group	(GSE24065),	Doxorubicin	 treatment	 in	MCF7	 cells	 can	 influence	 the	 expression	 of	 many	 DNAJC	 proteins,	 mainly	 in	 a	 repressive	fashion	(Fig.	9A).	For	this	reason,	I	decided	to	investigate	if	other	members	of	DNAJC	family	could	be	involved	in	drug	resistance,	given	that	many	of	them	are	poorly	studied,	especially	in	the	 cancer	 field.	 I	 analyzed	 the	 expression	 of	 the	 five	 highly	 repressed	 members	 by	Doxorubicin	 treatment	 using	 the	 triple	 negative	 breast	 cancer	 dataset	 (GSE43502),	 and	 I	found	that	only	DNAJC14	was	statistically	down-regulated	in	recurrent	triple	negative	breast	cancers	 (Fig.	9B).	Then,	 I	 checked	DNAJC14	potential	as	predictive	marker	by	Kaplan-Meier	plotter,	 and	 observed	 a	 positive	 correlation	 between	 high	 expression	 and	 relapse-free	survival,	which	motivated	me	 in	 further	exploring	DNAJC14	role	 in	breast	cancer	resistance	and	its	possible	link	with	ETV7	(Fig.	9C).				
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RESULTS-Figure	9:	A)	DNAJC	family	expression	in	microarrray	data	from	MCF7	cells	treated	with	Doxorubicin	(GSE24065).	B)	Expression	analysis	of	the	highly	down-regulated	DNAJC	genes	upon	Doxorubicin	treatment	in	the	 dataset	 GSE43502	 referred	 to	 breast	 cancer	 recurrence.	 C)	 Kaplan	Meier-plotter	 analysis	 for	 relapse-free	survival	in	breast	cancer	patients	with	high	or	low	expression	for	DNAJC14.	*	indicates	P-value	(T	-test)<	0.05.			
5.10	DNAJC14	is	a	novel	ETV7	target		Supported	by	the	MCF7	microarray	analysis	reporting	a	strong	repression	of	DNAJC14	upon	Doxorubicin,	I	validated	its	transcriptional	response	to	different	DNA	damaging	drugs	both	in	MCF7	 and	 in	MDA-MB-231	 cells	 (Fig.	 10A	 and	 Fig.	 10B).	 DNAJC14	 showed	 repression	 only	upon	Doxorubicin	and	5-Fluorouracil	 in	MCF7,	and	only	upon	Doxorubicin	and	Nutlin-3a	 in	MDA-MB-231	cells.	Doxorubicin	was	still	 representing	 the	most	effective	drug	 in	repressing	DNAJC14,	as	was	the	case	for	DNAJC15,	but	prolonged	Doxorubicin	treatment	was	effectively	repressing	 DNAJC14	 only	 in	MCF7	 cells	 but	 not	 in	MDA-MB-231	 cells	 (Fig.	 10D).	 DNAJC14	repression	 upon	 DNA	 damaging	 drugs	 was	 marginally	 recapitulated	 in	 lymphocytes	 (Fig.	
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10C).	To	determine	 if	DNAJC14	expression	 could	be	 controlled	by	ETV7,	 I	 performed	ETV7	over-expression	experiments	 in	MCF7	cells	 (transient	 transfection)	and	quantified	DNAJC14	expression	 by	 qPCR.	 Notably,	 ETV7	 over-expression	was	 associated	with	 the	 repression	 of	endogenous	DNAJC14,	 supporting	 the	hypothesis	 of	DNAJC14	 as	 an	ETV7	 target	 (Fig.	 10G).	Further	 determination	 of	 the	 role	 of	 ETV7	 on	 DNAJC14	 was	 performed	 by	 Gene	 Reporter	Assay,	which	 confirmed	 the	 ETV7-mediated	 repression	 of	DNAJC14,	 both	 in	MCF7	parental	and	MCF7	p53	KO	cells,	without	any	relevant	difference	between	the	two	cell	lines	(Fig.	10E).	Repression	was	observable	also	in	MDA-MB-231	parental	and	p53	KO	cells,	with	a	statistically	relevant	 reduction	 of	 the	 basal	 level	 of	 the	 reporter	 gene	 even	 upon	 the	 transfection	 of	 an	empty	vector	in	MDA-MB-231	p53	KO	when	compared	to	the	parental	MDA-MB-231	cells	(Fig.	10F).	To	validate	this	observed	effect	of	mutant	p53	absence	on	DNAJC14	expression	in	MDA-MB-231	 cells,	 I	 silenced	p53	 and	 checked	how	 this	 could	 influence	 the	 expression	 levels	 of	DNAJC14.	 Silencing	 of	 p53	 alone	 resulted	 in	 a	 marked	 down-regulation	 of	 DNAJC14	expression,	 which	 was	 also	 increasing	 its	 Doxorubicin-mediated	 repression	 (Fig-10I).	Conversely,	 neither	 wild	 type	 nor	 mutant	 p53	 (R282Q	 and	 G279E)	 were	 able	 to	 shape	DNAJC14	expression	when	simply	over-expressed	in	MDA-MB-231	p53	KO	cells,	meaning	that	other	 transcription	 factors	are	needed	 for	regulating	 its	 transcription	(Fig.	10J).	 	ChIP-qPCR	experiments	 confirmed	 mutant	 p53	 binding	 to	 DNAJC14	 promoter	 in	 mock	 and	 more	prominently	in	Doxorubicin-treated	condition;	in	this	particular	case,	the	putative	consensus	p53	binding	site	is	a	full	site	(DNAJC15	promoter	contains	a	p53	half	site;	Fig.10N).	Also	wild	type	p53	was	able	to	be	recruited	on	the	DNAJC14	promoter	in	MCF7	cells		both	in	mock	and	upon	Doxorubicin	 treatment	(Figure	10L).	Given	the	possible	cooperation	between	p53	and	p65,	 I	 also	 checked	 p65	 occupancy	 in	 DNAJC14	 promoter	 in	MCF7	 and	MDA-MB-231	 cells	(putative	localization	of	p65,p53,	and	ETV7	response	elements	is	reported	in	Figure	10K).	In	MCF7	 cells,	 p65	 was	 found	 in	 the	 DNAJC14	 promoter	 in	 mock	 and	 upon	 Doxorubicin	treatment	 (Fig.	 10M),	whereas	 in	MDA-MB-231	 cells	 p65	was	 not	 able	 to	 bind	 to	DNAJC14	promoter	 (Fig.	 10O).	 Therefore,	 the	 ETV7-mediated	 down-regulation	 of	 DNAJC14	 seen	 in	Gene	 Reporter	 Assays	 with	 MDA-MB-231	 cells	 bearing	 mutant	 p53,	 can	 suggest	 that,	probably,	 the	 presence	 of	 p65	 on	 DNA	 can	 stabilize	 mutant	 p53	 binding,	 especially	 when	bound	to	an	exogenous	reporter	plasmid.		Moreover,	to	finally	determine	DNAJC14	as	a	direct	target	of	ETV7,	I	performed	ChIP-qPCR	assays.	ETV7	occupancy	within	the	DNAJC14	promoter	region	 was	 observed	 in	 mock	 condition	 and	 was	 further	 enhanced	 upon	 Doxorubicin	treatment	(Fig.	10H).	Lastly,	to	understand	if	DNAJC14	repression	was	playing	a	role	in	ETV7-mediated	 chemoresistance,	 the	 sensitivity	 of	 MDA-MB-231	 cells	 to	 increasing	 amount	 of	
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Doxorubicin	 and	 silencing	 of	 DNAJC14	 with	 oligonucleotides	 (siRNA)	 was	 measured	 (Fig.	10P).	 Results	 provided	 conflicting	 data,	 since	 silencing	 was	 increasing	 breast	 cancer	 cells	sensitivity	to	Doxorubicin	at	lower	doses,	and	increasing	resistance	only	at	higher	doses	(Fig.	10P).	
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RESULTS-Figure	 10:	 A-B-C)	 qPCR	 analysis	 of	 DNAJC14	 expression	 upon	 different	 DNA	 damaging	 and	 p53	activating	drug	treatment	in	MCF7	(A),	in	MDA-MB-231	cells	(B),	and	in	healthy	donors-derived	lymphocytes	(C,	each	 color	 corresponds	 to	 a	 different	 patient).	 D)	 qPCR	 analysis	 of	 DNAJC14	 expression	 upon	 prolonged	 (14	days)	treatment	in	MCF7	and	MDA-MB-231	cells.	E-F)	Gene	Reporter	Assay	for	DNAJC14	promoter	upon	ETV7	transient	 overexpression	 in	 parental	 or	 p53	 KO	MCF7	 (E)	 and	 in	MDA-MB-231	 cells	 (F).	 G)	 qPCR	 analysis	 of	DNAJC14	 repression	 upon	 ETV7	 transient	 expression	 in	 MCF7	 cells.	 H)	 ChIP-qPCR	 for	 ETV7	 occupancy	 on	DNAJC14	promoter	in	MDA-MB-231	cells	over-expressing	ETV7,	and	treated	with	Doxorubicin.	I)	qPCR	analysis	for	the	measurement	of	DNAJC14	and	p53	expression	upon	p53	silencing	and	Doxorubicin	treatment	(1,5µM,	16	hours)	in	MDA-MB-231	cells.	J)	qPCR	analysis	for	the	measurement	of	DNAJC14	and	p53	expression	upon	wild	type	or	mutant	p53	over-expression	(48	hours)	in	MDA-MB-231	KO	cells.	K)	Graphical	representation	of	of	the	localization	of	predicted	ETV7,	p53,	and	p65	Response	Elements	(REs)	and	the	TSS	 in	 the	DNAJC14	promoter.	Arrows	indicate	regions	amplified	by	the	primers	used	for	the	ChIP-PCR	assay.	Localization	is	reported	using	the	human	UCSC	GRCh38/hg38	as	reference	genome.	L-N)	ChIP-qPCR	assay	for	wild	type	p53	(L)	and	mutant	p53	(N)	occupancy	on	the	DNAJC14	promoter	in	MCF7	and	MDA-MB-231	cells	treated	with	Doxorubicin	(1,5µM,	16	hours).	M-O)	ChIP-qPCR	for	p65	occupancy	on	the	DNAJC14	promoter	in	MCF7	(M)	and	MDA-MB-231	cells	(O)	treated	with	Doxorubicin	 (1,5µM,	16	hours).	P)	MTT	assay	of	MDA-MB-231	cells	upon	DNAJC14	silencing	and	Doxorubicin	treatment	of	72	hours.	**	indicates	P-value	(T-test)	<	0.01.	
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5.11	Doxorubicin	and	p53	might	influence	ETV7	protein	stability			Given	 the	 findings	 obtained	 so	 far,	 I	 considered	 an	 ETV7	 ChIP-seq	 experiment	 as	 next	essential	step	to	understand	at	a	global	scale	which	are	the	ETV7	targets	and	to	try	to	identify	a	 possible	 link	 between	 its	 activity	 as	 transcriptional	 repressor	 and	 its	 role	 in	 cancer	 cells	drug	resistance.	Therefore,	 in	 order	 to	 understand	 the	 optimal	 experimental	 conditions	 for	 ETV7	 ChIP-seq	analysis,	 I	performed	a	chromatin	and	nuclear	extraction	 in	MDA-MB-231	parental	and	p53	KO	cells	both	over-expressing	ETV7,	given	the	different	responses	observed	in	Gene	Reporter	Assays	for	DNAJC15	and	DNAJC14.	In	particular,	ETV7	expression	in	chromatin	fraction	was	barely	visible	in	MDA-MB-231	parental	ETV7	over-expressing	cells,	whereas	was	already	high	in	MDA-MB-231	p53	KO	ETV7	over-expressing	cells	(Fig.	11A).	In	both	cell	lines,	Doxorubicin	treatment	was	 increasing	ETV7	expression	 in	both	 the	nuclear	and	chromatin	 fraction	 (Fig.	11A).	 To	 check	 if	 the	 different	 ETV7	 expression	 in	 the	 absence	 of	 mutant	 p53	 could	 be	 a	consequence	of	the	direct	interaction	of	mutant	p53	to	ETV7,	I	performed	a	Co-IP	experiment	in	MDA-MB-231	cells	overexpressing	ETV7,	and	I	observed	a	weak	interaction	signal	between	mutant	p53	and	ETV7,	which	has	to	be	better	explored	(Fig.	11B).		Binding	of	mutant	p53	to	endogenous	ETV7	was	not	possible	to	determine,	since	endogenous	ETV7	protein	 levels	are	too	 low	 (Fig.11C).	 To	 further	 explore	 the	 possible	 role	 of	 mutant	 p53	 on	 ETV7	 protein	stability,	 I	 transiently	over-expressed	 two	p53	mutants	 (respectively,	R282Q	and	G279E)	 in	MDA-MB-231	 p53	 KO	 cells	 and	 checked	 for	 ETV7	 protein	 expression	 by	 Western	 Blot	analyses	(Fig.	11D).	The	over-expression	of	p53	was	confirmed	and	interestingly,	it	appeared	that	both	the	p53	mutants	tested	were	able	to	decrease	protein	levels	of	ETV7.	This	reduction	in	ETV7	signal	was	remarkably	visible	in	the	cytoplasmic	extracts,	but	it	was	also	evident	in	the	nuclear	ones.	To	better	 visualize	 this	 effect,	 I	 transiently	over-expressed	ETV7	 in	MDA-MB-231	 cells,	 co-transfected	 along	 with	 the	 two	 p53	 mutants	 and	 I	 checked	 the	 ETV7	expression	 by	 Western	 Blot	 (Fig.	 11E).	 This	 analysis	 clearly	 showed	 how	 mutant	 p53	overexpression	can	decrease	protein	expression	of	ETV7	both	at	 the	cytoplasmic	and	at	 the	nuclear	level,	thus	confirming	that	the	increased	expression	of	ETV7	observed	in	nuclear	and	chromatin	fractions	in	MDA-MB-231-ETV7	p53	KO	cells	are	directly	linked	to	the	absence	of	p53,	which	possibly	might	influence	ETV7	protein	stability.			
	 65	
Bearing	in	mind	that	not	always	high	protein	 levels	are	related	to	higher	chromatin	binding	ability,	I	decided	to	include	all	these	tested	conditions	in	the	ChIP-seq	experiment.	Given	the	redundant	nature	of	ETS	factors	and	the	fact	that	their	binding	ability	can	change	due	to	the	presence	of	different	cofactors,	testing	ETV7	binding	in	different	contexts,	could	possibly	lead	to	a	more	trustable	in	vivo	consensus	sequence.			
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RESULTS-Figure	 11:	 A)	Western	Blot	 analysis	 of	 chromatin	 and	 nuclear	 extracts	 of	MDA-MB-231	 cells	 over-expressing	ETV7	 and	bearing	mutant	 p53	or	 deleted	 for	mutant	 p53	 (p53	KO),	 and	 treated	with	Doxorubicin	(1,5µM,	 16	 hours).	 B)	 Co-IP	 for	 studying	 the	 possible	 mutant	 p53	 and	 ETV7	 interactions	 by	 p53	 immuno-
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precipitation	in	MDA-MB-231	cells	overexpressing	ETV7	in	mock	and	in	Doxorubicin	treated	condition.	C)	Co-IP	for	studying	the	p53	and	endogenous	ETV7	putative	interaction	by	p53	immuno-precipitation	in	MDA-MB-231	cells	 in	 mock	 and	 in	 Doxorubicin	 treated	 condition.	 D)	 Western	 Blot	 analysis	 of	 endogenous	 ETV7	 protein	expression	upon	mutant	p53	transient	overexpression	(48	hours)	in	MDA-MB-231	p53	KO	cells.	E)	Western	Blot	analysis	of	exogenous	ETV7	protein	expression	upon	transient	transfection	of	ETV7	and	mutant	p53	in	MDA-MB-231	p53	KO	cells.	Alpha	actinin	and	H3	are	used	as	respectively	as	controls	for	cytoplasmic	and	nuclear	extracts.	UN	stands	for	the	untransfected	control.	
		
5.12	ETV7	ChIP-seq	analysis			The	 first	 ETV7	 ChIP-seq	 experiment	 was	 performed	 using	 the	 best	 quality	 ChIP-grade	antibody	available	 in	 the	market,	which	was	validated	 in	 the	 laboratory	 like	 the	one	having	the	highest	 IP	efficiency.	MDA-MB-231	cells	with	or	without	p53	and	over-expressing	ETV7	were	 used	 since	 endogenous	 ETV7	 protein	 level	 are	 not	 enough	 abundant	 to	 obtain	 a	reasonable	amount	of	material	 from	immuno-precipitation	with	standard	ChIP	procedure	to	be	used	for	the	following	NGS	sequencing.			ETV7	ChIP-seq	data	that	passed	the	quality	control	filters	(Q20	filter,	adapter	trimming)	and	the	de-duplication	 step	were	uniquely	mapped	and	were	 in	 average	76.2%	of	 the	 raw	data	(for	each	condition	in	average	4,937,893	reads).	The	average	median	length	of	fragments	was	250	bases	and	SISSR	peak	calling	method	generated	a	very	small	number	of	peaks,	especially	for	 the	MDA-MB-231	 p53	 KO	 cells	 treated	with	 Doxorubicin	 (Fig.	 12.1A).	 Overlap	 between	peaks	 determined	 using	 IgG	 or	 Input	 as	 controls	 were	 highly	 similar,	 showing	 an	 average	overlap	higher	 than	80%,	meaning	 that	 both	 can	be	used	 as	 good	quality	 controls.	Overlap	between	 peaks	 found	 in	 different	 conditions	was	 very	 low	when	 compared	 to	 the	 p53	 KO	Doxorubicin	condition,	given	the	low	number	of	peaks	relative	to	this	condition,	but	among	all	the	 other	 cases	 overlaps	were	 of	 the	 order	 of	 30%	 (Fig.	 12.1B).	 Circos	 plots	 generated	 by	Metascape	(METASCAPE.ORG;	Tripathi	et	al.	2015)	graphically	showed	the	overlap	between	targets	found	in	different	conditions	and	GO	common	to	the	targets	highlighted	in	blue	(Fig.	12.1C).	 Approximately	 more	 than	 half	 of	 the	 genes	 for	 each	 conditions	 are	 somehow	connected	and	shared	among	conditions.	 In	general,	 the	presence	of	 few	overlapping	genes	among	 all	 different	 conditions	 underlines	 the	 importance	 of	 cofactors	 for	 ETV7	 binding	ability,	 and	 only	 two	 target	 genes	 were	 common	 in	 all	 four	 tested	 conditions:	 DPEP1	 and	MBOAT2.	
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RESULTS-Figure	 12.1:	 A-B)	 Tables	 reporting	 numbers	 of	 peaks	 and	 overlap	 across	 the	 different	 tested	conditions	by	ETV7	ChIP-seq.		C)	Circos	Plot	obtained	by	Metascape	analysis;	purple	lines	are	connecting	shared	genes	 across	 conditions	 and	blue	 lines	 are	 connecting	 genes	 sharing	 similar	 gene	ontologies.	Red	 and	Orange	circle	segments	helps	in	visualizing	shared	genes	across	conditions.				To	obtain	 information	 relative	 to	 the	ETV7	 in	vivo	 consensus	 sequence,	ChIP-seq	data	were	subjected	 to	 HOMER	 analysis	 for	 unknown	motifs,	 successfully	 obtaining	 a	 logo	 consistent	with	the	in	vitro	data	(with	the	exception	of	the	base	5’	to	the	GGAA	core)	(Fig.	12.2A).		Then,	HOMER	analysis	was	re-analyzed	in	relation	to	known	motifs.	The	first	9	known	motifs	bound	 by	 ETV7	 appeared	 to	 be	 the	 consensus	 sequences	 for	 other	 ETS	 factors,	 which	confirmed	the	characteristic	redundancy	of	ETS	family	binding	to	DNA	(Fig.	12.2A).	Motif	of	ETV6,	the	closest	ETS	member	to	ETV7,	is	unfortunately	not	present	in	the	HOMER	software	and	therefore,	it	is	not	listed.		In	order	to	obtain	information	relative	to	the	enrichment	of	ETV7	targets	across	the	different	tested	 conditions,	 I	 performed	 an	 enrichment	 analysis	 with	 the	 Metascape	 tool	
C
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METASCAPE.ORG	(Tripathi	et	al.,	2015).	Given	the	very	small	number	of	peaks	relative	to	p53	KO	 Doxorubicin,	 this	 condition	 is	 not	 reported	 in	 the	 heatmap	 relative	 to	 the	 enrichment	analysis	 by	Metascape	 (Fig.	 12.2B).	 The	 remaining	 3	 conditions	 showed	 all	 enrichment	 for	Chagas	disease,	a	tropical	parasitic	disease	which	in	some	cases	can	also	lead	to	heart	damage.	They	also	all	showed	enrichment	in	processes	relative	to	development,	such	as	animal	organ	morphogenesis	 and	 cellular	 component	 biogenesis.	 An	 interesting	 enrichment	 especially	 in	relation	 to	 cancer	 biology	 is	 represented	 by	 the	 regulation	 of	 the	 endopeptidase	 activity	involved	in	apoptotic	process,	that	could	possibly	mediate	additional	oncogenic	properties	of	ETV7.	 In	 untreated/mock	 conditions	 either	 having	 or	 not	 mutant	 p53,	 ETV7	 targets	 were	enriched	for	other	biological	processes	important	for	cancer	progression	and	dissemination,	such	as	migration	(possible	ETV7	control	on	migration	is	reported	in	Annex	1.1)	,	cell	junction	assembly,	 extracellular	 matrix	 organization,	 and	 TGF-β	 signaling.	 Other	 processes	 were	enriched	only	 in	presence	of	mutant	p53;	specifically,	 the	response	to	gamma	radiation	and	the	 negative	 regulation	 of	 the	 immune	 system	 process,	 thus	 suggesting	 that	 the	 binding	 of	ETV7	 to	 these	 genes	 could	 be	 possibly	 directly	 or	 indirectly	 influenced	 by	 mutant	 p53.	Conversely,	other	pathways	were	enriched	only	 in	absence	of	mutant	p53,	 such	as	 the	TNF	signaling.	 Doxorucibin	 treatment	 seems	 to	 influence	 ETV7	 binding	 in	 terms	 of	 enrichment	relative	 to	 ETV7	 targets	 (as	 expected	 from	 the	 analysis	 in	Western	 blot,	 where	 a	 stronger	signal	 within	 chromatin	 enriched	 fraction	 was	 obtained;	 Fig.	 11A),	 showing	 the	 biggest	enrichment	 for	 embryonic	 pattern	 specification,	 in	 line	 with	 previous	 finding	 relative	 to	inhibitory	function	of	ETV7	in	differentiation.		I	then	extended	the	enrichment	analysis	to	the	Enrichr	tool	considering	ETV7	targets	common	in	at	least	two	conditions	(http://amp.pharm.mssm.edu/Enrichr/)(Chen	et	al.	2013;	Kuleshov	et	al.	2016	and	Fig.	12.2C).	The	most	enriched	KEGG	pathway	and	GO	biological	process	was	the	TGF-β	 signaling,	which	was	also	present	 in	 the	Metascape	enrichment	analysis	 together	with	 Chagas	 disease.	 Other	 enriched	 pathways	 found	were	 referring	 to	 pathogen	 response	and	 respiratory	 burst,	 which	 are	 suggesting	 a	 role	 for	 ETV7	 in	 shaping	 inflammatory	response.	 In	 order	 to	 gain	 insights	 on	 possible	 ETV7	 cofactors	 or	 transcription	 factors	cooperating	 or	 counteracting	 the	 ETV7	 transcriptional	 activity,	 I	 performed	 an	 enrichment	analysis	 for	 transcription	 factors	with	reported	ChIP-seq	binding	ability	 in	 the	ETV7	targets	(unfortunately	 p53	 data	 are	 still	 not	 present	 in	 the	 ChIP-seq	 data	 considered	 by	 the	 tool).	Among	 the	 enriched	 transcription	 factors,	 CTBP2	 and	 SIN3A	 are	 both	 transcriptional	repressors	and	have	already	been	reported	as	interactors	of	ETV6,	the	closest	ETS	member	to	ETV7	(Wang	and	Hiebert,	2001;	Roukens	et	al.,	2010).	For	this	reason,	they	might	represent	
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good	 putative	 ETV7	 interactors,	 favoring	 the	 ETV7-mediated	 transcriptional	 repression.	EGR1,	PML,	NR3C1,	TEAD4	are	all	associated	with	tumor	suppressive	functions,	thus	probably	they	are	mediating	an	increase	in	transcription	of	the	ETV7	targets,	acting	in	an	opposite	way,	probably	 by	 recruiting	 EP300	 (found	 as	 second	most	 enriched	 transcription	 factor).	 Given	that	most	of	them	are	positive	regulators	of	differentiation,	this	confirms	again	the	reported	role	of	ETV7	as	negative	regulators	of	cell	differentiation	(Carella	et	al.,	2006).	CEBPB	is	more	involved	in	inflammatory	response,	thus	probably	counteracting	the	negative	action	of	ETV7	on	inflammatory	genes.		The	 diseases	 prevalently	 associated	 to	 ETV7	 targets	 include	 anemia,	 in	 line	with	 the	 ETV7	reported	 role	 in	 red	blood	 cell	 development	 (Quintana	et	al.,	 2014)	 and	 the	Charcot-Marie-Tooth	disease,	an	incurable	genetic	inheritable	neuropathy.			
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RESULTS-Figure	 12.2:	 A)	 in	 vivo	ETV7	 consensus	 sequences	 calculated	with	Homer	 unknown	Motif	 analysis	performed	on	ETV7	ChIP-seq	(left	logo)	and	with	Homer	Analysis	for	known	motifs	(right	logo)	with	indicated	P-values	and	percentage	of	targets.	B)	Enrichment	analysis	performed	with	Metascape	online	tool	and	relative	to	
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enriched	ontology	clusters	specific	to	each	ChIP-seq	condition	tested.	C)	Enrichment	analysis	performed	with	the	Enrichr	software	on	ETV7	ChIP-seq	found	targets,	and	relative	to	pathways,	biological	processes,	 transcription	factors,	and	diseases.	Reported	P-values	are	referring	to	the	enrichment	statistical	analysis	performed	by	the	two	softwares,	for	which	a	detailed	information	is	provided	on	the	relative	websites.			Furthermore,	Metascape	was	interrogated	to	understand	if	localization	of	ETV7	binding	sites	was	linked	to	different	groups	of	genes	belonging	to	similar	ontologies.	Figure	12.3	A	reports	the	 relative	distribution	of	ETV7	peaks	 localization,	 showing	a	majority	of	binding	peaks	 in	the	 intragenic	 region	 and	 a	 relative	 small	 number	 of	 peaks	 within	 the	 promoter	 regions.	Interestingly,	Metascape	analysis	 (Fig.	12.3B)	 showed	 that	ETV7	binding	 regions	 relative	 to	promoters	were	enriched	in	genes	related	to	the	interferon	response,	which	is	one	of	the	most	recognized	processes	in	literature	as	activator	of	ETV7	(Park	et	al.,	2013;	Rempel	et	al.,	2013;	Contreras	 et	 al.,	 2015;	 Ignatius	 Irudayam	 et	 al.,	 2015).	 Conversely,	 ETV7	 peaks	 present	 in	intra-	 or	 inter-genic	 regions,	 were	more	 enriched	 in	 cancer	 related	 processes,	 such	 as	 cell	growth,	apoptosis,	and	cell-substrate	adhesion	and,	interestingly,	TGF-β	signaling	enrichment	was	 restricted	 to	 intergenic	 regions	 (Fig.	 12.3B).	 ENCODE	 visualization	 of	 the	 ETV7	 peak	region	 relative	 to	binding	 to	DPEP1	 in	parental	 untreated	 cells	 is	 reported	 in	Figure	12.3C.	The	calculated	SISSR	peak	length	is	around	350	bp,	but	the	actual	peak	length	appears	larger,	thus	 possibly	 supporting	 the	 reported	 DNA	 binding	 of	 ETV7	 in	 form	 of	 oligomer	 (Kar	 and	Gutierrez-Hartmann,	2013;	Selvaraj,	Kedage	and	Hollenhorst,	2015).		
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RESULTS-Figure12.3:	 A)	 Circos	 plot	 for	 genomic	 localization	 of	 ETV7	 binding	 regions	 found	 by	 ChIP-seq	analysis.	 B)	 Enriched	 ontology	 clusters	 relative	 to	 the	 genomic	 localization	 of	 ETV7	 binding	 site	 (found	 by	Metascape	 analysis).	 C)	 Configuration	 of	 the	 peak	 region	 (DPEP1)	 for	 ETV7	 enrichment,	 visualized	 in	 the	ENCODE	genome	browser	(using	UCSC	hg19	as	reference	genome).		
	
	
5.13	ETV7	can	regulate	the	TGF-β 	pathway		Since	TGF-β	pathway	was	found	among	the	enriched	pathways	relative	to	ETV7	targets	both	by	Metascape	and	Enrichr	analysis,	some	ETV7	targets	involved	in	this	signaling	(SKI,	SMAD6,	
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ID1	and	FKBP1A)	were	validated	by	qPCR	in	ETV7	over-expressing	cells	(Fig.	13A).	All	these	genes	are	negative	regulators	of	TGF-β-mediated	response,	at	different	levels,	meaning	that	a	repression	 of	 these	 genes	 mediated	 by	 ETV7	 could	 possibly	 lead	 to	 a	 constitutive	 TGF-β	pathway	activation.	All	 tested	genes	were	 repressed	 in	MDA-MB-231-ETV7	 cells,	 except	 for	SKI,	whose	expression	was	only	slightly	decreasing	but	did	not	reach	statistical	significance.	ChIP-qPCR	analysis	in	MDA-MB-231-ETV7	cells	confirmed	ETV7	occupancy	in	all	these	genes	with	 an	 enrichment	 pattern	 reflecting	 the	 qPCR	 repression	 data	 (Fig.	 13B).	 To	 assess	 the	possible	predictive	prognostic	value	for	these	TGF-β	pathway-related	genes	in	breast	cancer	(SKI,	 SMAD6,	 ID1,	 FKBP1A:	 it	 will	 be	 called	 ETV7/TGF-β	 signature),	 Kaplan	 Meier-plotter	relative	to	relapse-free	survival	(RFS)	was	exploited,	and	a	modest	correlation	between	 low	gene	expression	of	the	ETV7/TGF-β	signature	and	worse	prognosis	in	breast	cancer	patients	was	observable	(Fig.	13C).	GOBO	online	tool	was	also	interrogated	to	check	gene	expression	association	 with	 outcome	 for	 this	 group	 of	 genes,	 specifically	 relative	 to	 RFS	(co.bmc.lu.se/gobo)	 (Ringnér	 et	 al.,	 2011).	 Differently	 from	 Kaplan-Meier	 plotter,	 GOBO	Hazard	Ratio	graph	stratifies	the	expression	data	into	three	quantiles	based	on	the	expression	levels	of	the	interrogated	genes,	which	are	respectively	depicted	i)	with	a	grey	line	for	the	low	expression	quantile,	 ii)	with	a	red	line	for	the	intermediate	and	iii)	with	a	 light	blue	line	for	the	 high	 expression	 quantile.	 Furthermore,	 GOBO	 tool	 also	 allows	 a	 multivariate	 analysis	using	 lymph	 node	 status,	 cancer	 size,	 ER	 status,	 histological	 grade	 and	 patients’	 age	 as	covariates	and	RFS	as	endopoint.	GOBO	results,	reported	in	Figure	13	D,	confirmed	the	Kaplan	Meier-plotter	 analysis,	 showing	 a	 correlation	 between	 low	 expression	 of	 the	 ETV7/TGF-β	signature	 and	 worse	 prognosis	 relative	 to	 all	 breast	 cancer	 types.	 Moreover,	 multivariate	analysis	showed	a	relevant	correlation	between	expression	of	these	genes	and	both	the	tumor	size	and	the	lymph	node	status	of	patients	(Fig.	13E).	Specifically,	low	gene	expression	of	the	ETV7/TGF-β	signature	was	mostly	found	in	breast	cancer	with	an	average	size	larger	than	20	mm	and	in	lymph	node-positive	patients.	The	subgroup,	where	this	signature	can	best	predict	patients’	outcome,	is	represented	by	the	ER	positive	and	lymph	node	negative	one,	that	i	salso	the	largest	group	analyzed	(Fig.	13F).			 		
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RESULTS-Figure	13:	A)	qPCR	analysis	of	TGF-β	signaling	genes	(found	in	ETV7	ChIP-seq)	in	MDA-MB-231	cells	over-expressing	ETV7.	B)	Validation	of	ETV7	binding	to	TGF-β	 signaling	genes	by	ChIP-qPCR	analysis	 in	MDA-MB-231-ETV7	cells.	NSB	is	the	control	for	non	specific	binding	of	the	ETV7	antibody	(in	this	case	GTF2H5	was	used).	C)	Kaplan	Meier-plotter	analysis	 for	 the	ETV7/	TGF-β	 signature	 (SKI,	 SMAD6,	 ID1,	FKBP1A)	and	breast	
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cancer	 patients’	 outcome.	 Numbers	 below	 the	 x	 axis	 represent	 the	 number	 of	 patients	 analyzed	 at	 each	 time	interval	(50,	100,	150,	200,	250	months)	during	the	follow-up	study.	HR	stands	for	Hazard	Ratio,	a	value	above	zero	 indicates	 a	worse	 prognosis	 associated	 to	 high	 gene	 expression,	whereas	 a	 value	 below	 zero	 indicates	 a	worse	prognosis	associated	to	low	gene	expression.	D)	GOBO	analysis	for	Relapse-Free	survival	in	breast	cancer	patients	and	associated	expression	of	the	ETV7/	TGF-β	signature.	E)	Multivariate	analysis	for	the	ETV7/	TGF-β	signature	and	reported	features,	performed	by	GOBO	analysis.	F)	Kaplan-Meier	plot	obtained	by	GOBO	analysis	of	the	ETV7/	TGF-β	signature	for	the	ER	positive	and	lymph	node	negative	patients	subset.	In	Kaplan-Meier	plots	calculated	 by	 GOBO	 tool	 (D	 and	 F)	 above	 the	 x	 axis	 is	 reported	 the	 interval	 of	 each	 expression	 quantile	 and	relative	number	of	patients	analysed.	Grey	line	refers	to	the	low	expression	quantile,	red	to	the	intermediate	and	light	blue	line	to	the	high	expression	quantile.	**	indicates	P-value	(T-test)	<0.01			
	
5.14	Novel	ETV7	targets	can	predict	breast	cancer	patients	relapse-free	survival	
	The	ETV7	targets	common	to	at	least	two	conditions	of	ChIP-seq	were	interrogated	in	Kaplan	Meier-plotter	 relative	 to	 breast	 cancer	 patients.	 Seventy-seven	 percent	 of	 the	 genes	 had	 a	Hazard	Ratio	below	zero,	meaning	 that	 an	 increased	expression	of	most	of	 the	ETV7	 target	genes	was	 associated	with	 a	 better	 prognosis	 in	 terms	 of	 relapse-free	 survival.	 Nine	 ETV7	target	genes	were	showing	a	striking	association	with	patients	prognosis,	with	a	Hazard	Ratio	less	 than	 0.7	 and	 an	 associated	 constistent	 statistically	 significant	 P-Value	 for	 the	 log	 rank	test.	 Figure	 14A	 reports	 these	 9	 ETV7	 targets	 gene	 with	 predictive	 value	 in	 breast	 cancer	patients.	 This	 ETV7-target	 signature	 of	 9	 genes	 (named	 as	 9-gene	 signature)	 proved	 to	 be	very	 effective	 in	 predicting	 patients’	 outcome	 when	 combined,	 reaching	 a	 Hazard	 Ratio	 of	0.48,	meaning	 that	 the	 relapse-free	 time	 almost	 doubled	 in	 presence	 of	 high	 expression	 of	these	 genes	 (Fig.	 14B).	 Similarly	 to	 the	 ETV7/TGF-β	 signature,	 also	 this	 9-gene	 signature	showed	a	strong	association	between	gene	expression	and	both	tumor	size	and	lymph	node	status,	 and	 the	 subset	where	 it	 best	performed	 in	 terms	of	 outcome	prediction	was	 the	ER	positive	and	lymphonode	negative	patients’	one.			
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RESULTS-Figure	 14:	 A)	 Kaplan	 Meier-plotter	 analysis	 for	 relapse-free	 surival	 in	 breast	 cancer	 patients	expressing	high	or	low	levels	of	the	novel	ETV7	targets	found	by	ChIP-seq.	Numbers	below	the	x	axis	represent	the	 number	 of	 patients	 analyzed	 at	 each	 time	 interval	 (50,	 100,	 150,	 200,	 250	months)	 during	 the	 follow-up	study.	 HR	 stands	 for	 Hazard	 Ratio;	 a	 value	 above	 zero	 indicates	 a	 worse	 prognosis	 associated	 to	 high	 gene	expression,	 whereas	 a	 value	 below	 zero	 indicates	 a	 worse	 prognosis	 associated	 to	 low	 gene	 expression.	 	 B)	Kaplan	Meier-plotter	and	GOBO	analyses	 for	relapse-free	survival	 in	breast	cancer	patients	expressing	high	or	low	levels	of	the	9	genes	in	average	(9-gene	signature).	 In	Kaplan-Meier	plots	calculated	by	GOBO	tool	(on	the	right)	the	interval	of	each	expression	quantile	and	relative	number	of	patients	analysed	is	reported	above	the	x	axis.	 Grey	 line	 refers	 to	 the	 low	 expression	 quantile,	 red	 to	 the	 intermediate	 and	 light	 blue	 line	 to	 the	 high	expression	quantile.			
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5.15	DPEP1	and	DPYD	are	novel	ETV7	targets	involved	in	drug	resistance,	also	to	5-
Fluorouracil		Upregulation	of	ABCB1	suggests	that	ETV7	is	mediating	a	multi-drug	resistant	phenotype,	but	to	better	validate	this	hypothesis	I	decided	to	check	ETV7	over-expressing	cells	survival	to	5-Fluorouracil,	a	drug	whose	resistance	has	not	been	associated	to	ABCB1	but	to	different	multi-drug	tranporters	(Pan	et	al.,	2016).	Another	reason,	why	I	selected	5-Fluorouracil,	is	the	fact	that	 it	 is	 commonly	 used	 in	 combination	 with	 Doxorubicin	 and	 Cyclophosphamide	 for	 the	treatment	of	 advanced	breast	 cancer,	 in	 the	 so-called	FAC	 regimen	 (F	=	5-Fluorouracil;	A	=	Doxorubicin,	also	known	as	Adriamycin;	C	=	Cyclophosphamide).	Therefore,	I	performed	MTT	assay	treating	with	increasing	concentrations	of	5-Fluorouracil	(72	hours	treatment)	in	both	control	 and	 ETV7-overexpressing	 MDA-MB-231	 cells	 (Fig.	 15A).	 ETV7-mediated	 resistance	was	 confirmed	 also	 for	 5-Fluorouracil,	 underlying	 the	 importance	 of	 ETV7	 in	 shaping	 the	response	to	FAC	therapy	(Fig.	15A).	Furthermore,	ETV7-mediated	resistance	to	5-Fluorouracil	was	observable	also	in	the	osteosarcoma	cell	line	U2OS	over-expressing	ETV7	(Fig.	15B).	To	widen	the	search	 for	putative	ETV7	targets	 involved	 in	drug	resistance	to	both	Doxorubicin	and	 5-Fluorouracil,	 I	 took	 adavantage	 of	 the	 ChIP-seq	 results	 to	 search	 for	 known	 genes	whose	repression	associates	to	drug	resistance.			Among	the	9	gene-signature,	DPEP1	was	the	only	one	found	in	all	tested	ChIP-seq	conditions,	suggesting	an	important	role	of	the	regulation	of	this	gene	by	ETV7.	Furthermore,	this	gene	is	already	known	to	exert	relevant	 function	in	the	drug	response.	For	this	reason,	 I	decided	to	determine	 DPEP1	 expression	 upon	 ETV7	 over-expression	 in	 MDA-MB-231	 cells,	 which	showed	a	relevant	repression	of	DPEP1	in	comparison	with	the	control	cells	(Fig.	15C).	Then,	to	validate	DPEP1	as	a	direct	target	of	ETV7,	I	performed	ChIP-qPCR	assays	in	MDA-MB-231-ETV7	cells	and	validate	ETV7	occupancy	on	the	DPEP1	promoter	(Fig.	15D).	I	then	continue	the	research	for	putative	targets	by	performing	a	comparative	analysis	between	ETV7	ChIP-seq	data	and	published	microarray	analysis	in	ETV7	over-expressing	Lin-	cells	(Carella	et	al.,	2006).	 In	both	experiments	 I	 found	DPYD,	a	gene	 involved	 in	 the	5-Fluorouracil	catabolism.	To	validate	 the	 regulation	of	 this	gene	mediated	by	ETV7,	 I	measured	by	qPCR	analysis	 the	expression	of	DPYD	in	ETV7	over-expressing	cells	(Fig.	15C)	and	by	ChIP-qPCR	the	binding	of	ETV7	to	DPYD	enhancer	region	(Fig.	15D).	The	DPYD	repression	upon	ETV7	over-expression	and	ETV7	binding	 to	DPYD	enhancer,	defined	DPYD	as	a	novel	ETV7	direct	 target,	 critically	important	for	5-Fluorouracil-related	cellular	response	and	toxicity	(Gross	et	al.,	2008;	Deng	et	
al.,	2014;	Wu	et	al.,	2016).	Once	added	to	the	9-gene	signature	found	by	ChIP-seq,	the	newly	validated	DNAJC15	and	DPYD	genes	were	able	 to	enhance	 the	predictive	power	of	 the	gene	
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signature,	 making	 it	 to	 reach	 the	 Hazard	 Ratio	 of	 0.42	 according	 to	 Kaplan	 Meier-plotter	results	(11-gene	signature,	Fig.	15E).	Predictive	power	was	confirmed	also	by	GOBO	analysis,	and	particularly	relative	to	cancer	size	and	lymph	node	status,	and	particularly	in	the	subset	of	ER	positive	breast	cancers.		
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RESULTS-Figure	 15:	 A)	 MTT	 analysis	 for	 survival	 of	 MDA-MB-231-ETV7	 cells	 and	 empty	 control	 upon	 5-Fluorouracil	 treatment	(72	hours,	 increasing	concentrations).	B)	MTT	analysis	 for	survival	of	U2OS-ETV7	cells	and	 empty	 control	 upon	 5-Fluorouracil	 treatment	 (72	 hours,	 increasing	 concentrations).	 C)	 qPCR	 analysis	 for	DPEP1	 and	 DPYD	 expression	 in	 MDA-MB-231	 cells	 overexpressing	 ETV7	 compared	 to	 the	 empty	 control.	 D)	ChIP-PCR	analysis	 for	ETV7	occupancy	 in	DPEP1	and	DPYD	ETV7	binding	sites	 in	MDA-MB-231-ETV7	cells	E)	Expression	 analysis	 of	 the	 11-gene	 signature	 (9-gene	 signature	 +	 DNAJC15	 and	 DPYD)	 and	 associated	 breast	cancer	patients’	 relapse	 free	 survival,	 calculated	 starting	 from	 the	 left	panel	 first	 by	Kaplan	Meier-plotter	 and	then	 by	 GOBO	 analysis,	 relative	 to	 all	 breast	 cancer	 patients,	 and	 in	 the	 right	 panel	 the	 corresponding	multivariate	 analysis	 and	 the	 Keplan	Meier-plot	 for	 the	 ER	 positive	 breast	 cancer	 patients	 subset.	 In	 Kaplan-Meier	plots	calculated	by	GOBO	tool	(on	the	right)	the	interval	of	each	expression	quantile	and	relative	number	of	 patients	 analysed	 is	 reported	 above	 the	 x	 axis.	 Grey	 line	 refers	 to	 the	 low	 expression	 quantile,	 red	 to	 the	intermediate	and	light	blue	line	to	the	high	expression	quantile.			*	indicates	P-value(T-test)	<0.05	and	**	indicates	P-value(T-test)	<0.01.			 	
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6. DISCUSSION 
 Chemotherapy	 itself	 can	 lead	 to	 chemoresistance	 through	 a	 complex	 molecular	 network.	Focusing	on	critical	transcription	factors,	able	to	trigger	and	control	this	intricated	network,	could	 undercover	 key	 connections	 and	 promising	 targets	 involved	 in	 the	 outbreak	 of	chemoresistance.			Specifically,	 DNA	 damaging	 drugs	 proved	 to	 effectively	 activate	 the	 expression	 of	 ETV7,	 a	transcription	 factor	 belonging	 to	 the	 ETS	 family,	 with	 few	 reported	 oncogenic	 roles.	 ETV7	activation	by	DNA	damaging	drugs	was	observed	 in	breast	 cancer	 cells,	 but	proved	 to	be	 a	conserved	mechanism,	exploited	by	various	cancer	cells	(lung,	melanoma,	osteosarcoma)	and	normal	 cells	 (lymphocytes,	 endothelial	 cells,	 fibroblasts).	 Conservation	 of	 the	 activation	mechanism	 suggests	 its	 importance	 in	 cellular	 responses	 to	 certain	 drugs.	 This	 project	focused	on	the	role	of	ETV7	activation	upon	chemotherapy	specifically	in	breast	cancer	cells.	However,	 effectors	 and	 regulatory	 mechanisms	 involved	 in	 ETV7-mediated	 transcriptional	repression	in	cancer	cells	can	be	shared	with	normal	cells.	Therefore,	understanding	the	role	of	ETV7	in	cancer	cells	could	potentially	help	also	to	direct	studies	in	normal	cells.		ETV7	activation	in	breast	cancer	cells	was	studied	respectively	in	two	breast	cancer	cell	lines,	that	differ	 in	molecular	and	histopathological	 terms:	 luminal	A	breast	 cancer-derived	MCF7	cells,	expressing	wild	type	p53,	and	triple	negative	breast	cancer	derived	MDA-MB-231	cells,	bearing	 the	 p53	 mutant	 R280K.	 MCF7	 cells	 showed	 a	 very	 strong	 response	 in	 terms	 of	activation	of	ETV7	transcription,	being	Etoposide	the	least	effective	and	Doxorubicin	the	most	effective	drug.	Furthermore,	transcriptional	activation	of	ETV7	was	also	observed	in	response	to	prolonged	Doxorubicin	 treatment	 in	MCF7	cells,	 suggesting	a	potential	key	role	 for	ETV7	activation	 in	 cell	 survival.	 Interestingly,	 an	 enrichment	 of	 ETS	 binding	 site	was	 reported	 in	genes	 differentially	 expressed	 upon	 Doxorubicin	 treatment,	 which	 supports	 the	 possible	active	role	in	transcription	exerted	by	ETV7	or	other	ETS	factors	in	response	to	Doxorubicin	treatment.	 Nevertheless,	 Doxorubicin	 activation	 was	 not	 a	 typical	 response	 to	 this	 drug	shared	by	other	ETS	factors.	Microarray	data	from	MCF7	cells	clearly	showed	that	ETV7	was	the	 only	 ETS	 gene	 potently	 activated	 by	 Doxorubicin	 treatment,	 whereas	 SPDEF	 and	 ELF2	were	repressed	by	this	treatment,	also	confirmed	by	qPCR	data.	This	might	suggest	that	ETV7,	SPDEF	and	ELF2	have	different	or	even	opposite	biological	functions,	which	is	in	line	with	the	few	data	reporting	tumor	suppressor	roles	for	the	two	latter	proteins	(Feldman	et	al.,	2003;	
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Turner,	Moussa,	et	al.,	2007;	Ando	et	al.,	2016;	Guan	et	al.,	2017).	Similarly	to	MCF7	cells,	 in	MDA-MB-231	 cells,	 Doxorubicin	was	 the	most	 potent	 inducer	 of	 ETV7	 gene	 transcriptional	activation,	 but	 the	 levels	 of	 induction	 were	 much	 lower	 with	 respect	 to	 MCF7	 cells.	Conversely,	upon	prolonged	Doxorubicin	 treatment	higher	ETV7	activation	was	 reported	 in	MDA-MB-231	cells	in	comparison	with	MCF7	cells.	Another	relevant	difference	between	these	two	cell	lines	is	represented	by	the	different	occupancy	of	either	wild	type	or	mutant	p53	on	the	 ETV7	 promoter.	 In	 fact,	mutant	 p53	 is	 already	 present	 on	 the	 ETV7	 promoter	 in	 basal	condition	 and	 increases	 its	 occupancy	upon	Doxorubicin	 treatment;	whereas	wild	 type	p53	can	 be	 retrieved	 on	 the	 ETV7	 promoter	 in	 MCF7	 cells	 only	 in	 presence	 of	 Doxorubicin.	Possibly,	 mutant	 p53	 is	 already	 able	 to	 promote	 ETV7	 transcription	 without	 Doxorubicin	treatment	 and	basal	 ETV7	 expression	 is	 higher	 in	MDA-MB-231	 cells	 compared	with	MCF7	cells,	 as	 reported	by	He	 and	 colleagues	 in	2007	 (He	et	al.,	 2007).	 Thus,	 probably,	 a	weaker	induction	 of	 ETV7	 is	 needed	 in	 these	 cells	 to	 activate	 its	 network.	 Alternatively,	 despite	mutant	 p53	 seems	 to	 retain	 the	 ability	 to	 bind	ETV7	promoter,	 transactivation	potential	 of	wild	 type	p53	 in	 terms	of	 recruiting	cofactors	 (i.e.	 chromatin	remodelers)	could	differ	 from	mutant	 p53,	 and	 therefore	 ETV7	 activation	 could	 be	 altered.	 	 Another	 difference	 between	MCF7	 and	 MDA-MB-231	 cells	 stands	 in	 the	 expected	 different	 response	 to	 Nutlin-3a,	 that	didn’t	 show	 any	 ability	 to	 shape	 ETV7	 expression	 in	MDA-MB-231,	 confirming	 that	mutant	p53	R280K		escapes	the	p53		protein	stability	control	exerted	by	MDM2.	5-Fluorouracil	was	also	 not	 able	 to	 activate	 ETV7	 expression	 in	 MDA-MB-231	 cells,	 whereas	 Etoposide	 and	Camptothecin	 activated	 ETV7,	 suggesting	 that	 the	 different	 mechanisms	 of	 DNA	 damage	activation	behind	these	different	drugs	are	influencing	ETV7	transcription.	In	this	respect,	the	inhibition	 of	 topoisomerase	 is	 a	more	 potent	 inducer	 with	 respect	 to	 the	 inhibition	 of	 the	thymidylate	 synthase.	 This	 project	 reported	 a	 role	 for	 ETV7	 in	 promoting	 drug	 resistance;	therefore,	 the	observation	that	ETV7	can	be	differently	activated	by	cytotoxic	drugs	used	 in	chemotherapy	(based	on	their	mechanism	of	action)	with	respect	to	the	patient-	and	cancer-specific	context,	can	be	helpful	in	light	of	personalized	medicine.			The	 critical	 role	 of	 inflammation	 in	 promoting	 chemoresistance	 and	 the	 role	 of	 ETV7	 in	triggering	chemoresistance	are	directly	linked,	being	ETV7	also	activated	by	NFκB,	belonging	to	 a	 signature	 of	 genes	 associated	 with	 breast	 cancer	 aggressiveness	 and	 synergistically	activated	 by	 the	 combined	 treatment	 of	 Doxorubicin	 and	 TNF-α	 in	MCF7	 cells	 (Bisio	 et	al.,	2014).		
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An	 important	 finding	 came	 from	 the	 validation	 of	 p53’s	 role	 in	 the	 activation	 of	 ETV7	transcription.	p53	was	shown	to	bind	the	ETV7	promoter	upon	Doxorubicin,	TNF-α	and	the	combined	 treatment	 in	 MCF7	 cells.	 The	 transcriptional	 induction	 of	 ETV7,	 an	 oncogene,	 is	unexpected	and	contradictory	with	the	standard	p53	tumor	suppressor	functions.	Given	the	conservation	 of	 ETV7	 activation	 in	 different	 cell	 types,	 it	 could	 be	 that	 p53-mediated	transcription	 of	 ETV7	 is	meant	 to	 exert	 tumor	 suppressor	 roles	 in	 normal	 cells,	 but	 it	 acts	differently	in	transformed	cells.	This	is	in	line	with	the	reported	potential	control	of	ETV7	on	the	 TGF-β	 pathway,	 which	 controls	 cell	 death	 in	 normal	 cells	 but	 promotes	 metastasis	 in	advanced	 cancers.	 p65	 was	 also	 able	 to	 bind	 to	 the	 ETV7	 promoter	 upon	 all	 treatments,	confirming	the	positive	control	exerted	by	NFκB	on	ETV7	activation.		
Synergistic	 transactivation	 potential	 of	 ETV7	 upon	 Doxorubicin	 and	 TNF-α	 combined	treatment	was	also	observed	in	MDA-MB-231	cells,	although	at	a	lower	magnitude	compared	to	MCF7	 cells.	 Probably	 other	 transcription	 factors,	which	 are	 not	 present	 in	MDA-MB-231	cells,	 can	 be	 involved	 in	 ETV7	 activation	 in	 MCF7	 cells.	 In	 fact,	 CRISPR/Cas9	 experiments	directed	to	knock-out	the	expression	of	either	p53	and	p65	showed	a	stronger	impact	in	MDA-MB-231	cells	with	respect	to	MCF7	cells.	It	could	also	be	that	mutant	p53,	which	proved	to	be	able	to	bind	to	the	ETV7	promoter,	needs	p65	to	efficiently	activate	the	transcription	of	target	genes,	 and,	 similarly	 mutant	 p53	 is	 essential	 to	 activate	 p65	 in	 MDA-MB-231	 cells,	 upon	Doxorubicin	treatment.		The	complexity	of	the	regulatory	mechanisms	controlling	ETV7	transcription	is	amplified	by	the	activatory	roles	played	by	STAT3	in	MDA-MB-231,	where	an	increase	in	phosphorylation	of	STAT3	was	detected	upon	Doxorubicin	treatment.		In	MCF7	cells	there	was	no	activation	of	STAT3	 pathway	 and	 loss	 of	 STAT3	 increased	 ETV7	 activation.	 Furthermore,	 testing	 the	response	to	a	STAT3	activatory	signal	in	MCF7	in	terms	of	ETV7	transcription,	could	also	help	the	understanding	the	role	of	STAT3	in	this	cell	line.				Relatively	recently,	epigenetic	modulators	proved	to	be	effective	in	enhancing	chemotherapy	potency	 in	different	 types	of	cancer	 including	breast	cancer	(Strauss	and	Figg,	2016).	 In	the	case	 of	 ETV7	 activation,	 the	 histone	 mark	 H3K4	 trimethylation	 was	 increased	 upon	Doxorubicin,	 TNF-α	 and	 combined	 treatment,	 whereas	 only	 weak	 signal	 was	 seen	 for	acetylation.	 This	 information	 could	 be	 useful	 to	 design	 a	 therapy,	 which	 minimizes	 ETV7	transcription	upon	chemotherapy.		
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Since	no	literature	data	are	available	relative	to	the	specific	role	of	ETV7	in	breast	cancer,	and	the	 reported	 significant	activation	upon	DNA	damaging	drugs,	 I	 investigated	 the	 survival	of	MDA-MB-231	cells	over-expressing	ETV7	(MDA-MB-231-ETV7)	upon	Doxorubicin	treatment.	MDA-MB-231	cells	were	selected	in	order	to	have	a	model	able	to	more	closely	resemble	the	clinical	 settings	 of	 most	 patients	 treated	 with	 chemotherapy	 (advanced	 stage	 and	 triple	negative)	 and	 over-expression	 strategy	 was	 chosen	 instead	 of	 silencing,	 because	 previous	results	of	the	laboratory	I	am	joining,	showed	a	dramatic	breast	cancer	cell	death	upon	ETV7	silencing.	 ETV7	 over-expressing	 cells	 were	 significantly	 more	 resistant	 to	 Doxorubicin	treatment	with	respect	to	their	empty	control	cells.	This	ETV7-mediated	increased	resistance	to	Doxorubicin	was	also	observed	in	MCF7	cells	(see	Annex	2.3)	and	in	osteosarcoma	cell	line	U2OS,	suggesting	a	conserved	role	 for	ETV7	in	drug	resistance.	Furthermore,	MDA-MB-231-ETV7	 also	 showed	 an	 increased	 migratory	 potential	 and	 increased	 ability	 in	 anchorage-independent	 growth	 (see	 Annex	 1.1),	 supporting	 a	 key	 oncogenic	 role	 for	 this	 protein	 in	breast	 cancer	 cells.	 This	 study	 is	 mainly	 focused	 on	 the	 role	 of	 ETV7	 in	 drug	 resistance	especially	in	relation	to	its	role	as	transcription	factor,	aiming	at	the	investigation	of	novel	key	transcriptional	 circuitries	 that	 can	 be	 pharmacologically	 targeted,	 in	 order	 to	 ultimately	improve	breast	cancer	 treatment	efficacy.	 In	support	 to	ETV7	role	 in	drug	resistance,	MDA-MB-231	cells	over-expressing	ETV7	showed	an	increased	Doxorubicin	efflux	from	nuclei	and	a	consequent	reduced	nuclear	accumulation	of	Doxorubicin.	Another	relevant	characteristic	of	ETV7	 over-expressing	 cells,	 was	 the	 increased	 expression	 of	 the	 ABC	 transporter	ABCB1/MDR1/P-glycoprotein.	 Probably	 the	 increased	 efflux	 from	 nuclei	 could	 be	 directly	linked	to	ABCB1	transporter,	being	able	to	localize	also	in	the	nuclear	membrane	(Molinari	et	
al.,	2002).	The	calculated	 increased	Doxorubicin	efflux	area	 from	nuclei	 could	eventually	be	indicative	 for	 an	 increased	 Doxorubicin	 accumulation	 inside	 cytoplasmic	 organelles,	 which	could	also	be	promoted	by	ABCB1	 (Molinari	et	al.,	 2002).	A	 link	between	ETV7	and	ABCB1	comes	from	the	novel	finding	of	DNAJC15	as	an	ETV7	target.	DNAJC15	is	a	negative	regulator	of	 c-Jun	 pathway,	 blocking	 c-Jun-mediated	 ABCB1	 transcription;	 DNAJC15	 transcriptional	repression	mediated	by	ETV7	 is,	 therefore,	 leading	 to	an	 increased	expression	of	ABCB1,	as	seen	in	ETV7	over-expressing	cells	(Hatle	et	al.,	2007).		
To	 achieve	 the	 discovery	 of	 DNAJC15	 as	 a	 mediator	 of	 ETV7-driven	 drug	 resistance	phenotype,	 I	 first	 performed	 a	 comparative	 analysis	 of	 a	 list	 of	 genes	 often	 found	hypermethylated	and	repressed	in	breast	cancer,	which	were	proven	to	be	directly	linked	to	drug	response	(Boettcher,	Kischkel	and	Hoheise,	2010).	ETV7	is	a	 transcriptional	repressor,	
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therefore	I	focused	my	attention	on	repressed	genes	and,	particularly,	I	restricted	the	search	for	 potential	 targets	 to	 hypermethylated	 genes,	 because	 ETS	 factor	 motifs	 are	 over-represented	 in	methylated	 regions,	 particularly	 in	 hematopoietic	 stem	 and	 progenitor	 cells	(Hogart,	Lichtenberg	and	Ajay,	2012).	 I	 then	applied	 two	 filters	 to	get	 to	 the	best	predicted	ETV7	targets:	first,	I	analyzed	the	response	to	Doxorubicin	of	the	six	genes	listed	by	Boettcher	and	 co-workers	 (Boettcher,	 Kischkel	 and	 Hoheise,	 2010),	 using	 the	 microarray	 analysis	 of	Doxorubicin-treated	MCF7	cells	available	in	our	group,	and	then	I	checked	the	most	repressed	genes	by	qPCR	in	MCF7	cells	treated	with	Doxorubicin,	TNF-α,	and	the	combined	treatment.	DNAJC15	was	 the	only	gene	synergistically	 repressed	by	 the	combined	 treatment.	DNAJC15	repression	was	then	tested	upon	treatment	with	p53	activating	and	DNA	damaging	drugs	in	MCF7,	 MDA-MB-231,	 and	 healthy	 donors-derived	 lymphocytes.	 The	 pattern	 of	 DNAJC15	repression	 very	 much	 mirrored	 the	 one	 of	 ETV7	 activation,	 being	 Doxorubicin	 the	 most	potent	 DNAJC15	 repressor	 both	 in	 MCF7	 and	MDA-MB-231	 cells,	 and	 being	 Etoposide	 the	least	 effective	 drug	 in	 inducing	 ETV7	 and	 repressing	 DNAJC15.	 DNAJC15	 repression	 was	found	also	upon	prolonged	Doxorubicin	treatment,	as	for	ETV7	activation,	both	in	MCF7	and	MDA-MB-231	 cells.	 In	 MDA-MB-231	 cells	 there	 was	 no	 response	 upon	 Nutlin-3a	 and	 5-Fluorouracil	treatment,	as	it	was	the	case	for	ETV7	activation.	DNAJC15	repression	upon	DNA	damaging	drugs	was	also	conserved	 in	 lymphocytes	derived	 from	healthy	donors.	For	some	donors	there	was	an	appreciable	inverse	correlation	between	ETV7	and	DNAJC15	expression,	especially	 in	 Doxorubicin	 condition.	 These	 expression	 studies	 showed	 a	 clear	 inverse	correlation	between	ETV7	and	DNAJC15,	which	was	recapitulated	by	ETV7	over-expression	experiments,	either	transiently	in	MCF7	cells,	or	stably	in	MDA-MB-231	cells,	both	leading	to	DNAJC15	 repression.	 ChIP-qPCR	 analysis	 confirmed	 ETV7	 occupancy	 within	 the	 DNAJC15	promoter	in	MDA-MB-231	cells	over-expressing	ETV7.	Increased	occupancy	was	observed	in	the	 presence	 of	 Doxorubicin,	 which	 was	 associated	 with	 increased	 ETV7	 abundance	 in	chromatin	 and,	 more	 generally,	 in	 nuclear	 fractions.	 Doxorubicin	 could	 possibly	 activate	specific	 pathways,	 responsible	 for	 ETV7	 post-translational	modifications	which	 increase	 its	protein	 stability.	 For	 example,	 ETV7	 has	 a	 high	 affinity	 for	 p38	 kinase,	 which	 is	 a	 kinase	known	 to	 be	 induced	 by	 Doxorubicin,	 providing	 a	 link	 and	 a	 possible	 explanation	 for	 the	increase	 in	protein	 level,	which,	 in	 the	 case	of	over-expression,	 cannot	be	 simply	 related	 to	increased	 transcription	 of	 endogenous	 ETV7	 (Poizat	 et	 al.,	 2005;	 Selvaraj,	 Kedage	 and	Hollenhorst,	2015).		
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The	ability	of	ETV7	to	repress	DNAJC15	transcription	was	confirmed	by	Gene	Reporter	Assay	performed	 in	MCF7	cells	by	co-transfecting	ETV7	expression	vector	and	a	 reporter	plasmid	harboring	a	fragment	of	the	DNAJC15	promoter	upstream	the	luciferase	reporter	gene.	It	was	then	asked	if	the	presence	or	absence	of	either	wild	type	or	mutant	p53	could	influence	ETV7-dependent	 repression	 of	 DNAJC15.	 According	 to	 ChIP-seq	 data	 of	 Nutlin-3a	 treated	 MCF7	cells,	p53	itself	can	bind	to	the	DNAJC15	promoter		(chr13:42495669-42496026)	(Nikulenkov	
et	al.,	2012).	 It	 is	also	known	that	some	ETS	factors	can	interact	with	p53;	among	them,	the	interaction	between	ETS2	and	mutant	p53	is	well	studied	and	responsible	for	drug	resistance	to	 Etoposide	 (Do	 et	 al.,	 2012).	 In	 MCF7	 cells	 transiently	 over-expressing	 ETV7,	 ETV7-mediated	repression	of	DNAJC15	didn’t	change	in	the	absence	of	p53,	meaning	that,	in	these	cells,	the	presence	of	p53	is	not	essential	or	not	competing	for	ETV7-mediated	repression	of	DNAJC15.	 In	MDA-MB-231	 cells	 the	 repression	 of	 DNAJC15	was	 not	 noticeable	 in	 parental	cells	 upon	 ETV7	 over-expression,	 but	 in	 the	 absence	 of	 mutant	 p53	 there	 was	 a	 relevant	decrease	 in	 the	basal	 transactivation	of	DNAJC15	reporter	plasmid,	and	a	strong	repression	upon	ETV7	over-expression,	suggesting	 that	possibly	mutant	p53	can	somehow	interfere	or	block	ETV7	binding	to	the	promoter.	Therefore,	I	checked	whether	wild	type	and	mutant	p53	were	able	to	bind	nearby	the	ETV7	binding	site	 in	the	DNAJC15	promoter,	where	a	half	site	consensus	 region	 for	p53	 is	 present.	 ChIP-qPCR	assays	 for	p53,	 obtained	by	 amplifying	 the	same	 region	used	 for	ETV7	ChIP-qPCRs,	 showed	p53	occupancy	 on	 the	DNAJC15	promoter	both	 in	 MCF7	 and	 MDA-MB-231	 cells.	 Notably,	 in	 MCF7	 cells	 p53	 occupancy	 substantially	decreased	 upon	Doxorubicin	 treatment,	whereas	 ETV7	 occupancy	 increased	 in	 presence	 of	Doxorubicin,	suggesting	a	possible	competition	between	wild	type	p53	and	ETV7,	rather	than	a	 cooperation	 in	 binding.	 ChIP-qPCR	 assays	 in	MDA-MB-231	 cells	 showed	 that	 also	mutant	p53	 could	 bind	 nearby	 the	 ETV7	 binding	 region	 in	 the	 DNAJC15	 promoter,	 despite	 the	occupancy	 levels,	 in	 terms	 of	 %	 of	 Input,	 are	 much	 more	 reduced	 for	 mutant	 p53	 and	differently	 from	 wild	 type	 p53,	 are	 increasing	 upon	 Doxorubicin	 treatment.	 Given	 the	increased	 repression	 of	 DNAJC15	 observed	 in	 MDA-MB-231	 cells	 both	 in	 Gene	 Reporter	Assays	 in	 absence	 of	 p53,	 and	 the	 increased	 repression	 of	 DNAJC15	 gene	 expression	 upon	Doxorubicin	 and	 transient	 silencing	 of	 p53	 in	 MDA-MB-231	 cells,	 it	 seems	 that	 p53	 and,	especially	mutant	 p53,	 could	 somehow	 compete	 with	 the	 repressive	 action	 of	 ETV7.	 Upon	Doxorubicin	treatment,	ETV7	repressive	action	is	winning	against	p53,	 leading	to	a	relevant	repression,	which	is	mirrored	by	a	decreased	occupancy	of	wild	type	p53.	Alternatively,	even	if	an	 increased	binding	 is	observed	for	mutant	p53	upon	Doxorubicin	treatment,	 it	could	be	that	probably	alone	it	may	not	be	able	to	actively	promote	DNAJC15	transcription.	Among	the	
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possible	transcription	factors	reported	to	be	able	to	assist	mutant	p53	transcriptional	action,	I	focused	on	p65,	which	also	has	a	good	predicted	binding	site	very	near	to	both	ETV7	and	p53	response	 elements	 in	 the	 DNAJC15	 promoter.	 Therefore,	 p65	 ChIP-qPCR	 assays	 were	performed	in	both	MCF7	and	MDA-MB-231	cells,	which	revealed	that	also	p65	can	bind	to	the	DNAJC15	promoter	and	that	its	binding	is	decreasing	upon	Doxorubicin	treatment,	suggesting	a	possible	competition	 in	binding	with	ETV7	also	 for	 this	 transcription	 factor.	Furthermore,	the	 fact	 that	 Doxorubicin	 treatment	 totally	 abolished	 p65	 occupancy	 in	MDA-MB-231	 cells,	suggests	 that	 possibly	 p65	 is	 essential	 to	 support	 mutant	 p53	 negative	 action	 on	 ETV7	mediated	 repression,	 given	 the	 fact	 that	 ETV7-mediated	 repression	 is	 still	 winning	 against	p53	 despite	 an	 increased	 mutant	 p53	 occupancy	 is	 visible	 in	 presence	 of	 Doxorubicin.	Moreover,	 the	 fact	 that	 p53	 over-expression	 alone	 in	 p53	 KO	 cells	 wasn’t	 able	 to	 shape	DNAJC15	expression	confirms	the	essential	role	of	p65	or	other	cofactors	in	supporting	p53	transcriptional	control	on	DNAJC15	expression.		This	ChIP-qPCR	data	can	also	explain	why	the	over-expression	 of	 ETV7	 is	 already	 leading	 to	 DNAJC15	 repression	 also	 in	 cells	 harboring	mutant	p53,	whereas	in	Gene	Reporter	Assays	this	is	not	visible	in	presence	of	p53.	It	could	be	that	the	promoter	region	and	organization	cloned	in	the	reporter	plasmid	is	more	prone	for	the	binding	of	mutant	p53	and	p65	with	respect	 to	 the	 “real”	and	more	complex	chromatin	organization	 of	 the	 endogenous	 promoter,	 thus	 blocking	 the	 ETV7	 binding	 and	 its	 related	repressive	actions.		
In	 addition	 to	 these	 possible	 competitive	 interactions	 between	 p53	 and	 ETV7,	 co-immunoprecipitation	 studies	 (using	 cell	 lysates	 enriched	 for	 the	 chromatin	 fraction	 from	MDA-MB-231	cells	over-expressing	ETV7)	suggested	a	possible	physical	interaction	between	mutant	 p53	 and	 ETV7.	 This	 hypothesis	 has	 to	 be	 better	 explored	 in	 the	 future	 since	 over-expression	 experiments	 could	 eventually	 give	 a	 false-positive	 result	 of	 interaction,	 but	unfortunately	 endogenous	ETV7	protein	 levels	 are	 too	 low	 to	 appreciate	 a	possible	protein	interaction	 by	 standard	 Co-IP	 technique.	 In	 line	 with	 this	 possible	 negative	 interaction	between	mutant	 p53	 and	 ETV7	 are	 the	 data	 showing	 a	 higher	 ETV7	 protein	 expression	 in	chromatin	 and	 nuclear	 extracts	 in	 MDA-MB-231	 cells	 deleted	 for	 p53	 but	 over-expressing	ETV7,	 compared	 to	 the	 parental	 MDA-MB-231-ETV7	 over-expressing	 cells.	 Doxorubicin	treatment	 was	 responsible	 for	 an	 increased	 ETV7	 protein	 expression	 in	 nuclear	 and	chromatin	 fractions	 in	both	cell	 lines.	 It	 could	be	also	 that	mutant	p53	can	 indirectly	 shape	ETV7	stability	thanks	to	 its	reported	control	on	proteasome,	thereby	 leading	to	a	decreased	proteasomal	 degradation	 of	 ETV7	 in	 absence	 of	 mutant	 p53	 (Walerych	 et	 al.,	 2016).	
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Doxorubicin	treatment	can	also	possibly	influence	cofactors	needed	by	mutant	p53	to	exert	its	regulatory	 functions	 on	 ETV7	 stability.	 Alternatively,	 Doxorubicin	 can	 possibly	 lead	 to	 an	increased	 stability	 of	 ETV7	 protein	 mediated	 by	 post-translational	 modifications	 such	 as	phosphorylation,	 occurring	 independently	 from	 mutant	 p53,	 in	 line	 with	 the	 observed	increased	 protein	 level	 of	 endogenous	 ETV7	 seen	 in	 MCF7	 cells	 treated	 with	 Doxorubicin.	Nevertheless,	it	could	be	that	this	observed	difference	in	protein	levels	could	be	related	to	the	different	position	where	 the	exogenous	ETV7	 integrated	 into	 the	 two	different	clones.	Thus	procedures	 to	 assess	 the	 chromatin	 and	 nuclear	 expression	 of	 ETV7	 protein	 in	 different	clones	derived	from	MDA-MB-231	p53	KO	cells	over-expressing	ETV7	are	planned	to	be	done	in	 the	 near	 future.	 Furthermore,	 to	 better	 determine	 the	 possible	 effect	 of	 p53	 on	 ETV7	protein	stability,	experiments	with	 transient	silencing	of	p53	 in	both	parental	MDA-MB-231	cells	 and	 MDA-MB-231	 cells	 over-expressing	 ETV7	 cells	 are	 needed.	 In	 support	 to	 the	hypothesis	of	a	mutant	p53-dependent	control	of	ETV7	protein	stability	are	the	data	showing	a	decrease	in	ETV7	protein	expression	(both	the	endogenous	and	the	ectopically	transfected	ETV7),	 as	 demonstrated	 by	 cytoplasmic	 and	 nuclear	 fractions,	 upon	 over-expression	 of	different	p53	mutants	in	MDA-MB-231	p53	KO	cells.	However,	the	two	mutant	forms	of	p53	used	 in	 these	 experiments	 (R282Q	 and	 G279E)	 are	 different	 from	 the	 one	 constitutively	present	 in	 parental	MDA-MB-231	 cells	 (R280K),	 thus	 additional	 experiments	using	 the	p53	mutant	R280K	could	be	necessary	to	better	confirm	this	hypothesis.	Furthermore,	it	could	be	possible	 that	 wild	 type	 p53	 might	 have	 a	 different	 effect	 on	 ETV7	 protein	 stability,	 and,	therefore,	 it	 might	 not	 be	 able	 to	 destabilize	 ETV7	 protein	 as	 efficiently	 as	 mutant	 p53.	Experiments	in	this	direction	could	also	possibly	clarify	the	differences	observed	in	DNAJC15	repression	 from	 Gene	 Reporter	 Assays	 performed	 in	MCF7	 and	MDA-MB-231	 cells,	 where,	possibly,	mutant	p53	could	better	destabilize	the	chromatin-bound	ETV7	protein	with	respect	to	wild	type	p53	(p53	and	ETV7	REs	are	somewhat	close	within	the	DNAJC15	promoter,	see	Figure	7I).		
To	 confirm	 that	 DNAJC15	 represents	 a	 critical	 ETV7	 target	 in	mediating	 drug	 resistance,	 I	transiently	 overexpressed	 DNAJC15	 in	 MDA-MB-231-ETV7	 cells	 and	 observed	 that,	 upon	DNAJC15	 increased	 expression,	 these	 cells	 became	 more	 sensitive	 to	 Doxorubicin,	 and	concomitantly	ABCB1	expression	decreased,	partially	rescuing	the	ETV7-dependent	resistant	phenotype.	 To	 test	 the	 potential	 power	 of	 the	 discovered	 ETV7-DNAJC15	 mechanism	 in	predicting	 patients	 outcome,	 I	 interrogated	 the	 expression	 of	 ETV7	 and	 DNAJC15	 in	 the	dataset	GSE43502,	which	collected	data	on	cancer	recurrence	of	triple	negative	breast	cancer	
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patients	 after	 neoadjuvant	 chemotherapy	 and,	 therefore,	 closely	 resembles	 the	 conditions	used	 for	 the	 experiments	 done	 in	 vitro.	 ETV7	 expression	 was	 increased	 in	 patients	 with	recurrent	disease,	despite	not	in	a	statistically	significant	fashion.	DNAJC15	was	strongly	and	statistically	significantly	decreased	in	patients	with	recurrent	disease.	ETV7	activation	levels	upon	chemotherapy	can	vary	among	patients,	also	according	to	the	presence	of	other	different	transcription	 factors,	 the	 different	 level	 of	 ETV7	 before	 the	 treatments,	 the	 different	 drugs	used,	 as	 it	 was	 observed	 for	 breast	 cancer	 cells	 in	 vitro.	 Furthermore,	 being	 an	 unstable	protein,	 ETV7	 activation	 can	 be	 restricted	 in	 time,	 thus	 explaining	 the	 lack	 of	 statistical	significance	in	ETV7	expression.	Conversely,	ETV7-mediated	repression	could	potentially	lead	to	stable	epigenetic	silencing	of	DNAJC15,	because	this	gene	is	known	to	be	controlled	by	DNA	methylation	(Shridhar	et	al.,	2001).		
Given	 that	 DNAJC15	 over-expression	 is	 difficult	 to	 pursue	 in	 clinical	 settings,	 a	 possible	therapeutic	 strategy	 is	 to	 block	 ABCB1-mediated	 drug	 efflux	 and	 increase	 Doxorubicin	therapeutical	 efficacy.	 This,	 associated	 with	 the	 concomitant	 decrease	 in	 the	 related	cardiotoxicity,	 might	 be	 provided	 by	 the	 treatment	 with	 flavonoids,	 for	 instance	 Quercetin	(Dong	et	al.,	2014;	Cote	et	al.,	2015;	Liu	et	al.,	2016;	Lv	et	al.,	2016;	Minaei	et	al.,	2016).	ETV7	over-expressing	 cells	 were	 more	 sensitive	 to	 Quercetin	 cytotoxic	 action,	 that,	 given	 the	pleiotropic	action	of	this	natural	compounds,	can	only	partially	suggest	an	important	role	for	ABCB1	expression	in	the	survival	of	these	cells.	Interestingly,	ETV7	expression	was	repressed	upon	Quercetin	treatment	in	MDA-MB-231	cells,	probably	due	to	Quercetin	negative	action	of	NFκB	pathway	activation	(Indra	et	al.,	2013).	Genistein,	an	isoflavone,	was	also	able	to	repress	ETV7	 expression	 in	 MDA-MB-231	 cells,	 proposing	 that	 possibly	 ETV7	 repression	 can	generally	occur	upon	flavonoids	administration.		
To	broaden	 the	analysis	of	ETV7	 roles	 in	breast	 cancer	 and	possibly	discover	novel	 targets	relevant	for	ETV7	drug	resistant	phenotype,	I	performed	a	ChIP-seq	experiment	for	ETV7	in	two	different	cell	 lines	over-expressing	ETV7,	expressing	or	not	mutant	p53	(parental	MDA-MB-231-ETV7	 and	 MDA-MB-231-ETV7	 p53	 KO),	 either	 untreated	 or	 treated	 with	Doxorubicin.	In	general	the	number	of	peaks	found	by	ETV7	ChIP-seq	was	quite	small	(around	100	peaks	 for	 each	 condition,	 except	MDA-MB-231-ETV7	p53	KO	 treated	with	Doxorubicin	that	 only	 counted	 10	 peaks),	 in	 line	 with	 the	 previous	 microarray	 analysis	 of	 cells	 over-expressing	ETV7,	where	only	a	limited	number	of	genes	was	differentially	expressed	(Carella	
et	al.,	 2006).	 A	 possible	 explanation	 for	 this	 phenomenon	 can	 be	 related	 to	 the	 oligomeric	
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conformation	 of	 ETV7	 in	 the	 process	 of	 binding	 DNA	 that	 made	 difficult	 the	 detection	 of	binding	peaks;	 in	 fact,	 the	visualization	of	peaks	showed	 that	 the	peaks	calculated	by	SISSR	are	 actually	 representing	 just	 a	 part	 of	 the	 ETV7	 binding	 region.	 Another	 important	information	that	can	be	retrieved	from	peak	visualization	is	the	high	fold	change	of	ETV7	IP	signal	with	respect	to	both	the	IgG	and	the	Input	signals.	This	might	suggest	that	ETV7	can	be	a	very	specific	transcription	factor,	able	to	reach	very	high	occupancy	in	few	specific	regions,	therefore	 potentially	 consistent	with	 the	 low	 number	 of	 peaks	 obtained	 by	 ETV7	 ChIP-seq	analysis.	Despite	the	low	number	of	peaks	detected	in	general,	the	overlap	in	terms	of	ETV7	targets	present	 in	different	 conditions	or	 sharing	 a	 similar	 gene	ontology	was	 conspicuous,	suggesting	an	important	ETV7-mediated	regulation	of	specific	genes.	In	particular,	as	shown	by	 Metascape	 analysis,	 ETV7	 target	 genes	 mostly	 shared	 among	 different	 conditions	 were	enriched	 for	 the	 response	 to	 Chagas	 disease	 (also	 observed	 in	 the	 enrichment	 analysis	performed	 with	 Enrichr	 software),	 the	 animal	 organ	 morphogenesis,	 the	 regulation	 of	cysteine-type	 endopepetidase	 activity	 involved	 in	 apoptotic	 process,	 and	 the	 regulation	 of	cellular	component	biogenesis.	This	suggests	 that	ETV7	might	play	an	 important	role	 in	 the	control	of	parasitic	diseases,	in	addition	to	the	reported	control	on	viral	infection	(Rempel	et	
al.,	2013;	Ignatius	Irudayam	et	al.,	2015).	Nevertheless,	being	this	project	mostly	inherent	to	cancer	 biology,	 emphasis	 should	 be	 given	 to	 the	 observed	 enrichment	 in	 the	 cysteine-type	endopeptidase	 activity	 relative	 to	 apoptosis.	 	 This	 possible	 control	 exerted	 by	 ETV7	 on	caspase	activity	would	confirm	previously	reported	data	regarding	ETV7	over-expression	and	related	 decreased	 apoptotic	 rate	 observed	 in	 lymphoid	 and	 hematopoietic	 stem	 cells	(Cardone	et	al.,	2005;	Carella	et	al.,	2006).	The	enrichment	observed	 in	processes	of	animal	organ	morphogenesis	and	cellular	component	biogenesis	can	be	linked	to	the	reported	ETV7	negative	control	on	differentiation	(Sakurai	et	al.,	2003;	Kawagoe	et	al.,	2004;	Quintana	et	al.,	2014).	In	general,	processes	found	to	be	enriched	in	3	different	ChIP	conditions,	appeared	to	be	related	to	previously	reported	biological	roles	of	ETV7,	and	therefore	could	be	helpful	to	better	characterize	how	ETV7,	in	terms	of	transcriptional	control,	can	regulate	them.	Among	the	 enriched	 ontology	 clusters	 found	 in	 at	 least	 two	 conditions,	 and	 specifically	 in	 the	untreated	 ones,	 both	 in	 presence	 and	 in	 absence	 of	 mutant	 p53,	 many	 cancer	 related	pathways	 were	 found,	 such	 as	 regulation	 of	 extracellular	 matrix	 and	 collagen	metabolism,	migration,	and	cell	junction	assembly.		
The	TGF-β	 pathway	was	 also	 found	 to	 be	 enriched	 in	 at	 least	 two	ChIP-conditions	 both	 by	Metascape	 and	 Enrichr	 analysis.	 Binding	 and	 repression	 of	 some	 ETV7	 targets	 involved	 in	
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TGF-β	 pathway	were	validated,	 and	notably,	 they	were	all	 negative	 regulators	of	 the	TGF-β	signaling,	 thus	 suggesting	a	positive	activation	of	 this	pathway	upon	ETV7	over-expression.	Moreover,	 the	 expression	 of	 these	 TGF-β-related	 genes	 was	 able	 to	 predict	 breast	 cancer	patients’	outcome	especially	in	terms	of	their	lymphonode	status	and	tumor	size,	and	with	the	highest	predictive	power	in	ER	positive	cells.	Possibly,	crosstalk	between	ER	and	TGF-β	could	play	 a	 role	 in	 determining	 a	 worse	 outcome	 (Matsuda	 et	 al.,	 2001).	 ETV7	 control	 on	 this	pathway	could	also	suggest	a	growth	arrest	effect	of	ETV7	activation	upon	DNA	damaging	in	normal	 cells,	 given	 that	 TGF-β	 in	 normal	 cells	 and	 in	 early	 stage	 cancer	 is	 responsible	 for	growth	inhibition.	Furthermore,	the	positive	control	exerted	by	ETV7	on	this	pathway	can	be	very	meaningful	in	cells	that	have	mutant	p53	and	activated	Ras	signaling,	such	as	MDA-MB-231,	given	that	their	ternary	complex	with	Smads	promotes	p63	inhibition	and	stimulates	the	metastatic	spread	(Adorno	et	al.,	2009).		
A	good	enrichment	among	ETV7	targets	in	drug	response	process	(seen	by	Enrichr	analysis),	confirmed	 the	 observed	 ETV7	 role	 in	 drug	 resistance.	 Among	 the	 targets	 involved	 in	 drug	response,	DPEP1	(Dehydropeptidase	I)	showed	a	strong	ETV7	peak,	and	 it	was	one	the	two	targets	common	in	all	four	ChIP-seq	conditions;	therefore	it	represented	an	interesting	target	to	validate.	Binding	and	repression	by	ETV7	were	confirmed	by	qPCR	and	ChIP-qPCR	in	MDA-MB-231-ETV7	 cells,	 and	 DPEP1	 was	 also	 interrogated	 for	 prognostic	 relevance	 using	 the	Kaplan	Meier-plotter	web	tool	and	interrogating	breast	cancer	cases,	where	a	low	expression	was	 indeed	associated	with	 reduced	 survival.	DPEP1	 is	 a	metalloproteinase	 responsible	 for	the	 that	 hydrolysis	 of	 dipeptides,	 and	 it	 is	 part	 of	 the	 glutathione	metabolism,	where	 high	glutathione	 level	 resulting	 from	DPEP1	 loss	 can	 lead	 to	 drug	 resistance	 (Balendiran,	Dabur	and	Fraser,	2004).	A	loss	of	DPEP1	expression	was	found	in	breast	cancer	and	Wilm’s	tumor	(Cohen-Salmon	 et	 al.,	 1993;	 Green	 et	 al.,	 2009),	 whereas	 an	 over-expression	 was	 found	 in	colorectal	 carcinoma	 compared	 to	 adjacent	 tissue	 (Hao	 et	al.,	 2017).	 	 DPEP1	 can	 positively	regulate	 colon	 cancer	 metastasis	 (Park	 et	 al.,	 2016)	 and,	 conversely,	 it	 can	 inhibit	 cancer	invasion	and	promote	chemosensitivity	 in	pancreatic	ductal	carcinoma,	where	it	can	predict	clinical	outcome	(G.	Zhang	et	al.,	2012).	This	thesis	reports	a	novel	type	of	DPEP1	regulation	mediated	 by	 ETV7,	 and	 proposes	 a	 role	 for	 DPEP1	 in	 ETV7-mediated	 drug	 resistance	 and	predictive	role	for	DPEP1	in	breast	cancer	aggressiveness,	which	could	be	further	investigated	also	in	other	types	on	cancer.		
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ETV7-mediated	 drug	 resistance	 was	 also	 tested	 upon	 another	 unrelated	 cytotoxic	 drug,	 5-Fluorouracil,	 which	 is	 frequently	 used	 in	 breast	 cancer	 chemotherapy	 in	 combination	with	Doxorubicin	in	the	FAC	regimen	(5-Fluorouracil,	Doxorubicin,	Cyclophosphamide).	MDA-MB-231	cells	over-expressing	ETV7,	showed	an	increased	survival	also	upon	treatments	with	this	drug,	 suggesting	 that	 the	 drug	 response-phenotype	 linked	 to	 ETV7	 can	 be	 considered	 as	 a	multi-drug	resistance	one.	Resistance	to	both	Doxorubicin	and	5-Fluorouracil	was	monitored	also	in	the	U2OS	osteosarcoma	cells	over-expressing	ETV7.	To	explain	the	observed	resistance	to	5-Fluorouracil,	 I	searched	for	potential	putative	targets,	 in	addition	to	DPEP1,	specifically	involved	 in	 the	metabolism	of	 this	drug,	by	merging	 the	novel	ETV7	ChIP-seq	data	with	 the	reported	ETV7	microarray	analysis	(Carella	et	al.,	2006).	DPYD	was	present	in	both	analyses	and	 its	 repression	by	miR-21	was	 associated	with	 increased	 resistance	 to	5-Fluorouracil	 in	human	colon	cancer	HT-29	(Deng	et	al.,	2014).	qPCR	and	ChIP-qPCR	analysis	confirmed	the	ETV7-mediated	repression	of	this	gene,	but	additional	rescue	analysis	is	needed	to	prove	the	direct	involvement	of	DPYD	in	ETV7-mediated	5-Fluorouracil	resistance.	Furthermore,	given	the	conflicting	evidences	regarding	its	role	in	chemoresistance	reported	in	colon	and	gastric	cancer	 (Wu	 et	 al.,	 2016)	 a	 deeper	 study	 of	 this	 gene	 involvement	 in	 breast	 cancer	chemoresistance	is	of	paramount	importance.			
ChIP-seq	 enrichment	 analysis	 also	 suggested	 a	 potential	 role	 for	 ETV7	 in	 the	 control	 of	inflammation,	given	the	presence	of	many	inflammation-related	pathways,	such	as	pathogen	response	 (specifically	 Trypanosomiasis	 and	 HTLV-1),	 adipocytokine	 signaling,	 response	 to	wounding,		and	respiratory	burst,	which	represents	an	important	response	of	immune	cells	to	infection.	ETV7	is	a	recognized	interferon	stimulated	gene,	but	a	better	understanding	the	role	of	 ETV7	 in	 inflammation	 is	 needed	 and	 could	 uncover	 relevant	 information	 for	 cancer	immunotherapy.	 This	 project	 reported	 an	 increased	 expression	 of	 ETV7	 upon	 respiratory	syncytial	virus	 (RSV)	 infection,	with	an	associated	downregulation	of	DNAJC14	(Annex	1.2).	DNAJC14	 is	 a	 co-chaperone	 protein	with	 a	 known	 role	 in	 viral	 replication	 of	 flavivirus	 and	yellow	fever	virus	(Yi	et	al.,	2012;	Bozzacco	et	al.,	2016).	It	is	here	reported	for	the	first	time,	as	 a	 novel	 ETV7	 direct	 target	 confirmed	 by	 qPCR,	 Gene	 Reporter	 Assay	 and	 ChIP-qPCR	analysis.	 DNAJC14	 was	 the	 most	 repressed	 gene	 of	 the	 DNAJC	 family	 in	 MCF7	 cells	 upon	Doxorubicin	treatment,	and	a	DNAJC14	expression	decrease	was	found	in	Doxorubicin	and	5-Fluorouracil	 treated	MCF7	 cells	 and	 only	 upon	Doxorubicin	 and	Nutlin-3a	 in	MDA-MB-231	cells.	 The	 mechanism	 of	 repression	 is	 also	 partially	 conserved	 in	 healthy	 donors-derived	lymphocytes	 treated	 with	 DNA	 damaging	 agents.	 These	 differences	 in	 terms	 of	 repression	
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between	DNAJC14	and	DNAJC15	 suggest	 that	different	 co-repressors	 and	epigenetic	 factors	are	 involved	 in	 the	 repression	 of	 the	 two	 genes.	 ETV7	 repression	 and	 binding	 within	 the	DNAJC14	 promoter	 were	 confirmed	 by	 ChIP-qPCR,	 with	 an	 increased	 occupancy	 upon	Doxorubicin	 treatment,	as	demonstrated	 for	DNAJC15.	 Its	repression	seen	 in	Gene	Reporter	Assays	was	detected	both	in	presence	of	wild	type	or	mutant	p53,	but	without	p53,	the	basal	levels	of	activation	were	much	lower	than	in	the	presence	of	mutant	53.	These	observations	are	supported	by	the	results	from	transient	silencing	of	p53	in	MDA-MB-231	cells,	where	the	reduction	in	p53	levels	was	sufficient	to	lead	to	a	relevant	repression	of	DNAJC14	expression.	Conversely,	when	either	wild	 type	or	mutant	p53	are	 transiently	over-expressed	 in	p53	KO	MDA-MB-231	cells,	 there	were	no	observable	effect	on	DNAJC14	expression,	suggesting	that	p53	needs	other	 transcription	 factors	or	 cofactors	 to	 support	 the	basal	 expression	 levels	of	DNAJC14.	To	 investigate	whether	p53	was	 able	 to	bind	nearby	 the	ETV7	 response	 element	also	 in	 the	DNAJC14	promoter,	 I	 first	searched	 for	p53	binding	sites	and	 found	a	consensus	full	site	next	to	the	ETV7	one.	Then,	I	performed	ChIP-qPCR	analyses	in	both	MCF7	and	MDA-MB-231	 cells,	 and	 I	 confirmed	 both	wild	 type	 and	mutant	 p53	 occupancy	 on	 the	 DNAJC14	promoter,	which	was	 respectively	decreasing	 in	MCF7	and	 increasing	 in	MDA-MB-231	 cells	upon	 Doxorubicin	 treatment,	 as	 it	 was	 observed	 for	 DNAJC15.	 In	 MCF7	 cells,	 also	 p65	displayed	 positive	 occupancy	 in	 the	 DNAJC14	 promoter,	 that	 decreased	 upon	 Doxorubicin,	thus	 suggesting	 that	 p65	 could	 be	 essential	 for	 supporting	 positive	 regulation	 of	 this	 gene	together	with	p53.	In	MDA-MB-231	cells,		p65	was	not	retrieved	on	the	DNAJC14	promoter	in	any	conditions	and	this	could	explain	why,	differently	from	DNAJC15,	in	Gene	Reporter	Assays	repression	of	DNAJC14	 transcription	was	also	visible	 in	presence	of	mutant	p53,	 given	 that	probably	 mutant	 p53	 in	 absence	 of	 p65	 is	 not	 able	 to	 bind	 enough	 tightly	 to	 mask	 ETV7	binding	on	the	promoter	region	on	the	reporter	plasmid.		DNAJC14	 was	 also	 the	 only	 DNAJC	 member,	 besides	 DNAJC15,	 which	 was	 repressed	 by	Doxorubicin,	and	at	the	same	time	was	also	down-regulated	in	a	statistically	significant	way	in	recurrent	 breast	 cancer	 patients	 after	 neoadjuvant	 chemotherapy.	 Notably,	 its	 decreased	expression	was	also	associated	with	poorer	prognosis	in	breast	cancer	patients,	according	to	Kaplan	Meier-plotter	 analysis.	 In	vitro	 analysis,	 using	MDA-MB-231	 and	 silencing	DNAJC14,	showed	conflicting	results	relative	to	its	potential	role	in	drug	resistance,	showing	increased	drug	 sensitivity	 at	 lower	 doses	 and	 increased	 resistance	 at	 higer	 doses.	 Probably	 ETV7-mediated	 DNAJC14	 repression	 exerts	 a	 more	 prominent	 role	 in	 the	 control	 of	 immune	responses	 rather	 than	 in	 cancer	 cell	 survival	 upon	 chemotherapy.	 Nevertheless,	 DNAJC14	overexpression	studies	are	needed	to	better	determine	its	involvement	in	drug	resistance	and	
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to	 effectively	 compare	 with	 results	 obtained	 with	 DNAJC15.	 In	 addition,	 survival	 analysis	should	be	extended	to	other	breast	cancer	cells,	since	in	MDA-MB-231	there	was	no	DNAJC14	repression	upon	prolonged	Doxorubicin	 treatment,	suggesting	 that	probably	 in	 this	cell	 line	its	 repression	 is	 not	 relevant	 for	 drug	 resistance.	 Furthermore,	 extending	 the	 analysis	 of	DNAJC14	repression	and	ETV7	activation	upon	other	types	of	viral	infection	could	potentially	explain	 the	 link	 between	 viral	 infection	 types	 enriched	 in	 ETV7	 ChIP-seq	 targets	 (Epstein-Barr,	HIV1,	and	papilloma)	and	their	increased	predisposition	to	develop	cancer.		ChIP-seq	 data	 enrichment	 referred	 to	 diseases	 and,	 in	 particular,	 anemia,	 confirming	 a	previous	reported	role	for	ETV7	in	the	development	of	red	blood	cells	(Quintana	et	al.,	2014)	and	 also	 added	 novel	 ETV7	 potential	 targets	 involved	 in	 this	 function	 (CUBN,	 RPS19,	 and	TERC).	An	enrichment	 in	 lymphoma	also	agreed	with	 the	reported	evidence	as	oncogene	 in	this	type	of	cancer	(Cardone	et	al.,	2005).		Furthermore,	ChIP-seq	analysis	suggested	a	role	for	ETV7	in	the	rare	genetic	disorder	Charcot-Marie-Tooth	disease	(through	the	targets	SH3TC2	and	NDRG1).	
Another	important	achievement	of	the	ChIP-seq	was	the	discovery	of	the	first	reported	in	vivo	binding	site	for	ETV7,	which	as	expected	contained	the	GGAA	core	as	in	the	previous	in	vitro	consensus	sequences	reported	so	far.	Interestingly,	I	was	able	to	identify	specific	features	of	the	 boundary	 sequences,	 which	 are	 very	 critical	 for	 determining	 the	 specificity	 of	 ETS,	 as	more	 similar	 to	 the	 first	 two	 reported	 consensus	 sequences	 	 (Potter	 et	al.,	 2000;	 Gu	 et	al.,	2001)	compared	to	the	latest	reported	one	obtained	by	microwell-based	transcription	factor-DNA-binding	assays	(Wei	et	al.,	2010).		The	ChIP-seq	analysis	showed	that	ETV7	could	bind	in	
vivo	with	very	high	affinity	 to	motifs	representing	consensus	sequence	of	other	ETS	 factors,	thus	confirming	the	redundancy	property	of	ETS	factors.	The	best	known	consensus	sequence	bound	by	ETV7	was	the	one	of	ETS1.	Given	the	high	statistical	relevance	of	the	binding	to	the	ETS1	 motif	 and	 the	 low	 number	 of	 peaks	 detected	 by	 ChIP-seq,	 it	 is	 very	 unlikely	 that	 it	resulted	 from	 indirect	 binding	 of	 ETV7	 to	 DNA,	mediated	 by	 ETS1;	 despite	 the	 interaction	between	ETS1	 and	 ETV7	 already	 reported	 in	 the	 literature	 (Vivekanand	 and	Rebay,	 2012).	More	 probably,	 it	 can	 be	 that	 ETV7	 and	 ETS1	 can	 share	 some	 targets,	 but	 their	 activator	signals	can	differ;	for	example	low	level	of	JNK1	phosphorylation	could	be	enough	to	activate	ETV7,	 whereas,	 based	 on	 the	 different	 affinities,	 ETS1	 would	 require	 higher	 level	 of	 JNK1	phosphorylation	 for	 activation	 (Selvaraj,	 Kedage	 and	Hollenhorst,	 2015).	 In	 addition	 to	 the	different	 phosphorylation	 regulation,	 it	 could	 be	 that	 these	 ETS	 are	 recruited	 to	 the	 same	targets	by	different	cofactors,	varying	among	cancer	type	and	context.	The	second	best	known	
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motif	bound	by	ETV7,	is	the	one	of	ERG,	an	oncogenic	ETS	factors,	that	contrarily	from	ETS1	and	ETV7	mainly	acts	as	transcriptional	activator	and	is	frequently	over-expressed	as	a	result	of	 chromosomal	 translocations	 in	 prostate	 cancer.	 ERG	 was	 recently	 reported	 as	downregulated	 in	 breast	 cancer	 compared	 to	 normal	 tissue,	 and	 expressed	 at	 low	 level	especially	 in	 basal	 subtype,	 inversely	 correlating	 with	 the	 expression	 of	 ETV7,	 which	 was	markedly	increased	in	this	subtype	and	in	general	in	breast	cancer	(Piggin	et	al.,	2016).		It	can	be	that,	in	breast	cancer,	ERG	regulates	some	common	targets	with	ETV7,	but	the	first	exerts	a	transcriptional		activation,	whereas	the	second	a	repression,	suggesting	the	reason	why	they	negatively	 correlate.	 Furthermore,	 similarly	 to	 ETS1,	 different	 post-translational	modifications	 control	 ERG,	which	 has	 a	 really	 high	 affinity	 for	 ERK2	 (Selvaraj,	 Kedage	 and	Hollenhorst,	2015).	 	As	 third	best	motif	bound	by	ETV7	was	classified	 the	one	 for	ETV1,	an	important	ETS	 factor	 for	prostate	 cancer	metastasis,	 that	 can	 substitute	ERG	when	 it	 is	not	over-expressed;	possibly	ETV7	could	represent	another	substitute	when	also	ETV1	is	missing	(Watson	et	al.,	2010).		
ChIP-seq	 data	 also	 provided	 some	 clues	 on	 possible	 ETV7	 cofactors	 involved	 in	transcriptional	 repression,	 for	 example	 CTBP2	 and	 SIN3a	 represent	 very	 interesting	candidates,	being	both	co-repressors	and	able	to	associate	to	ETV6,	which	is	the	closest	ETS	factor	related	to	ETV7	(Wang	and	Hiebert,	2001;	Roukens	et	al.,	2010).		Other	 enriched	 transcription	 factors	 able	 to	 bind	 ETV7	 response	 elements,	 were	 all	 tumor	suppressor	 genes	 and	 linked	 to	 transcriptional	 activation,	 therefore	 they	 could	 probably	represent	ETV7	competitors	rather	than	interactors.	Nevertheless,	it	couldn’t	be	excluded	that	upon	 specific	 condition,	 the	 interaction	 of	 ETV7	 with	 some	 cofactors	 could	 also	 lead	 to	transcriptional	activation	of	certain	targets.			Another	 feature	 of	 ETV7	 binding	 highlighted	 by	 ChIP-seq	 analysis	 was	 the	 preferential	binding	to	intragenic	regions	in	the	cell	lines	and	conditions	analyzed.	It	could	be	that	in	other	cells,	especially	in	normal	cells,	binding	dynamics	could	differ.	In	fact,	most	of	the	intragenic	ETV7	peaks,	were	present	 in	genes	enriched	in	cancer	related	processes,	whereas	promoter	ETV7	peaks	were	mostly	found	on	genes	enriched	for	processes	related	to	inflammation	and	interferon	response.	 It	 could	be	 that	 the	presence	of	other	 factors	 in	cancer	cells	 can	direct	ETV7	binding	to	intragenic	regions.	Relatively	recently,	it	was	shown	that	Ets-1	can	associate	with	 Smad4	 and	 this	 complex	 preferentially	 binds	 to	 intragenic	 region	 of	 FPGS	 gene	 (Raz,	Stark	 and	 Assaraf,	 2014).	 Ets-1	 is	 the	 most	 similar	 gene	 to	 ETV7	 in	 terms	 of	 consensus	
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sequence	 (according	 to	 Homer	 analysis),	 therefore	 it	 can	 be	 that	 Smad	 proteins	 can	 also	interact	 with	 ETV7	 and	 help	 its	 binding	 to	 intragenic	 region.	 This	 would	 also	 explain	 the	observed	control	of	ETV7	on	the	TGF-β	signaling,	that	could	sustain	ETV7	transcription	itself	by	activating	specific	Smads.	Alternatively,	the	binding	to	intragenic	region	can	suggest	other	type	 of	 transcriptional	 regulation	mediated	 by	 ETV7,	 such	 as	modulation	 of	 transcriptional	elongation	or	prevention	of	spurious	transcriptional	initiation	(Neri	et	al.,	2017). 	ETV7	targets	(common	in	at	least	two	ChIP-seq	conditions)	were	also	interrogated	using	the	Kaplan	 Meier-plotter	 and	 9	 targets	 genes	 (that	 I	 called	 9-gene	 signature)	 showed	 a	remarkable	 correlation	 between	 increased	 expression	 and	 better	 survival	 in	 breast	 cancer	patients,	 each	 with	 a	 statistically	 significant	 Hazard	 Ratio	 lower	 than	 0.7.	When	 the	 mean	expression	of	these	genes	was	interrogated	by	both	Kaplan	Meier-plotter	and	GOBO	analysis,	it	 showed	 a	 strong	 predictive	 power,	 even	 increased	 if	 considering	 the	 additional	 ETV7	targets	 reported	 in	 this	 project,	 DNAJC15	 and	 DPYD,	 generating	 the	 so-called	 11-gene	signature.	Multivariate	 analysis	 showed	 that,	 both	 the	 9-	 and	 the	 11-gene	 signatures,	were	particularly	powerful	in	predicting	patients’	cancer	size	and	lymphonode	status,	especially	in	ER	positive	breast	cancer.	Usually,	this	type	of	breast	cancer	is	treated	with	hormone	therapy,	however	in	case	of	i)	hormone	therapy	failure	or	ii)	in	presence	of	a	larger	size	cancer	or	iii)	in	the	 neoadjuvant	 setting	 also	 in	 this	 type	 of	 cancer,	 chemotherapy	 is	 commonly	 used	 as	 a	treatment	 option	 in	 this	 type	 of	 cancer.	 Therefore,	 this	 signature	 could	 have	 a	 clinical	relevance	also	in	this	group	of	patients,	and	these	results	can	eventually	suggest	that	ER	could	somehow	 influence	 or	 cooperate	 in	 the	phenotype	driven	by	 	 the	differential	 expression	of	these	genes.	Nevertheless,	it	has	to	be	considered	that	these	data	could	be	influenced	by	the	fact	 that	 the	ER-positive	group	 in	the	GOBO	analysis	has	many	more	samples	respect	 to	the	others	analyzed	(such	as	the	ER-negative	one);	thus	the	statistical	power	could	be	improved	simply	because	of	the	larger	group	analyzed.	For	some	of	the	signature	genes	(ACSL5,	PTPRJ,	GNAO1,	 PVT1),	 there	 were	 already	 reported	 association	 with	 breast	 cancer	 (Keane	 et	 al.,	1996;	Smart	et	al.,	2012;	Spring	et	al.,	2015;	Sarver	et	al.,	2016;	Sharma	et	al.,	2016;	W.	C.	Chen	
et	al.,	 2016;	 Yan	 et	al.,	 2017).	 Specifically,	 increased	 expression	 of	 ACSL5	 predicted	 a	 good	prognosis	 for	 breast	 cancer	 patients	 (W.	 C.	 Chen	 et	 al.,	 2016),	 consistent	 with	 the	 results	shown	here	by	Kaplan	Meier-plotter.	PTPRJ	was	found	to	inhibit	breast	cancer	growth	and	a	decrease	 in	 its	 expression	 was	 observed	 in	 breast	 cancer	 tissue	 compared	 to	 normal	mammary	tissue	and	was	associated	to	poor	survival	(Keane	et	al.,	1996;	Smart	et	al.,	2012).	Conflicting	data	reported	an	oncogenic	role	for	PTPRJ	in	promoting	breast	cancer	cell	invasion	
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(Spring	et	al.,	 2015).	A	breast	 tumor	promoting	 role	 is	 reported	 also	 for	GNAO1	and	PVT1,	respectively,	 mutated	 GNAO1	 promotes	 growth	 of	 mammary	 epithelial	 cells	 and	 PVT1	accellerates	mammary	tumors	also	by	cooperating	with	MYC	(Sarver	et	al.,	2016;	Sharma	et	
al.,	2016;	Yan	et	al.,	2017).	Conversely,	GNAO1	and	PVT1	are	reported	here	as	ETV7	targets	whose	high	expression	 is	predictive	 for	 good	prognosis	 in	breast	 cancer;	 therefore	a	better	understanding	on	their	role	in	different	breast	cancer	subtypes	and	stages	could	better	clear	out	their	role	in	cancer	progression.				The	 remaining	 5	 genes	 have	 so	 far	 no	 reported	 evidence	 in	 breast	 cancer;	 therefore,	 they	could	represent	promising	novel	targets	and	molecular	markers	for	precise	investigations.	In	particular,	 CPNE5	 has	 a	 remarkable	 striking	 Hazard	 Ratio	 (0.59),	 and	 it	 is	 the	 most	unexplored	 gene,	with	no	publication	 referring	 to	 cancer,	 but	 having	 just	 3	 publications	 on	rodent	anxiety,	alcohol	dependence	and	obesity,	and	an	hypothesized	role	in	the	development	of	murine	central	nervous	system	(Ding	et	al.,	2008,	2017;	Wang	et	al.,	2015).		Some	 of	 the	 identified	 ETV7	 target	 genes	 have	 already	 a	 reported	 role	 in	 drug	 resistance,	supporting	 this	novel	ETV7	 function	 that	 is	 the	 focus	of	 this	project.	 Specifically,	TRIM41	 is	directly	 linked	 to	 the	 drug	 resistance	 process	 driven	 by	 ABCB1-mediated	 increased	 efflux.	TRIM41	is	an	E3	ubiquitin	ligase	responsible	for	the	degradation	of	PKC,	and	PKC	promotes	drug	resistance	through	the	increased	efflux	by	ABCB1	(C.	W.	Kim	et	al.,	2015).	Given	that	its	mechanism	 of	 action	 closely	 resembles	 the	 ETV7-mediated	 drug	 resistance	 mechanism	observed	 here,	 TRIM41	 could	 represent	 another	 important	 ETV7	 target	 involved	 in	 drug	resistance.	UBR1	is	another	E3	ubiquitin	ligase,	which	was	found	to	be	associated	with	drug	resistance	 to	 Imatinib	 (Eldeeb	and	Fahlman,	2014),	 to	 alkylating	 agents	 (Leng	et	al.,	 2015),	and	to	Hsp90	inhibitors	(Sultana,	Theodoraki	and	Caplan,	2012).	PTPRJ	loss	was	also	found	to	be	responsible	for	5-Fluorouracil	resistance	in	cervical	carcinoma,	representing	an	additional	target	besides	DPEP1	and	DPYD	for	the	observed	5-Fluorouracil	resistance	mediated	by	ETV7	(Yan	et	al.,	2015).	 	Tumor	promoting	roles	and	decreased	expression	of	some	of	these	ETV7	targets,	have	already	been	associated	with	increased	metastasis	and	worse	prognosis	in	some	types	of	cancer.	Therefore,	 they	could	play	an	 important	role	also	 in	breast	cancer.	TRIM41	decrease	was	associated	with	metastasis	in	colorectal	cancer	(P.	Zhang	et	al.,	2012),	UBR1	loss	was	 observed	 to	 accelerate	 lymphomagenesis	 (Chen	 et	 al.,	 2006),	 and	 ACSL5	 was	 down-regulated	in	squamous	cell	lung	cancer	(Molina-Pinelo	et	al.,	2014).	Furthermore,	PTPRJ	loss	was	seen	to	predict	worse	prognosis	in	esophageal	squamous	cell	carcinoma	and	promoting	migration	 of	 hepatocellular	 carcinoma	 (Luo	 et	 al.,	 2015;	 Qiao	 et	 al.,	 2016),	 and	 down-regulation	 of	 GNAO1	 was	 linked	 to	 increased	 proliferation	 and	 senescence	 inhibition	 in	
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hepatocellular	 carcinoma	 (Pei	 et	 al.,	 2013).	 Finally,	 ADCY1	 was	 found	 down-regulated	 in	rectal	adenocarcinoma	metastasis	(Hua	et	al.,	2017),	found	hypermethylated	in	glioblastoma	(Ma	 et	al.,	 2015),	 and	 its	 loss	 represents	 a	 biomarker	 for	 osteosarcoma	 tumorigenesis	 and	therapeutics	(Li	et	al.,	2010).	Given	all	 these	cancer-associated	reported	roles	 for	 these	novel	ETV7	 targets,	 it	 is	worth	 to	investigate	whether	also	these	genes	can	be	regulated	by	ETV7	in	other	types	of	cancer.			 	
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7. CONCLUSIONS AND FUTURE 
PERSPECTIVES 
	In	 conclusion,	 this	 project	 reported	 a	 novel	 involvement	 for	 ETV7	 in	 breast	 cancer,	 and	specifically,	in	the	regulation	of	drug	resistance	to	Doxorubicin	and	5-Fluorouracil,	two	drugs	often	used	 in	 combination	 for	breast	 cancer	 treatment.	The	ETV7-mediated	drug	 resistance	was	 characterized	 by	 an	 increased	 Doxorubicin	 efflux	 from	 nuclei	 associated	 with	 an	increased	expression	of	the	ABC	transporter	ABCB1.	The	co-chaperone	DNAJC15	is	a	negative	regulator	of	the	ABCB1	transcriptional	activation	mediated	by	c-Jun,	and	ETV7	proved	to	be	able	to	bind	and	repress	DNAJC15,	therefore	leading	to	increased	ABCB1	expression	and	the	related	resistance.	However,	ETV7-DNAJC15	circuitry	represents	only	one	mechanism	of	the	complex	drug	resistance	machinery	triggered	by	ETV7.	By	performing	the	first	reported	ChIP-seq	for	ETV7,	I	provided	evidence	regarding	the	in	vivo	ETV7	consensus	sequence	and	targets,	which	 is	 planned	 to	 be	 further	 reinforced	 by	 performing	 RNA-seq	 analysis	 on	 ETV7	 over-expressing	 cells	 combined	 with	 Doxorubicin	 treatment.	 Some	 targets	 were	 validated	 and	showed	biological	implications	in	both	drug	resistance	and	the	regulation	of	TGF-β	pathway.	Nevertheless,	a	better	understanding	of	the	ETV7-dependent	control	of	TGF-β	pathway	has	to	be	 established	 in	 future,	 together	 with	 the	 contribution	 of	 ETV7	 on	 the	 5-FU	 resistance.	DPEP1	and	DPYD	genes	were	validated	as	ETV7	repressed	targets,	but	rescue	experiments	are	further	 needed	 to	 confirm	 their	 direct	 involvement	 in	 	 ETV7-mediated	 5-FU	 resistance.	Furthermore,	 a	 group	 of	 ETV7	 targets	 found	 by	 ChIP-seq	 showed	 a	 strong	 correlation	between	 high	 expression	 and	 associated	 good	 prognosis	 in	 breast	 cancer	 patients.	 Among	them,	CPNE5,	a	completely	unexplored	gene	in	cancer,	might	probably	open	up	new	horizons	for	breast	cancer	research.	By	controlling	this	wide	spectrum	of	targets,	ETV7	targeting	could	represent	a	very	promising	therapeutic	strategy	to	overcome	or,	better,	to	avoid	the	outbreak	of	 drug	 resistance.	 A	 possible	 targeting	 strategy	 could	 either	 rely	 on	 triplex-forming	oligonucleotide	 specifically	 targeting	 ETV7	 promoter,	 as	 in	 the	 case	 of	 another	 ETS	 factor,	ETS2	 (Carbone	et	al.,	 2004),	 or	 targeting	 	 the	phosphorylation	events	 responsible	 for	ETV7	activation,	as	reported	for	the	ETS	factors	ETV1	and	ELK3	(Pop	et	al.,	2014;	Semenchenko	et	
al.,	 2016).	 So	 far,	 there	 are	 no	 clear	 studies	 on	 post-translational	modifications	 controlling	ETV7	 activation,	 except	 for	 the	 high	 affinity	 for	 JNK1	 (Selvaraj,	 Kedage	 and	 Hollenhorst,	2015).	 In	 this	 project,	 I	 observed	 an	 increased	 ETV7	 protein	 stability	 upon	 Doxorubicin	
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treatment,	that	could	be	probably	mediated	by	post-translational	modifications,	and	could	be	helpful	 to	 direct	 future	 studies	 in	 the	 field.	 Furthermore,	 a	 complex	 relationship	 between	ETV7	and	p53	is	proposed	by	this	study	and	it	is	aimed	to	be	better	clarified,	both	in	terms	of	competition	 in	 binding	 of	 some	 ETV7	 targets	 and	 in	 terms	 of	 possibly	 controlling	 ETV7	protein	stability.	The	conserved	ETV7	transcriptional	activation	upon	DNA	damaging	drugs	in	normal	 cells	 and	 its	 influence	 on	 TGF-β	 pathway	 suggested	 that	 ETV7	 could	 have	 a	 tumor	suppressor	role	 in	normal	cells,	 that	needs	 to	be	better	explored.	Therefore,	when	planning	ETV7	targeting,	it	will	be	of	paramount	importance	to	specifically	target	ETV7	in	cancer	cells.	Notably,	ETV7-mediated	drug	resistance	to	Doxorubicin	and	5-Fluorouracil	was	also	observed	in	the	osteosarcoma	cell	line	U2OS,	and	ETV7	novel	targets	were	already	associated	with	drug	resistance	in	various	cancer	types.	Therefore,	extending	to	other	cancer	types	the	analysis	of	ETV7	 role	 on	 drug	 resistance	 can	 hold	 important	 promises,	 especially	 in	 the	 light	 of	simplifying	the	drug	resistance	complexity.	Lastly,	a	possible	role	of	ETV7	in	controlling	viral	infection	was	also	briefly	evaluated	and	specifically	in	response	to	respiratory	syncytial	virus	(Annex	 1).	 A	 better	 understanding	 of	 the	 role	 for	 ETV7	 activation	 and	 its	 novel	 target	DNAJC14	in	response	to	RSV	infection,	can	also	eventually	clear	out	a	possible	 link	between	infection	and	increased	susceptibility	to	cancer.				 	
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10. ANNEXES 
 
ANNEX	1.1:	ETV7	can	promote	breast	cancer	cell	migration	and	anchorage-independent	
growth		This	 study	 mainly	 focused	 on	 the	 transcriptional	 role	 of	 ETV7	 in	 breast	 cancer	 cells		chemoresistance.	However,	our	group	is	also	investigating	whether	ETV7	may	promote	breast	cancer	aggressiveness	by	influencing	also	other	biological	processes.	ETV7	was	identified	as	one	 of	 the	 top	 synergistically	 genes	 up-regulated	 by	 the	 combined	 treatment	 with	Doxorubicin	and	TNF-α	 in	MCF7	cells,	a	condition	that	has	been	associated	by	our	group	to	increased	migration	as	previously	stated	(Bisio	et	al.,	2014).	Therefore,	ETV7	may	be	directly	implicated	in	promoting	breast	cancer	cells	migration.	To	verify	this	hypothesis,	I	performed	wound	 healing	 assay	 in	 MDA-MB-231	 cells	 stably	 over-expressing	 ETV7	 compared	 to	 the	clone	 stably	 transfected	 with	 an	 empty	 vector.	 MDA-MB-231	 cells	 over-expressing	 ETV7	showed	increased	reclosure	percentage	(Annex	Fig.	1.1A),	therefore	supporting	the	supposed	theory	 of	 a	 possible	 role	 for	 ETV7	 in	 breast	 cancer	migration.	 Given	 the	 toxicity	 related	 to	ETV7	silencing	observed	by	our	laboratory	in	breast	cancer	cells,	it	is	not	possible	to	further	check	the	ETV7	role	in	migration	by	gene	silencing.	In	addition,	I	explored	the	ability	of	ETV7	to	promote	anchorage-independent	growth	by	the	soft	agar	colony	formation	assay	using	as	a	a	model	 the	MDA-MB-231-ETV7	 and	 the	 empty	 cells.	 Annex	 Figure	 1.1B	 shows	 the	 higher	number	 of	 colonies	 found	 in	ETV7	over-expressing	 cells	with	 respect	 to	 the	 empty	 control,	thus	supporting	a	relevant	implication	for	ETV7	also	in	anchorage-independent	cell	growth.		
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ANNEX-Figure1.	1:	A)	Representative	pictures	for	wound	healing	assay	in	MDA-MB-231-ETV7	and	Empty	cells,	showing	the	wound	and	the	distance	between	the	two	edges	at	time	0	and	after	16	hours	from	the	generation	of	the	wound.	The	graph	on	the	right	indicates	calculated	mean	reclosing	percentages	of	8	indipendent	samples.	B)	Representative	results	for	soft	agar	assay	in	MDA-MB-231-ETV7	and	Empty	cells;	on	the	left	are	presented	images	obtained	at	the	stereomicroscope	and,	on	the	right,		a	graph	of	the	counted	number	of	colonies	from	three	independent	biological	replicates.	*	indicates	P-value	(T-test)<	0.05	and		**	indicates	P-value	(T-test)<	0.01.	
	
ANNEX	1.2:	A	possible	role	for	ETV7	in	RSV	infection		ChIP-seq	 enrichment	 analysis	 suggested	 a	 role	 for	 ETV7	 in	 inflammation	 and	 response	 to	pathogens,	 including	 viruses,	 for	 which	 the	 activation	 of	 ETV7	was	 already	 reported	 upon	HCV	 infection	 (Rempel	 et	 al.,	 2013).	 Therefore,	 I	 wanted	 to	 determine	 if	 ETV7	 was	 	 also	activated	upon	other	types	of	viral	 infection.	 I	observed	ETV7	activation	upon	RSV	infection	
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and	a	 concomitant	DNAJC14	 repression	 in	CRL4050	 (an	 immortalized	 cell	 line	 from	human	normal	lung	airway	tissue),	MCF7	and	MDA-MB-231	cells	(Annex	Fig.	1.2).	This	suggests	that	probably	the	decrease	of	DNAJC14	is	more	involved	in	the	inflammation	response	rather	than	in	 the	 direct	 regulation	 of	 drug	 response.	 Nevertheless,	 from	 this	 data	 it	 is	 not	 possible	 to	determine	if	ETV7	is	the	responsible	for	DNAJC14	repression	or	if	this	occours	independently.				
	
ANNEX-Figure1.	2:	A)	qPCR	analysis	of	ETV7,	DNAJC14	and	DNAJC15	expression	upon	RSV	infection	in	CRL4050	cells.	B-C)	qPCR	analysis	of	ETV7,	DNAJC14	and	DNAJC15	expression	upon	RSV	infection	(RSV4,	5days)	in	MCF7	(B)	and	in	MDA-MB-231	cells	(C).	**	indicates	P-value	(T-test)<	0.01.		 	
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ADDITIONAL	ANNEXES:	Personal	contribution	as	author	in	published	articles			During	the	first	year	of	PhD	project,	I	contributed	to	Bisio	et	al.	2014	manuscript,	performing	the	nuclear	and	cytoplasmic	protein	fractionation	followed	by	Western	Blot	analysis,	and	the	ChIP-qPCR	analysis	of	 selected	genes.	This	 study	was	 the	 starting	point	 for	my	PhD	project	based	on	the	analysis	of	ETV7	functions,	one	of	the	highly	synergistically	activated	genes	by	Doxorubicin	and	TNF-α	combined	treatment	in	breast	cancer	cells	(ANNEX2.1).		Among	the	list	of	genes	synergistically	activated,	we	identified	also	LAMP3,	a	member	of	the	LAMP	 family,	 for	 which	 it	 was	 still	 missing	 in	 the	 literature	 a	 review	 summarizing	 the	involvement	 of	 its	 family	 in	 cancer	 and	 that	 motivated	 my	 interest	 in	 writing	 a	 review,	recently	submitted	to	“Seminars	in	Oncology”	journal	in	its	revised	version	(ANNEX2.4).	Furthermore,	my	acquired	experience	in	ChIP-qPCR	assay	was	also	exploited	for	contributing	to	 the	Tebaldi,	Zaccara	et	al.	2015	manuscript	 (ANNEX2.2)	 for	 the	validation	of	p53	 targets	discovered	by	bioinformatical	analysis.		Lastly,	 most	 of	 the	 data	 presented	 in	 this	 thesis	 project	 are	 collected	 in	 the	 manuscript	 I	wrote,	which	was	recently	submitted	to	“Breast	Cancer	Research”	journal	(ANNEX2.3).			
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ABSTRACT
The p53 and NFκB sequence-specific transcription factors play crucial roles 
in cell proliferation and survival with critical, even if typically opposite, effects 
on cancer progression. To investigate a possible crosstalk between p53 and NFκB 
driven by chemotherapy-induced responses in the context of an inflammatory 
microenvironment, we performed a proof of concept study using MCF7 cells. 
Transcriptome analyses upon single or combined treatments with doxorubicin 
(Doxo, 1.5μM) and the NFκB inducer TNF-alpha (TNFα, 5ng/ml) revealed 432 up-
regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFα 
treatment. 239 up-regulated and 161 repressed genes were synergistically regulated 
by the double treatment. Annotation and pathway analyses of Doxo+TNFα selectively  
up-regulated genes indicated strong enrichment for cell migration terms. A panel 
of genes was examined by qPCR coupled to p53 activation by Doxo, 5-Fluoruracil 
and Nutlin-3a, or to p53 or NFκB inhibition. Transcriptome data were confirmed for 
12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were synergistically up-regulated after Doxo+TNFα and dependent both on p53 and 
NFκB. Migration assays consistently showed an increase in motility for MCF7 cells 
upon Doxo+TNFα. A signature of 29 Doxo+TNFα highly synergistic genes exhibited 
prognostic value for luminal breast cancer patients, with adverse outcome correlating 
with higher relative expression. We propose that the crosstalk between p53 and NFκB 
can lead to the activation of specific gene expression programs that may impact on 
cancer phenotypes and potentially modify the efficacy of cancer therapy.
INTRODUCTION
Cancer cells are continuously exposed to a number 
of signaling cues that reflect the distinct nature of the 
microenvironment at primary tumor site, metastastic 
lesions and potentially also during circulation in the blood 
stream [1–4]. Therapeutic intervention strategies can 
result in acute changes in microenvironment signaling, 
acting also through non-transformed cellular components 
resident at the primary tumor site [3, 5]. Cellular responses 
to changes in the microenvironment requires coordinated 
activation of sequence-specific transcription factors [6], 
among which NFκB and p53 have a prominent role and 
often opposing functions [7].
The p53 tumor suppressor gene is activated in 
response to a large number of cellular stress signals, 
including genotoxic stress, carbon and oxygen 
deficiencies, excessive proliferation signals [8, 9]. 
There are >150 established p53 target genes that link 
p53 to many different biological outcomes [10–14]. 
ANNEX 2.1
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The NFκB family of sequence-specific transcription factors 
consists of essential regulators of immune, inflammatory, 
proliferative and apoptotic responses [15], and their 
activation generally results in the onset of pro-survival 
signals [16]. The most common form of the NFκB complexes 
is the p50/RELA (p65) heterodimer. p53 and NFκB 
activation occurs simultaneously in response to diverse 
stress conditions, including genotoxic stress and NFκB 
proteins are frequently de-regulated in cancer, resulting in 
constitutive activation [17]. Competition between p53 and 
NFκB for a common limiting cofactor such as p300 can 
result in mutual inhibition [17, 18]. However, examples of 
positive interactions have also been reported. For example, 
it was shown that p65 can induce the p53 target gene p21 by 
direct binding to its promoter [19] and participates in p53-
dependent apoptosis [20]. Several human Toll-like receptors 
(TLRs), whose signaling leads to NFκB activation [21], 
were identified as direct p53 target genes both in cancer cells 
and primary cells [22] and it was demonstrated that p53 and 
NFκB can cooperate in the activation of pro-inflammatory 
genes in primary human monocytes and macrophages [23].
To investigate more globally the transcriptional 
crosstalk between p53 and NFκB we performed a proof 
of concept study using breast cancer-derived MCF7 
cells treated with Doxorubicin, Tumor Necrosis Factor 
alpha (TNFα) and a combination of the two compounds 
(Doxo+TNFα). Our results demonstrated a synergistic 
interaction between p53 and NFκB transcription factors, 
which can lead to the reprogramming of cell fate and 
enhanced migratory potential. Seven genes (PLK3, 
LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were established as synergistically up-regulated after 
Doxo+TNFα and dependent both on p53 and NFκB. A 29-
gene signature of highly synergistic genes up-regulated 
by Doxo+TNFα appeared to have prognostic value in a 
cohort of luminal breast cancer patients [24].
RESULTS
Striking transcriptome changes upon the 
combination of Doxorubicin and TNFα treatment 
of MCF7 cells
We first investigated the potential crosstalk between 
Doxorubicin (Doxo) and TNFα treatment using gene 
reporter assays in the human breast adenocarcinoma-
derived MCF7 cells (Figure S1A). p53-dependent 
responsiveness of the P21 and MDM2 promoter plasmid 
constructs was observed following Doxo treatment and 
confirmed by p53 silencing. The transactivation of the 
P21 and MDM2 constructs was reduced upon addition 
of TNFα to Doxo, suggesting possible inhibition of p53 
activity by NFκB. Mutual inhibition of the p53 and p65/
RELA proteins has been previously shown on p21 [17], 
while both inhibition and cooperation were reported at the 
BAX gene [18, 20]. However, this effect was not observed 
at the level of the endogenous P21 and MDM2 genes 
(Figure S1B), which showed similar level of activation 
in response to either Doxo alone or Doxo+TNFα. An 
NFκB reporter construct was responsive to both Doxo and 
TNFα as single treatments and showed a strong increase 
following the double treatment that was unaffected by 
p53 silencing. On the contrary, the endogenous TNFα 
and MCP1 NFκB target genes were weakly responsive 
to Doxo alone, highly induced by TNFα treatment, 
and showed intermediate induction levels upon double 
treatment. Hence, canonical p53 or NFκB target genes 
did not exhibit synergistic transcriptional responses to the 
combined treatment with doxorubicin and TNFα.
Next we performed a genome-wide transcriptome 
analysis after Doxo, TNFα, or the combination of the 
two compounds using the Agilent 4 × 44k array and 
single color labeling. Differentially expressed genes 
(DEGs) were selected based on rank product test, 
setting a threshold of 0.05 on the percentage of false 
positives (pfp) and a threshold of 2 on the absolute log2 
fold changes. The double treatment more than doubled 
the number of DEGs (Figure 1). The vast majority 
of DEGs resulting from the single treatments were 
also differentially expressed in the double treatment. 
Gene Ontology (GO) as well as pathway and upstream 
regulators analyses (DAVID, http://david.abcc.ncifcrf.
gov/; IPA, http://www.ingenuity.com/) confirmed 
activation of p53 signaling upon Doxo treatment as 
most significant pathway, and apoptosis induction 
as the most significantly enriched GO terms among 
up-regulated DEGs (Figure 1A-C). TNFα treatment 
also resulted in gene annotation terms consistent with 
NFκB activation, such as regulation of T cell activation. 
The gene annotation of DEGs resulting from the double 
treatment was enriched for terms typical of the two 
single treatments (e.g. T cell activation and apoptosis 
regulation among the up-regulated DEGs). TP53 as an 
upstream regulator was less significant in the double 
treatment compared to the Doxo single treatment, while 
p65/RELA, NFKBIA, IRF7 and STAT1 appeared to 
be even more enriched in the double treatment compared 
to TNFα single treatment (Figure 1B). The double 
treatment not only led to a higher number of DEGs, but 
resulted in quantitative differences in gene expression 
levels compared to the single treatments. We applied a 
rigorous filter and identified 212 repressed, 361 induced 
DEGs that were synergistically regulated by the double 
treatment Doxo+TNFα (see Methods) (Figure 1D). 
Notably, this subgroup of up-regulated DEGs was 
enriched for cell migration GO biological process 
along with the expected canonical terms for p53 and 
NFκB. Collectively, our systematic analysis indicates 
a vast network of genes that can be mutually affected 
by combined activation of p53- and NFκB-dependent 
responses.
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Doxorubicin + TNFα transcriptional synergy 
identifies new direct p53 and NFκB target genes
We selected fifteen genes for validation experiments 
based on (a) statistical analysis of synergistic up-regulated 
DEGs, (b) prior knowledge on direct regulation by either 
p53 or NFκB, (c) availability of ChIP-seq data for both 
transcription factors, and (d) gene functions in relation to 
cancer biology. The selected list contains genes encoding 
players of the control of various cellular processes, 
e.g. cell proliferation (PLK3, DUSP5, PLAU, GBX2, 
ETV7, EDN2), apoptosis (TNFRSF10B, UNC5B), 
inflammation (LAMP3, EGR2), development (GBX2, 
SOX9, NPPC, FOXC1) and cell migration (SNAI1, 
PLAU, UNC5B, NTN1, EDN2).
For twelve of the 15 genes we confirmed a 
synergistic response to the Doxo+TNFα treatment by 
qPCR (Figure 2A). Most of them were independently 
reported as putative targets of either p53, p65 or both 
according to published ChIP-seq data (for p65, http://
genome.ucsc.edu/ENCODE) [14, 25]. A potential direct 
contribution of NFκB on the observed gene expression 
Figure 1: A vast array of genes responds selectively to Doxorubicin and TNFα in MCF7 cells. (A) Number of DEGs 
identified after single or combined treatment (see Methods for statistical filters). Most significant gene ontology terms of down- or 
up-regulated DEGs, according to DAVID (http://david.abcc.ncifcrf.gov). (B) Predicted upstream regulators of the DEGs for the indicated 
treatments, according to IPA (IPA, http://www.ingenuity.com). The color code reflects the enrichment or depletion of the listed transcription 
factors targeting the DEGs from the array analysis. (C) Statistically relevant pathways predicted to be modulated in response to the 
indicated treatments according to IPA. (D) Number of DEGs that are synergistically regulated by the double treatment according to two 
different statistical filters (see Materials and Methods). The most significant gene ontology terms are also indicated.
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changes was evaluates using the small molecule 
inhibitor BAY 11–7082 (BAY) used as single agent or in 
combination with Doxo or/and TNFα (Figure 2B). Eight 
of the twelve validated synergistic DEGs were tested 
and for five of them BAY markedly inhibited the effect 
of Doxo+TNFα, or of TNFα alone. TNFα treatment led 
to higher levels of nuclear p65, while Doxo alone or in 
the combined treatment did not significantly impact p65 
nuclear protein levels. BAY treatment led to a slight 
reduction of p65 nuclear levels, which was paralleled 
by an increase in the cytoplasm (Figure 2C). p53 protein 
levels were induced to similar levels by the different 
treatment combinations (Figure S2).
The five genes that showed more convincing 
p65 dependence on the synergistic response to 
Doxo+TNFα (PLK3, NTN1, UNC5B, ETV7, LAMP3) 
were investigated more deeply to establish a direct role 
of wild type p53 in their transcription. MCF7 cells were 
treated with the chemotherapeutic agent 5-Fluorouracil 
(5FU) or with the MDM2 inhibitor Nutlin-3a, alone or in 
combination with TNFα. Both p53-inducing molecules 
were at least additive with TNFα in the responsiveness 
of the five genes (Figure 2D). Although the magnitude 
of the synergistic response was higher with Doxo, the 
fact that three different p53-activating treatments led 
to up-regulation of these five genes strongly suggested 
a direct role of p53. We next employed an MCF7 clone 
with stable knock-down of p53 and the HCT116 p53-/- 
cell line, to further establish p53-dependence of the five 
genes expression upon Doxo treatment. Matched MCF7 
vector and HCT116 p53+/+ were used as a comparison 
(Figure 2E, F). Invariably, Doxo responsiveness was 
strongly reduced in the p53-defective cells. Previous 
reports in the literature demonstrated or suggested p53-
dependent regulation of PLK3, NTN1 and UNC5B. Our 
results confirm those findings and establish, for the first 
time, the possibility of synergistic regulation by NFκB. 
PLK3, a polo-like kinase, is an important regulator of 
the cell cycle and it is involved in the control of hypoxia 
signaling pathway [26]. NTN1 is ligand for both DCC1 
and UNC5B receptors whose signaling can potentially 
modulate p53 activity, impacting on the decision between 
cell survival and cell death [27]. LAMP3 is a lysosomal 
membrane associated protein important in dendritic 
cells and potentially involved in tumor invasion [28], 
while ETV7 is a transcription factor associated to cell 
proliferation and tumorigenesis [29].
Given the lack of definitive evidence for LAMP3 
and ETV7 being direct p53 targets and since our finding 
of synergistic responsiveness, we examined p53 and 
(Continued )
Figure 2: p53- and p65-dependent up-regulation of selected synergistic DEGs. (A) Twelve out of fifteen selected synergistic 
DEGs were validated by qPCR. Plotted are the average fold change relative to the mock condition and three reference genes (GAPDH, 
B2M, ACTB) and the standard deviations of three biological replicates. “^” marks genes responding in synergistic manner to the double 
treatment. p53 and p65 occupancy data from available ChIP-seq datasets are summarized below each gene name. (B) Impact of the NFκB 
inhibitor BAY 11-7082 on the synergistic gene expression response plotted as in panel A. “*” Significant inhibition of by BAY when 
combined to Doxo + TNFα (t-test, p<0.01). NPPC and SNAI1 were also tested but their expression levels were not affected by BAY 
treatment. 
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p65 occupancy in MCF7 cells treated with Doxo or TNFα 
(Figure 3). p53 occupancy was detected both for ETV7 
and LAMP3 as well as for the positive control P21, in 
Doxo treated cells. For ETV7 p53 occupancy appeared 
to increase also after TNFα treatment. P21 was the only 
target for which p53 appeared to be bound also in the 
mock condition, a result consistent with previous data 
[30]. p53 occupancy levels were not distinguishable 
between Doxo and Doxo+TNFα treatment.
Both LAMP3 and ETV7 exhibited p65 occupancy in 
TNFα treated cells, although to a lower extent compared 
to the positive control MCP1. For the three promoter 
regions, occupancy was increased also by Doxo treatment 
alone, but no additive effect of the double treatment was 
apparent, except for a trend with LAMP3. On the contrary 
lower occupancy at MCP1 was detected in double treated 
cells. This latter result is consistent with the MCP1 mRNA 
expression changes (Figure S1B).
Hence, we identified genes whose expression is 
co-regulated by Doxo and TNFα. The gene expression 
studies conducted with different p53-activating molecules, 
the use of cells lines with different p53 status, and the 
chromatin immune-precipitation studies collectively 
established a direct role for p53 and p65 on the 
transcriptional regulation of PLK3, NTN1, ETV7, UNC5B 
and LAMP3. However, we did not find a direct correlation 
between occupancy levels at predicted promoter binding 
sites and gene expression changes.
Figure 2: (C) p65 nuclear (NE) and cytoplasmic (CE) relative protein levels under the different treatments used in panel B. M = mock; 
D = Doxo; T = TNFα; B = BAY. Proteins were fractionated as described in Materials and Methods. GAPDH and histone 3 (H3) served 
as controls for cytoplasmic and nuclear fraction respectively. As controls, a cytoplasmic mock fraction sample (CE) is loaded together 
with the nuclear proteins and vice versa a nuclear mock sample (NE) in included in the cytoplasmic blot. (D) 5-fluorouracil and Nutlin-3a 
induced expression of 5 selected DEGs alone or in combination with TNFα. Results were obtained and are plotted as in A. (E), (F) The 
relative expression of the 5 selected genes shown in panel C was tested in doxorubicin treated matched cell lines differing for p53 status 
(MCF7 vector and shp53, D; HCT116 p53+/+ and p53-/-, E).
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Doxorubicin + TNFα treatment enhances the 
migration potential of MCF7 cells
Both the gene ontology enrichments of synergistic 
DEGs and the known function of the fifteen genes chosen 
for validation suggested the possible activation of gene 
expression programs influencing cell motility, epithelial 
mesenchymal transition (EMT) or even stem-like 
phenotypes. Projected to an in vivo context, the crosstalk 
of signals present in an inflammatory microenvironment 
could have a negative impact on the efficacy of 
chemotherapy, possibly by enhancing tumor cell plasticity. 
To begin exploring this hypothesis, we investigated 
migration and invasion potential of MCF7 cells treated 
with Doxo, TNFα or both. Three different experimental 
approaches consisting in real-time cell migration analysis 
(Figure 4A), transwell migration test (Figure 4B) and 
wound healing assay (Figure 4D) consistently showed 
higher migration potential of double-treated MCF7 cells, 
while the invasion phenotype was unaffected by all three 
types of treatment (Figure 4C).
Several studies suggest that EMT not only enhances 
the motility and invasiveness of cancer cells, but also 
provides additional aggressive features such as stemness 
and therapeutic resistance [31]. Indeed, several of the 15 
synergistic DEGs we validated are directly or indirectly 
associated with acquisition of stem-like phenotypes in 
normal or cancer cells, particularly SNAI1 [32, 33], 
SOX9 [34] and GBX2 [35]. Different lines of evidence 
indicate that breast cancer stem cells (BCSCs) display 
increased cell motility, invasion, and overexpress genes 
that promote metastasis [36] and can be traced by CD44+/
CD24-/low surface marker expression [37]. We asked if 
the Doxo+TNFα treatment could enhance the stem-like 
subpopulation of the MCF7 cell line (Figure 4E). FACS 
analysis showed that the CD44+/CD24- subpopulation 
virtually disappeared after all treatments. Therefore, the 
higher motility observed upon double treatment cannot be 
directly related to the expression of these surface markers, 
hence to putative stem-like features.
Prognostic value of Doxorubicin + TNFα 
synergistic DEGs
Since luminal type breast cancer, of which MCF7 
is considered as a model, frequently retains wild type 
p53 and NFκB responsiveness, we asked if Doxo+TNFα 
synergistic DEGs could be endowed with prognostic 
significance. Up-regulated DEGs were further filtered 
by selecting genes that were strongly responsive to the 
double treatment but minimally responsive to the single 
ones (see Materials and Methods). A signature list of 
Figure 3: Occupancy analysis establishes ETV7 and LAMP3 as direct p65 and/or p53 target genes. (A) Relative 
quantification of immune-precipitated gene fractions by qPCR from MCF7 cells subjected to Doxo or TNFα single treatments and to the 
double treatment. The antibodies used for the immune-precipitations are listed. P21 was used as positive control, while ACTB was used 
as a negative control. Plotted are the average percentages relative to input signals. Error bars represent the standard errors of at least three 
biological replicates. (B) as in A, but probing p65 occupancy. MCP1 was used as positive control. The IgG antibody controls were anti-
mouse (A) or anti-rabbit (B) to match the specific primary antibodies. (C) The position of the primers used for the qPCR and the location 
of predicted p53 and p65 binding sites in the ETV7 and LAMP3 genes are depicted.
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Figure 4: Doxo+TNFα leads to enhanced MCF7 motility but ablates the stem-like side population. (A) Real-time migration 
assays examined by xCELLigence. Plotted are the average results of four biological repeats. Cell Index is proportional to the number of cells 
migrating through a hole in the culture plate. The treatments relative to the different curves are indicated. (B) Relative transwell migration 
values quantified by a fluorescence readout (see Materials and Methods). Average and standard deviation of triplicate biological replicates are 
presented. The applied treatments are listed on the x-axis. (C) As for B, but measuring the invasion potential of MCF7. (D) Images of a wound 
healing assay obtained at T0 or T24. Composite (3×3) images were acquired using an automated Zeiss microscope and the AxioVision3.1 
software. (E) Cell sorting results based on intensity of CD44 and CD24 surface markers on 30000 cells. Q1 individuates the CD44+/CD24-(low) 
cells, considered as stem-like. The percentages in the four quadrants after the various treatments are presented in the table.
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29 genes (DT29) was generated (Figure 5A) and used to 
interrogate clinical data using the KM plotter tool [38]. 
Interestingly, breast cancer patients with luminal type A 
diagnosis who underwent chemotherapy and exhibited 
higher relative expression of DT29 genes showed poorer 
prognosis (Figure 5B). The same was true for luminal A 
patients with lymph node infiltration or luminal A grade 2 
(Figure 5C, D).
Analysis of Doxorubicin and TNFα crosstalk in 
lung cancer-derived and HUVEC cells
We extended our analysis to another pair of cancer 
cell lines that differ for p53 status. A549 (p53 wild type) 
and H1299 (p53 null) lung cancer derived cells were 
treated with Doxo or/and TNFα or/and BAY. Expression 
of PLK3, NTN1, ETV7, UNC5B and LAMP3 was 
measured by qPCR (Figure 6A-E). The impact of the 
various treatments on p65 nuclear and cytoplasmic, p53 
and p21 protein levels was also evaluated (Figure 6F, 6G). 
In the p53 null H1299 cells the relative expression changes 
of all the genes was invariably much lower compared to 
A549 cells. However, NTN1 was weakly TNFα inducible 
and ETV7 was weakly Doxo+TNFα responsive. Instead in 
A459 cells NTN1, ETV7 and LAMP3 were synergistically 
up-regulated by Doxo+TNFα, while PLK3 and UNC5B 
were additive. The magnitude of induction upon Doxo 
was often one order of magnitude higher compared 
to TNFα alone. Transient transfection assays with the 
κB luciferase reporter construct were performed using 
different concentrations of TNFα or BAY (Figure S3). 
Based on the results, 10ng/ml TNFα and/or 20μM BAY 
were chosen for the qPCR experiments, although the 
reduction of TNFα-induced reporter activity was modest, 
albeit significant. At the endogenous gene level in A549 
cells we did not observe the inhibitory effect of BAY on 
either TNFα-induced changes or Doxo+TNFα, with the 
possible exception of UNC5B (Figure 6A-E). However, 
BAY treatment reduced the Doxo responsiveness of these 
genes, which might be dependent on its effect on the 
activation of NFκB by endogenous production of TNFα. 
In the p53 wild type A549 cells, p53 and p21 protein 
levels were induced by Doxo and not affected by the 
treatment with TNFα. Total p65 levels were unaffected 
by all treatments in both cell lines (Figure 6F). Nuclear 
p65 protein levels were increased in response to TNFα or 
Figure 5: Prognostic significance of a 29-gene list of synergistic Doxo+TNFα DEGs. (A) Top list of 29 genes (DT-29) 
exhibiting minimal responsiveness to Doxo or TNFα as single agents, but strong synergy upon combined treatment. A heat map view of 
the gene expression results is presented (see Materials Methods for statistical filters). Occupancy of both for p65 and p53 in the vicinity 
of the transcription start sites of these genes has been summarized from ChIP-seq data available in the literature. (B-E) Kaplan-Meier 
plots stratifying a breast cancer patient cohort based on the relative expression of the DT-29 gene list and relapse free survival. Graphs 
were generated with the KM-plotter tool (ref). Patients’ numbers are listed below the graph. Hazardous Ratio and the statistical analysis is 
reported for selected patients subgroups: (B) luminal A patients who underwent chemotherapy treatment (n = 111); (C) luminal A patients 
with a Grade 2 cancer at diagnosis (n = 385); (D) luminal A patients with lymph node infiltration at diagnosis (n = 447) and (E) the entire 
cohort of luminal A patients (n = 1509). Patients with a diagnosis of Luminal A breast cancer subtype were selected as the p53 status is not 
available in KM plotter, but this subgroup of breast cancer is expected to be strongly enriched for cases retaining wild type p53 protein.
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Figure 6: PLK3, NTN1, ETV7, UNC5B and LAMP3 responsiveness in lung cancer cell lines. (A-E) Relative fold change 
expression of the indicated genes and after the listed treatments in A549 (p53 wild type) and H1299 (p53 null) cells, measured by qPCR. 
Average and standard deviations of three biological replicates are presented. (F) Western blot of total p65, p53 and the p53 target p21. 
GAPDH was used as loading control. (G) Western blot of nuclear and cytoplasmic protein fractions were performed as for Figure 2C.
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Doxo+TNFα in both A549 and H1299 cells (Figure 6G). 
Interestingly, BAY treatment alone or in combination led 
to a reduction in p65 nuclear accumulation (Figure 6G).
HUVEC primary cells were also subjected to Doxo 
and TNFα single or double treatment and the expression 
of the same panel of five genes was tested by qPCR 
(Figure S4). Results among biological repeats varied, but 
in the majority of tests, all genes with the exception of 
LAMP3 were Doxo responsive; NTN1 and ETV7 were 
also TNFα responsive. No synergistic up-regulation by the 
double treatment could be consistently established. p53 
and p65 protein levels confirmed i) the activation of p53, 
with a similar level of p53 protein in the double treatment, 
and ii) the p65 proficiency of this cell line.
DISCUSSION
Wild type p53 functions are intricately related to 
multiple tumor suppressor pathways, primarily acting 
in cell autonomous manner to restrain cell proliferation 
and including cell death and senescence in response 
to genotoxic and many other types of cellular stresses 
[8, 9]. Furthermore, p53 also contributes to modulate 
the microenvironment in a non-cell autonomous 
manner [39]. p53 has also been linked to inhibition of 
EMT, for example through an indirect stimulation of 
E-cadherin expression [40]. At the same time, paracrine 
signaling in mice triggered by Doxorubicin were found 
to stimulate EMT and metastatic potential of cancer 
cells, in part through NFκB activation [3]. Many studies 
have highlighted the potential contribution of NFκB-
induced signaling in the acquisition of cancer cell traits 
conducive to chemoresistance and higher metastasis 
risk [2] [41]. While, the canonical functions of p53 and 
NFκB are consistent with the co-occurrence of p53 
inactivation and NFκB hyper-activation that is frequent in 
cancer [7], recent studies provided examples of positive 
cooperation between p53 and NFκB that would occur 
in specific cell types, such as antigen presenting cells or 
macrophages, and contribute to physiological responses, 
such as for example in the process of innate immunity and 
inflammation [12, 22, 23, 42].
Here we modeled the impact of a first line 
chemotherapeutic drug leading to genotoxic stress and 
p53 activation, using exposure to the immune cytokine and 
NFκB activator molecule TNFα as a variable, mimicking 
the effect of an inflammatory microenvironment. We 
used transcriptome analysis as primary endpoint and 
uncovered a vast network of differentially expressed 
genes that selectively responds to combined treatment 
with Doxorubicin and TNFα. Furthermore, genes that 
were synergistically up-regulated by both treatments 
appeared to endow cells with higher motility potential 
in vitro. Analyses of the annotated gene functions related 
to the aforementioned genes also revealed the possibility 
of an induced epithelial mesenchymal transition upon 
combination of the treatments. For example, SNAI1 
appeared to be regulated in more than additive manner 
by the double treatment, as well as LAMP3, a lysosomal 
protein previously associated with metastasis risk [28, 
43]. Multiple cytokines and secreted factors, including 
IL6, IL17, IL15 and its receptor, S100A8 and S100A9, 
CXCL12 and several Serpins were also identified as 
synergistic DEGs (Table S1). The presence of S100A8, 
S100A9 and CXCL12 among synergistic DEGs raises 
the possibility that, unlike the case of the triple negative 
cell line MDA-MB-231 for which S100A8-mediated 
signaling appeared to require heterotypic cell interactions 
[3] contributing to metastasis potential, in MCF7 cells 
this signaling could become homotypic or even autocrine. 
A marked difference in secreted factors and associated 
signaling among MDA and MCF7 cells was elegantly 
shown in recent studies [4].
A direct contribution of p65/RELA and p53 
in the observed gene expression changes elicited by 
Doxorubicin and TNFα was inferred for some of the 
synergistic DEGs by modulating pharmacologically or 
genetically p65 or p53 activities. However, we cannot 
exclude at this stage a (Doxo+TNFα)-dependent, but 
p53- or NFκB- independent gene expression changes. 
For example, NFkB can functionally interact with 
AP-1 [44–46] or ER [47], which in turn can modulate 
p53-dependent responses [48] [49] [50].
Among the most synergistic genes, 29 appear to 
be prognostic in luminal A breast cancer patients who 
underwent chemotherapy, where their higher expression 
correlated with adverse outcome. The majority of luminal 
A breast cancers are wild type for p53 [51], although data 
is not available to stratify patients for p53 status in the 
KM plotter tool [24]. Based on available ChIP-seq data 
[14, 25, 52, 53], 20 of these 29 genes are putative targets 
of either p53 or p65 and 10 of them are putative targets of 
both factors (Figure 5). This result raises the possibility 
of an unexpected negative outcome of chemotherapy in 
the context of an inflammatory microenvironment. The 
prognostic significance of this gene signature needs 
in-depth evaluation in independent patients cohorts. If 
confirmed, the results would further support the value 
of combining treatments activating p53 and repressing 
NFκB [7].
Given that the crosstalk between Doxorubicin 
and TNFα and the interplay between p53 and NFκB 
would occur in cells residing or infiltrating the tumor 
microenvironment, the ultimate in vivo outcome of these 
functional interactions may vary and cannot be directly 
predicted from our study using a pure culture of MCF7 
cells in vitro. Here we have explored Doxo+TNFα 
impact on HUVEC cells and also on a p53 wild type lung 
adenocarcinoma-derived cancer cell line. Although limited 
by the number of genes tested, the results suggest that a 
positive crosstalk between Doxorubicin and TNFα can 
be a general characteristic of different cell types and is 
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at least in part p53-dependent, based on the results with a 
p53 null lung cancer cell line. Furthermore, while we have 
addressed here the functional interactions between two 
small molecules, cells are constantly exposed to a complex 
milieu of signaling factors. However, both p53 and NFκB 
are master regulators, often contributing a dominant trait 
in gene expression changes to their target genes. Nuclear 
receptors, including Estrogen Receptors (ERs) can also 
modulate NFκB as well as p53 functions [54–56] and 
have critical roles in breast cancer etiology. We also 
explored the impact of ER function in the transcriptional 
programs responding to Doxorubicin and TNFα exposure, 
using estrogen-depleted culture conditions and adding 
17β-estradiol (10-9M, E2) as variable (Table S2 and GSE 
24065). However, the combination of E2 to Doxo and 
TNFα resulted only in 15 and 11 selective up- and down-
regulated DEGs, respectively (Table S3). A hierarchical 
cluster analysis of all the treatments confirmed graphically 
the large difference between TNFα- and Doxo-induced 
transcriptomes and also the significant impact of TNFα 
when combined to Doxo, while E2 had a minor effect both 
in the combination with Doxo and with Doxo + TNFα 
(Figure S5).
With this study we established an example of 
positive cooperation between p53 and NFκB, in the 
context of the responses of an epithelial cancer cell to 
standard chemotherapy but in the presence of active 
signaling by a pleiotropic inflammatory cytokine, such as 
TNFα. A signature gene of the consequent transcriptional 
reprogramming appears to be prognostic in breast cancer 
patients. Associated gene functions indicate the potential 
acquisition of enhanced cell plasticity and motility and 
provide a rationale to investigating mechanisms resulting 
in acquired chemoresistance, particularly for luminal A 
breast cancer, but potentially with general implication 
for p53 wild type tumors of different tissue types, and 
for overcoming such resistance by targeting NFκB. The 
unexpected positive crosstalk between p53 and NFκB 
emerging from our and other very recent studies [23] 
may represent an evolutionary consequence of anti-
viral and infection responses towards which NFκB is 
an established master regulator [57], but the p53 and 
p73 family member are emerging as important/critical 
contributors [42, 58, 59].
MATERIALS AND METHODS
Cell lines and culture conditions
MCF7 (p53 wild type, expressing p65 and positive 
for ERs) and HUVEC (Human Umbilical Vein Endothelial 
Cells) cells were obtained from ICLC (Genoa, Italy), while 
A549 from ATCC (Manassas, VA, USA). H1299 cells were 
a gift of Dr. Resnick’s laboratory (NIEHS, NIH, RTP, NC, 
USA); HCT116 p53+/+ and p53-/- of Dr. Vogelstein’s (John 
Hopkins Kimmel Cancer Center, Baltimore, MD, USA). 
MCF7-shp53 or control MCF7-vector cells were provided 
by Dr. Agami (Netherlands Cancer Institute, Amsterdam, 
The Netherlands). Cells were cultured in DMEM or 
RPMI media supplemented with 10% FBS, or Medium 
199 (Lonza Milan, Italy) supplemented with 50 units/
ml Low Serum Growth Supplements (Life Technologies, 
Milan, Italy) in the case of HUVEC cells that were also 
cultured on 0.1% gelatin pre-coated plastics. Media were 
supplemented by 2mM L-Glutamine and 1XPenicillin/
Streptomycin mixture (Pen/Strep), and Puromycin (0.5 μg/
mL) in the case of MCF7-shp53 and –vector cells. When 
appropriate, cells were maintained in DMEM without 
Phenol Red (Lonza) supplemented with Charcoal/Dextran 
treated FBS (Hyclone, GE Healthcare, South Logan, 
UT, USA).
Drug treatments
Doxorubicin (Doxo, 1.5 μM), 5-Fluorouracil (5FU, 
375 μM), Nutlin-3a (10 μM) were used to stabilize p53 
protein. When needed TNFα (5ng/ml in MCF7 and 10ng/
ml in H1299, A549 and HUVEC cells –based on dose-
response tests with gene reporter assays) or BAY11-7082 
(10μM or 20μM in H1299 and A549) were added to the 
culture medium. All compounds were from Sigma-Aldrich 
(Milan, Italy).
Microarray experiment and data analysis
Total RNA was extracted from 4 biological 
replicates using the Agilent Total RNA Isolation Mini Kit 
(Agilent Technologies, Santa Clara, CA, USA). Samples 
with RNA Integrity Number (RIN) above 9 (Agilent 2100 
BioAnalyzer) were processed. Details are provided with 
the Gene Expression Omnibus (GEO) (www.ncbi.nlm.
nih.gov/geo) submission (GSE24065) and in [56]. The 
output of Feature Extraction (Agilent standard protocol 
GE1_107_Sep09) was analyzed with the R software for 
statistical computing and the Bioconductor library of 
biostatistical packages. Probes with low signals were 
removed in order to filter out the unexpressed genes 
and keep only probes with acceptable signals in most 
of the replicates. Signal intensities across arrays were 
normalized by quantile normalization. Signal intensities 
from probes associated with the same gene were averaged. 
This procedure resulted in quantitative signals for 14095 
HGNC genes. To identify potential target genes of 
Doxorubicin and TNFα, we compared the signals after 
the double treatment (Doxo+TNFα) and the two single 
treatments relative to the untreated control (mock). 
DEGs were selected applying a statistical test based on 
rank products implemented in RankProd Bioconductor 
package, setting a threshold of 0.05 on the percentage of 
false positives (pfp) and a threshold of 2 on the absolute 
log2 fold changes [60]. Every treatment was compared to 
the mock condition (Table S1, S2 and Figure S5).
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To select genes with synergistic effect, i.e. genes 
whose expression variations were more than additive in 
the double treatment with respect to single treatments, a 
further comparison between the double treatment samples 
and all the remaining samples (single treatments and 
control samples) was performed (double treatment vs all). 
Synergistic DEGs were selected applying an additional 
pfp filter (pfp<0.005) derived from this comparison, to 
the list of DEGs resulting from the “double treatment 
vs mock” comparison. A more stringent criterion was 
obtained by calculating the synergistic effect (SE) of 
the double treatment as the observed difference between 
the fold change of the double treatment and the sum of the 
fold changes of the single treatments (SE=log2 FC double 
treatment – (log2 FC Doxorubicin + log2 FC TNFα). 
We filtered genes with SE>0 for up-regulated DEGs, 
SE<0 for down-regulated genes (Figure 1). To select 
genes where the up-regulation contribution of each single 
treatment was low respect to the up-regulation of the 
double treatment, the ratio of the single/double treatments 
was calculated, applying a 0.25 filter on them (FC 
Doxorubicin/FC double treatment <0.25 and FC TNFα/
FC double treatment <0.25) (see Table S1, S2).
RNA isolation and quantitative qPCR
Total RNA was extracted using Qiagen RNeasy Kit 
(Qiagen). cDNA was converted from 1 µg of RNA using 
M-MuLV reverse transcritptase and RevertAid cDNA 
Synthesis kit (ThermoFisher, Milan, Italy). qPCR was 
performed on a Bio-Rad CFX384 (Bio-Rad, Milan, Italy). 
TaqMan gene expression assays (Applied Biosystems, Life 
Technologies) and Probe MasterMix (Kapa Biosystems, 
Resnova, Rome, Italy) were used starting with 25ng of 
cDNA as previously described [56, 61]. GAPDH, B2M or 
ACTB served as reference genes.
Western blot
Protein extraction and immunodetections were 
performed as previously described [62], using ECL Select 
detection reagent (GE Healthcare) and anti-p53 (DO-1) 
anti-RelA/p65 (C-20) anti- p21 (C19), anti-GAPDH (6C5) 
(Santa Cruz Biotechnology, Heidelberg, Germany). When 
appropriate, nuclear and cytoplasmic fractionation was 
performed. MCF7, A549 and H1299 cell lines were seeded 
on 100mm Petri dishes and treated at 80% confluence 
with Doxo, TNFα, BAY or the combination of the drugs 
for 16 hours. Cells were harvested and cytoplasmic and 
nuclear proteins were extracted using NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Pierce, ThermoFisher 
Scientific), following the instructions provided by the 
manufacturer. 20 μg of nuclear and cytoplasmic extracts 
were loaded on a 12% poly-acrylamide gel and transferred 
to nitrocellulose membranes. Antibodies used for detection 
were: anti-Histone H3 (clone #: ab1791, AbCam, Milan, 
Italy) and anti-Lamin A/C (clone #: 2032, Cell Signaling, 
Milan, Italy) used as nuclear loading control, and anti-
GAPDH used as cytoplasmic loading control.
Chromatin immunoprecipitation assay
We used previously described protocols [63, 64]. 
The following antibodies were used: anti-p53 (DO-1), 
anti-p65 (C-20) and IgG (sc-2025 or sc-2027) (Santa Cruz 
Biotechnology). ChIP-qPCR experiments were performed 
using Sybr MasterMix (Kapa Biosystems) and 2 μl of 
enriched DNA. Results were analyzed by the comparative 
Ct method (ΔCt) and normalized as % of input. Regions 
in the promoter of GAPDH or ACTB and p21 or 
MCP1 genes served as negative and positive controls, 
respectively. Primers were selected using Primer 3 
(http://primer3.ut.ee/).
Migration and wound healing assays
The migration potential of MCF7 cells was 
monitored by a real-time technique using the 
xCELLigence Instrument (Acea Biosciences, Euroclone) 
and CIM-16 plates, following manufacturer’s instructions. 
Prior to the analysis, cells were grown in estrogen-free 
medium for two days and left untreated (mock) or treated 
with Doxo, TNFα or the combination. 16 hours after 
the treatments, cells were detached and added to the top 
chamber in serum-free medium. Migration was detected 
every 10 minutes for 24 hours. We used 0.5% and 5% 
FBS as chemo-attractant. Migration and Invasion were 
also measured by QCMTM Fluor 24-Well Cell Migration 
and Cell Invasion kits (Merck-Millipore, Milan, Italy), 
according to manufacturer’s instructions. For wound 
healing, cells were seeded in 12-well plates and treated 
with Doxo, TNFα or the combination. After 16 hours a 
scratch was introduced using a 10 μl pipette tip. Images of 
the same field were acquired immediately (T0) and after 
24 hours (T24) using an automated Zeiss microscope and 
the AxioVision3.1 software in multidimensional mode 
with mosaic (3x3) acquisition.
Flow cytometry
MCF7 cells, seeded and treated as described 
above, were washed with PBS and harvested by 0.05% 
trypsin/0.025% EDTA. The cells were washed again 
with PBS containing 2% FBS before being subjected 
to antibody binding, a combination of fluorochrome-
conjugated monoclonal antibodies against human CD44 
(APC) and CD24 (FITC) or their respective isotype 
controls (BD Biosciences, Milan, Italy) and incubated on 
ice in the dark for 30 minutes. Cells were then washed 
twice with PBS/2% FBS and resuspended in PBS. Flow 
cytometry analysis was conducted using a FACSCanto II 
instrument (BD Biosciences).
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Whole-genome cartography of p53 response
elements ranked on transactivation potential
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Abstract
Background: Many recent studies using ChIP-seq approaches cross-referenced to trascriptome data and also to
potentially unbiased in vitro DNA binding selection experiments are detailing with increasing precision the p53-directed
gene regulatory network that, nevertheless, is still expanding. However, most experiments have been conducted
in established cell lines subjected to specific p53-inducing stimuli, both factors potentially biasing the results.
Results: We developed p53retriever, a pattern search algorithm that maps p53 response elements (REs) and ranks
them according to predicted transactivation potentials in five classes. Besides canonical, full site REs, we developed
specific pattern searches for non-canonical half sites and 3/4 sites and show that they can mediate p53-dependent
responsiveness of associated coding sequences. Using ENCODE data, we also mapped p53 REs in about 44,000 distant
enhancers and identified a 16-fold enrichment for high activity REs within those sites in the comparison with genomic
regions near transcriptional start sites (TSS). Predictions from our pattern search were cross-referenced to ChIP-seq,
ChIP-exo, expression, and various literature data sources. Based on the mapping of predicted functional REs near TSS,
we examined expression changes of thirteen genes as a function of different p53-inducing conditions, providing
further evidence for PDE2A, GAS6, E2F7, APOBEC3H, KCTD1, TRIM32, DICER, HRAS, KITLG and TGFA p53-dependent
regulation, while MAP2K3, DNAJA1 and potentially YAP1 were identified as new direct p53 target genes.
Conclusions: We provide a comprehensive annotation of canonical and non-canonical p53 REs in the human genome,
ranked on predicted transactivation potential. We also establish or corroborate direct p53 transcriptional control
of thirteen genes. The entire list of identified and functionally classified p53 REs near all UCSC-annotated genes
and within ENCODE mapped enhancer elements is provided. Our approach is distinct from, and complementary
to, existing methods designed to identify p53 response elements. p53retriever is available as an R package at:
http://tomateba.github.io/p53retriever.
Keywords: p53, Response element, Transactivation potential, Distal enhancer
Background
The p53 tumor suppressor is certainly one of the most
studied sequence-specific transcription factor to date.
Yet, much has still to be learned to fully describe its
transcriptional regulatory network, both in terms of the
crosstalk with other transcription factors and in terms of
the entire spectrum of regulated transcriptional target genes,
that can be both up-regulated or down-regulated [1–6].
Recently, several genome-scale techniques such as
ChIP-on-chip, ChIP-seq, and, more recently, ChIP-exo,
have provided us with different and largely non-
overlapping maps of p53 bound sites in the human gen-
ome in response to specific stimuli [7–17]. Correlation
between occupancy data and modulation of transcrip-
tion levels of nearby genes helped identifying additional
direct p53 target genes, of which >200 have been estab-
lished [2, 15]. Furthermore, new methodologies are re-
fining the potential to map the p53 network taking also
into account the kinetics of transcriptional initiation
[18, 19]. It is worth noting that, to date, most experi-
ments have been developed in cancer-derived cell lines
that may represent an adapted environment potentially
biasing a comprehensive annotation of physiological
p53 target sites [7, 20]. To this respect, the impact of
specific p53-inducing stimuli and the differentiation/
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ANNEX 2.2
tissue context of the cell have not been systematically
investigated [4, 7, 8, 21, 22].
Considerable attention has been given to the sequence
and structural features of p53 binding sites that provide
for p53 recruitment to target sites [2, 5, 6]. It is now
more clear that the loose definition of p53 response
element (RE) [23] that has been used for many years
comprises a wide range of DNA binding affinity, occu-
pancy rates and transactivation potentials measured by
various types of assays, and that specific differences in
the definition of p53 REs are evident between purely
in vitro biochemical assays and in vivo occupancy mea-
surements [24–28].
The canonical p53 consensus found in many identified
binding sites of mostly up-regulated p53 target genes
consists of two copies of the palindromic half-site
RRRCWWGYYY separated by a spacer of 0–13 bp, in
which R = purine, W =A or T and Y = pyrimidine. The-
oretically, each p53 monomer binds five nucleotides –
i.e., one monomer binds the I° quarter site R1R2R3C1
W1 and the second monomer the II° quarter site
W2G1Y1Y2Y3-. As reviewed previously, the rather degen-
erate p53 consensus sequence, reflects the established
observation that in virtually all cases of validated p53
REs, an optimal consensus site is not found, because of
mismatches, in some cases resulting in partial binding
sites, referred to as non-canonical REs [5, 24, 29]. This
has raised the hypothesis of a selection pressure to limit
the intrinsic potential of p53 proteins to target binding
sites, thereby allowing for modulation of p53-induced
transcriptional changes by signal transduction pathways
affecting p53 protein amount, DNA binding potential,
quaternary structures and/or availability of multiple
trans-factors [30–36]. For example, p53 REs with lower
DNA binding affinity appear to be more frequent in tar-
get genes involved in apoptosis [28]. Consistent with this
hypothesis, optimized p53 REs have been recently stud-
ied in experimental models and in vitro for their kinetic
and thermodynamic interactions with p53 as well as
transactivation potential and shown to provide for high
level of p53-mediated transactivation even at low p53
protein levels [25].
Functional assays in a defined experimental setting
provided by the yeast S. cerevisiae have been extensively
used to characterize the transactivation potential of p53
RE in isogenic conditions and exploit variable expression
of p53 under an inducible promoter to yield a matrix of
transactivation results, to some extent comparable in
precision to that of a biochemical assay in a test tube [5,
24, 26, 28, 37–41]. Further, high correlation was re-
ported between results in yeast and transactivation or
occupancy data in cancer cell lines [24, 27]. For example,
experiments in this model system led to identify functionally
active half-site and 3/4 site (3Q) p53 REs, a group of REs
collectively considered as non-canonical that were then
mapped and validated also in human cells [7].
Here we have combined all the data obtained so far
with the yeast-based p53 transactivation assay and devel-
oped an algorithm, p53retriever, to scan DNA sequences,
identify p53 REs and classify them based on predicted
transactivation potential into five broad categories. As
unique features, this algorithm takes into account co-
operative interactions between groups of mismatches in
two p53 dimers and scores also non-canonical REs.
Specifically we used this approach to map functional
p53 REs in the proximity of all annotated coding genes,
searched for high affinity p53 REs in the entire genome,
and mapped functional p53 REs within ENCODE-
defined distant enhancer regions. The predictive power
of mapping p53 REs with high functional score near
transcription start sites (TSS) was validated for a panel
of 13 genes, using cell lines differing for p53 status, two
p53-inducing stimuli and measuring relative expression
by qPCR at three time points. APOBEC3H, E2F7, GAS6,
TRIM32, PDE2A, KCTD1, DICER, MAP2K3, DNAJA1,
HRAS, KITLG, TGFA and potentially YAP1 were con-
firmed or identified as p53 target genes.
Results and discussion
Development and implementation of p53retriever, a
pattern search code that identifies canonical and
non-canonical p53 REs based on predictions from
transactivation assays
In general, the degree of p53 binding depends on various
factors including the state of the p53 protein, its cofac-
tors, and the sequence composition of the p53-RE [5,
32]. Because easier to predict than the p53 state, compu-
tational algorithms were developed to explore p53 bind-
ing through sequence motif analysis. The majority of
these algorithms, such as p53MH [42], do not directly
consider the response element (RE) potential to drive
p53-dependent transactivation. On the contrary, p53re-
triever is based on a set of manually curated rules, de-
rived from a compendium of p53 transactivation data
obtained using a yeast-based assay [24, 26, 37, 43, 44].
REs are scored from five (= highly functional REs ac-
tivity) to one (= unlikely functional REs) (Fig. 1a). The
grade represents the inferred transactivation potential
rather than being an indication of the percent similarity
to the canonical p53 consensus sequence. For full site
p53 REs the grade considers a severe negative impact of
a spacer between the two half sites larger than two nu-
cleotides (Fig. 1c). Variable p53-RE spacer lengths are
known to affect transactivation capacity. Only two previ-
ous studies tried to incorporate the spacer length as one
of the relevant features [11, 45], calculating a penalty
score directly proportional to spacer length. Also in our
algorithm, based on previous results, we attribute high
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negative impact to spacers longer than two nucleotides
(Fig. 1c). Indeed, REs with a long spacer length are also
confirmed to be rarely bound by p53 in vivo [7, 14, 46, 47].
Many of the computational approaches for identifying
putative p53-REs define how similar that putative bind-
ing site is to the consensus, but do not consider the local
context of single mismatches within the RE. In our
approach mismatches from consensus are also weighted
depending on their position within the RE 20-mer
sequence, given the finding that mismatches in the
quarter sites at the interface between the two half sites
have a more severe impact likely due to cooperative
interactions among two p53 dimers [28] (Fig. 1b). In
addition, interaction effects between groups of mis-
matches are also considered. In general, any combination
of mismatches is penalized in a different way according
to their location, considering that p53 is functionally
active as a tetramer, that each p53 monomer interacts
with a 5 nt motif (quarter site) and that the p53 tetramer
is thought to be assembled as a dimer of dimers [48]. If
groups of mismatches are localized in the same “quarter”
of the RE, the score is less penalized than if the same
mismatches were scattered in different quarters (Fig. 1b).
Importantly, non-canonical REs consisting of 3Q sites
and ½ sites [5, 7] are considered functional p53 REs
with specific pattern searches. A graphical view of these
features presented as “penalty matrix” summarizes
the main features of our pattern search (Fig. 1c). The
complete list of the rules used to attribute the functional
score is presented (Additional file 1). The p53retriever
pattern search algorithm, together with functions to better
visualize search results, has been implemented as an R
package and is available for download at: http://tomateba.
github.io/p53retriever.
Fig. 1 Summary of RE sequence features and associated grades in p53retriever. a Grade: classification of REs reflecting associated functional scores.
The color code matching the 5 different grades will be maintained in all figures. b Mismatch label: classification of mismatches in different positions.
High penalties are given to mismatches located in the core consensus sequence (label A and B), lower penalties are given when mismatches are
gradually distant from the core (label C and D). Label O is given to a site without mismatches. Mismatches group penalties: different penalties are
attributed to groups of mismatches according to how they are scattered or grouped along the site. c Schematic representation of the main rules on
which p53retriever search algorithm is based. The full list of rules is listed in Additional file 1. The p53 consensus sequence is presented, grouping
dinucleotide motifs that were revealed to provide a specific impact on transactivation potentials, based on our previous studies (see text for details)
[28]. Penalties are indicated by an increment in the number of the “-” symbol and a color code broadly matching the grade scale. Single mismatches
are more penalized when affecting a base in the internal portion of the RE, as indicated. On the contrary, the AT motif at the center of the CWWG
core is a positive feature, particularly in the case of non-canonical REs (3Q = 3Q sites and half sites)
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Distribution of identified p53 response elements around
human promoters
We applied p53retriever to the set of sequences in the
human genome placed around annotated transcriptional
start sites (TSS), selecting a window from -10 kb to 10 kb.
The entire list of identified REs, chromosomal coordinates,
official gene name, distance from TSS and RE sequence
features resulting in the given grade, is available in
Additional file 2.
The distribution of identified p53 REs grouped based on
the functional score, shows a very large preponderance of
“grade 1” REs, that are considered as unlikely functional
(Fig. 2a). Also, the distribution of RE scores is highly
skewed, with only 0.05 % of REs obtaining the highest
grade, supporting the hypothesis of a selecting pressure to
reduce p53 binding affinity and provide plasticity in the
modulation of p53-mediated stress responses in vivo
[4, 28]. Very recent analyses confirmed that p53 REs that
are more highly conserved in evolution are relatively weak
p53 RE sites displaying lower levels of occupancy com-
pared to higher affinity REs that exhibit low evolutionary
conservation [47]. Grade five sequences either lack
entirely mismatches, or contain two or fewer mismatches
in the external positions (R1,Y6/R4,Y3, see Fig. 1c), and
contain the positive AT motif in the CWWG core. The
vast majority of REs that can be considered functional are
in the grade two category. Predicted to be poorly respon-
sive on their own, these REs could participate in the regu-
lation of gene expression conditional to other features,
such as the local sequence context of promoter architec-
ture. Included in the grade two category are ~30 % of all
half sites mapped (Fig. 2a). A unique feature of our search
tool is the specific pattern search for non-canonical 3Q
sites. Interestingly, even though mismatches in the two
internal quarter sites have an higher impact on p53 trans-
activation for 3Q sites compared to full sites, and thus
result in a final lower grade, many 3Q sites obtained a
grade higher than 2. Hence, a great number (13,744) of
p53 REs are predicted to be functional even though the
entire motif is not present. This observation strongly
supports recent reports suggesting that p53 REs match
the consensus in one half site, with the two central quarter
sites being somehow less variable [14]. It is also consistent
with the recent report of the frequent identification of
p53 half-sites among p53 ChIP-seq peaks lacking full
sites [47].
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Fig. 2 Analysis of p53 REs found in human promoters. a Pie chart displaying the distribution of grades associated to REs found in all human
promoters. b Comparison between the frequencies of REs found in human promoters, and the frequencies of REs found in scrambled promoter
sequences after applying local permutations (to preserve the local GC content). The comparison is shown for each grade. The ratio is 1 if the
frequency is the same, > 1 if the frequency is higher in real promoters, <1 if the frequency is higher in scrambled promoters. All enrichments are
significant, the binomial test p-value is 4.84E-04 for grade 5 (**), <1E-15 for all the other grades (***). c p53 occupancy metaprofile, based on the
position of REs in all human promoters, centered on the TSS position. The grey histogram displays the probability distribution of all REs independently
from the grade. Colored lines represent the density distribution of REs with higher grades (the grade threshold corresponding to each color is
displayed in the legend). The specific positions of grade 5 REs are dotted in yellow under the histogram. d p53 occupancy metaprofile, based
on the position of REs in the human promoters of 228 p53 target genes, published in [15]. The color scheme is the same as in panel C. The
specific positions of grade 4 and 5 REs are dotted under the histogram (in yellow for grade 5, red for grade 4)
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We compared the results obtained searching within
human promoters with what we would expect by chance,
by applying p53retriever to sets of scrambled sequences
obtained by local permutations of real promoter se-
quences (see Methods and Additional file 3: Table S1).
Local permutations allowed us to preserve the local GC
content of promoter regions, showing in fact an increase
in GC content around the TSS (see Additional file 3:
Figure S1). From this analysis we could determine that the
frequency of REs in the global set of human promoters is
slightly but significantly higher than the frequency of REs
in scrambled sequences (Fig. 2b). This soft enrichment is
plausible, given that we are considering all known human
TSS and not specific populations of genes. Grade five and
three are the most enriched class of REs when comparing
the frequency of each grade (Fig. 2b).
Mapping all the REs considering their position with re-
spect to the TSS, we obtained an occupancy metaprofile of
p53 REs, displayed in Fig. 2c. This occupancy profile reveals
a general decrease of REs in the region proximal to TSS
(from -2 kb to +2 kb). This decrease affects all REs, inde-
pendently from the grade, and appears to be a consequence
of the local increase in GC content, since we observed the
same effect in scrambled sequences when applying local
permutations (Additional file 3: Figure S2). Overall the REs
reduction (approximately of ¼.) could be interpreted as a
selection against a high density of active p53 REs from pro-
moter regions of non-target genes that is limited to about 2
kbs from TSS. This reduction is driven by the general in-
crease in GC content around the TSS, which more globally
is instrumental in the interplay between chromatin con-
formation and transcription processes. On the other hand,
when restricting our analysis to the promoter region of
known p53 targets, we found an entirely different land-
scape. Fig. 2d displays the promoter occupancy metaprofile
of REs identified by p53retriever in a group of 189 HGNC
genes listed as targets of p53 in literature and collected in
[15, 45]. Interestingly, this profile shows the highest prob-
ability density in the region closer to the TSS, especially for
functional REs with grade four and five (red line in Fig. 2d).
Indeed, recent data reported a prevalence of p53 REs
nearby the TSS of known target genes [16, 47].
Comparison with other p53 binding site datasets and
search tools
To further verify if p53retriever recognized already
established p53 binding sites, we compared our approach
with lists of p53 target genes and REs previously reported.
The detailed results of all comparisons are contained in
Additional file 4.
First, we used our method to score 81 REs sequences
that are consistently bound by p53 according to seven
different ChIP-seq datasets, reported in [15]. All these
sequences were picked by p53retriever as potentially
functional. Interestingly, excluding one sequence, all p53
REs from this list obtained a grade greater than one with
the majority being of grade 5, confirming that our tool can
discriminate functional and well-known REs (Fig. 3a).
Next, we applied p53retriever on p53 REs obtained by
Chip-exo analysis [14], providing near-nucleotide resolution
of p53 bound sites in response to a variety of genotoxic
stresses. (Fig. 3b). While 28 % of sites were not classified,
the majority of bound sequences from ChIP-exo obtained a
grade greater than 1, with a predominance of grade four
and five, (Fig. 3b, left panel). Interestingly, we saw a clear
correlation between higher relative occupancy and higher
RE grade (Fig. 3b, right panel). Looking in more detail to
the “no grade” group, we noticed that all non-scored
sequences differed from the canonical RE site for features
which are highly penalized by our algorithm, like a number
of mismatches higher than three scattered on three
different quarter sites. Nevertheless, we could show that
these not-scored sequences are mostly characterized by low
occupancy values (white boxplot in Fig. 3b right panel,
Wilcoxon rank sum test p-value=1.29E-09). Consistently,
when considering the subset of regions increasingly bound
by p53 after all the stimuli used in [14], the percentage of
“no grade” drops to 17.6 % (Additional file 3: Figure S3).
We also extended the comparison to a Chip-seq dataset,
reported in [17] (Fig. 3c) and obtained an overall similar
distribution of RE grades. The percentage of regions with
“no grade” is 22.8 %.
Next, we extended the comparisons to other lists of
REs, starting from two small collections of reported p53
REs, based on heterogeneous experimental approaches
[2, 15, 45]. Only a minority of those REs obtained the
highest grade, and the proportion of sequences not
scored as potentially functional was approximately 40 %
(Additional file 3: Figure S4). It has to be said that the
REs reported in those lists are not guaranteed to be the
ones actually or solely responsible for the responsiveness
of the associated genes to p53.
Even though total mRNA levels are an indirect measure-
ment of p53 transcriptional activity, they reflect the
transcriptome status upon p53 activation. Thus, we did an
additional comparison using microarray data obtained
after p53 activation upon Doxorubicin treatment of MCF7
cells [49]. The majority of differentially expressed, up-
regulated genes turned out to have a p53 binding sites
with grade three (Fig. 3d), and exhibited a specific enrich-
ment of REs with grade >3 near the TSS (Additional file 3:
Figure S5). Similar comparisons were done with lists of
p53 target genes in curated databases such as TRANSFAC
and IPA. Again, the majority of these genes have a RE of
grade three predicted by p53retriever in their promoter
region (Fig. 3d). Using Ingenuity Pathway analysis (IPA),
grade five and grade four human promoters revealed a
strong p53 pathway signature (Additional file 5).
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Finally, we compared p53retriever results with the
standard PWM approach, using two PWMs provided by
the JASPAR database (see Methods). All REs identified
by p53retriever in the set of human promoters were
scored in parallel with both JASPAR PWMs: the com-
parison with the JASPAR PWM derived from ChIPseq
data is shown in Fig. 3e. Although there is a high agree-
ment on REs with the maximum grade, very close to the
optimal p53 consensus, the comparison shows diver-
gences between the two methods for the lower grades.
For example, a considerable population of REs assigned
to grade four by p53retriever receives very low scores
from JASPAR. This is likely due to the presence of ¾
sites that are over-penalized by the PWM approach. On
the other hand, many REs with low grades are highly
scored by JASPAR, that doesn’t penalize groups of scat-
tered mismatches. Apart from grade 1, we can observe a
linear trend between the two scoring systems if we look
at the median values of the boxplots displayed in Fig. 3e,
so we can conclude that the two approaches are distinct
and complementary. On the other hand, the second
JASPAR matrix, based on SELEX data, gives misleading
results, since even optimal REs (grade 5) receive low
scores (Additional file 3: Figure S6).
High grade p53 REs are enriched in distant enhancers
Recent functional genomics approaches, particularly
resulting from the ENCODE initiative, have revealed
that transcription is rather pervasive, that enhancer se-
quence can be very distant, at least in terms of primary
sequence, from genes, and that active enhancers can be
mapped based on specific histone code marks [50, 51].
Hence, we exploited this rich body of available informa-
tion to map p53 REs in distal enhancer sites, using
DNAse hypersensitive sites tracks. We filtered out sites
overlapping with promoter regions defined in the previ-
ous sections, and considered a population of 43,787 dis-
tal regions, whose length distribution is displayed in
Fig. 4a. p53retriever was run on this set of regions, and
the complete results are provided in Additional file 6.
The grade distribution of REs found in distal DNAse re-
gions is displayed in Fig. 4b. The frequency of REs in
these regions is significantly higher than the frequency
found in human promoters and also in random se-
quences (Fig. 4c and Additional file 3: Figure S7). The
overall fold enrichment is 3.54, but this trend grows pro-
portionally to the grade of the REs, reaching a peak with
grade 5. In fact, 144 high grade REs are found within
DNAse hypersensitive sites (Fig. 4b), more than in the
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Fig. 3 Comparison of p53retriever with other p53 binding site datasets and tools. a Pie chart displaying p53retriever classification on a list of 81
regions commonly identified by 7 different ChIP-seq experiments [15]. b Left panel: pie chart displaying p53retriever classification on a list of
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entire human promoter dataset. The fold enrichment of
grade five REs is 16.3 (Fig. 4c). Presently, it is undeter-
mined if this enrichment for high quality binding sites
reflects a common trend for sequence-specific transcrip-
tion factors or a distinct feature of p53 family proteins.
Consistent with our results, higher levels of p53 occu-
pancy in distal enhancers compared to promoters was
very recently reported based on ChIP-seq analysis of
lymphoblastoid cell lines treated with doxorubicin [47].
Additionally, Chip-seq analysis reported in [17] allowed
us to expand the study of p53 REs in enhancers regions.
In fact that paper provided p53 bound regions classified
as enhancers based on ENCODE annotation or as proto-
enhancers, where p53 could act as pioneer transcription
factor. Interestingly, this latter group showed an enrich-
ment for high scoring (grade four and grade five) p53 REs
according to p53retriever and a lower proportion of se-
quences with no grade (Fig. 4d, top panel).
New direct p53 target genes identified based on the p53
RE functional search tool
High-activity, or non-canonical p53 REs predicted to be
moderately active were mapped by our tools near the
TSS of genes that are not completely established or
novel putative direct p53 target genes. To infer the pre-
dictive power of the pattern search on p53-dependent
transcriptional changes, 13 genes were selected and their
expression was tested followed by qPCR in cell lines dif-
fering for p53 status (MCF7, two derivative clone so
called MCF7 vector and MCF7shp53, HCT p53+/+ and
HCT p53−/−) and at different time points (8, 16, 24 h)
after p53 activation by two different treatments, i.e.,
Doxorubicin -a genotoxic chemotherapeutic drug- and
Nutlin-3A -an MDM2 inhibitor- (Fig. 5a) (Additional file
7). Results support p53-dependent up-regulation for
most genes. The p53-dependency is confirmed by the
absence of induction in HCT p53−/− and MCF7shp53
cell lines, despite the different p53 status between the
two cells lines (a p53-null and a partial knockdown cell
line, respectively). In some cases, the increase in gene
expression compared to the mock condition was time-
dependent. Differences in these kinetic features were
apparent between the two treatments applied. E2F7 was
inducible by Doxorubicin at different time points, while
after Nutlin-3A treatment an early up-regulation was
followed by repression, which appeared to be p53-
dependent. GAS6 and KCTD1 had a similar trend espe-
cially in MCF7 cells. Differences were noted between
MCF7 and the MCF7-vector derivative clone in the
magnitude or the kinetics of relative expression changes
(e.g., PDE2A, APOBEC3H, KCTD1, DNAJA1, DICER).
Nine of the thirteen candidates (PDE2A, GAS6, E2F7,
APOBEC3H, KCTD1, TRIM32, TGFA, KITLG, HRAS)
were selected among the list of genes having both a
predicted binding sites in our algorithm output with a
grade higher or equal to 2, and a reported p53 binding
sites on ChIPseq datasets [7, 8]. For all of them except
TRIM32, total mRNA levels are also reported as upregu-
lated after Doxorubicin treatment by microarray data [49].
Although the induction is not directly proportional to the
grade, we confirmed p53 dependent induction by qPCR
for all of them in time/cell line dependent manner. Even
though TRIM32 is not upregulated after Doxorubicin
treatment in all the tested cell lines, it is upregulated upon
Nutlin-3A treatment, confirming ChIP-seq data. Besides
their p53 binding sites, these candidates were selected
because of their reported involvement in cell-cycle control
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and tumor progression (PDE2A, E2F7, GAS6, TRIM32,
HRAS, KITLG and TGFA), in transcription (KCTD1), and
DNA editing (APOBEC3H) (see Supplementary Text in
Additional file 3).
For the remaining four genes, whose REs are displayed
in Fig. 5b, we performed a chromatin-immunoprecipitation
experiment in MCF7 cells treated with Doxorubicin for
16 h. Weak p53 occupancy was observed by qPCR at
DNAJA1 and MAP2K3 loci after doxorubicin treatment,
while a region containing a predicted grade 3 category p53
RE in the YAP1 gene showed evidence for p53 occupancy
in the mock condition. Our results did not support direct
p53 binding to the DICER promoter, consistent with a
previous study [52] (Fig. 5c).
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Overall, we propose DNAJA1, MAP2K3 and potentially
YAP1 as new direct p53 target genes, although the level of
transactivation was relatively low.
DNAJA1 can act as a co-chaperone of Hsc70 that was
previously associated to radioresistance phenotype in wild
type p53 glioblastoma cells treated with farnesyltransferase
inhibitors [53]. Recently, overexpression of DNAJA1 was
associated with a reduction of pancreatic cancer cell
survival and with c-Jun repression [54].
MAP2K3 participates in the MAP kinase cascade and
can phosphorylate p38. This protein was identified as a
senescence-promoting factor in human breast epithelial
cells [55]. However, it has also been associated to tumor
invasion potential and to be regulated at transcriptional
level by NFY, NF-κB and gain-of-function mutant p53 [56].
The Yes-associated protein 1 (YAP1) is a transcriptional
regulator involved in the Hippo signaling pathway.
Evidences support both an oncogenic and a tumor sup-
pressor role for YAP1, linked to ABL1-induced apoptosis
[57]. YAP1 protein was found capable to bind the p53
promoter and a positive feedback loop was proposed
based on the finding that p53 can bind the YAP promoter
[58]. In part consistent with this view we found p53-
dependent YAP1 gene up-regulation both after doxorubicin
and Nutlin-3A treatment.
Conclusions
Several previous tools were developed to identify bona fide
p53 response elements, starting with pioneering in vitro se-
lection experiments that led to the initial and still accepted
definition of the consensus p53 RE [11, 42, 45, 59, 60]. The
majority of these tools were based on position weight
matrices derived from results of in vitro approaches,
namely competitive gel shift assays and SELEX, more
recently integrated with results obtained from Chromatin
immunoprecipitation experiments. A systematic effort to
quantify changes in DNA binding affinity (dissociation
constants) using fluorescence anisotropy titration led to
the development of a p53 binding site predictor algorithm
[60]. This tool was also used to search genome wide for
high affinity p53 REs and to map naturally occurring
single nucleotide polymorphisms (SNPs) that can impact
on the DNA binding affinity of p53. The functional
relevance of SNPs within p53 REs has been established in
several reports [15, 24, 27, 44, 61].
All position weight matrix approaches assume additive
contributions of the individual positions within the RE
sequence, and except for [45] and [11], all tools do not
specifically weigh the impact of spacers between half site
decameric RE motifs in the 0-13 nt range. This spacer
length was in fact considered neutral in the initial in vitro
experiments [23]. However, DNA binding assays where RE
sequence are embedded in longer DNA molecules, com-
petitive binding experiments in microfluidics, Chromatin
Immunoprecipitation assays, yeast- and mammalian-cell
based transactivation assays all indicate that even a single
nucleotide spacer between p53 RE half sites can reduce
transactivation potential [5, 24, 27, 44]. In fact, when the
spacer is longer than 2–3 nt the two decameric half sites no
longer show cooperative interactions [24, 28, 62], although
when the distance in primary sequence approach one
helical pass, transactivation potential appears to increase
beyond additivity [24], yet remaining much lower compared
to the absence of a spacer. The negative impact of spacer is
even more dramatic for TAp73 [62] and TAp63 proteins,
but not for ΔNp63 [63], suggesting that the structure as
well as the sequence of DNA binding sites can lead to con-
formational changes in the quaternary tetrameric structure
of p53 family proteins, and that intrinsic differences exist in
the oligomerization state of these proteins [64].
We have coded in p53retriever sequence and structural
features of p53 REs impacting on transactivation potential
that were revealed in the past several years using our
yeast-based transactivation assay [5, 26, 28, 63, 65, 66].
The resulting algorithm has several distinctive features
compared to previous tools, particularly for scoring inter-
actions among groups of mismatches, non-canonical 3Q
sites and half sites p53 REs, weighing the impact of
consensus mismatches considering their position within
the full site RE sequence, i.e., giving higher penalty to
mismatches in the two internal quarter sites, and weighs
consensus sequence variations within dinucleotide motifs
in the core and flanking regions [28] (Fig. 1, Additional file
1). Possible interactions between nearby half site p53 REs
or clusters of full site and 3Q sites are currently not
considered by our algorithm.
We mapped and ranked functional REs near TSS for all
annotated transcripts in UCSC (Additional file 2). Further,
we exploited ENCODE data and provide a cartography
of ranked p53 REs within distant DNAse hypersensitive
sites, considered as distant enhancers (Additional file
6). In these regions we found a significant 16-fold
enrichment of high grade REs with respect to the basal
frequency expected by chance or observed in promoter
regions. An enrichment for high grade REs was also
found among proto-enhancer sequences bound by p53
identified by ChIP-seq [17]. It is worth noting that our re-
sults represent a projection from all DNAse hypersensitive
sites, irrespective of the specific tissues in which they are
active. Tissue variability may influence which REs are
selectively bound. An additional layer of complexity is
represented by the known interplay between different
transcription factors. This important aspect is not
included in our analysis that is focused on p53 alone.
Although the data on which the algorithm is construed
are the outcome of transactivation assays measured from
chromatinized promoter-reporter construct, the isogenic
nature of the yeast-based functional assays, minimizes
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most variables potentially impacting on transactivation by
p53; at the same time distinct chromatin features of the
natural context of the REs’ location in vivo may certainly
influence the associated gene transcriptional responsive-
ness to p53. Hence the yeast-based results might be more
similar to ChIP-seq and ChIP-exo results, albeit with a
more quantitative power.
Undoubtedly different ChIP-seq experiments do not
agree with each other and there is limited overlap among
the results obtained with different cell lines or using differ-
ent treatments to activate p53. While global differences in
occupancy could be related to differences in accessibility
between different tissue-derived cells or to distinct p53
post-translational modifications or cofactors activated by
different treatments, it was interesting to find that the list
of p53 bound sites that are common to multiple ChIP-
experiments were highly enriched for high scoring (grade
four and grade five) REs and none of them failed to be
classified by our tool (Fig. 3a). Instead, when examining
individual ChIP-seq or even, although to a lower extent,
ChIP-exo data, 20 % to 30 % of p53 bound fragments did
not contain a motif scored by p53retriever. While those
sites may represent examples of p53 proteins tethered to
DNA by protein interactions, the manual inspection of
“no grade” sites from the ChIP-exo datasets showed that
the majority of these sites resemble p53 response elements
but contain several (three or more) “core” mismatches
scattered on three different quarter sites. These multiple
mismatched REs are not presently scored by p53retriever,
but would probably result in weak responsiveness.
Consistently, the majority of no grade ChIP-exo REs
showed lower occupancies (Fig. 3b right panel).
Finally, we decided to validate a few of the predictions
from the pattern search, particularly for non-canonical 3Q
sites using cell lines as a model. 13 genes with mapped
functional REs were chosen. Overall, despite our algo-
rithm doesn’t consider the system complexity of transcrip-
tional regulation in living cells and the response variability
upon each different p53 stimulus, results support p53-
dependent transactivation for the majority of them. Based
on the combined qPCR and ChIP results we conclude that
DNAJA1, MAP2K3, and potentially YAP1 can be consid-
ered new direct p53 target genes, linking p53 to yet
additional potential biological outcomes. Furthermore,
our data further establish the very recent findings of
PDE2A, GAS6, E2F7, APOBEC3H, KCTD1, TRIM32,
HRAS, KITLG and TGFA as p53 target genes.
Methods
Implementation of pattern search rules in p53retriever
We implemented the set of manually curated rules
(Additional file 1) in an R package called p53retriever.
p53retriever source and binary files are available
on Github, at (http://tomateba.github.io/p53retriever/).
p53retriever contains a main function that identifies poten-
tial REs. This function needs as input an arbitrary DNA
sequence, and returns a table containing information about
the identified REs, such as position, sequence, spacer
length, mismatch label and grade. The format of the output
is similar to Additional file 6. Many functions are also
provided in order to graphically display the results. The
package is documented with usage examples, and fully
integrated with other CRAN and Bioconductor packages.
In particular, p53retriever depends only on the previous
installation of the Bioconductor Biostrings package.
Human promoters dataset
Human promoter sequences were extracted from the
UCSC database (http://genome.ucsc.edu/) considering, for
each transcript with a distinct TSS, the 20 kB region
surrounding the transcription binding site (genome build
GRCh37/hg19). The final dataset consists of 23,541 pro-
moter sequences, associated to distinct UCSC identifiers
and corresponding to 18,355 HGNC genes.
Human distal DNase regions dataset
Encode DNase-seq regulatory regions (genome build
GRCh37/hg19) were obtained from the following cell
lines: Gm12878, H1hesc, Helas3, Hepg2, Hmec, Hsmm,
Hsmmt, Huvec, K562, Monocd14, Nha, Nhdfad, Nhek,
Nhlf, Osteobl, Hsmmfshd, Lncap, Nb4, Nt2d1,Panc1. The
consensus was defined as the merge of all the regions that
were present in at least two cell lines. Only distal regions,
with more than 10 kb from the nearest annotated TSS,
were kept in the dataset, in order to avoid overlap with
promoter regions. The final dataset consists of 43,787
regions, with a mean length of 673.3 bases.
Simulations with random sequences
Sets of scrambled promoter sequences were generated by
local permutations (bin size = 500 nt) of human promoter
sequences (−10 kb, +10 kb from TSS). This allowed to
preserve the local GC content in the random model; p53
REs were then identified and classified with p53retriever.
The random simulation was run ten times, and the results
were compared to REs identified in real human promoters.
Set of random sequences were generated, with the same
number and the same GC content (44 %) of human DNA
sequences; p53 REs were then identified and classified
with p53retriever. The random simulation was run ten
times, and the results were compared to REs identified in
human distal DNase regions promoters.
Pathway analysis of DEGs
All pathways analyses were performed using IPA (www.
ingenuity.com). Only direct interactions were considered
in the setting parameters.
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Comparison with other datasets
Several lists of p53 targets, identified by their HGNC
symbol, were extracted from online databases such
as Biobase TRANSFAC (http://www.biobase-international.
com/product/transcription-factor-binding-sites) and IPA,
or from previous publications, referenced in the main text.
These lists were used to select populations of genes among
our dataset of human promoters, and analyze the grade of
the REs identified by p53retriever (as shown in Fig. 2d).
Several sets of p53 RE sequences or p53 bound regions
were taken from previous publications, referenced in
the main text. p53retriever was run directly on these
sequences (as shown in Fig. 3a, b, c).
Comparison with JASPAR PWMs
Two PWMs for p53 were downloaded from the JASPAR
database (http://jaspar.genereg.net/). One PWM, MA0106.1,
is built on SELEX data, while the second, MA0106.2, is
built on ChIPseq data. The original values of the down-
loaded PWMs were based on nucleotide frequencies and
therefore more similar to Positional Frequency Matrices.
These frequency values were transformed in log2 prob-
ability ratio values with the PWM function implemented
in the Bioconductor Biostring package, using a multi-
nomial model with a Dirichlet conjugate prior to calculate
the estimated probability of base b at position i. The final
score of a match ranges from 0 to 1. All REs identified by
p53retriever in the set of human promoters were scored
with JASPAR PWMs: the comparison with MA0106.2 is
shown in Fig. 3d, while the comparison with MA0106.1 is
shown in Additional file 3: Figure S2.
Cell lines and culture conditions
The human breast adenocarcinoma-derived MCF7 cell
line (p53 wild type) was obtained from the InterLab Cell
Line Collection bank, ICLC (Genoa, Italy) while the colon
adenocarcinoma HCT116 (p53+/+) cell line and its p53−/−
derivative were a gift from B. Vogelstein (The Johns
Hopkins Kimmel Cancer Center, Baltimore, Maryland,
USA). MCF7 cells stably expressing an shRNA targeting
p53 (MCF7shp53) or control cells (MCF7vector) were
kindly provided by Dr. Agami (Netherlands Cancer
Institute, Amsterdam). Cells were normally maintained in
DMEM or RPMI (BioWhittaker, Lonza, Milan, Italy) sup-
plemented with 10 % FCS, antibiotics (100 units/ml penicil-
lin plus 100 mg/ml streptomycin) and 2 mM glutamine.
Puromycin (Sigma-Aldrich, Milan, Italy) was used to main-
tain the selection, at 0.5 μg/mL as final concentration.
RNA extraction
Cells were seeded into 6-well plates and allowed to reach
70-80 % of confluence before treating with 1.5 μM Doxo-
rubicin or 10 Μm Nutlin-3A. Doxorubicin was purchased
from Sigma-Aldrich (Milan, Italy) while Nutlin-3A was
obtained from Alexis Biochemicals (Enzo Life Science,
Exeter, UK). After 8 h, 16 h or 24 h of treatment cells were
harvested and total RNA was extracted using RNeasy Mini
Kit (Qiagen, Milan, Italy) according to the manufacturer’s
instructions. In-column DNAse treatment (RNase-Free
DNase Set, Qiagen, Hilden, Germany) was performed to
remove DNA contamination during the extraction. Purity
of RNAs (A260/A280 value of 1.8–2.1) and concentration
were measured using the Nanodrop spectrophotometer.
qPCR
cDNA was generated starting from 1 μg of RNA by using
the RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas, Milan, Italy) in 20 μL as final volume follow-
ing manufacturer’s instructions. Primers were designed by
Primer-BLAST performing in silico analysis as well as
standard curves to define assay specificity and efficiency
(Additional file 7). All qPCR assays were performed on
CFX Touch Real-Time PCR Detection System (Bio-rad,
Milan, Italy) in a 384-well plate format. Optimal primer
concentrations (200nM-400nM) were determined by iden-
tifying conditions resulting in the lowest Cq combined
with absence of primer dimer formation. Reaction
volumes were set at 10 μl. SYBR Green assays contained
5X KAPA SYBR FAST qPCR Mastermix (Kapa Biosystems,
Resnova, Rome, Italy), 400 nM each primer (MWG,
Operon, Ebersberg, Germany) and 25 ng of cDNA. Initial
thermal cycling conditions were 1 cycle of 95 °C for 3
mins, followed by 40 cycles of 95 °C for 30 s, 60 °C for
20 s, 72 °C for 60 s. At the end a melt curve analysis was
performed. Post-run relative mRNA quantification was
obtained using the comparative Cq method (ΔΔCq), where
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
β-2microglobulin (B2M) served as reference genes.
ChIP assays
MCF7 cells were cultured in complete medium in a 150-
mm Petri dishs and when reaching 70/80 % confluence
were treated for 16 h with Doxo. The procedure for cross-
linking, sonication, IP and analysis followed a previously
described protocol [49]. Antibodies used for ChIP assays
were: p53 (DO-1) and IgG (sc-2025 or sc-2027) (Santa
Cruz Biotechnology®) (Millipore). ChIP analysis was
performed with the comparative Cq method (ΔΔCq) and
normalized as % of input, using β-actin gene as negative
control and p21 as positive control for p53 enrichment.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files. p53-
retriever source and binary files are available on Github,
at (http://tomateba.github.io/p53retriever/).
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Additional files
Additional file 1: Complete list of the rules used to attribute the
functional score in the pattern search algorithm.
Additional file 2: Complete list of identified REs within human
propoter regions (−10 kb, 10 kb from TSS). The list contains
chromosomal coordinates, official gene name, distance from TSS and RE
sequence features resulting in the given functional grade.
Additional file 3: Figures S1–S7, Table S1 and Supplementary
Information.
Additional file 4: Comparison between p53retriever classification
and lists of published p53 bound regions.
Additional file 5: Gene lists from data curated Ingenuity Pathway
(TP53 Canonical Pathway) were compared to prediction and
functional ranking of p53 REs. The RE grade is stated in the name of
the various worksheets. A) Grade four and grade five. B) All grade 3, 4,
and 5.
Additional file 6: Complete list of identified REs within ENCODE
distal DNAse regions. The list contains chromosomal coordinates and
RE sequence features resulting in the assigned functional grade.
Additional file 7: qPCR data summarized in Figure 5. For each gene,
time point and treatment time, the average fold change of three
biological repeats is presented along with the Standard Deviation.
The results obtained with different cell lines are presented in different
worksheets
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ABSTRACT 
Background: Breast cancer treatment often includes Doxorubicin as adjuvant as well as 
neoadjuvant chemotherapy. Despite its cytotoxicity, cells can develop drug resistance to 
Doxorubicin. Transcription factors have important roles in shaping cell responses to 
chemotherapy. Among them is ETV7, a poorly characterized ETS transcription repressor that is 
involved in different cancer types. Here, we investigated the effects of ETV7 expression on 
Doxorubicin-resistance in breast cancer, and the regulation of its novel identified target DNAJC15. 
Methods: Using MCF7 and MDA-MB-231 as breast cancer cell models, cells were treated with 
several chemotherapeutic drugs and mRNA expression was analyzed by RT-qPCR. We assessed 
doxorubicin-resistance by cell viability assay (MTT) and drug efflux dynamics by imaging. Direct 
binding of ETV7 was tested by site-directed mutagenesis, gene reporter assays, and ChIP. 
Methylation analysis was performed by bisulfite PCR followed by sequencing and by 5-Aza-2’-
deoxycytidine treatment. Publicly available microarrays from breast cancer patients were 
interrogated to evaluate the prognostic value of ETV7 and DNAJC15 expression. 
Results: We found that Doxorubicin and other chemotherapeutic drugs induced the expression of 
ETV7, which led to down-regulation of DNAJC15, a co-chaperone protein whose low expression 
was previously associated with drug resistance in breast and ovarian cancer. There was a 
corresponding reduction in Doxorubicin sensitivity of MCF7 and MDA-MB-231 cells.  We identified 
the binding site for ETV7 within the promoter of DNAJC15 and also found that DNA methylation 
may be a factor in ETV-mediated transcriptional repression at the DNAJC15 promoter. This inverse 
correlation between ETV7 and DNAJC15 expression in breast cancer cells in terms of Doxorubicin 
resistance correlated well with treatment responses of breast cancer patients with recurrent 
disease. In addition, we demonstrated that ETV7-mediated Doxorubicin resistance involves 
increased Doxorubicin efflux via nuclear pumps, which could be rescued in part by DNAJC15 up-
regulation.  
Conclusions: We propose a novel role for ETV7 in breast cancer, and we identify DNAJC15 as a 
new target gene responsible for ETV7-mediated Doxorubicin-resistance. A better understanding of 
the opposing impacts of Doxorubicin could improve the design of combinatorial adjuvant regimens 
with the aim of avoiding resistance and relapse. 
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BACKGROUND  
 
Chemotherapy is commonly adopted for the pre- and post-surgical treatment of many solid 
tumors, including breast cancer, and it is still the only therapeutic option for most cases of 
metastatic spread. Among the drugs used in different regimens, Doxorubicin is often employed 
and is one of the most effective [1]. This drug is an anthracyclin intercalator that  poisons 
topoisomerase II, thereby causing DNA damage and subsequent cytotoxicity [2]. As for most 
chemotherapeutic agents, several unwanted side-effects have been reported and, unfortunately, 
Doxorubicin is also known for late-onset cardiotoxicity determined by a complex cascade of events 
[3]. Despite the efficacy of Doxorubicin and other chemotherapeutic drugs, cancer cells may 
develop chemoresistance, resulting in treatment failure and recurrence. Indeed, there are many 
survival strategies available to cancer cells and some of them can even be activated by 
chemotherapy itself. Some activation mechanisms can lay the groundwork for unwanted future 
resistance to treatment, which can be driven or stimulated by the activation of pro-survival or pro-
tumorigenic transcription factors, such as NF-NB [4, 5] and FOXM1 [6, 7]. Moreover, Doxorubicin 
can lead to an increased expression of drug efflux pumps such as MRP1 in breast cancer [8] and to 
activation of the anti-apoptotic cascade HER3-PI3K-AKT in ovarian cancer [9].  
 
ETV7 (Ets Variant Gene 7) is a transcription factor belonging to the ETS (E26 transformation-
specific) family of transcriptional regulators. Various ETS factors, such as ETS1, ETS2, PU1, FLI1 and 
ERG, are distinguished for their pro-tumorigenic functions and are involved in chromosomal 
translocations often associated with Ewing’s sarcoma and prostate cancer [10]. ETV7 is a poorly 
characterized protein that can act as a transcriptional repressor, which presents an 85-amino acid 
ETS domain responsible for binding a purine rich GGAA core motif in the regulatory regions of 
target genes. The protein also has a conserved pointed (PNT) protein-protein interaction domain, 
required for the formation of homo-/hetero-dimers and oligomers and involved in transcriptional 
repression [11, 12]. Given the presence of the PNT domain, ETV7 can either self-associate or form 
hetero-dimers/oligomers with ETV6/TEL, a highly related ETS family member with tumor 
suppressor functions that also acts as transcriptional repressor [13]. In contrast, ETV7 is generally 
acknowledged to be an oncoprotein, and some of its pro-tumorigenic functions result from its 
ability to directly bind and inhibit ETV6-mediated gene repression [14].  
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Deregulated high ETV7 expression levels has been linked to hepatocellular carcinoma [15] and to 
leukemia [10, 16]. Over-expressed ETV7 can also cooperate with EP-MYC in promoting 
lymphomagenesis and blocking Myc-induced apoptosis [17]. Furthermore, ETV7 is able to enhance 
the Ras-driven transformation in fibroblasts and shows pro-proliferative and anti-differentiation 
roles observed in myeloid and lymphoid cells [10, 17]. In contrast, ETV7 can act as a tumor 
suppressor in nasopharingeal carcinoma through binding SERPINE1 promoter and decreasing its 
expression [18]. Further, ETV7 down-regulation has been reported in drug resistant gastric cancer 
cells [19]. 
 
We recently observed in human breast cancer cells that ETV7 can be transcriptionally activated 
upon Doxorubicin treatment and synergistically induced by the combined treatment with 
Doxorubicin and TNFD. Among the possible activators of its transcription, we identified tumor 
suppressor p53 and NFNB (p65) as transcription factors able to directly bind to ETV7 promoter 
[20].  
 
Interestingly, ETV7 and DNAJC15 expression appear to inversely correlate upon Doxorubicin 
treatment and also upon interferon gamma expression. ETV7 is recognized as an interferon 
stimulated gene, whereas down-regulation of DNAJC15 has been reported in interferon gamma 
treated macrophages [21]. DNAJC15 plays an intriguing role among the tumor suppressor genes 
whose repression is associated with tumor aggressiveness and chemoresistance. It belongs to the 
HSP40/DNAJ family of co-chaperones, mostly involved in helping ATP hydrolysis and thus the 
activation of the HSP70 chaperone with its roles in protein folding, trafficking, interaction, import 
and export [22, 23].  
 
DNAJC15 is often hyper-methylated and repressed in malignant pediatric tumors [24], 
neuroblastoma [25], Wilm’s tumor and melanoma [26]. Furthermore, its down-regulation 
associates with increased drug resistance in ovarian and breast cancer [27, 28]. Using MCF7 breast 
cancer cells, Hatle and colleagues observed that in Doxorubicin-resistant clones, the low 
expression of DNAJC15 in the Golgi network was responsible for the degradation of some proteins 
including the transcription factor c-JUN [29]. Therefore, inhibition of DNAJC15 resulted in 
increased levels of c-JUN protein, which was ultimately responsible for increased transcription of 
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 5 
the multidrug transporter ABCB1/MDR1 [29]. Other studies have reported the localization of 
DNAJC15 inside the mitochondrial inner membrane where it can control the respiratory chain and 
thus the production of ROS [30]. Inside the mitochondria it can also help mitochondrial import of 
proteins by favoring the ATP hydrolysis of a chaperone member of the TIMP23 translocase [26]. 
DNAJC15 exerts its tumor suppressor role also by promoting the release of pro-apoptotic 
molecules through the mitochondrial permeability transition pore complex [31].  
 
In this study we identify a novel circuitry for Doxorubicin resistance in breast cancer cells where 
ETV7 acts as major player. Given the pro-tumorigenic roles of ETV7, its activation upon 
Doxorubicin treatment represents one of the unwanted side-effects that could possibly unleash a 
drug resistance mechanism. In particular, ETV7 appears to trigger the activation of a resistance 
circuitry by directly binding and, therefore, repressing the transcription of some tumor suppressor 
genes. Specifically, we demonstrate that ETV7 can repress DNAJC15 in a methylation-dependent 
manner. We propose a novel drug resistance mechanism directly driven by Doxorubicin whereby 
Doxorubicin itself induces the up-regulation of ETV7 that, in turn, down-regulates DNAJC15 
expression giving rise to Doxorubicin resistance in breast cancer cells.   
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METHODS 
 
Cell culture conditions and treatments 
MCF7 and U2OS were obtained from Interlab Cell Line Collection bank (Genoa, Italy). A549 were 
from ATCC (Manassas, VA, USA), while A375M and MDA-MB-231 were a gift from, respectively, 
Dr. D. Bergamaschi (Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and 
The London School of Medicine & Dentistry, UK) and Prof. A. Provenzani (CIBIO, University of 
Trento, Italy). MCF7 and U2OS cells were grown in DMEM medium supplemented with 10% FBS, 
2mM L-Glutamine and 2mM of Penicillin/Streptomycin; MDA-MB-231 cells in the same medium 
with the addition of 1% Non-Essential Amino acids. A549 and A375M were cultured in RPMI 
medium + 10% FBS, 2mM L-Glutamine and 2mM of Penicillin/Streptomycin.  
BJ1-hTERT cells were obtained from Dr. K Lobachev (Georgia Institute of Technology, GA, USA) and 
were grown in MEM medium supplemented with 10% FBS, 2mM L-Glutamine, 2mM of 
Penicillin/Streptomycin and Puromycin. 
Lymphocytes were obtained from healthy donors through the facilities of the Clinical Research 
Unit and NIEHS. For lymphocytes culture and treatment conditions please refer to Methods 
section in Menendez et al., 2011 [47].  
Doxorubicin (Sigma-Aldrich, Milan, Italy) was used at the concentration of 1.5PM (for all cells 
except for U2OS and BJ1-hTERT cells, which were treated with 0.5PM Doxorubicin) for 16 hours 
treatment in the case of qPCR analysis and western blotting and at different concentrations for 72 
hours for MTT viability assays.  
24 hours treatments were performed with the following drugs and concentrations: Etoposide 
50PM (Enzo Life Science, Rome, Italy), Nutlin-3a 10PM, 5-FluoroUracil (5FU) 375PM, 
Camptothecin 0.5PM, Everolimus 50 nM, Tamoxifen 1PM, Imatinib 3PM (Selleckchem, Aurogene, 
Rome, Italy). Compounds were purchased from Sigma-Aldrich when not specifically indicated. 
5-Aza-2’-deoxycytidine (Sigma-Aldrich) treatment was performed for 48 hours at the 
concentration of 5PM.  
Quercetin and Genistein were purchased from Extrasynthese (Genay, Lyon, France), and 
treatments were performed for 16 hours at the concentration of 50PM for Quercetin and 30PM 
for Genistein.  
 
Plasmids 
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The expression vectors pCMV6-Entry-Empty, pCMV6-Entry-ETV7 and pCMV6-Entry-DNAJC15 C-
terminally tagged with DDK-Myc tags were purchased from Origene (Tema Ricerca, Bologna, Italy).  
pGL4.26-DNAJC15 reporter was obtained by cloning the promoter region of DNAJC15 (-299 to 
+512 bp from TSS according to the Eukaryotic Promoter Database, http://epd.vital-it.ch/) 
amplified with Q5 High Fidelity DNA Polymerase (New England Biolabs, Euroclone, Milan, Italy) 
and the following primers (Eurofins Genomics, Ebersberg, Germany): Fw: 
GCCTCGAGCAGCACAAACTCATTTGAGGG and Rv: GCAAGCTTAGGCGGCCCGGAGACTCAAG. Purified 
PCR product was inserted into pGL4.26 backbone using Xho I and Hind III restriction 
endonucleases. Cloning was checked by restriction analysis and direct sequencing (Eurofins 
Genomics). For site-directed mutagenesis of this vector please refer to the section below. The pRL-
SV40 (Promega) vector constitutively expressing the Renilla reniformis luciferase cDNA was used 
as transfection efficiency control for gene reporter assays.  
 
Generation of stable pCVM6-Entry-ETV7 and Empty MCF7 and MDA-MB-231 cells  
In order to get MCF7 and MDA-MB-231 cells stably over-expressing ETV7 and the empty control, 
cells were seeded in 6-well plates and subsequently transfected for 48 hours with 1 Pg of pCMV6-
Entry-Empty or pCMV6-Entry-ETV7 (Origene) using Lipofectamine LTX and Plus Reagent (Life 
Technologies, Thermo Fisher Scientific, Milan, Italy) or FuGene HD (Promega, Milan, Italy) 
respectively for MCF7 and MDA-MB-231 cells. Afterwards, cells were splitted and Geneticin (Life 
Technologies) was added at a concentration of 600 and 800Pg/ml respectively for MCF7 and MDA-
MB-231 cells; each 3 days medium was replaced and after 4 cycles of selection, single cell cloning 
was performed according to the Corning protocol for cell cloning by Serial dilution in 96 well plate. 
During the single cell cloning procedure Geneticin concentration was gradually reduced till 300 
(MCF7) and 400Pg/ml (MDA-MB-231).  
 
RNA isolation and RT-qPCR 
Total RNA was extracted using the Illustra RNA spin Mini Kit (GE Healthcare, Milan, Italy), 
converted to cDNA with the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) 
and RT-qPCR was performed with 25 ng of template cDNA in 384 wells-plate (BioRad, Milan, Italy) 
using the Kapa Sybr Fast qPCR Master Mix (Kapa Biosystems, Resnova, Ancona, Italy) and the 
CFX384 Detection System (BioRad). YWHAZ and B2M genes were used as housekeeping genes to 
obtain the relative fold change by the ''Ct method as previously described [48]. Primer 
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 8 
sequences were designed using Primer-BLAST designing tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/), checked for specificity and efficiency, and are 
listed in Supplementary Table 1 (Eurofins Genomics). 
 
Western Blot 
Total protein extracts were obtained by lysing the cells in RIPA buffer and proteins were quantified 
by the BCA method (Pierce, Thermo Fisher Scientific); 20-50 Pg of protein extracts were loaded on 
7.5% and 12% polyacrylamide gels and western blotting was performed as previously described 
[49, 50]. Transferred proteins were probed over-night at 4°C with specific antibodies diluted in 1% 
non-fat skim milk-PBS-T solution: GAPDH (6C5, sc-32233), ETV7/TEL2 (F-8, sc-376137X), ETV7/TEL2 
(H-88, sc-292509), Histone H3 (FL-136, sc-10809), D-Actinin (H-2, sc-17829), DNMT3A (GTX129125, 
GeneTex, Prodotti Gianni, Milan, Italy). Antibodies were obtained from Santa Cruz Biotechnologies 
(Milan, Italy) when not specifically indicated. Detection was performed with ECL Select reagent 
(GE Healthcare) using a ChemiDoc XRS+ (BioRad) or UVITec Alliance LD2 (UVITec Cambridge, UK) 
imaging systems.  
In order to separate cytoplasmic and nuclear fractions of proteins, MCF7 cells were seeded in 
p150 dishes and treated with Doxorubicin for either 6 or 16 hours. Cytoplasmic proteins were 
extracted following the instructions of NE-PER kit (Thermo Fisher Scientific). Alternatively, in order 
to enrich the nuclear extracts for chromatin-associated proteins, pellets remaining from 
cytoplasmic extraction were directly resuspended in 1x Loading Buffer and boiled. Approximately, 
150 Pg of nuclear protein extracts and 50 Pg of cytoplasmic protein extracts were loaded on a 
polyacrylamide gel, blotted and detected as described above. Histone H3 and GAPDH were used 
respectively as controls for nuclear and for cytoplasmic extracts.  
 
Gene reporter Assay 
24 hours prior transfection, 7 x 104 MCF7 cells were seeded in 24 well-plate. Cells were 
transfected with Lipofectamine LTX and Plus Reagent (Thermo Fisher Scientific) along with 250ng 
pGL4.26-DNAJC15 reporter, 250ng pCMV6-Entry-Empty or pCMV6-Entry-ETV7 vectors, and 50ng 
pRL-SV40 for each well. After 48 hours, cells were washed once in PBS and lysed in 1X PLB buffer 
and luciferase activity measurements were performed using the Dual-Luciferase Reporter Assay 
System (Promega) as previously described [45, 51] and detected using the Infinite M200 plate 
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 9 
reader (Tecan, Milan, Italy). Renilla luciferase activity was used as indicator of transfection 
efficiency and used to obtain the Relative Light Unit (RLU) measure.  
 
Site-directed mutagenesis 
Site-directed mutagenesis was performed using GENEART Site-Directed Mutagenesis kit (Life 
Technologies) according to manufacturer’s instructions. In order to mutate ETV7 binding sites 
within pGL4.26-DNAJC15 (substituting the GGA conserved bases with ATC random sequence), the 
reporter plasmid was first methylated and then amplified with AccuPrime Pfx DNA Polymerase 
(InVitrogen, Life Technologies) in a mutagenesis reaction with the following primers (Eurofins 
Genomics):  
BS1_Fw: GGGAAGAAAGGCTGCCCatcAGGGGGTCAGGAAAGC;  
BS1_Rv: GCTTTCCTGACCCCCTgatGGGCAGCCTTTCTTCCC;     
BS2_Fw: GGTGAGAAGGGTATCTgatGGGAACCTCGCCTTTAA;   
BS2_Rv: TTAAAGGCGAGGTTCCCatcAGATACCCTTCTCACC. 
Mutagenesis was then followed by an in vitro recombination reaction to enhance efficiency and 
colony yield. Mutated plasmids (pGL4.26-DNAJC15-BS1 and -BS2) were subsequently transformed 
into DH5D-T1R E. coli competent cells, which circularize the linear mutated DNA and exploits 
McrBC endonuclease activity to digest methylated DNA. Complete and correct mutagenesis was 
verified by direct sequencing (Eurofins Genomics). 
 
Bisulfite-conversion 
Genomic DNA was extracted from MCF7 cells left untreated, treated with Doxorubicin or over-
expressing pCMV6-Entry-Empty or -ETV7 vectors. DNA and RNA extractions were obtained from 
the same samples using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Milan Italy).  
Purified DNA was then denaturated and subjected to bisulfite conversion with the EZ DNA 
Methylation-Lightning™ Kit (Zymo Research, Euroclone) according to manufacturer’s 
recommendations. The resulting product was subsequently PCR amplified and sequenced using 
the following bisulfite-specific primers (Eurofins Genomics): Fw: 
TTGGTAGGATTTATTAGTTTTTGTTGG; Rv: CACCCAACTAATCTTTATATTTTTAATAAA. 
 
Doxorubicin Efflux Analysis 
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1.5 x 104 MDA-MB-231 cells were seeded in a 96 well-plate; the subsequent day, 10 or 20PM 
Doxorubicin was added for 3 hours and cells were analyzed with the Operetta High Content 
Imaging System (Perkin Elmer, Milan, Italy) at CIBIO High Throughput Screening Facility exploiting 
the intrinsic fluorescence of Doxorubicin. By using the Harmony 4.1 PhenoLOGIC software nuclear 
and cytoplasmic regions were detected; successively, the relative ratio of nuclear respect to 
cytoplasmic fraction from Doxorubicin signal was calculated. To measure the Doxorubicin efflux 
area, the Doxorubicin spot area into the cytoplasm was measured (see Suppl. Fig2a for details).  
 
Viability Assay 
Cells were seeded in a 96 well-plate and treated with different concentrations of Doxorubicin for 
72 hours. Medium was removed and wells were washed with 1X PBS to avoid possible reduction 
effects of the added compound with MTT reagent (Sigma-Aldrich). Ten Pl of MTT was added to 
100 Pl of fresh medium and left in incubation for 3 hours. Afterwards, medium was accurately 
removed and cells were lysed in 100 Pl of DMSO (Sigma-Aldrich), and a colorimetric measure was 
performed at the Infinite M200 plate reader (Tecan). Viability was calculated as a % ratio of viable 
cells treated with the indicated drug respect to an untreated control.  
 
Chromatin Immunoprecipitation Assay 
MDA-MB-231-ETV7 and MDA-MB-231-Empty cells were seeded in p150 dishes (four dishes each 
condition) and ChIP-PCR was performed following a revised version of Myers Lab protocol. Mouse 
monoclonal anti-ETV7/TEL2 antibody (F-8, sc-376137X, Santa Cruz Biotechnologies) and normal 
mouse IgG (sc-2025, Santa Cruz Biotechnologies) were used for immunoprecipitation. Two Pl of 
purified immmunoprecipitated DNA was then used for qPCR analysis and calculation was 
performed using the ΔCt method in respect to non-immunoprecipitated DNA (% of input) as 
previously detailed described [52]. A genomic region within GTF2H5 gene was used a negative 
control. A list of the primers sequences that were used for ChIP-PCR analysis is presented in 
Supplementary Table 1 (Integrated DNA Technologies, Coralville, IA, USA and Eurofins Genomics). 
MCF7 cells were seeded in p150 dishes and transiently transfected with 10Pg of pCMV6-Entry-
Empty or -ETV7 vectors using Lipofectamine LTX and Plus Reagent (Thermo Fisher Scientific) for 48 
hours. ChIP was performed using the same protocol used for MDA-MB-231 using anti-ETV7/TEL2 
(H-88, sc-292509) and normal rabbit IgG (sc-2027, Santa Cruz Biotechnologies) for 
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immunoprecipitation. qPCR on purified immunoprecipitated DNAs was performed as indicated 
above. 
 
Co-Immunoprecipitation 
MCF7 were seeded in p150 dishes and transiently transfected with pCMV6-Entry-ETV7 as above 
(Origene). 48 hours post-transfection cells were lysed in CHAPS buffer and then incubated over-
night with an anti-ETV7 antibody (H-88, sc-292509) or normal rabbit IgG (sc-2027) previously 
bound to Dynabeads protein A magnetic beads (Life Technologies). Beads were then washed and 
the immunoprecipitated lysate was eluted and loaded on a polyacrylamide gel for SDS-PAGE. 
 
Analysis of genome-wide data 
Available expression arrays from our group (GSE24065, Agilent-014850 Whole Human Genome 
Microarray 4x44K G4112F) were analyzed for the specific genes of interest as previously described 
[20, 34]. 
Expression data of MCF7 cells resistant to Adriamycin -MCF7/ADR- (e.g. Doxorubicin) were 
obtained from Affymetrix Human Genome U133 Plus 2.0 Array platform and downloaded from 
GEO (GSE76540). Two transcripts for each gene of interest (ETV7, DNAJC15 and ABCB1) were 
available and expression averages were calculated. 
Expression levels of ETV7 and DNAJC15 were obtained from microarray data of Triple Negative 
Breast Cancer patients who underwent neoadjuvant chemotherapy protocols (GSE43502, 
Affymetrix Human Genome U133 Plus 2.0 Array). The study included 25 patients (out of 47) 
showing recurrence. 
 
Statistical analysis 
When appropriate, Student’s t-test was applied for statistical significance. We selected throughout 
the manuscript the two-sample Student’s t-test for unequal variance. 
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RESULTS  
 
ETV7 is activated by Doxorubicin and other DNA damaging drugs in cancer and normal cells 
 
To investigate the differential expression of ETV7 in response to various stimuli in breast cancer 
cells we tested a panel of cytotoxic drugs in MCF7 cells. We observed a substantial induction of 
ETV7 expression with many of the treatments, especially DNA damaging drugs, among which 
Doxorubicin was the most effective inducer of ETV7 expression in comparison with 5FU, 
Camptothecin and Etoposide (Figure 1A). The treatment with Nutlin-3a, a p53 specific activator 
[32] also triggered an increment in ETV7 mRNA levels while Everolimus (mTOR inhibitor), Imatinib 
(tyrosine kinase inhibitor) and Tamoxifen (estrogen modulator) had no effect (Figure 1A). 
Moreover, ETV7 transcriptional activation by Doxorubicin in MCF7 cells was reflected by an 
increase in protein levels in the nuclear compartment (Suppl. Figure 1A), highlighting its role as a 
transcriptional regulator. 
 
We extended the analysis to the breast cancer cell line MDA-MB-231 and confirmed the induction 
of ETV7 upon treatments with DNA damaging agents, especially Doxorubicin (Figure 1B). 
Nevertheless, the levels of ETV7 induction in this cell line were not as high as in MCF7. The 
reduced level might be explained by the presence of a mutant nonfunctional form of p53 in MDA-
MB-231, since p53 is an activator of ETV7 transcription [20]. Doxorubicin treatment also induced 
ETV7 in other cancer-derived cell lines: lung adenocarcinoma (A549), osteosarcoma (U2OS) and 
melanoma (A375M) (Suppl. Figure 1B). Given the activation in the various cancer cell lines, we 
investigated ETV7 expression in normal cells. We treated lymphocytes obtained from healthy 
donors and two non-cancerous cell lines (immortalized normal fibroblasts BJ1-hTERT and 
immortalized normal mammary cells MCF10A). These results along with those from cancer cell 
lines establish that ETV7 induction is a conserved response to DNA damaging treatments (Figure 
1C and Suppl. Figure 1B).  
 
 
ETV7 can promote resistance to Doxorubicin in breast cancer cells  
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Given the observation that ETV7 is potently activated in response to Doxorubicin treatment, we 
hypothesized that it may be involved in drug resistance. To test this, we generated stable MCF7 
and MDA-MB-231 cell lines over-expressing this transcription factor (Suppl. Figure 2A and 2B, 
respectively) and evaluated whether this could influence the survival upon Doxorubicin treatment. 
Importantly, ETV7 over-expression exerted a strong protective role against Doxorubicin induced 
cell death in both cell lines (Figure 2A-B). Interestingly, this effect was also visible in non-breast 
cancer cells as shown for the osteosarcoma U2OS cells stably over-expressing ETV7 (Suppl. Figure 
2C-D). To better understand the mechanism of resistance, we monitored the nuclear efflux of 
Doxorubicin exploiting its light emission property in the ETV7 over-expressing MDA-MB-231 cells 
relative to their empty-vector counterpart. By measuring the ratio of nuclear to cytoplasmic 
Doxorubicin and the area of Doxorubicin efflux from the nuclei, we found a statistically significant 
decrease of nuclear Doxorubicin in the MDA-MB-231 cells over-expressing ETV7 that 
corresponded to an increased nuclear efflux of Doxorubicin (Figure 2C-D and Suppl. Figure 2E, 
showing details regarding the selection of nuclear and cytoplasmic regions). This indicates that 
ETV7 might influence the expression of ABC transporters such as ABCB1/PgP, ABCC1/MRP1, and 
ABCB4/MDR2 thereby leading to an increased survival. In particular, we were able to demonstrate 
that ABCB1 was up-regulated upon ETV7 over-expression in MCF7 and MDA-MB-231 cells (Suppl. 
Figure 2F and 2G, respectively).  
 
 
DNAJC15 is a good target for ETV7-mediated drug resistance 
 
To further understand how ETV7, as a transcriptional repressor, could influence drug resistance, 
we searched for its putative targets by restricting the analysis to genes whose silencing is already 
known to be involved in Doxorubicin resistance in breast cancer cells. In particular, we considered 
a list of six genes (BRCA1, ESR1, DNAJC15, CDH1, RAB6C and SULF2) whose hyper-methylation 
correlates with Doxorubicin resistance in breast cancer (Table 1 from Boettcher et al., 2010 [33] 
and available at the Archive of Functional Genomics Data, accession number #E-MEXP-2698, using 
the ArrayExpress tool). To restrict the search to the most promising ETV7 targets, we analyzed the 
expression of this group of genes in microarray data that we previously described with 
Doxorubicin treated MCF7 cells available (GSE24065, Gene Expression Omnibus, GEO, NCBI [20, 
34]). Given that Doxorubicin potently activated ETV7 expression, we expected to observe 
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significant down-regulation of its targets upon the same treatment condition. Out of the six genes, 
three of them -DNAJC15, BRCA1 and ESR1- displayed a strong down-regulation pattern upon 
Doxorubicin treatment (Suppl. Figure 3A). No significant effects were observed for CDH1 and 
RAB6C, while SULF2 was induced after Doxorubicin treatment. Moreover, most DNAJC family 
members were repressed upon Doxorubicin in MCF7 cells, based on the previously mentioned 
microarray data (Suppl. Figure 3B). Therefore, we validated some of the highly down-regulated 
members of DNAJC family with RT-qPCR experiments in Doxorubicin-treated MCF7 cells and 
confirmed the repression of DNAJC2, C7, C14, C15 and C17 in response to Doxorubicin treatment 
(Figure 3A). Furthermore, DNAJC15 has already been reported to be involved in the negative 
regulation of ABCB1 transcription, thereby potentially explaining the ETV7-mediated ABCB1 up-
regulation and, at least partially, the drug resistance mechanism associated with ETV7 [29]. We 
decided to focus our attention on DNAJC15 as putative mediator of the ETV7-dependent 
Doxorubicin resistance. We extended the analysis of DNAJC15 repression to other DNA damaging 
agents in MCF7, MDA-MB-231 cells and in lymphocytes (Figures 3B, 3C and 3D, respectively), and 
verified DNAJC15 down-regulation in response to most of these agents. 
 
 
ETV7 transcriptionally regulates DNAJC15 expression  
  
Since we observed that ETV7 and DNAJC15 expression were inversely correlated in response to 
several stimuli and given the presence of two putative ETV7 binding sites in the DNAJC15 
promoter, we investigated the possibility of direct ETV7 influence on DNAJC15 expression. First, 
we demonstrated that the modulation of ETV7 expression inversely affected the mRNA levels of 
DNAJC15. Specifically, ETV7 over-expression led to a small but significant, repression of DNAJC15 
both in MCF7 (Figure 4A) and MDA-MB-231 (Suppl. Figure 4A) cells. 
 
In order to assess whether transcriptional repression was associated with ETV7 binding to 
DNAJC15, we cloned a region of the DNAJC15 promoter containing two putative binding sites for 
ETV7 into a pGL4.26 luciferase reporter vector. We found that ETV7 over-expression in MCF7 cells 
was able to decrease the expression of the luciferase reporter gene under the control of the 
DNAJC15 promoter (Figure 4B). We then performed site-directed mutagenesis to mutate the most 
conserved bases within the two putative ETV7-binding sites into the reporter vector in order to 
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demonstrate the contribution of these two binding sites in DNAJC15 repression. The mutation of 
the binding site 1 (BS1 – chr.13:43'597’329-43'597'335) did not affect the ETV7-mediated down-
regulation of luciferase activity. However, disruption of binding site 2 (BS2 – chr.13:43'597’624-
43'597'632) prevented repression of the luciferase reporter induced by ETV7, demonstrating the 
importance of ETV7 binding to this site in the repression of DNAJC15 (Figure 4B). 
 
Furthermore, we were able to demonstrate with chromatin immunoprecipitation the direct 
binding of ETV7 to the DNAJC15 promoter region (BS2) in both MCF7 and MDA-MB-231 cells 
(Figure 4C and Suppl. Figure 4B, respectively). In particular, in MDA-MB-231 cells over-expressing 
ETV7, the binding to DNAJC15 promoter was markedly stimulated by Doxorubicin treatment. In 
order to better clarify this effect, we analyzed the distribution of ETV7 protein within the nucleus 
and found that upon Doxorubicin treatment the ETV7 protein was strongly enriched in the nuclear 
fraction especially in chromatin-associated structures (Suppl. Figure 4C). 
 
 
ETV7 represses DNAJC15 expression by DNA methylation  
 
 DNAJC15 is recognized to be a methylation-controlled gene, and its methylation-induced down-
regulation has been associated with chemoresistance [29]. We investigated whether ETV7-
mediated repression was dependent on DNA methylation. The methylation of CpGs in the 
promoter of DNAJC15 in MCF7 cells following ETV7 over-expression or Doxorubicin treatment was 
determined by bisulfite-conversion of genomic DNA followed by PCR and direct sequencing. In 
response to Doxorubicin, the promoter of DNAJC15 showed increased methylation of CpGs, which 
was even more evident upon ETV7 over-expression, as shown in Figure 5A. Moreover, ETV7-
mediated effects on DNAJC15 transcript levels were abolished by treatment with the DNA 
methyltransferase (DNMT) inhibitor 5-Aza-2’-deoxycytidine (5-Aza) (Figure 5B), demonstrating 
that ETV7 repression of DNAJC15 expression is indeed methylation dependent. 
 
Given that DNMTs play key roles in Doxorubicin resistance as demonstrated for Adriamycin-
resistant MCF7 cells [35], we hypothesized a possible direct interaction between ETV7 and DNMTs 
mediating the methylation and subsequent repression of the DNAJC15 promoter. Analysis of the 
expression of the DNMT1, DNMT3A and DNMT3B genes in our microarray data from Doxorubicin-
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treated MCF7 cells (GSE24065 [20, 34]) (Suppl. Figure 5A) and validation by RT-qPCR (Figure 5C), 
revealed the up-regulation of only DNMT3A among these DNMTs. Conversely, both DNMT1 and 
DNMT3B were down-regulated in response to the treatment. Moreover, a similar trend could be 
observed for DNMTs expression in response to ETV7 over-expression in MCF7 cells, even if the 
only statistically significant alteration in expression was for DNMT1 (Suppl. Figure 5B). To test the 
putative interaction of ETV7 with DNMT3A as a candidate mediator of DNAJC15 repression, we 
performed immunoprecipitation of ETV7 and found the direct interaction of ETV7 with DNMT3A in 
MCF7 cells transiently over-expressing ETV7 (Figure 5D).  
 
 
DNAJC15 over-expression partially rescues ETV7-mediated drug resistance  
 
To address the idea that ETV7-mediated drug resistance is, at least partially, dependent on the 
repression of DNAJC15, we over-expressed DNAJC15 in MCF7 and MDA-MB-231 cells stably over-
expressing ETV7 and analyzed cellular viability upon Doxorubicin treatment. Cells over-expressing 
DNAJC15 became more sensitive to Doxorubicin-mediated cell death, thus confirming this 
pathway as a mechanism exploited by ETV7 for drug resistance (Figure 6A-B).  Furthermore, 
DNAJC15 over-expression was also able to down-regulate ABCB1 expression in MCF7 as well as 
MDA-MB-231 cells over-expressing ETV7, in accord with its reported negative role on ABCB1 levels 
(Suppl. Figure 6A-B). 
 
ETV7-DNAJC15 clinical relevance and possible therapeutic strategy   
 
We confirmed a dramatic decrease in DNAJC15 and corresponding increase in ETV7 expression in 
reported microarray analysis performed with Adriamycin (i.e. Doxorubicin) resistant MCF7 cells 
(MCF7/ADR, GSE76540, [36]) as shown in Figure 7A. Moreover, this effect was associated with a 
large increase in ABCB1 expression in MCF7/ADR cells, an observation consistent with what is 
observed in MCF7 and MDA-MB-231 cells over-expressing ETV7 (Suppl. Figure 2F-G). 
 
To address possible clinical relationships between ETV7, DNAJC15 and Doxorubicin treatment, we 
evaluated data obtained from 25 chemoresistant samples among 47 neoadjuvant chemotherapy-
treated triple negative breast cancer (TNBC) patients (GSE43502, [37]). There is an inverse 
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correlation between increased ETV7 and strongly decreased DNAJC15 expression in TNBC patients 
associated with recurrence. These data indicates that ETV7-mediated repression of DNAJC15 could 
be linked to a worse prognosis in breast cancer patients (Figure 7B).  
 
Given that the over-expression of a particular gene is still a challenging approach for therapeutic 
purposes, we tried to overcome ETV7-mediated drug resistance using Quercetin, a flavonoid 
recently shown to both increase therapeutic efficacy of Doxorubicin [38-40] and to reduce its 
cardiotoxicity [41, 42], and the isoflavone Genistein, which can inhibit topoisomerase II [43] and 
DNMTs [44] or act as a phytoestrogen [45]. The sensitizing action of flavonoids has not been fully 
elucidated yet, but it seems to involve the MDR transporter action. Surprisingly, we noticed that 
both flavonoids Quercetin and Genistein were able to reduce ETV7 expression in MDA-MB-231 
cells, thereby suggesting a novel mechanism of sensitization for cancer cells (Figure 7C). Notably, 
MDA-MB-231 cells that over-express ETV7 were more sensitive to Quercetin relative to the empty 
counterpart, thereby unveiling a mechanism that could represent a promising target for ETV7-
mediated resistance in cancer cells (Figure 7D).  
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DISCUSSION  
 
ETV7 has been recognized in the literature as an oncoprotein for blood cancers but its role in solid 
cancers is still poorly studied [10, 17]. In this work we showed that ETV7 is activated in response to 
different DNA damaging agents in breast cancer cells, but its expression is not affected by other 
types of anti-cancer treatments such as estrogen antagonists, tyrosine kinase or mTOR inhibitors 
(Figure 1). We observed that this transcriptional activation is conserved in different cancer cell 
types and normal cells including lymphocytes obtained from healthy donors, thus highlighting its 
biological relevance. Moreover, we have demonstrated that ETV7 can directly promote resistance 
of breast cancer cells to standard-of-care chemotherapy, i.e. Doxorubicin (Figure 2). The ETV7-
dependent mechanism of chemoresistance exploited by breast cancer cells involves the direct 
efflux of Doxorubicin from the nucleus of cells over-expressing ETV7 (Figure 2). This observation 
led us to hypothesize that the effect can be driven by membrane-associated transporters and, 
interestingly, we found that cells over-expressing ETV7 showed higher expression levels of ABCB1, 
a member of the family of ABC transporters (Suppl. Figure 2). Despite being mainly expressed on 
the plasma membranes, ABCB1 protein has often been detected on nuclear membranes and Golgi 
compartments [46], possibly mediating the phenomenon of resistance to Doxorubicin observed in 
breast cancer cells in this study. 
 
As a transcription factor, ETV7 can influence the expression of a complex range of targets that may 
result in the observed increased survival. Among the various possible ETV7 targets, we proposed 
DNAJC15, a co-chaperone member of the HSP40 family, reported to affect ABCB1 expression and 
anti-cancer drug efflux [29] DNAJC15 has already been reported to be frequently hyper-
methylated and repressed in breast cancer cells resistant to therapy [27] [28]. However, which 
direct players were causing its transcriptional repression in breast cancer was not known. We 
confirmed the DNAJC15 repression triggered by Doxorubicin involves the direct binding of ETV7 on 
DNAJC15 promoter. We were also able to identify the precise promoter region that ETV7 uses to 
reduce the expression of DNAJC15 located at +377 bp from the TSS (Figures 3 and 4). Given 
reports of DNAJC15 hyper-methylation and decreased expression in cancer [28], we investigated 
whether ETV7 could modulate DNAJC15 expression through this mechanism. By mapping the CpG 
islands that are methylated in response to Doxorubicin and ETV7 over-expression in breast cancer 
cells, we demonstrated that ETV7-dependent DNAJC15 transcriptional repression is methylation-
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mediated (Figure 5). We speculate that this may be achieved through the direct recruitment of the 
DNA methyltransferase DNMT3A on chromatin mediated by ETV7 given our observation of 
physical interaction between the two proteins (Figure 5).  
 
In Figure 8, we propose a model for the novel mechanism of Doxorubicin resistance in breast 
cancer cells that includes a pivotal role for ETV7, which is directly activated by this 
chemotherapeutic drug. The induced ETV7 acts as a direct negative regulator of DNAJC15 
expression through the DNA methylation of the promoter region via DNMT3A. DNAJC15 
repression leads to the efflux of the drug from the nucleus, a process possibly driven by loss of the 
DNAJC15-dependent repression of ABCB1.   
 
A better knowledge of the transcriptional repressors that impact DNAJC15 expression could help 
inform clinical treatment strategies in order to avoid or minimize the activation of one of its direct 
repressors such as ETV7. A combinatorial treatment could disrupt this resistance circuitry driven 
by ETV7. Based on our findings, we suggest considering combined treatment of Doxorubicin with 
Quercetin as a therapeutic strategy, given its protective role against Doxorubicin cardiotoxicity 
and its negative action on ETV7 expression (Figure 7).  
 
Taken collectively, our results uncovered a novel molecular mechanism that underlies the 
resistance to a standard-of-care treatment for breast cancer (Doxorubicin), providing insights on 
the players that take part in this process: ETV7, DNMT3A and DNAJC15 all of which have the 
potential for pharmacological targeting. Moreover, it is worth noting that our findings provide the 
first evidence for a role of ETV7 expression and function in the resistance to Doxorubicin in breast 
cancer cells. We propose that further analyses on additional ETV7 targets could help investigations 
for novel breast cancer prognostic markers. 
 
In general, given the complex universe beyond chemoresistance in cancer cells, it is of paramount 
importance to search for downstream master regulators like transcription factors. Despite the 
difficulties beyond their targeting, understanding how to restrict their activation and activity could 
provide a more promising therapeutic strategy than simply targeting a specific resistance effector.  
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CONCLUSIONS 
  
Uncovering pathways and mechanisms involved in drug resistance is an urgent and critical aim for 
breast cancer research oriented to improve treatment efficacy. Here, we uncovered a novel 
mechanism of resistance directly activated by Doxorubicin treatment where the transcriptional 
repressor ETV7 plays a major role. Specifically, we demonstrated that ETV7 can transcriptionally 
repress DNAJC15 thereby triggering Doxorubicin-resistance. These findings can help to better 
understand how resistance to conventional chemotherapy can be hindered and possibly tackled 
pharmacologically.  
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ABBREVIATIONS 
ETV7: Ets Variant Gene 7; ETS: E26 Transformation-Specific; DNAJC15: DNAJ Heat Shock Protein 
family (Hsp40) member C15; ABCB1: ATP Binding Cassette subfamily B member 1; DNMT3A: DNA 
Methyl-Transferase 3A; 5-Aza: 5-Aza-2’-deoxycytidine; TNBC: Triple Negative Breast Cancer; ADR: 
Adriamycin. 
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FIGURE LEGENDS 
 
Figure 1: DNA damaging drugs promote ETV7 transcriptional activation. RT-qPCR analysis of ETV7 
expression upon different chemotherapeutics treatment in breast cancer-derived MCF7 (A) and 
MDA-MB-231 cells (B), and in healthy donors-derived lymphocytes (C). Bars represent average 
Fold Changes relative to the untreated condition and standard deviations of at least three 
biological replicates. * = p-value < 0.01. 
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Figure 2: ETV7 can trigger breast cancer resistance to Doxorubicin. A-B) MTT Assays for survival 
analyses upon Doxorubicin treatment in MCF7 (A) and in MDA-MB-231 (B) cells over-expressing 
ETV7 with respect to their empty control. C) Analysis of the ratio between nuclear and cytoplasmic 
intensity of Doxorubicin in MDA-MB-231 cells over-expressing ETV7 compared with their empty 
control, performed through Operetta Perkin Elmer Software. D) Analysis of the cytoplasmic area of 
Doxorubicin efflux in MDA-MB-231 cells over-expressing ETV7 in comparison to their empty 
counterpart. Images are reporting one representative analyzed by Operetta PerkinElmer Software. 
Experiments are done in quadruplicate. * = p-value < 0,01. 
 
Figure 3: DNAJC15 expression is repressed by DNA damaging drugs. A) RT-qPCR analysis in MCF7 
cells of the expression of a selected group of DNAJC family members repressed upon Doxorubicin 
treatment according microarray analysis (GSE24065). B-C) Expression analysis of DNAJC15 mRNA 
upon different chemotherapeutics treatment in breast cancer-derived MCF7 (B) and MDA-MB-231 
cells (C), and in healthy donors-derived lymphocytes (D). Bars represent averages Fold Changes 
relative to the untreated condition of at least three biological replicates and standard deviations. * 
= p-value < 0.01. 
 
Figure 4: ETV7 can repress DNAJC15 expression at the transcriptional level. A) RT-qPCR analysis 
of ETV7 and DNAJC15 expression in MCF7 cells transfected with pCMV6-Entry-Empty or pCMV6-
Entry-ETV7 plasmids. B) Gene reporter assay of MCF7 cells transiently over-expressing pCMV6-
Entry-Empty or pCMV6-Entry-ETV7 along with pGL4.26-DNAJC15 reporter plasmid or the pGL4.26-
DNAJC15-BS1 or -BS2 plasmids mutated in the putative ETV7 binding sites. Data are normalized 
using pRL-SV40 and are shown as fold of induction relative to the empty control. C) ChIP-PCR of 
DNAJC15 and GAPDH (control) promoter regions in MCF7 transfected with pCMV6-ETV7. Shown is 
the percentage enrichment of EVT7 or control (IgG) bound to DNAJC15 promoter region in respect 
to INPUT DNA. For all the panels, bars represent averages and standard deviations of at least three 
biological replicates. * = p-value < 0.01. 
 
Figure 5: ETV7 can regulate DNAJC15 expression in a methylation-dependent manner. A) 
Methylation status of CpGs within DNAJC15 promoter analyzed by bisulfite conversion followed by 
PCR and direct sequencing in MCF7 untreated, treated with Doxorubicin for 16 hours or 
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transfected with pCMV6-Entry-Empty or pCMV6-Entry-ETV7 plasmids. Methylated CpGs are 
shown as black dots, whereas unmethylated CpGs as white dots. B) RT-qPCR analysis of DNAJC15 
expression in MCF7 transfected with pCMV6-Entry-Empty or pCMV6-Entry-ETV7 and treated with 
DMSO or 5-Aza-2’-deoxycytidine for 48 hours. C) RT-qPCR analysis of DNMT1, DNMT3A and 
DNMT3B expression in MCF7 treated with Doxorubicin for 16 hours. D) Western blot of DNMT3A 
and ETV7 on the immunoprecipitation with an antibody against ETV7 or normal IgG as control and 
on INPUT lysates in MCF7 transfected with pCMV6-Entry-ETV7 plasmid. * = p-value < 0.01. 
 
Figure 6: DNAJC15 over-expression can rescue Doxorubicin sensitivity. MTT Assay of ETV7-over-
expressing MCF7 (A) and MDA-MB-231 (B) cells transiently transfected with pCMV6-Entry-Empty 
or pCMV6-Entry-DNAJC15 plasmids and treated with Doxorubicin 1,5 PM or 3 PM for 72 hours. 
Experiments are done in quadruplicate. * = p-value < 0.01. 
 
Figure 7: ETV7 and DNAJC15 levels inversely correlate with clinical status of breast cancer 
patients and ETV7 can be exploited pharmacologically. A) ETV7, DNAJC15 and ABCB1 expression 
levels from microarray data (GSE76540) of MCF7 cells resistant to Adriamycin -MCF7/ADR- (e.g. 
Doxorubicin). Presented are the averages and standard deviations of at least three biological 
replicates. B) ETV7 and DNAJC15 expression levels from microarray data of Triple Negative Breast 
Cancer patients treated with neoadjuvant chemotherapy who were showing recurrence or not for 
the disease (GSE43502). C) ETV7 expression levels measured by RT-qPCR from MDA-MB-231 cells 
untreated (Mock) or treated with Quercetin 50PM or Genistein 30PM for 16 hours. Bars represent 
averages and standard deviations of at least three biological replicates. D) MTT assay in MDA-MB-
231 cells over-expressing ETV7 or its empty vector and treated with increasing concentration of 
Quercetin. Experiments are done in quadruplicate. * = p-value < 0.01. 
 
Figure 8: Model for ETV7 leading to Doxorubicin resistance in breast cancer cells through the 
methylation-dependent repression of DNAJC15. A graphical description of the novel model for 
ETV7-dependent Doxorubicin resistance is presented. In normal conditions ETV7 and DNMT3A are 
maintained at basal levels (particularly low in case of ETV7) and DNAJC15 can be regularly 
expressed. In response to Doxorubicin treatment, ETV7 levels get elevated and DNMT3A slightly 
increases as well. Induced ETV7 can then accumulate into the nucleus and specifically to 
chromatin-enriched regions. In the nucleus, ETV7 recruits DNMT3A (through direct interactions 
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with putative additional cofactors) on target DNA (DNAJC15 promoter in this case) that in turn it is 
responsible for the methylation of CpGs. This will result in DNAJC15 repression and ultimately will 
lead to chemoresistance, partly through exclusion of the drug from the nucleus. EBS: ETV7 Binding 
Site. Methylated CpGs are shown as filled circles, whereas unmethylated CpGs as empty circles.  
 
Additional file 1: SUPPLEMENTARY MATERIALS 
 
Suppl. Figure 1: A) Western Blot analysis of nuclear and cytoplasmic extracts of Doxorubicin-
treated MCF7 cells. Alpha-Actinin serves as loading control while Histone 3 is used as a control for 
nuclear fractionation. B) RT-qPCR analysis of ETV7 expression upon Doxorubicin treatment in 
cancer cell lines A375M, A549, U2OS and non-cancerous cell lines MCF10a and BJ1. Bars represent 
average Fold Changes relative to the untreated condition and standard deviations of at least three 
biological replicates. * = p-value < 0.01.  
 
Suppl. Figure 2: A-B) Western Blot analysis of ETV7 over-expressing clones, relative to MCF7 (A), 
MDA-MB-231 (B) and U2OS (C) cells stably transfected with the Empty vector. D) MTT Assay for 
survival analysis upon Doxorubicin treatment in U2OS cells over-expressing ETV7 with respect to 
their empty control. E) Doxorubicin nuclear efflux analysis using Operetta Imaging System, based 
on the detection of nuclear and cytoplasmic regions; the recognition of Doxorubicin efflux is done 
by calculating the fluorescence positive spots area (green spots in the panels on the left). This 
analysis was performed in MDA-MB-231 cells over-expressing ETV7 compared with their empty 
control cells. F-G) RT-qPCR analysis of ABCB1 expression in ETV7 over-expressing clones, MCF7-
based (F) and MDA-MB-231-based (G). * = p-value < 0.01. 
 
Suppl. Figure 3: A-B) Expression values from microarray data previously obtained by our group 
from MCF7 cells treated with Doxorubicin (GSE24065) of (A) the gene list the Boettcher group had 
obtained ([33] as hypermethylated genes upon resistance to Doxorubicin) and of (B) the DNAJC 
family members. Results are presented as logarithm of Fold Change from Doxorubicin-treated 
samples calculated over Mock condition. 
 
Suppl. Figure 4: A) RT-qPCR analysis of ETV7 and DNAJC15 expression in MDA-MB-231 over-
expressing pCMV6-Entry-Empty or pCMV6-Entry-ETV7 plasmids. B) ChIP-PCR of DNAJC15 and 
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GTF2H5 (control) promoter regions in MDA-MB-231 stably over-expressing ETV7 untreated or 
treated with Doxorubicin for 16 hours. C) Western Blot of chromatin and nuclear fractions of 
MDA-MB-231 over-expressing ETV7 upon treatment with Doxorubicin. Alpha-Actinin serves as 
loading control while Histone 3 is used as a control for chromatin-enriched nuclear fractions. * = p-
value < 0.01. 
 
Suppl. Figure 5: A) Expression of DNMT1, DNMT3A and DNMT3B from microarray analysis, 
measured in MCF7 cells treated with Doxorubicin (GSE24065). B) RT-qPCR analysis of DNMT1, 
DNMT3A and DNMT3B expression in MCF7 transfected with pCMV6-Entry-Empty or pCMV6-Etry-
ETV7 plasmids. * = p-value < 0.05. 
 
Suppl. Figure 6: RT-qPCR analysis of DNAJC15 and ABCB1 expression in ETV7-over-expressing 
MCF7 (A) and MDA-MB-231 (B) cells transiently transfected with pCMV6-Entry-Empty or pCMV6-
Entry-DNAJC15 plasmids. Bars represent averages and standard deviations of at least three 
biological replicates. * = p-value < 0.01. 
 
Suppl. Table 1: Sequences of the primers used for qPCR measurements (mRNA expression and 
promoter occupancy after ChIP assays). 
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Breast Cancer Research,  
Editor-in-chief, Associate Editors 
 
Trento, May 23nd 2017 
 
 
Dear Editors, 
 
 
We wish to submit to “Breast Cancer Research” the manuscript entitled: “ETV7-mediated 
DNAJC15 repression leads to Doxorubicin resistance in breast cancer cells” by 
Alessandrini F., Pezzè L., Menendez D., Resnick M.A., Ciribilli Y. 
Below we bring to the attention of the Editors the key points and the strengths of our 
manuscript along with the reasons and the novelty of the study. 
 
All authors are aware of and agreed to submit this manuscript and they have all 
contributed to the work described, sufficiently to be named as authors. Any other person 
or body with an interest in the manuscript, such as our employer is aware of the 
submission and agrees to it. On behalf of all the authors I hereby declare that there aren’t 
any competing financial interests or other conflicts of interest and we have provided a 
sentence within the manuscript declaring that. 
 
We would like to propose your journal an intriguing study regarding chemoresistance in 
breast cancer. In particular, we have uncovered a new mechanism of resistance to 
standard chemotherapy (i.e. Doxorubicin) exploited by breast cancer cells. The main 
player in this regulatory system is ETV7, a poorly characterized transcription factor that 
we showed is strongly activated in response to different DNA damaging agents in breast 
cancer cells.  
The premise of the study has been the fact that we previously published a story where the 
combined treatment with Doxorubicin and TNFalpha in MCF7 breast cancer-derived 
cells can lead to the activation of specific gene expression programs that may impact on 
cancer phenotypes and potentially modify the efficacy of cancer therapy (Bisio et al., 
2014). Among the genes that we found synergistically up-regulated, we identified ETV7 
as a potential tumor promoting factor. 
 
In the present study we were able to demonstrate that over-expression of ETV7 can lead 
to resistance to Doxorubicin in two different cellular models of breast cancer. The ETV7 
increased expression lead to the down-regulation of DNAJC15, a co-chaperone protein 
whose low expression was previously associated with drug resistance in breast and 
ovarian cancer. We have identified the binding site for ETV7 within the promoter of 
DNAJC15 and we have also found that DNA methylation contributes to ETV-mediated 
transcriptional repression at the DNAJC15 promoter. These findings of an inverse 
Personal Cover Click here to download Personal Cover renamed_d53cb.pdf 
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correlation between ETV7 and DNAJC15 expression in MCF7 cells in terms of 
Doxorubicin resistance, correlates well with treatment responses of breast cancer patients 
with recurrent disease, based on our analyses of reported genome-wide expression arrays. 
In addition, we have demonstrated that ETV7-mediated Doxorubicin resistance involves 
increased Doxorubicin efflux via nuclear pumps, which could be rescued in part by 
DNAJC15 up-regulation. 
 
In summary, with this work we provide a model for the novel mechanism of Doxorubicin 
resistance in breast cancer cells that includes a pivotal role for ETV7, which is directly 
activated by this chemotherapeutic drug (a figure within the manuscript depicts this new 
molecular mechanism). The activated ETV7 acts as a direct negative regulator of 
DNAJC15 expression through the DNA methylation of the promoter region via 
DNMT3A. DNAJC15 repression leads to the efflux of the drug from the nucleus, a 
process possibly driven by loss of the DNAJC15-dependent repression of ABCB1.   
These findings can help to better understand how resistance to conventional 
chemotherapy can be hindered and possibly tackled pharmacologically. 
 
We believe our manuscript will deliver insights to the reader on a relatively new and 
compelling topic, emphasizing the role of ETV7 as responsible of resistance to 
Doxorubicin in breast cancer cells, a gene that has only recently been associated with 
cancer progression and aggressiveness.  
 
 
Bisio A., Zámborszky J., Zaccara S., Lion M., Tebaldi T., Sharma V., Raimondi I., 
Alessandrini F., Ciribilli Y.*, Inga A.*. Cooperative interactions between p53 and NFκB 
enhance cell plasticity. Oncotarget. 2014 Dec 15;5(23):12111-25. 
* = corresponding authors 
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Lysosomes are important cytoplasmic organelles whose critical functions into the cells have only relatively recently
been acknowledged. In particular, despite the long-standing accepted concept about the role of lysosomes as cellular
machineries solely assigned to degradation, it has been demonstrated that they play active roles in homeostasis and
even in cancer biology. Indeed, it is now well documented that during the process of cellular transformation and cancer
progression lysosomes are changing localization, composition and volume and, through the release of their enzymes,
lysosomes can also enhance cancer aggressiveness. LAMPs, Lysosome Associated Membrane Proteins, represent a
family of glycosylated proteins present predominantly on the membrane of lysosomes whose expression can vary
among different tissues, suggesting a separation of functions. In this review we focus on the functions and roles of the
different LAMP family members with a particular emphasis on cancer progression and metastatic spread. LAMP
proteins are involved in many different aspects of cell biology and can influence cellular processes such as
phagocytosis, autophagy, lipid transport and aging. Interestingly, for all the five members identified so far, LAMP1,
LAMP2, LAMP3, CD68 and BAD-LAMP, it has been suggested a role in cancer. While this is well documented for
LAMP1 and LAMP2, the involvement of the other three proteins in cancer progression and aggressiveness has
recently been proposed and remains to be elucidated. Here we present different examples about how LAMP proteins
can influence and support tumor growth and metastatic spread, emphasizing the impact of each single member of the
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Seminars in Oncology,  
Editor-in-chief, Review Editor 
 
Trento, March 28th 2017 
 
 
Dear Editors, 
 
 
We wish to submit to “Seminars in Oncology” the manuscript entitled: “LAMPs: shedding 
light on cancer biology” by Alessandrini F., Pezzè L. and Ciribilli Y. 
 
All authors are aware of and agreed to submit this manuscript and they have all contributed 
to the work described, sufficiently to be named as authors. Any other person or body with 
an interest in the manuscript, such as our employer is aware of the submission and agrees 
to it. On behalf of all the authors I hereby declare that there aren’t any competing financial 
interests or other conflicts of interest. 
 
We would like to propose a review on a topic that is relatively novel in the cancer field. In 
this review we focus on the role of lysosomes in cancer, a topic that only more recently has 
become very interesting in oncology. Specifically, we concentrate on the functions and the 
impact of the different LAMP (Lysosome-Associated Membrane Proteins) family 
members with a particular emphasis on cancer progression and metastatic spread. LAMP 
proteins are involved in many different aspects of cell biology and can influence cellular 
processes such as phagocytosis, autophagy, lipid transport and aging. Interestingly, for all 
the five members identified so far, LAMP1, LAMP2, LAMP3, CD68 and BAD-LAMP, it 
has been suggested a role in cancer. While this is well documented for LAMP1 and 
LAMP2, for the other three proteins an involvement in cancer progression and 
aggressiveness has been proposed only recently. 
Here we present different examples about how LAMP proteins can influence and support 
tumor growth and metastatic spread, emphasizing the impact of each single member of the 
family. 
 
Below we bring to the attention of the Editors the key points and the strengths of our 
manuscript along with the reasons and the novelty of the proposed review. 
 
Brief explanation of the proposed review 
The amount of research material reporting the role of lysosomes in cancer is rapidly 
increasing in the last decade. Along with the research material also the number of reviews 
focusing on the general role of lysosomes in cancer is increasing. However, a review 
collecting all the data regarding role in cancer of lysosome-associated proteins is still 
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missing. Our motivation to sum up literature regarding this family of proteins is pushed by 
direct evidences observed in our laboratory specifically related to a member of this family. 
We have recently published a study to investigate a possible crosstalk between p53 and 
NFκB driven by chemotherapy-induced responses in the context of an inflammatory 
microenvironment (Bisio et al., 2014). In that work we propose that the crosstalk between 
p53 and NFκB can lead to the activation of specific gene expression programs that may 
impact on cancer phenotypes and potentially modify the efficacy of cancer therapy. 
Among the genes that were included, LAMP3 showed a nice correlation to tumor 
aggressiveness that we are further investigating through the generation of breast cancer 
cells able to over-express or silenced for LAMP3 gene. 
 
In the proposed review we would like to focus on the LAMP family of lysosomal proteins, 
given the recent evidences on its involvement in cancer. In particular, in this work we will 
highlight the role and impact of those proteins in cancer aggressiveness and metastatic 
spread. 
The proposed review will be organized with an introduction to contextualize the LAMP 
proteins and the lysosomes, illustrating the state of the art in the field. Then, we will focus 
on the LAMP family of proteins, describing the functions of each member with a particular 
emphasis on cancer. We will provide two figures, the first one to structurally visualize the 
5 members of the family and the second one to better explain the role of LAMPs in cancer 
biology. We will also provide a table listing for each LAMP protein the type of cancer it 
was involved, its role (pro- or anti-tumorigenic) and finally the relative references. A 
conclusions-section will close the manuscript.  
 
We believe our review will deliver insights to the reader on a relatively new and 
compelling topic, summarizing the role of this family of proteins that have been associated 
only recently to cancer progression and aggressiveness.  
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Dear Editors, 
 
 
We wish to submit to “Seminars in Oncology” a revised version of the manuscript we 
have recently submitted entitled: “LAMPs: shedding light on cancer biology” by 
Alessandrini F., Pezzè L. and Ciribilli Y. 
 
We appreciated the comments and suggestions provided by the Editor, and we have 
produced a modified version of the manuscript taking into account his specific requests. 
Specifically, all the concerns were addressed as outlined in the point-by-point response 
below. All the changes to the main text are in “track-change” mode. 
We hope that in its present form the manuscript can be considered acceptable for 
publication in Seminars in Oncology. 
 
 
Yours sincerely, 
 
 
Dr. Yari Ciribilli, PhD, Assistant Professor 
Laboratory of Molecular Cancer Genetics 
CIBIO, University of Trento 
Via Sommarive 9, 38123, Povo (TN), Italy 
+39 461 283173, yari.ciribilli@unitn.it 
 
 
Author's response to reviewers: 
 
1. The reviewer stated, we quote his words:  
We are explicitly looking for manuscripts that convey the information to readers in a very 
comprehensive manner and often the best way to do this is to summarize data in Tables. I 
would expect a separate table for each LAMP summarizing the data you cite for a pro-
tumorigenic roles. 
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In the revised version of the manuscript, we have produced five new tables that substitute 
the original one. In this new version, a specific table for each member of the LAMP 
family is generated summarizing the role in cancer that has been associated with each of 
them. 
 
2. The reviewer suggested a way to organize the tables; we cite his words again: 
The last column critically looks at the data. As you know a lot of the literature is 
comprised of examples of one study in one model and the value of that is uncertain, 
indeed it is often of no value. Thus I would question whether LAMP-1 can have all of the 
“pro-tumorigenic roles” you ascribe to it. Quite frankly I do not think it can have all of 
the roles you describe. 
The newly generated tables are now organized as suggested by the reviewer. We have also 
included a column where the strengths and weaknesses of the cited references were 
analyzed, and the reports were criticized accordingly.  
Regarding LAMP1 functions, in Table 1 each observation mentioned has been explained 
and analyzed for possible criticisms. 
 
3. Lastly, the reviewer requested additional figures, as stated: 
I would also ask you to consider adding another figure or two to better convey to the 
readers more information about LAMPs other than 1 and 2. 
In the original manuscript, we presented three figures, two general and one for the specific 
roles of LAMP1 and LAMP2 in cancer and immune cells. Following the suggestion of the 
reviewer, we have now added two new figures, and we have split Figure 2A-B in two 
separate figures (Figure 2 and 3) to make them uniform with the other figures. 
In the current version there are six figures: 
1. Organization of LAMP family of proteins; 
2. – 5. Localization and functions of LAMP1, LAMP2, DC-LAMP, CD68 in cancer and 
immune cells; 
6. Schematic summary of the roles in cancer carried out by LAMP proteins.  
 
 
HIGHLIGHTS
• Lysosomes play active roles in homeostasis and even in cancer biology.
• LAMP family members can influence various processes of cancer progression. 
• The role of each single member of the family in cancer is emphasized.
lysosomal enzymes triggers unregulated necrosis, while selective lysosomes permeabilization 
results in the induction of apoptosis (10, 11). As soon as lysosomal hydrolases are poured within the 
cytosol, they can take part in the execution of the apoptotic cascade by acting either in concert with 
the canonical caspases pathway or directly to actively cleave key cellular substrates (12, 13). 
However, the precise mechanisms by which lysosomes are involved in apoptosis are still largely 
unknown and currently under intense investigation.  
Relatively recently, the Sabatini’s group has identified the lysosomal surface as the subcellular site 
where mTORC1 (mammalian Target Of Rapamycin Complex 1) activation in response to amino 
acids occurs (14). mTOR, the main catalytic component of mTORC1, is an atypical 
serine/threonine kinase reported as master regulator of cell growth, energy production and protein 
synthesis (15); its functions are often deregulated in different diseases and in particular in cancer 
(16). These researchers have demonstrated that amino acids trigger the translocation of mTORC1 
complex to the lysosomes where it gets activated through the interaction with Rag GTPases, and 
Ragulator and Rheb, two proteins that are anchored to the lysosomes’ membrane (14). Active 
mTORC1 is responsible for the phosphorylation and the subsequent accumulation in the cytosol of 
TFEB, a nuclear transcription factor responsible for lysosomal biogenesis, thereby integrating 
signals from the lysosomes to the nucleus (17). 
 
ROLE OF LYSOSOMES IN CANCER 
During transformation and cancer progression lysosomes are changing localization, volume and 
composition and by releasing their enzymes they can increase cancer aggressiveness (4, 18). For 
instance, several lysosomal enzymes, including cathepsins, are over-expressed in different cancer 
types, such as breast, prostate and colon cancers (19, 20), and their expression levels can be 
endowed with clinical significance(11). Different reports have suggested that an increased 
production and subsequent secretion of these proteases via exocytosis can foster proliferation and 
invasion ability of cancer cells (19, 21, 22). Therefore, this can enhance cancer progression and 
metastasis formation by promoting the degradation of the extracellular matrix and increasing the 
angiogenesis potential (23). Indeed, inhibition of cathepsin B by synthetic cysteine protease 
inhibitors has been shown to effectively reduce the invasiveness of glioblastoma (24) and breast 
cancer cells (25). At the same time cancer cells are strongly dependent on lysosome function and 
are very sensitive to lysosome mediated cell death (1, 26).  
Lastly, it has been demonstrated that lysosomal dysfunction can promote the inclusion of lysosomal 
materials (e.g. proteins) to exosome cargo in order to simplify their elimination from cells (i.e. 
neurons affected by Alzheimer Disease) (27). Exosomes are small vesicles (30-100 nm in diameter) 
 
CHARACTERISTICS AND FUNCTIONS OF LYSOSOMES 
Lysosomes are eukaryotic acidic organelles originally thought to be exclusively involved in the 
degradation of intracellular and extracellular macromolecules into building blocks available for the 
cells. Lysosomes have only recently been recognized as crucial regulators of cell homeostasis and 
there is accumulating evidence of their involvement in different diseases such as neurodegenerative 
disorders, cardiovascular diseases and cancer (1, 2). Lysosomes are single membrane cytoplasmic 
organelles present in almost all eukaryotic cells. They exert several functions in the regulation of 
cell homeostasis including lysosomal exocytosis, cholesterol homeostasis and, possibly more 
importantly, the degradation of macromolecules, such as lipids, nucleic acids and proteins. This is 
achieved through the action of several hydrolases (more than 50 different lysosomal hydrolases 
have been described so far), among which cathepsins (proteases targeting either cysteine or aspartic 
residues) occupy a prominent place (3, 4). In particular, degradation of intracellular material is 
generally obtained via different forms of autophagy, whereas degradation of exogenous material 
occurs via endocytosis (1).  
In the mid-twentieth century, de Duve referred to lysosomes as “suicide bags” because of the 
important role of these organelles in cell death signaling (5). Indeed, lysosomes are implicated in 
three main distinct pathways of cell death: apoptosis, necrosis and autophagy (6). However, the 
recognition of autophagy as a cell death mechanism is still controversial, being a process aimed at 
survival during stress conditions that can also result is cell death (7). Specifically, the autophagic 
process (sometimes reported as type II programmed cell death) represents an evolutionarily well-
conserved pathway where entire organelles or part of cytoplasm are recycled as a response to 
starvation or to remove damaged organelles. This multi-step process is mediated through the 
formation of the so-called autophagosome, a double-membrane vesicle that subsequently will fuse 
with the lysosomes forming the autolysosome for the final degradation step (8). Lysosomes are the 
most critical components for a proper clearance of matured autophagosomes, which for instance can 
cause neurodegenerative disorders in case they accumulate as a result of not being properly 
digested. Alternatively, the phenomenon of lysosomal permeabilization and the consequent release 
of proteolytic enzymes into the cytosol has been globally recognized as “lysosomal pathway for 
apoptosis”. In this process lysosomes are not just passive bystanders, but rather play an active role 
that is tightly regulated. The factor considered a key determinant in the sort of cell death triggered 
by lysosomal enzymes, and precisely apoptosis vs. necrosis, is believed to be represented by the 
magnitude of lysosomal permeabilization, namely the amount of proteolytic enzymes released into 
the cytosol (9). A complete collapse of the organelle itself with the release of high levels of 
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lytic granules and the immune mediated destruction. Similarly, both LAMP1 and LAMP2 
expression has been associated to the ability of leukocytes to adhere to endothelium and migrate, 
therefore favoring the migration of cancer cells too (64). 
LAMP1 over-expression can also influence cancer progression from its normal localization inside 
the lysosomal membrane. In particular, increased expression of LAMP1 can influence lysosomal 
biogenesis and cancer cell viability: its knockdown in acute myeloid leukemia (AML) cells leads to 
diminished cancer cell viability through lysosome disruption(65). LAMP1 abnormal expression in 
the lysosomal membrane can also promote drug resistance by increasing lysosomal size and 
lysosomal exocytosis in rhabdomyosarcoma, soft tissue sarcomas, renal and colorectal cancers. This 
ultimately leads to drug sequestration into lysosomes and drug release via exocytosis, thereby 
causing drug resistance (66, 67). An increased lysosomal exocytosis is also responsible for an 
increased invasiveness of aggressive soft tissue sarcomas (68). However, a reduced expression of 
LAMP1 and LAMP2 have been reported in ovarian carcinoma cells resistant to cisplatin, 
suggesting that their role in drug resistance could either be drug specific or cancer cell type specific 
(69). Tissue and type specificity effect of LAMP1, could also explain some conflicting evidence 
regarding the tumor suppressing role of LAMP1 reported in pancreatic carcinoma and ovarian 
carcinoma cells exposed to ascites. Indeed, LAMP1 expression correlates with prolonged survival 
in pancreatic carcinoma, whereas ascites-mediated up-regulation of LAMP1 expression in ovarian 
carcinoma cells is responsible for a decreased cancer cell migration (70, 71).  
LAMP1 increased expression could be driven by the activation of specific cancer signaling 
pathways (such as STAT3, ETS1 and p65) or could be a result of a genetic amplification like in 
chronic lymphocytic leukemia and in a number of p53 null and basal-like breast cancers (ENCODE 
database (72, 73)). In the latter case, LAMP1 was seen to be over-expressed compared to normal 
mammary epithelium as a result of gene amplification, but this phenomenon was not correlating 
with patient survival (72, 73). Differently, a homozygous deletion within LAMP1 gene has been 
found in some cases of gastric carcinoma, thereby confirming again the opposing roles of LAMP1 
in cancer progression (74). 
LAMP1 is also commonly found expressed on the membrane of exosomes secreted by different 
types of tumors (28, 75). The exact role for LAMP1 expression on secreted exosomes is still 
unknown, however it could be involved in the different effects of exosomes on immune system by 
either promoting cancer antigens recognition or inducing immune tolerance to cancer cells (75, 76).  
LAMP2 has fewer reports on its involvement in cancer progression respect to LAMP1, but similarly 
to it, some contradictory functions are also reported. LAMP2 may regulate migration of ovarian 
increased expression of LAMP2 on the plasma membrane serving as protective shield (49). In 
addition to protection, LAMP1 and LAMP2 expression on the plasma membrane provide binding to 
E-selectin through sialyl-Lex residues and binding to galectin-3 through poly-N-acetyl-lactosamine 
(polyLacNAc)-substituted β1,6 branched N-glycans. Thereby, LAMP1 and LAMP2 are promoting 
both the adhesion of cancer cells to extracellular matrix, basement membrane and endothelium and 
the migratory potential of cells during metastasis (45, 50). Both LAMP1 and LAMP2 can also be 
modified by the alpha1,2-fucosyltransferases enzyme FUT1, which works by adding a fucose 
molecule to N-acetylglucosamine via α1,3-linkage and generates Lewis Y (LeY) antigens. The 
presence of these modified LeY termini on LAMP1 is increased in breast cancer cells with respect 
to the normal mammary counterpart and it has been associated with breast cancer cell migration 
(51, 52). The presence of this modification on both LAMP1 and LAMP2 is able to influence the 
localization of lysosomes and the autophagic flux, since FUT1 down-regulation has been 
demonstrated to lead to an accumulation of lysosomes to perinuclear regions and to correlate with 
increased autophagy and decreased mTORC1 activity (52).  
Despite the high expression of both LAMP1 and LAMP2 on the surface of some types of invasive 
cancer cells, it has been demonstrated that only the surface translocation of LAMP1, but not 
LAMP2, is correlating with the metastatic potential of melanoma, non-small cell lung cancer 
(NSCLC) and laryngeal squamous cell carcinoma (LSCC) (50, 53). One well described mechanism 
responsible for the LAMP1-mediated invasion in melanoma cells is caused by the high expression 
of polyLacNAc bound to LAMP1 which activates ERK and p38 pathway, thus leading to the 
secretion of matrix-metallo-protease-9 (MMP-9) and the consequent ECM remodeling (54). In 
other types of cancer, specifically glioblastoma, pancreatic and ovarian cancer, LAMP1 expression 
on the cell surface plays a role during early phases of cancer progression rather than in the 
metastatic process, thus suggesting different LAMP1 functions depending on the cancer type (55-
57). In these cases, the exact mechanism for LAMP1 tumor promoting role is still poorly studied, 
but there are data reporting a regulation of EGF pathway in some serous ovarian malignancies (56). 
Probably, LAMP1 when expressed on the plasma membrane can shape growth factor signaling, 
thereby modulating cancer development at various stages.   
LAMP1 expression on the cell surface is commonly found also in some types of immune cells, such 
as natural killer cells (NK cells) and T cells, where is commonly used as a marker for degranulation 
and active cytotoxicity (Figure 3) (58-63). In particular, in NK cells LAMP1 is necessary for an 
efficient expression of perforin in lytic granules, and at the same time to protect NK cells from 
damages during the cytotoxic granules exocytosis (60, 61). LAMP1 expression on cancer cells 
could possibly recapitulate the role carried out in immune cells, thus protecting cancer cells from 
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specific manner and can exert opposing functions (34, 35). Specifically, the LAMP-2A isoform is 
recognized to be responsible for chaperone-mediated autophagy (CMA), a process that targets 
specific proteins to degradation into the lysosomes via recognition of a definite motif within their 
amino acids sequence, and its loss is associated with the formation of α-synuclein-positive 
aggregates in Parkinson's disease (36). The LAMP-2B isoform is not involved in CMA, but 
mutations in its specific exon (exon 9) have been found in patients bearing a defective fusion 
process between lysosomes and autophagosomes, thus suggesting a function for this isoform in 
macroautophagy (37). Conversely, LAMP-2C has been demonstrated to act as an inhibitor of 
chaperone-mediated autophagy particularly in B cells and to be capable of mediating nucleic acids 
autophagy by binding to RNA and DNA (38, 39). Many different mutations have been found in 
LAMP2 gene and are causative of Danon disease, a severe condition characterized by skeletal and 
cardiac myopathy and cognitive impairment (40-42). Recently, it has been found that specifically 
the loss of the LAMP-2B isoform could represent the phenotypic leading cause of Danon disease, 
probably given its putative role in macroautophagy (43). A similar phenotype to Danon disease is 
recapped in LAMP2 knockout mice, whereas LAMP1 single knockout mice are viable and fertile 
and double LAMP1 and LAMP2 knockout mice show embryonic lethality, suggesting that these 
two proteins play key and partially overlapping functions in cellular homeostasis (30). Recently, 
LAMP2 deficiency has been also associated to pancreatitis, thereby strengthening the importance of 
a correct lysosomal/autophagic compartment and its associated proteins for cell homeostasis (44).  
Growing evidence of a role for lysosomes in different diseases has raised the interest in deciphering 
the role of LAMP1 and LAMP2 in cancer progression (examples for the roles of LAMP1 and 
LAMP2 in cancer are presented in Tables 1 and 2 and in Figures 2, 6). LAMP1 and LAMP2 
reported roles as pro-invasive and pro-metastatic factors refer to their abnormal localization to the 
plasma membrane of cancer cells, mainly in metastasizing human melanoma A2058 cells, human 
colon carcinoma CaCo-2 cells and human fibrosarcoma HT1080 cells (45). There is still no clear 
explanation on the way LAMP1 and LAMP2 translocate to plasma membrane but, possibly, this 
could be the result of a plasma membrane damage leading to lysosome fusion and exocytosis as a 
membrane repair mechanism (46). It has been proposed that Rab3a-dependent complex or the 
tumor protein D52 could possibly mediate the LAMP1 and LAMP2 trafficking to the plasma 
membrane (47, 48). It was shown in vitro that the translocation of LAMP2 could be driven by an 
acidic microenvironment, which possibly support the idea of the plasma membrane damage 
recruiting lysosomes and lysosomal associated membrane proteins to the plasma membrane (49). 
Specifically, in the early phases of in situ breast carcinoma progression, glycolytic metabolism and 
the absence of vascularization are generating an acidic microenvironment, which results in an 
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derived from the endosomal system that can be released from the cells and represent critical 
structures for different types of cellular communication (immune responses for instance)(28). 
Initially it was thought that the fusion of exosomes with lysosomes would serve exclusively for the 
removal of unnecessary exosomal materials (29), however, since exosome materials can be shuttled 
to neighboring or even distant cells, secretion of unwanted material to the extracellular environment 
within exosomes may have either positive or negative effects on surrounding cells. Therefore, also 
the interplay between exosomes and lysosomes may represent a novel layer of exploration for 
different pathologies including cancer. 
This review focuses on the role of a specific family of highly glycosylated membrane proteins 
usually found within lysosomal membranes known as lysosomal associated membrane proteins 
(LAMPs) and their involvement in cancer.  
LAMP FAMILY OF LYSOSOMAL PROTEINS 
LAMP family is characterized by an evolutionary conserved membrane-proximal LAMP domain, 
composed by around 200 amino acids and containing several conserved cysteine residues, which 
allow for the formation of two critical disulfide bonds (30). Other common features in the family 
are represented by i) a specific proline and two glycine residues in their single transmembrane 
region (30), ii) the presence of several N-linked glycosylation sites within their luminal domain (31) 
and iii) a short cytoplasmic tail harboring an endosomal and lysosomal sorting signal (32) (Figure 
1). 
LAMP family is composed of 5 known members: LAMP1/CD107a, LAMP2/CD107b, 
LAMP3/DC-LAMP, LAMP4/Macrosialin/CD68 and LAMP5/BAD-LAMP. LAMP1 and LAMP2 
are ubiquitously expressed in human tissues and cell lines, whereas LAMP3, CD68 and BAD-
LAMP are cell-type specific proteins. LAMPs are involved in a variety of cellular processes 
including phagocytosis, autophagy, lipid transport and aging (30); moreover, growing evidence 
suggests an important role for LAMP family members in cancer (Tables 1-5 and Figure 5). 
 
LAMP1 AND LAMP2  
LAMP1 and LAMP2 represent the major constituents of the lysosomal membrane, are classified as 
type I transmembrane proteins, share similar length and 37% amino acid sequence homology (30, 
33). Their structure is characterized by a highly glycosylated luminal region forming a glycoprotein 
layer in the lysosomal lumen, a transmembrane region and a C-terminal short cytosolic domain 
(Figure 1). LAMP1 has only one transcript, whereas LAMP2 presents three different splicing 
isoforms: LAMP2A, LAMP2B and LAMP2C (30, 33). LAMP2 isoforms are expressed in a tissue 
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LAMP3 has also been implicated in drug resistance; in particular, up-regulation of LAMP3 has 
been associated with resistance to chemotherapy and radiotherapy in breast cancer (112, 114), and 
its down-regulation could increase cisplatin sensitivity in prostate cancer cells (115). LAMP3 
expression could decrease the sensitivity of cancer cells to chemotherapy by modulating autophagy, 
whose ability to influence drug resistance has been extensively studied (116). LAMP3-mediated 
radiotherapy resistance was conversely attributed to its ability to positively regulate the DNA 
damage repair signaling response (114). 
Furthermore, Bisio A. and colleagues observed the synergistic induction of LAMP3, among a 
subset of genes, upon combined treatment with the chemotherapeutic drug Doxorubicin and the 
inflammatory cytokine TNF-α in breast cancer cells, suggesting a possible involvement of LAMP3 
in cancer related inflammation (117). 
Given that LAMP3 is highly expressed in DCs, it is essential to distinguish between its contribution 
to cancer when expressed by cancer cells or by dendritic cells infiltrating the tumor. For example, it 
has been observed that infiltration of LAMP3+ DCs in the sentinel lymph nodes of melanoma 
patients was correlated with the absence of metastasis in downstream lymph nodes (118). 
 
CD68/Macrosialin/LAMP4 
CD68, the human homologue to murine Macrosialin, is a heavily glycosylated transmembrane 
glycoprotein mainly localized in the endosomal/lysosomal compartment of macrophages showing a 
distinctive structure corresponding to the LAMP signature, with highest homology to LAMP3 (119, 
120). Similarly to LAMP3, CD68 contains only a single LAMP-like domain and a mucin-like 
domain (Figure 1)	(119); but, unlike LAMP3, which is mainly located within lysosomes, CD68 is 
rather found in endosomes and can rapidly shuttle to the plasma membrane (121).  
CD68 has been extensively used as a histological marker of macrophage lineage cells, since it is 
preferentially expressed by resident macrophages of multiple tissues, including macroglia in the 
brain, Kupffer cells in the liver and bone marrow macrophages (122-124). Although initially 
classified as a group D scavenger receptor due to its ability to bind oxidized low density 
lipoproteins (OxLDL) (125), CD68 silencing and knock-out experiments failed to affect OxLDL 
binding and uptake to macrophages (126, 127).  Beyond the use of CD68 as histological marker to 
identify macrophages, the apparent specificity of the expression of CD68 has proposed the use of 
CD68 transcriptional regulatory sequences to specifically drive in vitro and in vivo transgene 
expression, as well as for gene therapy approaches (89, 128, 129). However, recent studies show 
that a high expression of CD68 is not limited to macrophage cell lineage, but is observed also in 
other hematopoietic and non-hematopoietic cells (130, 131); therefore, CD68 should be considered 
also induced in an interferon-dependent way upon influenza A and hepatitis C virus infection and 
may play a role in the regulation of virus replication and infection at the post-entry stages (102, 
103). 
Growing evidence has shown that LAMP3 is over-expressed in various human tumors, where it 
correlates with poor prognosis (LAMP3 functions in cancer are summarized in Table 3 and Figures 
4, 6) (104, 105). Some recent studies revealed that LAMP3 might be important in tumor metastasis 
and resistance to therapies, suggesting LAMP3 as a molecular marker for the prognosis of various 
cancers (106, 107). Indeed, LAMP3 has been shown to be expressed at higher levels in several 
primary cancers compared to normal tissues, including cancers of the esophagus, colon, fallopian 
tube, ovary, uterus breast, and liver (90, 108). Moreover, the region 3q27, where LAMP3 gene is 
located, is often amplified in various types of cancers, in particular squamous cell carcinomas and 
penile carcinomas (109).		
LAMP3 over-expression into uterine cervical cancer cell lines is able to promote metastasis in vitro 
and in vivo (106), and its expression has been associated with lymph node metastasis (104),	(110)	
and increased migration in breast cancer cells	(95), suggesting a role for LAMP3 in the metastatic 
process (106). The mechanism employed by cancer cells to favor metastasis has not yet been 
completely elucidated; however, similarly to LAMP1 and LAMP2, its exposure on the plasma 
membrane could allow cancer cells to interact with endothelial cells. Nevertheless, LAMP3 
expression on the cellular plasma membrane could be detected only in specific circumstances on 
cancer cells, such as upon Influenza A virus infections in HeLa cells (102), whereas it could not be 
detected on the plasma membrane of other cancer cell lines, as MDA-MB-231 (95). Another 
possible mechanism by which LAMP3 expression can increase the metastatic potential of cancer 
cells is through the modulation of the autophagic flux, which is known to play key roles in cancer 
metastasis (111). Particularly, the cytoplasmic tail of LAMP3 seems to be required for the fusion of 
the autophagosome with the lysosome (i.e. maturation step), a process inhibited in LAMP3 
knockdown cancer cells (112). 
LAMP3 expression was also correlated with poor overall survival in head and neck squamous cell 
carcinomas (107, 108), uterine cervical cancer (106), gastric and colorectal cancers (105), whereas 
its expression levels, together with other pneumocyte-specific genes expression, has been associated 
with increased survival in the adenocarcinoma subgroup of non-small cell lung cancer (NSCLC) 
cohorts (113). These conflicting data could be due to the high levels of LAMP3 expression in lung 
normal tissue, where LAMP3 could play a specific role that could be compromised during cancer 
development. 
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compartment, belongs to the tetraspanin family	(88). In this review, we always refer to LAMP3 as 
the member of the LAMP family. 
LAMP3 is also called DC-LAMP, because it was firstly shown to be induced progressively upon 
maturation of human dendritic cells (DCs), where it transiently co-localizes with MHC class II 
molecules at the limiting membrane of specific intracellular compartments (i.e. MHC class II 
compartment, MIIC), and is thus considered as a marker of mature DCs in humans(89).  
In the same year of this observation, Ozaki and coworkers independently characterized LAMP3 as a 
gene specifically expressed in lung tissue, designated as TSC403 transcript(90). Indeed, LAMP3 is 
also highly expressed in another specific cell-type in mammals, normal and transformed type II 
pneumocytes (PnIIs)(91), which are pulmonary specialized cells important for the repopulation of 
lung tissue during normal homeostasis and injury, and responsible for surfactant synthesis, secretion 
and recycling (92, 93).  
The trend of LAMP3 expression in time and space is significantly different between human DCs 
and type II pneumocytes. Indeed, LAMP3 is transiently expressed in the MIIC compartment 
(responsible for the exposure of MHC class II/peptide complexes on the plasma membrane) during 
DCs’ maturation and then it accumulates in perinuclear lysosomes without localizing to the plasma 
membrane (89). Conversely, LAMP3 is constitutively expressed at the limiting membrane of PnII 
lamellar bodies (responsible for secretion of surfactant proteins, and also containing MHC class II 
molecules), and low levels of the protein could also be detected at the cell surface membrane in 
these cells	(91). Functional similarity between MIIC in DCs and lamellar bodies in PnIIs suggests a 
possible role for LAMP3 in the regulation of the exocytosis of these lysosomes, and particularly in 
MHC class II-restricted antigen presentation, which is a characteristic of both mature DCs and PnIIs 
(94). 
LAMP3 expression is induced by the unfolded protein response (UPR) activated by hypoxia 
condition (95) and this induction is mediated by the PERK/eIF2α arm of UPR (96). Further, 
proteasome inhibition induces LAMP3 expression in an ATF4 (a UPR transcription factor)-
dependent manner. Increased expression of LAMP3 is able to trigger autophagy, whereas 
preventing LAMP3 induction enhanced apoptotic cell death, thereby demonstrating that LAMP3 
regulation is important for proteasomal degradation and cell survival during proteasome 
dysfunction (97). Furthermore, a recent meta-analysis of genome-wide association studies in 
Parkinson disease has identified MCCC1/LAMP3 genetic locus associated with Parkinson disease 
risk (98, 99) 
LAMP3 expression is also driven by IFN-α during dendritic cells maturation(100), and it has been 
shown to regulate the expression of antiviral genes in cervical cancer (101). LAMP3 expression is 
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clear cell adenocarcinoma possibly through ANXA4 (Annexin A4), whose knockout in OVISE cell 
line resulted in a reduced expression of LAMP2 and it was associated with a loss of migration and 
invasion capability (77). LAMP2 is also highly expressed in poorly differentiated human gastric 
adenocarcinoma, hepatocellular carcinoma, salivary adenoid cystic carcinoma compared to normal 
tissues and in broncho-alveolar lavage fluid of patients with lung adenocarcinoma, representing one 
novel molecular marker for these cancer types (78, 79). It may be involved in the pathogenesis of 
multiple myeloma patients positive for a specific translocation BCL1/JH t(11;14)(q13;q32) and, 
therefore, used as a prognostic markers or therapeutic target (80).  
The specific LAMP2A isoform showed an increased expression in breast tumor tissues and a 
prognostic value in non-small cell lung cancer; indeed, LAMP2A inhibition or genetic knockdown  
resulted in the sensitization of tumor cells to doxorubicin and radiation therapy (81-83). Another 
important role reported for LAMP2A isoform in cancer refers to its involvement in immunogenic 
cell death, a type of apoptosis that stimulates anti-cancer immune response (84). In particular, 
LAMP2A isoform can induce the expression of calreticulin and the secretion of ATP upon 
mitoxantrone and hypericin-based photodynamic therapy, thus leading to immunogenic cell death, 
thereby suggesting opposing roles for this isoform in cancer (84).  
Another reported tumor suppressor role for LAMP2 stands on its ability to induce cell death upon 
depletion of the VEGF-NRP2 axis in prostate cancer cells. The up-regulation of LAMP2 and 
WDFY1 resulting from autophagy blockade caused by VEGF-NRP2 axis inhibition leads to 
increased cell death (85). Similar oncosuppressive effects have been observed in neuroblastoma 
cells cultured under hyperoxia, which causes up-regulation of LAMP2 and LC3-II, macro-
autophagy and ultimately induces apoptosis (86). A protective role of LAMP2 in drug resistance 
has been reported in lung cancer, where it is directly targeted by miR-487b-5p, a microRNA often 
found over-expressed in Temozolomide resistant lung cancer cells(87). 
LAMP2 is often found expressed on the membrane of exosomes secreted from immune cells but its 
role is still largely unknown; however, there could be a possible role for both LAMP1 and LAMP2 
exosomal expression in shaping immune system response (Figure 3)	(28).  
 
LAMP3/DC-LAMP 
Lysosomal-associated membrane protein 3 (LAMP3) is a 44 kDa protein and, unlike LAMP1 and 
LAMP2, which are ubiquitously expressed, LAMP3 is expressed only in specific conditions and 
tissues. To avoid ambiguity, it is worth noting that LAMP3 gene/protein name can be also wrongly 
referred to CD63, which, despite being a protein enriched in late endosomal and lysosomal 
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responses. Furthermore, a better understanding of LAMP1 role in cancer-derived exosomes and its 
effects on immune system is of paramount importance, also for future applications of exosomes in 
cancer immunotherapy. 
The other members of LAMP family are not extensively studied yet, but there is growing evidence 
supporting their pro-tumorigenic potential. For instance, LAMP3 and CD68, which are activated by 
various stimuli often present during cancer development and therapy, and are closely connected 
with inflammation, represent additional promising targets for cancer therapy. The mechanisms by 
which LAMP3 and CD68 expression can affect tumor progression is still to be elucidated, however, 
a possible explanation could be inferred from its role in the trafficking of MHC class II/peptide 
complexes (158), which is critical for antitumor immune response (159).  
Interestingly, LAMP3, CD68 and BAD-LAMP are highly expressed in immune cells and have 
shown to be associated with various types of tumors, either when expressed on immune or cancer 
cells. Therefore, it would be intriguing to investigate their role at the interplay between cancer and 
the immune system and to elucidate whether they could play a direct role in the immune response to 
cancer.  
In conclusion, a better knowledge of LAMP family and lysosomal role in cancer progression could 
represent a fruitful approach in cancer research. 
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factor able to address the GABA transporter (UNC-47) to the synaptic vesicles(154). In humans, 
like in mice, BAD-LAMP is expressed at higher levels in the brain, but, among blood cells, it is 
also specifically expressed in the type I IFN-producing primary plasmacytoid dendritic cells (pDCs) 
and transformed pDCs (blastic plasmacytoid dendritic cell neoplasms or BPDCNs), for which it 
represents a relevant biomarker (155). In these cells, BAD-LAMP is principally localized in the 
ER-Golgi intermediate compartment (ERGIC) and its expression is lost upon pDC activation by 
Toll-like Receptor (TLR) ligands (155).  
A second observation for an association between this poorly studied protein and cancer comes from 
the analysis of the expression of a set of genes, including BAD-LAMP, which has been shown to be 
correlated with a poor prognosis in stage II gastric cancer patients treated with chemo-radiotherapy 
(Table 5 and Figure 6) (156); however, it is not clear whether BAD-LAMP expression observed in 
the analyzed tissues is determined by pDCs infiltration within the tumor or by a higher expression 
of the protein in cancer cells. Further studies are required to establish the putative role of BAD-
LAMP in cancer. 
 
CONCLUSIONS 
A correct functioning of the lysosomal compartment represents a guarantor for an efficient cell 
homeostasis and a critical protection against various diseases, among them cancer. Differential 
expression of proteins associated with the lysosomal membrane, categorized as LAMP family 
members, can substantially influence various processes of cancer progression. This review 
inspected the various LAMP proteins and their reported roles in oncogenic processes, with 
conflicting evidence for some of the members.  
LAMP1 represents the most studied member of the family and together with LAMP2 is involved in 
various oncogenic processes, such as local cancer progression, ECM adhesion and remodeling, 
migration, drug resistance and metastasis. The strong potential of LAMP1 in cancer therapy 
encouraged the Sanofi S.A. pharmaceutical company to patent anti-LAMP1 antibodies and 
immunoconjugates for detection and treatment (patent number: WO2014102299). Furthermore, 
LAMP1 and LAMP2 expression on cancer cell plasma membrane renders them optimal targets for 
immunotherapy approaches. Nevertheless, LAMP1 has important reported roles in immune system, 
thus when planning its targeting by immunotherapies, its crucial to bear in mind the importance of 
specifically target LAMP1 and LAMP2 expressed on cancer cells. A decreased expression of 
LAMP1 in NK cells would reduce their perforin-mediated cytotoxicity, which represents the most 
efficacious NK-mediated cell death (157), thereby potently decreasing the anti-cancer immune 
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Importantly, CD68 association to cancer is not only related to its expression in TAMs, but also in 
tumor cells (131). For example, CD68 was found to be highly expressed in human gliomas by both 
microglia and tumor cells; its expression was associated with malignancy in these tumors, and was 
suggested as prognostic marker of reduced survival in human gliomas (148). This observation is in 
agreement with the fact that malignant tumor cells often express immune cells-markers to evade the 
immune system during the metastatic process, and, most frequently, it has been observed the 
expression of macrophage antigens, such as CD68, CD47, CD163 and DAP12 (149-151). The 
mechanism explaining the expression of macrophage antigens by tumor cells is still debated, and it 
seems to be mediated by genetic exchange either directed by direct macrophage-cancer cell fusion	
(152), or by exosome-mediated transfer (149). CD68 was found to be expressed in mouse 
macrophages-derived	 exosomes (153), thereby supporting the hypothesis that exosomes can 
mediate a genetic exchange between macrophages and cancer cells and, ultimately, it could also 
explain the CD68 expression in cancer cells. 
Although CD68 is widely used as diagnostic and prognostic marker for several malignancies, the 
role of this protein in cancer is still to be explained and further studies investigating its mechanism 
of actions are needed. 
 
BAD-LAMP/LAMP5 
The latest characterized LAMP protein is the C. elegans ortholog of UNC-46, BAD-LAMP (Brain 
and Dendritic Cell associated LAMP-like molecule), also known as LAMP5 or C20orf103. Unlike 
other LAMP family members, BAD-LAMP does not localize to late endosomes or lysosomes and, 
similarly to LAMP3 and CD68, its expression is limited to specific tissues. BAD-LAMP is a 280 aa 
protein with a transmembrane domain and a cytoplasmic tail containing a YKHM sequence, 
corresponding to a classic YXXΦ internalization and endosomal targeting signal. It also contains 
several N-glycosylation sites, as well as four cysteine residues separated by a fixed number of 
amino acids, allowing for the formation of the disulfide bonds required for the “LAMP-fold” 
(Figure 1) (32). 
David and co-workers first identified BAD-LAMP as a new LAMP family member in mice, where 
it is mainly expressed in specific subtypes of cortical projecting neurons. In these cells, BAD-
LAMP expression considerably increased after birth, suggesting its involvement in the late steps of 
neuronal differentiation. BAD-LAMP can be endocytosed and directed to uncharacterized vesicles 
clustered in the growth cone of developing axons or in defined dendritic domains, identified as a 
specific class of early neuronal endosomes(32). In C. elegans, BAD-LAMP ortholog UNC-46 
mutations cause defects in most GABA-mediated behaviors, and it has been proposed as a sorting 
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a non-specific marker of macrophages. 
Though it is unknown a role for CD68 in antigen processing, Song and colleagues observed that 
CD68-/- mononuclear phagocytes showed enhanced capacity of antigen presentation to CD4+ T 
cells, proposing that CD68 may have negative regulatory functions in MHC class II trafficking or 
antigen uptake and loading	(127). Interestingly, CD68 is expressed also in immature dendritic cells, 
and its expression progressively disappears during maturation at the same time as LAMP3 
accumulates in the lysosomes	(89) suggesting a putative competing role in the antigen presentation 
process.  
Immunohistochemical staining of bone specimens has identified CD68 expression in osteoclasts 
(124), which are multi-nucleated cells responsible for bone reabsorption during normal bone 
remodeling or pathological conditions (132), and genetic ablation of CD68 resulted in 
morphological alteration and functional defects in osteoclasts and increased bone in mice (133). 
Importantly, infiltration of CD68-positive cells is a marker for both inflammation and tumor 
progression (presented in Table 4 and Figures 5, 6) (134, 135). A population-based cohort study of 
malignant uveal melanoma observed diffuse infiltration of CD68-positive macrophages in 83% of 
analyzed tumors and the number of macrophages has been associated with largest basal tumor 
diameter (LBD), presence of epithelioid cells and high microvessel density (MVD) in areas of high 
vascularization (135), which represent independent high-risk indicators for metastasis in uveal 
melanoma (135, 136 1996).  
Tumor-associated macrophages (TAMs), for which CD68 represents one of the most recognized 
marker (137), are one of the most abundant population of normal cells in the tumor 
microenvironment and there is accumulating evidence for TAMs’ pivotal role in driving pro-
tumorigenic phenotype. Indeed, density of CD68+ TAMs is increased in poorly differentiated 
thyroid cancers (PDTCs), and high density of these cells correlates with invasion and decreased 
cancer-related survival in these advanced thyroid cancers (138). Furthermore, increased expression 
of CD68+ macrophages in the tumor stroma of triple-negative breast cancer (TNBC) patients after 
surgery and of patients with classic Hodgkin’s lymphoma correlates with poor prognosis (139, 140). 
In contrast, high CD68+ macrophages density correlates with increased overall survival in non-small 
cell lung cancer and esophageal squamous cell carcinoma	(141, 142). However, this discrepancy in 
the predictive power of CD68 for tumor prognosis could be due to several factors, including 
technical variability, specificity of the antibodies, and difference in the case series (143). We have 
reported here few evidence of the role of CD68+ macrophages in tumorigenic processes and we 
refer to other recent reviews for a comprehensive description of the role of TAMs in cancer (144-
147).  
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represents a marker for tumor-associated macrophages, where it can rapidly shuttle between the 
endosomal compartment and the plasma membrane. Recent observations suggest that CD68 may 
also have a negative role in the antigen presentation process. CD68 has recently been found to be 
also expressed by some cancer cells, where it is associated with increased malignancy, possibly 
caused by immune evasion mechanisms. Expression of this immune-cell marker by cancer cells 
could be explained by genetic exchange between macrophages and cancer cells, which is supported 
by the recent detection of CD68 in macrophages-derived exosomes. 
 
Figure 6. LAMP family roles in cancer progression. All the LAMP proteins are involved in 
cancer progression; LAMP1, LAMP2 and LAMP3 are also implicated in migration and stress or 
drug resistance. LAMP1 and LAMP2 also promote ExtraCellular Matrix (ECM) adhesion or 
remodeling whereas LAMP1 and LAMP3 can induce metastasis formation. CD68 is often 
expressed on Tumor Associated Macrophages (TAM).  
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FIGURE LEGENDS 
Figure 1. Structural organization of LAMP family members. Sequential boxes stand for 
domains, small flags indicates glycosylation residues and protein length is also provided for each 
depicted member. SP: signal peptide; LAMP: LAMP domain; H: hinge region; TM: transmembrane 
domain; C: cytoplasmic domain. 
 
Figure 2. LAMP1-LAMP2 subcellular localization and thier roles in cancer. LAMP1 and 
LAMP2 can influence cancer biology in different ways depending on their localization: on the 
plasma membrane they promote adhesion to endothelium and extracellular membrane (ECM), 
migration and metastasis; whereas on the lysosomal membrane they promote drug resistance by 
increasing lysosomal drug sequestration and lysosomal exocytosis. LAMP1 expression on the 
plasma membrane can also play a role in ECM remodeling and invasion, whereas LAMP2 can act 
as a protective shield. LAMP1 is often found expressed in tumor-derived exosomes but its role in 
exosome biology it is still unknown. 
 
Figure 3. LAMP1-LAMP2 subcellular localization and their roles in immune cells. LAMP1 
and LAMP2 in immune cells are acting as activation markers when expressed on the plasma 
membrane and they can promote adhesion to endothelium and migration. LAMP1 specifically has a 
crucial role in the degranulation process, whereas LAMP2 is expressed in immune cancer cells-
derived exosomes. 
 
Figure 4. LAMP3 subcellular localization and its roles in cancer and immune cells. LAMP3 
can localize to different cell compartments and therefore exert different functions. LAMP3 can be 
bound to the lysosomal membrane or to the plasma membrane and regulate migration, metastasis, 
and drug resistance in cancer cells. Moreover, its cytoplasmic tail plays a role in the process of 
fusion of the lysosome with the autophagosome, thereby modulating the autophagic process, which 
can also mediate its pro-tumorigenic functions. LAMP3 is also a marker for mature dendritic cells, 
in which it is progressively expressed during maturation. During this process LAMP3 co-localizes 
with MHC class II molecules (MHCII) within MHC class II compartment (MIIC), suggesting a 
possible role for LAMP3 in antigen presentation process. 
 
Figure 5. CD68 subcellular localization and its roles in cancer and immune cells. CD68 
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Table 5: Summary of cancer-associated functions for BAD-LAMP, LAMP5 [Lysosome Associated Membrane Protein-5], C20orf103
Pro-tumorigenic roles Evidence Strength / Weakness of the Evidence
Associated with poor prognosis (156) BAD-LAMP has been identified (through gene 
expression profiling with microarrays on FFPE 
samples) along with other 7 genes (part of the so 
called ”Gastric Cancer Prognostic Score”, GCPS) 
as high-risk gene for recurrence in 3 different 
cohorts of stage II gastric cancer patients who 
underwent adjuvant chemo-radiotherapy. A 
higher expression of BAD-LAMP was associated 
with poorer prognosis.
The GCPS was validated in more than 700 
stage II GC patients and proposed for the 
routine usage in the clinic. The increased 
BAD-LAMP expression was however 
significantly higher in stromal cells rather than 
in cancer cells, highlighting a more important 
role for BAD-LAMP in the tumor 
microenvironment.
Abbreviations: FFPE, Formalin-Fixed Paraffin-Embedded; GC, Gastric Cancer.
Table 4: Summary of cancer-associated functions for CD68, Macrosialin, LAMP4 [Lysosome Associated Membrane Protein-4]
Pro-tumorigenic 
roles
Evidence Strength / Weakness of the Evidence
Marker for pro-
tumorigenic 
TAMs in 
malignant uveal 
melanoma (135)
CD68+ tumor infiltrating macrophages were identified in 83% of 
malignant uveal melanoma patients (n=167). The abundance of 
CD68+ TAMs was found associated with parameters of known 
poorer prognosis, such as LBD (tumor dimension), heavy 
pigmentation and high MVD (presence of capillaries). Moreover, 
melanoma-specific mortality rate at 10 years from diagnosis was 
enhanced in patients with higher number of CD68+ macrophages.
The evidence regarding the enrichment of CD68+ 
macrophages in uveal melanoma and its association 
with aggressiveness is pretty strong. However, as 
expected from the functions identified so far for CD68 
protein, there is not a direct role for CD68 in cancer 
cells, rather it is relevant its impact on TAMs, where it 
represents one of the most used markers.
Associated with 
TAMs in 
Hodgkin’s 
lymphoma (137; 
140)
CD68 expression in TAMs was analyzed by IHC on tissue 
microarrays from lymph-node of classical Hodgkin’s lymphoma 
(cHL) patients (n=166), including 79 that showed treatment failure. 
CD68+ TAMs-enriched patients showed an at least 8-times lower 
progression-free survival compared to patients with very low 
levels of CD68+ TAMs (<5%) (137). Moreover, CD68 revealed to 
be more effective with respect to the conventional IPS value used 
for cHL samples (137).
In another study on 2 series of advanced cHL patients (n=266 and 
n=103), CD68 was used as macrophage marker in IHC staining 
along with CD163, LYZ and STAT1 (140). CD68 resulted to be the 
only marker associated with clinical features (140). 
At least two different studies from three independent 
patients’ cohorts proved the prognostic value of CD68 
positivity within tumor tissues of cHL patients, 
suggesting the effectiveness and the value of this 
measurement. The relevant drawback of the first 
observation is represented by the reduced number of 
cHL cases with very low levels of CD68+ TAMs and 
low risk patients (137).
Interestingly, the fact that only CD68 staining (among 
TAM markers) was significantly associated with 
clinical parameters, underlies the possibility that CD68 
could be also expressed by cancer cells (see below).
Marker for TAMs 
in advanced 
thyroid cancer 
(138)
CD68 was used as a marker for TAMs in studying thyroid cancers. 
Using tissue microarrays associated with IHC it was observed that 
TAMs density increased with the growing aggressiveness of 
thyroid cancer; specifically, from 27% in WDTC (n=33), to 54% in 
PDTC (n=37) and 95% in ATC (n=20). 
The correlation between CD68 positivity and tumor 
progression (increased grade, invasion property and 
decreased survival) in thyroid cancers is remarkable. 
Marker for TAMs 
in TNBCs (139)
CD68-positive TAMs were found in 71.45% of TNBC-derived 
samples. The increased presence of TAMs correlated with poorer 
prognosis and it was associated with enhanced expression of IL-6 
and CCL-5 diffusible factors.
Another report supporting the association of high 
infiltration of TAMs (measured as CD68 positive cells) 
with cancer progression and poorer prognosis also in 
TNBCs.
Associated to 
poor prognosis 
(148)
CD68 immunostaining was detected from histological sections of 
51 primary astrocytic tumors (11 benign astrocytomas, 40 
malignant tumors) and 8 relapses. CD68 signal was significantly 
higher in malignant tumors compared to benign ones (p=0.036). 
Moreover, a higher staining score for CD68 was associated with a 
poorer prognosis of OS for all the tumors analyzed (p<0.01), with 
a remarkable enrichment for anaplastic astrocytomas (p=0.021). 
CD68 can also be considered a marker for microglia 
and in gliomas the infiltration of macrophages and 
microglia has been established. This is in line with the 
characteristics mentioned above. Notably, here the 
authors show the presence of CD68 also on the 
surface of cancer cells as well as in U87 glioblastoma-
derived cell line.
Abbreviations: TAMs, Tumor-Associated Macrophages; LBD, Largest Basal Diameter; MVD, MicroVascular Density; IPS, International 
Prognostic Score; IHC, ImmunoHistoChemistry; WDTC, Well-Differentiated Thyroid Cancer; PDTC, Poorly Differentiated Thyroid Cancer; ATC, 
Anaplastic Thyroid Cancer; TNBCs, Triple Negative Breast Cancers; OS, Overall Survival.
showed that a stronger LAMP3 signal was associated with worse tumor 
stage (p=0.029), bigger size (p=0.012) and poorer prognosis (HR=5.706).
According to the last report on a cohort of 157 ESCC patients and 50 
uninvolved normal tissues (measuring LAMP3 mRNA levels) and 46 paired 
normal and cancerous tissues (to detect LAMP3 protein by IHC), elevated 
LAMP3 levels were correlated with OS (HR = 1.90) and DFS (HR = 1.80). 
Interestingly, increased expression of LAMP3 in cancer tissues correlated 
well with DNA Copy Number Amplification (observed in 35/50 cases). 
as independent prognostic markers for 
LSCC.
Taken collectively, all these studies, while 
relevant, reported retrospective analyses on 
human samples and the conclusions drawn 
might not apply to the general population. 
Moreover, there was not a direct impact on 
the therapeutic strategy used and the OS.
Resistance to 
hormonal therapy 
(112)
Researchers showed that in MCF7 breast cancer-derived cells the 
silencing of LAMP3 increased the sensitivity to hormonal therapy 
(tamoxifen). This observation was linked to the activation of autophagy, a 
process that was associated with tamoxifen resistance. Indeed, tamoxifen 
was able to induce LAMP3 mRNA levels, thus leading to breast cancer 
cells resistance. Interestingly, tamoxifen-resistant MCF7 cells showed 
LAMP3 mRNA levels 7-fold higher than tamoxifen-sensitive counterparts. 
Remarkably, high LAMP3 expression was found in advanced breast cancer 
patients with shorter progression-free survival (p=0.003) and post-relapse 
overall survival (p=0.040) that were treated with tamoxifen. 
Notably, the inhibition of autophagic process 
by silencing of associated genes such as 
MAP1LC3B, ATG5, and BECN1 resulted in 
an enhanced sensitivity to tamoxifen, 
suggesting that the impact of LAMP3 in 
autophagy is the crucial step to achieve 
tamoxifen resistance.
LAMP3 inhibition may be clinically relevant 
to hinder tamoxifen resistance in breast 
cancer.
Resistance to 
radiation therapy 
(114)
Silencing of LAMP3 (along with PERK and ATF4, other two members of the 
UPR during hypoxia) revealed to be able to sensitize MDA-MB-231 breast 
cancer cells to radiation therapy. This result seemed to be related to an 
attenuated DNA damage response during irradiation when LAMP3 was 
down-regulated by siRNA (measured by the quantification of γ-H2AX foci). 
Therefore, resistance to radiotherapy can be driven by up-regulation of 
LAMP3 (and PERK and ATF4) through UPR pathway and relies on an 
increase of DNA repair process. The effect was more evident with MDA-
MB-231 cells compared to MCF7 cells, another breast cancer-derived 
model that express wild-type p53. This could suggest that the presence of 
functional p53 may reduce the effectiveness of LAMP3 knock-down.
The specific mechanism underlying the 
LAMP3-dependent radio-resistance was not 
completely elucidated and can rely on 
autophagy,as shown for resistance to 
hormonal therapy. There are other pieces of 
evidence that MDA-MB-231 cells (but not 
others such as HCT116) can be sensitized 
by the treatment with the autophagy inhibitor 
chloroquine. Thus, these effects may be 
cancer type-dependent.
Resistance to 
chemotherapy 
(115)
Researchers proposed LAMP3 as a direct target of miR-205, a miRNA 
down-regulated during the EMT process in prostate cancer. miR-205 
impaired autophagy through levels reduction of the lysosome-associated 
proteins LAMP3 and RAB27A, thus enhancing the cytotoxic effects of 
cisplatin in prostate cancer cells. Similar effects were seen with the 
silencing of LAMP3 with synthetic oligonucleotides, confirming the putative 
role of LAMP3 expression in the resistance to cisplatin.
The researchers based the effects on 
LAMP3 via in silico predictions and indirect 
measurements, but they did not provide any 
direct evidence of miR-205 binding to 
LAMP3 mRNA.
Furthermore, while it is well established that 
miR-205 is repressed or lost in prostate 
cancer patients, the expression of LAMP3 in 
the same patients has not been evaluated.
Abbreviations: LSCC, Laryngeal Squamous Cell Carcinoma; ER, Estrogen Receptor; PR, Progesteron Receptor; IHC, ImmunoHistoChemistry; 
HNSCC, Head and Neck Squamous Cell Carcinoma; TMA, Tissue MicroArray; HR, Hazard Ratio; ESCC, Esophageal Squamous Cell 
Carcinoma; OS, Overall Survival; Disease-Free Survival; UPR, Unfolded Protein Response; EMT, Epithelial-to-Mesenchymal Transition.
Table 3: Summary of cancer-associated function for LAMP3 [Lysosome Associated Membrane Protein-3], DC-LAMP
Pro-tumorigenic 
roles
Evidence Strength / Weakness of the Evidence
Metastasis 
induction (106; 
95; 112)
Researchers demonstrated that upon ectopic over-expression of LAMP3 in 
a uterine cervical cancer cell line (TCS), cancer cells acquired a higher 
migratory potential (106). Moreover, in SCID mice 82% (9/11) of injected 
LAMP3 over-expressing TSC cells efficiently generated metastases 
(prevalently to liver and lung) compared to 9% (1/11) of controls (106). 
LAMP3 detection by RT-qPCR and IHC in lymph node metastases from 
cervical carcinoma patients revealed that distant metastasis formation was 
associated with a higher expression of LAMP3 higher levels (106).
In another study (95), an increased migration potential of breast cancer-
derived cells correlated with higher basal LAMP3 expression levels. 
Furthermore, LAMP3 knock-down resulted in a decreased migration 
potential of MDA-MB-231 cells after exposure to 1% O2. Moreover, MDA-
MB-231-derived spheroids showed reduced migratory properties and a 
lower invasion into collagen when depleted of LAMP3 (95).
Lastly, breast cancer patients with soft tissue metastases showed higher 
LAMP3 mRNA expression compared with ones with non-soft tissue or bone 
metastases (p=0.034) (112).
Results obtained in vitro are also supported 
by in vivo experiments. However, these 
results were based on over-expression 
experiments and therefore rely on excessive 
expression levels; thus they need to be 
further validated. Consequently, data were 
also confirmed by analyses on human 
patient samples (106). 
A stronger migration potential of LAMP3 
expressing cells was also found in breast 
cancer-derived cell lines and spheroids, 
structures that represent a more physiologic 
model of the disease (95).
Lymph node 
metastasis (104; 
110)
Despite the variability among samples, high level of LAMP3 mRNA was 
found in lymph node-positive breast cancer patients (n=183; p=0.019) and 
ER/PR-negative tumors (p<0.001) (104). Notably, loco-regional 
recurrences were found more frequently in breast cancer patients with high 
LAMP3 mRNA levels (p=0.032 log-rank) that underwent lumpectomy and 
treated with radiotherapy (p=0.009) (104).
Another report showed that by IHC staining from HNSCC patient biopsies, 
high expression of LAMP3 was restricted to normoxic regions of tumors 
and correlated with the occurrence of lymph node metastasis (110). 
Moreover, a worse metastasis-free survival was observed in patients 
showing higher levels of LAMP3 (110). 
These data underline the relevant role of 
LAMP3 in tumor progression and metastatic 
spread processes, also in patient-derived 
samples both from breast cancers (104) and 
HNSCC (110).
Surprisingly, the same group reported the 
controversial observation that while LAMP3 
expression is associated with hypoxic 
regions in breast cancer tumors (104), it is 
limited to normoxic regions in HNSCC (110). 
Poor overall 
survival of 
patients
(105; 106; 107; 
108)
Through IHC on TMA from gastric (n=750) and colorectal (n=479) cancer 
patients, LAMP3 expression was found significantly higher in cancer 
tissues in respect to normal or benign tissues. In both cancer types, there 
was a significant association between high LAMP3 levels and tumor stage 
and a poorer overall survival, respectively with a remarkable HR of 2.8 and 
2.9, also confirmed with multivariate analysis (HR=2.8 and 2.6).
In a second study conducted on patients with stage I or stage II uterine 
cervical cancers, who underwent radical hysterectomy (n=24), high LAMP3 
mRNA levels were associated with a poorer prognosis and higher mortality.
In another work, IHC analysis using TMA from LSCC patients (n=117) 
The association between high LAMP3 levels 
and clinical features and OS of gastric as 
well as colorectal cancer patients is 
remarkable.
The relevance of the results from the second 
study is limited by the reduced number of 
patients. 
A significant correlation between LAMP3 and 
TP53 expression was shown in LSCC, even 
if the authors considered LAMP3 and TP53 
Table 2: Summary of cancer-associated functions for LAMP2 [Lysosome Associated Membrane Protein-2]
Pro-tumorigenic 
roles
Evidence Strength / Weakness of the Evidence
Cancer pathogenesis 
(78; 80) 
Increased LAMP2 protein expression was reported in 
poorly differentiated human gastric adenocarcinoma with 
respect to adjacent gastric mucosal tissues (78). LAMP2 
gene is located in a region involved in BCL1/JH t(11;14) 
(q13;q32) translocation found in multiple myeloma 
patients (80). 
LAMP2 protein expression increase was used as a proxy for 
autophagy-lysosome signaling with no clear indications on 
its specific role in the signaling. There are conflicting data 
regarding the role of autophagy-lysosome circuitry in cancer 
pathogenesis (78). Functional studies supporting the 
pathogenic significance of LAMP2 in multiple myeloma are 
still missing (80). 
Cancer cell migration 
(52; 77) 
LAMP2 modification by FUT1 was reported to be able to 
control localization of lysosomes, which often shift from 
perinuclear to peripheral compartment in invasive cancer 
(52). LAMP2 protein expression was highly expressed in 
the invasive OVISE human ovarian clear cell 
adenocarcinoma cells, and ANXA4 knock-out decreased 
LAMP2 protein expression and migration (77). 
LAMP2 is not directly involved in the regulation of migration, 
but rather its modification by FUT1 plays a more important 
role (52). 
A direct LAMP2 knock-out experiment is needed to confirm 
its possible direct involvement in ovarian cancer cells 
migration (77). 
Support early cancer 
growth (49) 
LAMP2 expression on the plasma membrane supported 
early breast cancer progression by acting as a protective 
shield against the acidic extracellular microenvironment. 
The relevance for a LAMP2 role in survival within an acidic 
microenvironment was supported by strong data from both 
breast cancer cell lines and patients. The exact molecular 
mechanisms involved in LAMP2 protective action were not 
addressed in the reported study and are not discovered yet. 
Adhesion of cancer 
cells to ECM, 
basement membrane 
and endothelium (45) 
LAMP2 was observed by flow cytometry on the cell 
surface of A2058, HT1080 (human fibrosarcoma) and 
CaCo-2 (human colon adenocarcinoma) cells and their 
interaction with Galectin-3 was reported. 
Data are supported by previous studies but the fact that 
modifications of LAMP2 rather than their expression are 
reported as causal link with ECM adhesion diminishes the 
therapeutic potential of their targeting. 
Drug resistance (67) Increased protein expression of LAMP2 was reported 
in renal and colorectal cancer cells resistant to TKIs (67).  
This study didn’t a provide data regarding the mechanisms 
involved in the lysosomal control exerted by LAMP2 and 
how this could lead to increased drug secretion.
CMA activation (81; 
82)
Ectopic expression of LAMP2A isoform, through its key 
action on CMA, was able to support cell survival upon 
oxidative stress; conversely, its inhibition was promoting 
apoptosis and Doxorubicin-resistance in breast cancer 
cells (81). 
The inhibition of LAMP2A blocked the constitutive 
activation of CMA and led to the reduction of cell 
proliferation, the growth of preexisting tumors and 
promoted the metastatic potential of lung cancer cells 
(82).
LAMP2A key role in cancer was supported by its high 
expression in patients-derived invasive carcinoma 
compared with adjacent tissues and in several cancer cell 
lines. Given its direct control on CMA, LAMP2A inhibition 
could represent a very promising strategy for sensitizing 
cancer cells to chemotherapy (81; 82). 
Abbreviations: ECM, ExtraCellular Matrix; CMA, Chaperone-Mediated Autophagy; TKIs, Tyrosine Kinase Inhibitors.   
down-regulation by shRNA in murine melanoma cells 
B16F10, decreases the induction of the expression of 
MMP9 by p38 MAPK signaling, activated by Galectin-
3 binding to the polyLacNAc present on LAMP1 (54).
However, LAMP1 role in adhesion to ECM 
and ECM remodeling is indirect, since it uses 
Galectin-3 as mediator, giving more 
importance to LAMP1 role as a carrier of 
polyLacNAc rather than the protein itself. 
Other proteins can also be carrier of these 
modifications such as β1 integrin, rendering 
LAMP1 role in ECM regulation not exclusive 
(45; 54). 
Metastasis (50; 53) Anti-LAMP1 antibodies proved to reduce lung 
metastasis of murine melanoma cells B16F10 cells in 
4 mice. 
Data are supported by previous studies 
showing increased LAMP1 expression 
correlating with metastatic potential of human 
colon carcinoma and melanoma cells, and by 
silencing experiments linking LAMP1 
expression with metastatic potential. 
Nevertheless, the absence of a direct 
involvement diminishes the possible 
therapeutic potential of LAMP1 targeting. 
Cancer cell migration (51; 52) LAMP1 was found as a BR96 antigen and expressed 
on the cell surfaces domains responsible for 
locomotion (51). FUT1 was reported to be able to 
fucosylate LAMP1, thereby influencing lysosomes 
localization and promoting cell migration (52).
The link between LAMP1 expression and 
migration is not direct, but controlled by 
LAMP1 polylactosamine modifications and 
fucosylation, responsible for the binding to key 
antigens for migration such as BR96 (51-52). 
Drug resistance (66; 67; 68) Increased protein LAMP1 expression was shown in 
RMS cells resistant to AS-DACA (66) and in renal 
and colorectal cancer cells resistant to TKIs (67).  
Higher LAMP1 expression was found in human 
sarcomas associated with relapse, and its direct role 
in increasing lysosomal exocytosis was found to be 
responsible for promoting invasion and Doxorubicin-
resistance in human sarcomas. 
Increased LAMP1 protein expression was 
used as a proxy for the increased lysosomal 
capacity, without clearly stating the molecular 
mechanism involved in this process (66-67). 
In contrast, a detailed analysis of the role 
played by LAMP1 in lysosomal exocytosis is 
clearly stated by this paper (68). 
Abbreviations: EGF, Epidermal Growth Factor; EGFR, Epidermal Growth Factor Receptor; GESA, Gene-set Enrichment Analysis; TCGA, The 
Cancer Genome Atlas; AML, Acute Myeloid Leukemia; OS, Overall Survival; polyLacNAc, poly-N-AcetylLactosamines; RMS, 
RhabdoMyoSarcoma; AS-DACA, N-[2-(Dimethylamino)ethyl]Acridine-4-CarboxAmide; TKIs, Tyrosine Kinase Inhibitors.
Table 1: Summary of cancer-associated functions for LAMP1 [Lysosome Associated Membrane Protein-1]
Pro-tumorigenic roles Evidence Strength / Weakness of the Evidence
Early cancer progression (56) In OVCAR3 cells, LAMP1 was significantly up-
regulated 1.84-fold 24 h post-EGF treatment and 
significantly down-regulated 48 h post-EGF exposure 
(normalized ratio, 0.41) relative to vehicle-treated 
cells. Tissue microarray analysis for LAMP1 
demonstrated protein staining in 35% of ovarian 
serous adenocarcinoma core biopsies.
Although studies confirming the findings have 
not been reported, the observations were 
confirmed by GESA analysis performed using 
the TCGA database to assess the association 
of LAMP1 with EGFR-mediated signaling 
cascades and it revealed that LAMP1 is 
positively associated with EGFR-modulated 
molecular pathways (p <0.0060). 
Cancer cell survival (65) Screening identified the anti-malarial agent 
mefloquine as a compound that selectively kills AML 
cells and AML stem cells. A yeast genome-wide 
functional screen for mefloquine sensitizers, 
identified genes associated with the yeast vacuole, 
the homolog of the mammalian lysosome and 
demonstrated that mefloquine disrupts lysosomes, by 
permeabilizing the lysosome membrane, and 
releasing cathepsins into the cytosol.
Knock-down of LAMP1 and LAMP2 reduced 
AML cell viability, as did the treatment with 
lysosome disruptor, suggesting that lysosomal 
disruption preferentially targets AML cells and 
AML progenitor cells, thus providing a 
rationale for therapy. In support of this 
observation, artemisinins, artesunate (ART), 
and dihydroartemisinin (DHA), have been 
shown to be toxic to AML cells.
Local tumor progression (55) In glioblastomas, LAMP1 was detected in the 
cytoplasm of tumor cells, and in blood vessels. The 
percentage of LAMP1+ tumor cells and staining 
intensities increased with tumor grade. LAMP1 and 
CD133, a marker for stemness, were co-expressed 
suggesting that cancer stem cells contain LAMP1 
positive lysosomes. 
Data provided did not fully support the 
presence of higher number of lysosomes in 
cancer stem cells of glioblastomas. Moreover, 
despite the increase in LAMP1+ tumor cells 
with tumor grade, an association between 
LAMP1 expression and OS could not be 
found.
Cancer development (57) LAMP1 was identified as a sialylated glycoprotein 
from metabolically oligosaccharide engineered 
pancreatic cells. Immunohistochemistry, showed 
preferential expression of LAMP1 in tumor cells but 
not in paired non-tumor pancreatic ductal cells.
At odds with previous studies showing longer 
survival after resection for patients whose 
pancreatic tumors expressed high levels of 
LAMP1 mRNA. Furthermore, transfection of 
CAPAN-1 cells with LAMP1 showed 
decreased cell growth compared with the non-
transfected cells. Hence, the role for LAMP1 
in cancer development remains uncertain.
Adhesion of cancer cells to ECM, 
basement membrane and endothelium 
(45); ECM remodelling (54)
Flow cytometry experiments showed LAMP1 
expression on the cell surface of A2058, HT1080 
(human fibrosarcoma) and CaCo-2 (human colon 
adenocarcinoma) cells, further increasing upon 2 mM 
sodium butyrate treatment for 24 and 48 hr. FACS 
analysis proved interaction between LAMP1 
expressing cells A2052 and Galectin-3 (45). LAMP1 
Data are supported by previous studies 
showing increased expression of LAMP1 on 
the plasma membrane of highly metastatic 
cells compared to the poorly metastatic ones, 
associated with increased expression of 
carriers for polyLacNAc, that can represent 
ligand structures to cell-adhesion molecules. 
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